NO329682B1 - N-fenylarylsulfonamidforbindelse, og antagonist av EP1 reseptor og farmasoytisk preparat omfattende forbindelsen som aktiv bestanddel - Google Patents
N-fenylarylsulfonamidforbindelse, og antagonist av EP1 reseptor og farmasoytisk preparat omfattende forbindelsen som aktiv bestanddel Download PDFInfo
- Publication number
- NO329682B1 NO329682B1 NO20034007A NO20034007A NO329682B1 NO 329682 B1 NO329682 B1 NO 329682B1 NO 20034007 A NO20034007 A NO 20034007A NO 20034007 A NO20034007 A NO 20034007A NO 329682 B1 NO329682 B1 NO 329682B1
- Authority
- NO
- Norway
- Prior art keywords
- methyl
- amino
- isobutyl
- acid
- isopropyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 139
- 239000005557 antagonist Substances 0.000 title claims description 18
- 239000004480 active ingredient Substances 0.000 title claims description 8
- 101150058615 Ptger1 gene Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 5-methyl-2-furyl Chemical group 0.000 claims abstract description 50
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 21
- 102000005962 receptors Human genes 0.000 claims abstract description 15
- 108020003175 receptors Proteins 0.000 claims abstract description 15
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract description 11
- 230000027939 micturition Effects 0.000 claims abstract description 11
- 206010036018 Pollakiuria Diseases 0.000 claims abstract description 7
- 102000008866 Prostaglandin E receptors Human genes 0.000 claims abstract description 7
- 108010088540 Prostaglandin E receptors Proteins 0.000 claims abstract description 7
- 239000001257 hydrogen Substances 0.000 claims abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 5
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims abstract description 3
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims abstract description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 220
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 153
- 229940124530 sulfonamide Drugs 0.000 claims description 118
- 239000002253 acid Substances 0.000 claims description 97
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 claims description 96
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 90
- 239000005711 Benzoic acid Substances 0.000 claims description 59
- 235000010233 benzoic acid Nutrition 0.000 claims description 45
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 39
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 39
- 229930016911 cinnamic acid Natural products 0.000 claims description 39
- 235000013985 cinnamic acid Nutrition 0.000 claims description 39
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 16
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims description 11
- 231100000252 nontoxic Toxicity 0.000 claims description 10
- 230000003000 nontoxic effect Effects 0.000 claims description 10
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- 206010037660 Pyrexia Diseases 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 239000000460 chlorine Chemical group 0.000 claims description 7
- 229910052801 chlorine Chemical group 0.000 claims description 7
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 claims description 6
- 230000006698 induction Effects 0.000 claims description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 6
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 5
- 206010046543 Urinary incontinence Diseases 0.000 claims description 4
- 125000005907 alkyl ester group Chemical group 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000027950 fever generation Effects 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- VBPYYHZBHWQNKY-UHFFFAOYSA-N 3-[3-methyl-4-[[2-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]phenyl]prop-2-enoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC=C(C(F)(F)F)C=C1OCC1=CC=C(C=CC(O)=O)C=C1C VBPYYHZBHWQNKY-UHFFFAOYSA-N 0.000 claims description 3
- KCZHYRSBYSISRU-UHFFFAOYSA-N 3-[3-methyl-4-[[3-[(5-methylfuran-2-yl)sulfonyl-(2-methylpropyl)amino]naphthalen-2-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CC(C)C)C1=CC2=CC=CC=C2C=C1OCC1=CC=C(C=CC(O)=O)C=C1C KCZHYRSBYSISRU-UHFFFAOYSA-N 0.000 claims description 3
- DDECXYJJPKIXEY-UHFFFAOYSA-N 3-[3-methyl-4-[[6-[propan-2-yl(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound N=1C=CSC=1S(=O)(=O)N(C(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C=CC(O)=O)C=C1C DDECXYJJPKIXEY-UHFFFAOYSA-N 0.000 claims description 3
- SLHKHBZSGXVQFX-UHFFFAOYSA-N 3-[4-[[2-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]phenyl]prop-2-enoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC=C(C(F)(F)F)C=C1OCC1=CC=C(C=CC(O)=O)C=C1 SLHKHBZSGXVQFX-UHFFFAOYSA-N 0.000 claims description 3
- LGSYGWHHUFLCLI-UHFFFAOYSA-N 3-[4-[[6-[(4-methyl-1,3-thiazol-2-yl)sulfonyl-propan-2-ylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(C(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C=CC(O)=O)C=C1 LGSYGWHHUFLCLI-UHFFFAOYSA-N 0.000 claims description 3
- LPJLBUOIRQJTAH-UHFFFAOYSA-N 3-chloro-4-[[4-chloro-5-methyl-2-[propan-2-yl(pyridin-2-ylsulfonyl)amino]phenoxy]methyl]benzoic acid Chemical compound C=1C=CC=NC=1S(=O)(=O)N(C(C)C)C1=CC(Cl)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1Cl LPJLBUOIRQJTAH-UHFFFAOYSA-N 0.000 claims description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- PAUAESUQPKSFEF-UHFFFAOYSA-N 4-[[2-[propan-2-yl(1,3-thiazol-2-ylsulfonyl)amino]-5-(trifluoromethyl)phenoxy]methyl]benzoic acid Chemical compound N=1C=CSC=1S(=O)(=O)N(C(C)C)C1=CC=C(C(F)(F)F)C=C1OCC1=CC=C(C(O)=O)C=C1 PAUAESUQPKSFEF-UHFFFAOYSA-N 0.000 claims description 3
- JQCOUWNBDQATQD-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[(4-methyl-1,3-thiazol-2-yl)sulfonyl-propylamino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CCC)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1C JQCOUWNBDQATQD-UHFFFAOYSA-N 0.000 claims description 3
- HKYZMEKVLDVTFB-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[(5-methylfuran-2-yl)sulfonyl-prop-2-enylamino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound O1C(C)=CC=C1S(=O)(=O)N(CC=C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1C HKYZMEKVLDVTFB-UHFFFAOYSA-N 0.000 claims description 3
- AEANKAMGBZVZMQ-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[2-methylpropyl(pyridin-2-ylsulfonyl)amino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound C=1C=CC=NC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1C AEANKAMGBZVZMQ-UHFFFAOYSA-N 0.000 claims description 3
- TWMVCGIHQSAHEM-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[2-methylpropyl(pyridin-3-ylsulfonyl)amino]phenoxy]methyl]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1COC1=CC(C)=C(C)C=C1N(CC(C)C)S(=O)(=O)C1=CC=CN=C1 TWMVCGIHQSAHEM-UHFFFAOYSA-N 0.000 claims description 3
- HUSKYHHXCMIKGS-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1C HUSKYHHXCMIKGS-UHFFFAOYSA-N 0.000 claims description 3
- PDIHXAWISZWDRS-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[methyl-(5-methylfuran-2-yl)sulfonylamino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1C PDIHXAWISZWDRS-UHFFFAOYSA-N 0.000 claims description 3
- BIPADBRDQDDYLO-UHFFFAOYSA-N 4-[[4-chloro-5-methyl-2-[2-methylprop-2-enyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(=C)C)C1=CC(Cl)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1C BIPADBRDQDDYLO-UHFFFAOYSA-N 0.000 claims description 3
- KBPARJNQCKKDJC-UHFFFAOYSA-N 4-[[6-[(2-hydroxy-2-methylpropyl)-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound CC1=CSC(S(=O)(=O)N(CC(C)(C)O)C=2C(=CC=3CCCC=3C=2)OCC=2C=CC(=CC=2)C(O)=O)=N1 KBPARJNQCKKDJC-UHFFFAOYSA-N 0.000 claims description 3
- ZZQVRLPENZFYLY-UHFFFAOYSA-N 4-[[6-[(5-methylfuran-2-yl)sulfonyl-propan-2-ylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(C(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C(O)=O)C=C1 ZZQVRLPENZFYLY-UHFFFAOYSA-N 0.000 claims description 3
- CUYJEGYERUEYMP-UHFFFAOYSA-N 4-[[6-[methyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C(O)=O)C=C1 CUYJEGYERUEYMP-UHFFFAOYSA-N 0.000 claims description 3
- 241001237754 Algia Species 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 150000002431 hydrogen Chemical group 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- MQSJQFQDEHNUMO-UHFFFAOYSA-N 3-[3-methyl-4-[[6-[(4-methyl-1,3-thiazol-2-yl)sulfonyl-propylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CCC)C1=CC=2CCCC=2C=C1OCC1=CC=C(C=CC(O)=O)C=C1C MQSJQFQDEHNUMO-UHFFFAOYSA-N 0.000 claims description 2
- NARMEKHGSVNOBX-UHFFFAOYSA-N 3-[3-methyl-4-[[6-[2-methylprop-2-enyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(=C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C=CC(O)=O)C=C1C NARMEKHGSVNOBX-UHFFFAOYSA-N 0.000 claims description 2
- TXABTIGJIGZLCS-UHFFFAOYSA-N 3-[3-methyl-4-[[6-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C=CC(O)=O)C=C1C TXABTIGJIGZLCS-UHFFFAOYSA-N 0.000 claims description 2
- AYYHDPOKMMBQEM-UHFFFAOYSA-N 3-[3-methyl-4-[[6-[methyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C=CC(O)=O)C=C1C AYYHDPOKMMBQEM-UHFFFAOYSA-N 0.000 claims description 2
- POUBSLPBNFGQAO-UHFFFAOYSA-N 3-[4-[[2-[2-methylpropyl(pyridin-2-ylsulfonyl)amino]-5-(trifluoromethyl)phenoxy]methyl]phenyl]prop-2-enoic acid Chemical compound C=1C=CC=NC=1S(=O)(=O)N(CC(C)C)C1=CC=C(C(F)(F)F)C=C1OCC1=CC=C(C=CC(O)=O)C=C1 POUBSLPBNFGQAO-UHFFFAOYSA-N 0.000 claims description 2
- LBWJZHUGNUPISB-UHFFFAOYSA-N 3-[4-[[3-[(4-methyl-1,3-thiazol-2-yl)sulfonyl-propan-2-ylamino]naphthalen-2-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(C(C)C)C1=CC2=CC=CC=C2C=C1OCC1=CC=C(C=CC(O)=O)C=C1 LBWJZHUGNUPISB-UHFFFAOYSA-N 0.000 claims description 2
- OOKCHIGXDLJTJK-UHFFFAOYSA-N 3-[4-[[3-[(5-methylfuran-2-yl)sulfonyl-propan-2-ylamino]naphthalen-2-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(C(C)C)C1=CC2=CC=CC=C2C=C1OCC1=CC=C(C=CC(O)=O)C=C1 OOKCHIGXDLJTJK-UHFFFAOYSA-N 0.000 claims description 2
- MAGNVKOIELHLCE-UHFFFAOYSA-N 3-[4-[[4,5-dimethyl-2-[(5-methylfuran-2-yl)sulfonyl-(2-methylpropyl)amino]phenoxy]methyl]phenyl]prop-2-enoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C=CC(O)=O)C=C1 MAGNVKOIELHLCE-UHFFFAOYSA-N 0.000 claims description 2
- STDLEQZHOPZMTF-UHFFFAOYSA-N 3-[4-[[4,5-dimethyl-2-[2-methylpropyl(pyridin-2-ylsulfonyl)amino]phenoxy]methyl]-3-methylphenyl]prop-2-enoic acid Chemical compound C=1C=CC=NC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C=CC(O)=O)C=C1C STDLEQZHOPZMTF-UHFFFAOYSA-N 0.000 claims description 2
- ILTMQNRYNXMLNS-UHFFFAOYSA-N 3-[4-[[4,5-dimethyl-2-[2-methylpropyl(pyridin-3-ylsulfonyl)amino]phenoxy]methyl]-3-methylphenyl]prop-2-enoic acid Chemical compound C=1C=CN=CC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C=CC(O)=O)C=C1C ILTMQNRYNXMLNS-UHFFFAOYSA-N 0.000 claims description 2
- XYDIYHFBOGBMQA-UHFFFAOYSA-N 3-[4-[[4,5-dimethyl-2-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenoxy]methyl]-3-methoxyphenyl]prop-2-enoic acid Chemical compound COC1=CC(C=CC(O)=O)=CC=C1COC1=CC(C)=C(C)C=C1N(CC(C)C)S(=O)(=O)C1=NC(C)=CS1 XYDIYHFBOGBMQA-UHFFFAOYSA-N 0.000 claims description 2
- ACRRKHDCOYVBNO-UHFFFAOYSA-N 3-[4-[[4,5-dimethyl-2-[propan-2-yl(1,3-thiazol-2-ylsulfonyl)amino]phenoxy]methyl]phenyl]prop-2-enoic acid Chemical compound N=1C=CSC=1S(=O)(=O)N(C(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C=CC(O)=O)C=C1 ACRRKHDCOYVBNO-UHFFFAOYSA-N 0.000 claims description 2
- YVBMIUFKFRJIKX-UHFFFAOYSA-N 3-[4-[[4-chloro-5-methyl-2-[2-methylpropyl(pyridin-3-ylsulfonyl)amino]phenoxy]methyl]-3-methylphenyl]prop-2-enoic acid Chemical compound C=1C=CN=CC=1S(=O)(=O)N(CC(C)C)C1=CC(Cl)=C(C)C=C1OCC1=CC=C(C=CC(O)=O)C=C1C YVBMIUFKFRJIKX-UHFFFAOYSA-N 0.000 claims description 2
- QLYHJUNLCINBQT-UHFFFAOYSA-N 3-[4-[[5-chloro-4-methyl-2-[(5-methylfuran-2-yl)sulfonyl-(2-methylpropyl)amino]phenoxy]methyl]-3-methylphenyl]prop-2-enoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(Cl)C=C1OCC1=CC=C(C=CC(O)=O)C=C1C QLYHJUNLCINBQT-UHFFFAOYSA-N 0.000 claims description 2
- MOIRWZLTLCHZFQ-UHFFFAOYSA-N 3-[4-[[5-chloro-4-methyl-2-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenoxy]methyl]phenyl]prop-2-enoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(Cl)C=C1OCC1=CC=C(C=CC(O)=O)C=C1 MOIRWZLTLCHZFQ-UHFFFAOYSA-N 0.000 claims description 2
- BHVSBVVACASXJO-UHFFFAOYSA-N 3-[4-[[5-chloro-4-methyl-2-[propan-2-yl(pyridin-2-ylsulfonyl)amino]phenoxy]methyl]phenyl]prop-2-enoic acid Chemical compound C=1C=CC=NC=1S(=O)(=O)N(C(C)C)C1=CC(C)=C(Cl)C=C1OCC1=CC=C(C=CC(O)=O)C=C1 BHVSBVVACASXJO-UHFFFAOYSA-N 0.000 claims description 2
- YLXSHCBLGREHCG-UHFFFAOYSA-N 3-[4-[[6-[propan-2-yl(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound N=1C=CSC=1S(=O)(=O)N(C(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C=CC(O)=O)C=C1 YLXSHCBLGREHCG-UHFFFAOYSA-N 0.000 claims description 2
- WTCCEWIQTAHILZ-UHFFFAOYSA-N 3-chloro-4-[[4,5-dimethyl-2-[(5-methylfuran-2-yl)sulfonyl-propan-2-ylamino]phenoxy]methyl]benzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(C(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1Cl WTCCEWIQTAHILZ-UHFFFAOYSA-N 0.000 claims description 2
- RCLVSQKFUQWWTO-UHFFFAOYSA-N 3-chloro-4-[[5-chloro-4-methyl-2-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenoxy]methyl]benzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(Cl)C=C1OCC1=CC=C(C(O)=O)C=C1Cl RCLVSQKFUQWWTO-UHFFFAOYSA-N 0.000 claims description 2
- DGNQHLGIUHJYBS-UHFFFAOYSA-N 3-methyl-4-[[3-[(5-methylfuran-2-yl)sulfonyl-(2-methylpropyl)amino]naphthalen-2-yl]oxymethyl]benzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CC(C)C)C1=CC2=CC=CC=C2C=C1OCC1=CC=C(C(O)=O)C=C1C DGNQHLGIUHJYBS-UHFFFAOYSA-N 0.000 claims description 2
- GARDXZVRHGQFBL-UHFFFAOYSA-N 3-methyl-4-[[3-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]naphthalen-2-yl]oxymethyl]benzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC2=CC=CC=C2C=C1OCC1=CC=C(C(O)=O)C=C1C GARDXZVRHGQFBL-UHFFFAOYSA-N 0.000 claims description 2
- ZKUYQANALUPTNJ-UHFFFAOYSA-N 3-methyl-4-[[6-[(5-methylfuran-2-yl)sulfonyl-(2-methylprop-2-enyl)amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CC(=C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C(O)=O)C=C1C ZKUYQANALUPTNJ-UHFFFAOYSA-N 0.000 claims description 2
- DMANOXOHGWPFQR-UHFFFAOYSA-N 3-methyl-4-[[6-[(5-methylfuran-2-yl)sulfonyl-prop-2-enylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound O1C(C)=CC=C1S(=O)(=O)N(CC=C)C(C(=C1)OCC=2C(=CC(=CC=2)C(O)=O)C)=CC2=C1CCC2 DMANOXOHGWPFQR-UHFFFAOYSA-N 0.000 claims description 2
- UHJZALVJXBRXPI-UHFFFAOYSA-N 3-methyl-4-[[6-[(5-methylfuran-2-yl)sulfonyl-propylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CCC)C1=CC=2CCCC=2C=C1OCC1=CC=C(C(O)=O)C=C1C UHJZALVJXBRXPI-UHFFFAOYSA-N 0.000 claims description 2
- ULQAPKFRPBCHED-UHFFFAOYSA-N 4-[[2-[(2-hydroxy-2-methylpropyl)-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-4,5-dimethylphenoxy]methyl]-3-methylbenzoic acid Chemical compound CC1=CSC(S(=O)(=O)N(CC(C)(C)O)C=2C(=CC(C)=C(C)C=2)OCC=2C(=CC(=CC=2)C(O)=O)C)=N1 ULQAPKFRPBCHED-UHFFFAOYSA-N 0.000 claims description 2
- FAGFFRKVSJNTOV-UHFFFAOYSA-N 4-[[2-[2-methylpropyl(1,3-thiazol-2-ylsulfonyl)amino]-5-(trifluoromethyl)phenoxy]methyl]benzoic acid Chemical compound N=1C=CSC=1S(=O)(=O)N(CC(C)C)C1=CC=C(C(F)(F)F)C=C1OCC1=CC=C(C(O)=O)C=C1 FAGFFRKVSJNTOV-UHFFFAOYSA-N 0.000 claims description 2
- GWBSXBIFISDRSN-UHFFFAOYSA-N 4-[[2-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]benzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC=C(C(F)(F)F)C=C1OCC1=CC=C(C(O)=O)C=C1 GWBSXBIFISDRSN-UHFFFAOYSA-N 0.000 claims description 2
- FWNRVTNPVHRAFV-UHFFFAOYSA-N 4-[[2-[cyclopropylmethyl-(5-methylfuran-2-yl)sulfonylamino]-4,5-dimethylphenoxy]methyl]benzoic acid Chemical compound O1C(C)=CC=C1S(=O)(=O)N(C=1C(=CC(C)=C(C)C=1)OCC=1C=CC(=CC=1)C(O)=O)CC1CC1 FWNRVTNPVHRAFV-UHFFFAOYSA-N 0.000 claims description 2
- PVMOXLQHNRRVJX-UHFFFAOYSA-N 4-[[2-[ethyl-(5-methylfuran-2-yl)sulfonylamino]-4,5-dimethylphenoxy]methyl]-3-methylbenzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CC)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1C PVMOXLQHNRRVJX-UHFFFAOYSA-N 0.000 claims description 2
- YVPHNFSNFIZNLF-UHFFFAOYSA-N 4-[[3-[(5-methylfuran-2-yl)sulfonyl-(2-methylpropyl)amino]naphthalen-2-yl]oxymethyl]benzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CC(C)C)C1=CC2=CC=CC=C2C=C1OCC1=CC=C(C(O)=O)C=C1 YVPHNFSNFIZNLF-UHFFFAOYSA-N 0.000 claims description 2
- NLZQMCNXPUIFES-UHFFFAOYSA-N 4-[[3-[(5-methylfuran-2-yl)sulfonyl-propan-2-ylamino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxymethyl]benzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(C(C)C)C1=CC=2CCCCC=2C=C1OCC1=CC=C(C(O)=O)C=C1 NLZQMCNXPUIFES-UHFFFAOYSA-N 0.000 claims description 2
- MSBLROUFBNAIRR-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[(4-methyl-1,3-thiazol-2-yl)sulfonyl-prop-2-enylamino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound CC1=CSC(S(=O)(=O)N(CC=C)C=2C(=CC(C)=C(C)C=2)OCC=2C(=CC(=CC=2)C(O)=O)C)=N1 MSBLROUFBNAIRR-UHFFFAOYSA-N 0.000 claims description 2
- OYNUHSMXGIHAAZ-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[(4-methyl-1,3-thiazol-2-yl)sulfonyl-propan-2-ylamino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(C(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1C OYNUHSMXGIHAAZ-UHFFFAOYSA-N 0.000 claims description 2
- SUWMNAXQSQVTLW-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[(5-methylfuran-2-yl)sulfonyl-prop-2-enylamino]phenoxy]methyl]benzoic acid Chemical compound O1C(C)=CC=C1S(=O)(=O)N(CC=C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1 SUWMNAXQSQVTLW-UHFFFAOYSA-N 0.000 claims description 2
- CLQJPXDXLBNOSE-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[(5-methylfuran-2-yl)sulfonyl-propylamino]phenoxy]methyl]benzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CCC)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1 CLQJPXDXLBNOSE-UHFFFAOYSA-N 0.000 claims description 2
- MVZHWWYJLUFOEE-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[2-methylprop-2-enyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(=C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1C MVZHWWYJLUFOEE-UHFFFAOYSA-N 0.000 claims description 2
- ZDHHIXMUHRBWIV-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[2-methylpropyl(pyridin-2-ylsulfonyl)amino]phenoxy]methyl]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1COC1=CC(C)=C(C)C=C1N(CC(C)C)S(=O)(=O)C1=CC=CC=N1 ZDHHIXMUHRBWIV-UHFFFAOYSA-N 0.000 claims description 2
- GIWOONJNGCHMDO-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[2-methylpropyl(pyridin-2-ylsulfonyl)amino]phenoxy]methyl]benzoic acid Chemical compound C=1C=CC=NC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1 GIWOONJNGCHMDO-UHFFFAOYSA-N 0.000 claims description 2
- MKUCVKNNOZQFIC-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenoxy]methyl]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1COC1=CC(C)=C(C)C=C1N(CC(C)C)S(=O)(=O)C1=NC(C)=CS1 MKUCVKNNOZQFIC-UHFFFAOYSA-N 0.000 claims description 2
- PCTQXFIWRVGNJM-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[methyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1C PCTQXFIWRVGNJM-UHFFFAOYSA-N 0.000 claims description 2
- UZOYOTJHUJJNOV-UHFFFAOYSA-N 4-[[4-chloro-5-methyl-2-[2-methylpropyl(pyridin-2-ylsulfonyl)amino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound C=1C=CC=NC=1S(=O)(=O)N(CC(C)C)C1=CC(Cl)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1C UZOYOTJHUJJNOV-UHFFFAOYSA-N 0.000 claims description 2
- QDGXCDPYTMSLBV-UHFFFAOYSA-N 4-[[4-chloro-5-methyl-2-[2-methylpropyl(pyridin-3-ylsulfonyl)amino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound C=1C=CN=CC=1S(=O)(=O)N(CC(C)C)C1=CC(Cl)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1C QDGXCDPYTMSLBV-UHFFFAOYSA-N 0.000 claims description 2
- DPYJVEIBKFKKGB-UHFFFAOYSA-N 4-[[4-chloro-5-methyl-2-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenoxy]methyl]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1COC1=CC(C)=C(Cl)C=C1N(CC(C)C)S(=O)(=O)C1=NC(C)=CS1 DPYJVEIBKFKKGB-UHFFFAOYSA-N 0.000 claims description 2
- ZUFXSMKUUOIQNM-UHFFFAOYSA-N 4-[[4-chloro-5-methyl-2-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenoxy]methyl]benzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC(Cl)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1 ZUFXSMKUUOIQNM-UHFFFAOYSA-N 0.000 claims description 2
- YFVATGYHSZATIM-UHFFFAOYSA-N 4-[[4-chloro-5-methyl-2-[propan-2-yl(1,3-thiazol-2-ylsulfonyl)amino]phenoxy]methyl]benzoic acid Chemical compound N=1C=CSC=1S(=O)(=O)N(C(C)C)C1=CC(Cl)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1 YFVATGYHSZATIM-UHFFFAOYSA-N 0.000 claims description 2
- IULISNVATPYDGG-UHFFFAOYSA-N 4-[[5-chloro-4-methyl-2-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenoxy]methyl]benzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(Cl)C=C1OCC1=CC=C(C(O)=O)C=C1 IULISNVATPYDGG-UHFFFAOYSA-N 0.000 claims description 2
- JVCVCXMXUWYPHS-UHFFFAOYSA-N 4-[[6-[(4-methyl-1,3-thiazol-2-yl)sulfonyl-prop-2-enylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound CC1=CSC(S(=O)(=O)N(CC=C)C=2C(=CC=3CCCC=3C=2)OCC=2C=CC(=CC=2)C(O)=O)=N1 JVCVCXMXUWYPHS-UHFFFAOYSA-N 0.000 claims description 2
- ZETRIINSUUXDEG-UHFFFAOYSA-N 4-[[6-[(4-methyl-1,3-thiazol-2-yl)sulfonyl-propylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CCC)C1=CC=2CCCC=2C=C1OCC1=CC=C(C(O)=O)C=C1 ZETRIINSUUXDEG-UHFFFAOYSA-N 0.000 claims description 2
- MBXXNJUUZILUQX-UHFFFAOYSA-N 4-[[6-[(5-methylfuran-2-yl)sulfonyl-(2-methylpropyl)amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CC(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C(O)=O)C=C1 MBXXNJUUZILUQX-UHFFFAOYSA-N 0.000 claims description 2
- HVSYDWFUUNUCCR-UHFFFAOYSA-N 4-[[6-[2-methylpropyl(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound N=1C=CSC=1S(=O)(=O)N(CC(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C(O)=O)C=C1 HVSYDWFUUNUCCR-UHFFFAOYSA-N 0.000 claims description 2
- IOXMDBQCUCDLAF-UHFFFAOYSA-N 4-[[6-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C(O)=O)C=C1 IOXMDBQCUCDLAF-UHFFFAOYSA-N 0.000 claims description 2
- PURJCMPJBFMBSY-UHFFFAOYSA-N 4-[[6-[cyclopropylmethyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound CC1=CSC(S(=O)(=O)N(CC2CC2)C=2C(=CC=3CCCC=3C=2)OCC=2C=CC(=CC=2)C(O)=O)=N1 PURJCMPJBFMBSY-UHFFFAOYSA-N 0.000 claims description 2
- QWXFXSACBDRTCW-UHFFFAOYSA-N 4-[[6-[ethyl-(5-methylfuran-2-yl)sulfonylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]-3-methylbenzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CC)C1=CC=2CCCC=2C=C1OCC1=CC=C(C(O)=O)C=C1C QWXFXSACBDRTCW-UHFFFAOYSA-N 0.000 claims description 2
- LBUUMZNVTSLBHB-UHFFFAOYSA-N 4-[[6-[propan-2-yl(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound N=1C=CSC=1S(=O)(=O)N(C(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C(O)=O)C=C1 LBUUMZNVTSLBHB-UHFFFAOYSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 210000001635 urinary tract Anatomy 0.000 claims description 2
- FZPLCPKKSIFKQU-UHFFFAOYSA-N 3-[3-chloro-4-[[2-[2-methylpropyl(pyridin-3-ylsulfonyl)amino]-5-(trifluoromethyl)phenoxy]methyl]phenyl]prop-2-enoic acid Chemical compound C=1C=CN=CC=1S(=O)(=O)N(CC(C)C)C1=CC=C(C(F)(F)F)C=C1OCC1=CC=C(C=CC(O)=O)C=C1Cl FZPLCPKKSIFKQU-UHFFFAOYSA-N 0.000 claims 1
- WMBUYETUKIDMGI-UHFFFAOYSA-N 3-[3-chloro-4-[[2-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]phenyl]prop-2-enoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC=C(C(F)(F)F)C=C1OCC1=CC=C(C=CC(O)=O)C=C1Cl WMBUYETUKIDMGI-UHFFFAOYSA-N 0.000 claims 1
- CDTFSLDMJKFQKF-UHFFFAOYSA-N 3-[3-chloro-4-[[4,5-dimethyl-2-[2-methylpropyl(pyridin-3-ylsulfonyl)amino]phenoxy]methyl]phenyl]prop-2-enoic acid Chemical compound C=1C=CN=CC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C=CC(O)=O)C=C1Cl CDTFSLDMJKFQKF-UHFFFAOYSA-N 0.000 claims 1
- QEMXPQGLCRHPOA-UHFFFAOYSA-N 3-[3-chloro-4-[[4,5-dimethyl-2-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenoxy]methyl]phenyl]prop-2-enoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C=CC(O)=O)C=C1Cl QEMXPQGLCRHPOA-UHFFFAOYSA-N 0.000 claims 1
- OHVQRTZQVWAWNF-UHFFFAOYSA-N 3-[3-methyl-4-[[2-[(5-methylfuran-2-yl)sulfonyl-propan-2-ylamino]-5-(trifluoromethyl)phenoxy]methyl]phenyl]prop-2-enoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(C(C)C)C1=CC=C(C(F)(F)F)C=C1OCC1=CC=C(C=CC(O)=O)C=C1C OHVQRTZQVWAWNF-UHFFFAOYSA-N 0.000 claims 1
- IYLSDXVKNUSPER-UHFFFAOYSA-N 3-[3-methyl-4-[[3-[(5-methylfuran-2-yl)sulfonyl-propan-2-ylamino]naphthalen-2-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(C(C)C)C1=CC2=CC=CC=C2C=C1OCC1=CC=C(C=CC(O)=O)C=C1C IYLSDXVKNUSPER-UHFFFAOYSA-N 0.000 claims 1
- NYGUNMGSSLYLRI-UHFFFAOYSA-N 3-[3-methyl-4-[[6-[(4-methyl-1,3-thiazol-2-yl)sulfonyl-prop-2-enylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound CC1=CSC(S(=O)(=O)N(CC=C)C=2C(=CC=3CCCC=3C=2)OCC=2C(=CC(C=CC(O)=O)=CC=2)C)=N1 NYGUNMGSSLYLRI-UHFFFAOYSA-N 0.000 claims 1
- QTFKFHRURDGPHV-UHFFFAOYSA-N 3-[3-methyl-4-[[6-[(4-methyl-1,3-thiazol-2-yl)sulfonyl-propan-2-ylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(C(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C=CC(O)=O)C=C1C QTFKFHRURDGPHV-UHFFFAOYSA-N 0.000 claims 1
- VQQHUDHUUPBDGX-UHFFFAOYSA-N 3-[3-methyl-4-[[6-[(5-methylfuran-2-yl)sulfonyl-(2-methylpropyl)amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CC(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C=CC(O)=O)C=C1C VQQHUDHUUPBDGX-UHFFFAOYSA-N 0.000 claims 1
- FTNOSOSKOKZCHM-UHFFFAOYSA-N 3-[3-methyl-4-[[6-[(5-methylfuran-2-yl)sulfonyl-propan-2-ylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(C(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C=CC(O)=O)C=C1C FTNOSOSKOKZCHM-UHFFFAOYSA-N 0.000 claims 1
- XVJCODJQEJJLKE-UHFFFAOYSA-N 3-[3-methyl-4-[[6-[2-methylpropyl(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound N=1C=CSC=1S(=O)(=O)N(CC(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C=CC(O)=O)C=C1C XVJCODJQEJJLKE-UHFFFAOYSA-N 0.000 claims 1
- HPTZTMBBMYRSHN-UHFFFAOYSA-N 3-[4-[[3-[(5-methylfuran-2-yl)sulfonyl-(2-methylpropyl)amino]naphthalen-2-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CC(C)C)C1=CC2=CC=CC=C2C=C1OCC1=CC=C(C=CC(O)=O)C=C1 HPTZTMBBMYRSHN-UHFFFAOYSA-N 0.000 claims 1
- CRDOOCRFBRWZKI-UHFFFAOYSA-N 3-[4-[[4,5-dimethyl-2-[(4-methyl-1,3-thiazol-2-yl)sulfonyl-propan-2-ylamino]phenoxy]methyl]-3-methylphenyl]prop-2-enoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(C(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C=CC(O)=O)C=C1C CRDOOCRFBRWZKI-UHFFFAOYSA-N 0.000 claims 1
- MZLWEKMWOOSKCS-UHFFFAOYSA-N 3-[4-[[4,5-dimethyl-2-[(5-methylfuran-2-yl)sulfonyl-propan-2-ylamino]phenoxy]methyl]-3-methylphenyl]prop-2-enoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(C(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C=CC(O)=O)C=C1C MZLWEKMWOOSKCS-UHFFFAOYSA-N 0.000 claims 1
- OJVUJONKOQYZEK-UHFFFAOYSA-N 3-[4-[[4,5-dimethyl-2-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenoxy]methyl]-3-methylphenyl]prop-2-enoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C=CC(O)=O)C=C1C OJVUJONKOQYZEK-UHFFFAOYSA-N 0.000 claims 1
- YXRGYQBNGMCJFR-UHFFFAOYSA-N 3-[4-[[4-chloro-5-methyl-2-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenoxy]methyl]phenyl]prop-2-enoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC(Cl)=C(C)C=C1OCC1=CC=C(C=CC(O)=O)C=C1 YXRGYQBNGMCJFR-UHFFFAOYSA-N 0.000 claims 1
- GEFYJNATSUBWMG-UHFFFAOYSA-N 3-[4-[[5-chloro-4-methyl-2-[(5-methylfuran-2-yl)sulfonyl-(2-methylpropyl)amino]phenoxy]methyl]-3-methoxyphenyl]prop-2-enoic acid Chemical compound COC1=CC(C=CC(O)=O)=CC=C1COC1=CC(Cl)=C(C)C=C1N(CC(C)C)S(=O)(=O)C1=CC=C(C)O1 GEFYJNATSUBWMG-UHFFFAOYSA-N 0.000 claims 1
- ZOEZYAPROKZWAP-UHFFFAOYSA-N 3-[4-[[5-chloro-4-methyl-2-[2-methylpropyl(pyridin-2-ylsulfonyl)amino]phenoxy]methyl]-3-methylphenyl]prop-2-enoic acid Chemical compound C=1C=CC=NC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(Cl)C=C1OCC1=CC=C(C=CC(O)=O)C=C1C ZOEZYAPROKZWAP-UHFFFAOYSA-N 0.000 claims 1
- TWFYNQPPFIDXFZ-UHFFFAOYSA-N 3-[4-[[6-[(5-methylfuran-2-yl)sulfonyl-(2-methylprop-2-enyl)amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CC(=C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C=CC(O)=O)C=C1 TWFYNQPPFIDXFZ-UHFFFAOYSA-N 0.000 claims 1
- VSARAIGMOWICLI-UHFFFAOYSA-N 3-[4-[[6-[(5-methylfuran-2-yl)sulfonyl-propan-2-ylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(C(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C=CC(O)=O)C=C1 VSARAIGMOWICLI-UHFFFAOYSA-N 0.000 claims 1
- XMWFSUVCHIOMTJ-UHFFFAOYSA-N 3-[4-[[6-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C=CC(O)=O)C=C1 XMWFSUVCHIOMTJ-UHFFFAOYSA-N 0.000 claims 1
- UDJKGILHJMEKDG-UHFFFAOYSA-N 3-[4-[[6-[cyclopropylmethyl-(5-methylfuran-2-yl)sulfonylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound O1C(C)=CC=C1S(=O)(=O)N(C=1C(=CC=2CCCC=2C=1)OCC=1C=CC(C=CC(O)=O)=CC=1)CC1CC1 UDJKGILHJMEKDG-UHFFFAOYSA-N 0.000 claims 1
- JJQSEIBLHLYFLA-UHFFFAOYSA-N 3-[4-[[6-[cyclopropylmethyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]-3-methylphenyl]prop-2-enoic acid Chemical compound CC1=CSC(S(=O)(=O)N(CC2CC2)C=2C(=CC=3CCCC=3C=2)OCC=2C(=CC(C=CC(O)=O)=CC=2)C)=N1 JJQSEIBLHLYFLA-UHFFFAOYSA-N 0.000 claims 1
- HHPPAOJWEWZVAT-UHFFFAOYSA-N 3-[4-[[6-[methyl-(5-methylfuran-2-yl)sulfonylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C=CC(O)=O)C=C1 HHPPAOJWEWZVAT-UHFFFAOYSA-N 0.000 claims 1
- ZCFHRMQLXFMEBJ-UHFFFAOYSA-N 3-chloro-4-[[4,5-dimethyl-2-[(5-methylfuran-2-yl)sulfonyl-(2-methylpropyl)amino]phenoxy]methyl]benzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1Cl ZCFHRMQLXFMEBJ-UHFFFAOYSA-N 0.000 claims 1
- KKBGTYPZPQQXFQ-UHFFFAOYSA-N 3-chloro-4-[[4-chloro-5-methyl-2-[(4-methyl-1,3-thiazol-2-yl)sulfonyl-propan-2-ylamino]phenoxy]methyl]benzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(C(C)C)C1=CC(Cl)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1Cl KKBGTYPZPQQXFQ-UHFFFAOYSA-N 0.000 claims 1
- SHMDANSQLXMMII-UHFFFAOYSA-N 3-chloro-4-[[5-chloro-4-methyl-2-[(5-methylfuran-2-yl)sulfonyl-propan-2-ylamino]phenoxy]methyl]benzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(C(C)C)C1=CC(C)=C(Cl)C=C1OCC1=CC=C(C(O)=O)C=C1Cl SHMDANSQLXMMII-UHFFFAOYSA-N 0.000 claims 1
- QGVIHAIXIBUILJ-UHFFFAOYSA-N 3-chloro-4-[[5-chloro-4-methyl-2-[2-methylpropyl(pyridin-3-ylsulfonyl)amino]phenoxy]methyl]benzoic acid Chemical compound C=1C=CN=CC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(Cl)C=C1OCC1=CC=C(C(O)=O)C=C1Cl QGVIHAIXIBUILJ-UHFFFAOYSA-N 0.000 claims 1
- ZLLFLBHNCVMDHD-UHFFFAOYSA-N 3-methyl-4-[[2-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]benzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC=C(C(F)(F)F)C=C1OCC1=CC=C(C(O)=O)C=C1C ZLLFLBHNCVMDHD-UHFFFAOYSA-N 0.000 claims 1
- MYMRTMLPCWMMDW-UHFFFAOYSA-N 3-methyl-4-[[6-[(4-methyl-1,3-thiazol-2-yl)sulfonyl-propan-2-ylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(C(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C(O)=O)C=C1C MYMRTMLPCWMMDW-UHFFFAOYSA-N 0.000 claims 1
- INKACADTUYSFBJ-UHFFFAOYSA-N 3-methyl-4-[[6-[(5-methylfuran-2-yl)sulfonyl-(2-methylpropyl)amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CC(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C(O)=O)C=C1C INKACADTUYSFBJ-UHFFFAOYSA-N 0.000 claims 1
- DDENBRCBVUBTBI-UHFFFAOYSA-N 3-methyl-4-[[6-[(5-methylfuran-2-yl)sulfonyl-propan-2-ylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(C(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C(O)=O)C=C1C DDENBRCBVUBTBI-UHFFFAOYSA-N 0.000 claims 1
- OYFJWBAHIJXBFF-UHFFFAOYSA-N 3-methyl-4-[[6-[methyl-(5-methylfuran-2-yl)sulfonylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C(O)=O)C=C1C OYFJWBAHIJXBFF-UHFFFAOYSA-N 0.000 claims 1
- NYHJEMYFXBRVJO-UHFFFAOYSA-N 3-methyl-4-[[6-[propan-2-yl(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound N=1C=CSC=1S(=O)(=O)N(C(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C(O)=O)C=C1C NYHJEMYFXBRVJO-UHFFFAOYSA-N 0.000 claims 1
- RUZPDBKMOKUZCP-UHFFFAOYSA-N 4-[[2-[2-methylpropyl(pyridin-3-ylsulfonyl)amino]-5-(trifluoromethyl)phenoxy]methyl]benzoic acid Chemical compound C=1C=CN=CC=1S(=O)(=O)N(CC(C)C)C1=CC=C(C(F)(F)F)C=C1OCC1=CC=C(C(O)=O)C=C1 RUZPDBKMOKUZCP-UHFFFAOYSA-N 0.000 claims 1
- RCQXSISZWAGUHR-UHFFFAOYSA-N 4-[[2-[cyclopropylmethyl-(5-methylfuran-2-yl)sulfonylamino]-4,5-dimethylphenoxy]methyl]-3-methylbenzoic acid Chemical compound O1C(C)=CC=C1S(=O)(=O)N(C=1C(=CC(C)=C(C)C=1)OCC=1C(=CC(=CC=1)C(O)=O)C)CC1CC1 RCQXSISZWAGUHR-UHFFFAOYSA-N 0.000 claims 1
- CMJPKCGEXGCZKO-UHFFFAOYSA-N 4-[[2-[ethyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-4,5-dimethylphenoxy]methyl]-3-methylbenzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1C CMJPKCGEXGCZKO-UHFFFAOYSA-N 0.000 claims 1
- VNOZALZOQQSDDS-UHFFFAOYSA-N 4-[[3-[(4-methyl-1,3-thiazol-2-yl)sulfonyl-propan-2-ylamino]naphthalen-2-yl]oxymethyl]benzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(C(C)C)C1=CC2=CC=CC=C2C=C1OCC1=CC=C(C(O)=O)C=C1 VNOZALZOQQSDDS-UHFFFAOYSA-N 0.000 claims 1
- MVZVBWAHCUWYNJ-UHFFFAOYSA-N 4-[[3-[(5-methylfuran-2-yl)sulfonyl-(2-methylpropyl)amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxymethyl]benzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CC(C)C)C1=CC=2CCCCC=2C=C1OCC1=CC=C(C(O)=O)C=C1 MVZVBWAHCUWYNJ-UHFFFAOYSA-N 0.000 claims 1
- WOJONNAARQODFZ-UHFFFAOYSA-N 4-[[3-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]naphthalen-2-yl]oxymethyl]benzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC2=CC=CC=C2C=C1OCC1=CC=C(C(O)=O)C=C1 WOJONNAARQODFZ-UHFFFAOYSA-N 0.000 claims 1
- WKFBBMNDRWBDNW-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[(5-methylfuran-2-yl)sulfonyl-(2-methylprop-2-enyl)amino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CC(=C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1C WKFBBMNDRWBDNW-UHFFFAOYSA-N 0.000 claims 1
- QRLTVKDUVCTOHW-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[(5-methylfuran-2-yl)sulfonyl-(2-methylprop-2-enyl)amino]phenoxy]methyl]benzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CC(=C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1 QRLTVKDUVCTOHW-UHFFFAOYSA-N 0.000 claims 1
- KMCFKXRDCVFLRX-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[(5-methylfuran-2-yl)sulfonyl-(2-methylpropyl)amino]phenoxy]methyl]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1COC1=CC(C)=C(C)C=C1N(CC(C)C)S(=O)(=O)C1=CC=C(C)O1 KMCFKXRDCVFLRX-UHFFFAOYSA-N 0.000 claims 1
- YRIPINQDLRBGNN-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[(5-methylfuran-2-yl)sulfonyl-propan-2-ylamino]phenoxy]methyl]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1COC1=CC(C)=C(C)C=C1N(C(C)C)S(=O)(=O)C1=CC=C(C)O1 YRIPINQDLRBGNN-UHFFFAOYSA-N 0.000 claims 1
- ROYHRQSUMVOLSI-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[(5-methylfuran-2-yl)sulfonyl-propan-2-ylamino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(C(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1C ROYHRQSUMVOLSI-UHFFFAOYSA-N 0.000 claims 1
- ZNYJBZVQBPWQRF-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[2-methylpropyl(pyridin-3-ylsulfonyl)amino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound C=1C=CN=CC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1C ZNYJBZVQBPWQRF-UHFFFAOYSA-N 0.000 claims 1
- ZKHSUXIMLBKXQX-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[propan-2-yl(1,3-thiazol-2-ylsulfonyl)amino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound N=1C=CSC=1S(=O)(=O)N(C(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1C ZKHSUXIMLBKXQX-UHFFFAOYSA-N 0.000 claims 1
- YKXCWSJHOOEXEZ-UHFFFAOYSA-N 4-[[4-chloro-5-methyl-2-[(4-methyl-1,3-thiazol-2-yl)sulfonyl-propan-2-ylamino]phenoxy]methyl]benzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(C(C)C)C1=CC(Cl)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1 YKXCWSJHOOEXEZ-UHFFFAOYSA-N 0.000 claims 1
- QTWOGFMHMCIPTD-UHFFFAOYSA-N 4-[[4-chloro-5-methyl-2-[(5-methylfuran-2-yl)sulfonyl-propan-2-ylamino]phenoxy]methyl]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1COC1=CC(C)=C(Cl)C=C1N(C(C)C)S(=O)(=O)C1=CC=C(C)O1 QTWOGFMHMCIPTD-UHFFFAOYSA-N 0.000 claims 1
- MODYELFKQSKTDV-UHFFFAOYSA-N 4-[[4-chloro-5-methyl-2-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC(Cl)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1C MODYELFKQSKTDV-UHFFFAOYSA-N 0.000 claims 1
- LDGWZMWKZLCMJP-UHFFFAOYSA-N 4-[[5-chloro-4-methyl-2-[(5-methylfuran-2-yl)sulfonyl-(2-methylpropyl)amino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(Cl)C=C1OCC1=CC=C(C(O)=O)C=C1C LDGWZMWKZLCMJP-UHFFFAOYSA-N 0.000 claims 1
- GAWWULGEHXIHPS-UHFFFAOYSA-N 4-[[5-chloro-4-methyl-2-[(5-methylfuran-2-yl)sulfonyl-propan-2-ylamino]phenoxy]methyl]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1COC1=CC(Cl)=C(C)C=C1N(C(C)C)S(=O)(=O)C1=CC=C(C)O1 GAWWULGEHXIHPS-UHFFFAOYSA-N 0.000 claims 1
- BFXJRHWITYXYLX-UHFFFAOYSA-N 4-[[5-chloro-4-methyl-2-[2-methylpropyl(pyridin-2-ylsulfonyl)amino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound C=1C=CC=NC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(Cl)C=C1OCC1=CC=C(C(O)=O)C=C1C BFXJRHWITYXYLX-UHFFFAOYSA-N 0.000 claims 1
- KNUTZNHVAFTJCF-UHFFFAOYSA-N 4-[[5-chloro-4-methyl-2-[2-methylpropyl(pyridin-3-ylsulfonyl)amino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound C=1C=CN=CC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(Cl)C=C1OCC1=CC=C(C(O)=O)C=C1C KNUTZNHVAFTJCF-UHFFFAOYSA-N 0.000 claims 1
- UAIYSRKTKUDVIW-UHFFFAOYSA-N 4-[[5-chloro-4-methyl-2-[2-methylpropyl(pyridin-3-ylsulfonyl)amino]phenoxy]methyl]benzoic acid Chemical compound C=1C=CN=CC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(Cl)C=C1OCC1=CC=C(C(O)=O)C=C1 UAIYSRKTKUDVIW-UHFFFAOYSA-N 0.000 claims 1
- BPGMXWYTOZVRRG-UHFFFAOYSA-N 4-[[5-chloro-4-methyl-2-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenoxy]methyl]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1COC1=CC(Cl)=C(C)C=C1N(CC(C)C)S(=O)(=O)C1=NC(C)=CS1 BPGMXWYTOZVRRG-UHFFFAOYSA-N 0.000 claims 1
- RIQMXNBLDRHZKV-UHFFFAOYSA-N 4-[[6-[(4-methyl-1,3-thiazol-2-yl)sulfonyl-propan-2-ylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(C(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C(O)=O)C=C1 RIQMXNBLDRHZKV-UHFFFAOYSA-N 0.000 claims 1
- XIZKKINTXKVNNI-UHFFFAOYSA-N 4-[[6-[cyclopropylmethyl-(5-methylfuran-2-yl)sulfonylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]-3-methylbenzoic acid Chemical compound O1C(C)=CC=C1S(=O)(=O)N(C=1C(=CC=2CCCC=2C=1)OCC=1C(=CC(=CC=1)C(O)=O)C)CC1CC1 XIZKKINTXKVNNI-UHFFFAOYSA-N 0.000 claims 1
- GPGVIRYTCQAYRM-UHFFFAOYSA-N 4-[[6-[ethyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC)C1=CC=2CCCC=2C=C1OCC1=CC=C(C(O)=O)C=C1 GPGVIRYTCQAYRM-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 32
- 238000000034 method Methods 0.000 abstract description 31
- 238000002360 preparation method Methods 0.000 abstract description 27
- 239000003795 chemical substances by application Substances 0.000 abstract description 10
- 230000027455 binding Effects 0.000 abstract description 9
- 102000004169 proteins and genes Human genes 0.000 abstract description 9
- 108090000623 proteins and genes Proteins 0.000 abstract description 9
- 238000001727 in vivo Methods 0.000 abstract description 8
- 239000002221 antipyretic Substances 0.000 abstract description 4
- 229940125716 antipyretic agent Drugs 0.000 abstract description 4
- 208000026723 Urinary tract disease Diseases 0.000 abstract description 3
- 208000012931 Urologic disease Diseases 0.000 abstract description 3
- 208000014001 urinary system disease Diseases 0.000 abstract description 3
- 230000000202 analgesic effect Effects 0.000 abstract description 2
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 753
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 418
- 238000004809 thin layer chromatography Methods 0.000 description 268
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 114
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 102
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 94
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 40
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 38
- 239000000203 mixture Substances 0.000 description 33
- 239000000243 solution Substances 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 16
- 150000003461 sulfonyl halides Chemical class 0.000 description 16
- 239000012044 organic layer Substances 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 229960002986 dinoprostone Drugs 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 125000000623 heterocyclic group Chemical group 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 8
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- 210000003932 urinary bladder Anatomy 0.000 description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- AXDLQRHZUNCOIV-UHFFFAOYSA-N 4-methyl-1,3-thiazole-2-sulfonyl chloride Chemical compound CC1=CSC(S(Cl)(=O)=O)=N1 AXDLQRHZUNCOIV-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- 239000012300 argon atmosphere Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000003701 inert diluent Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- UQZVCDCIMBLVNR-TWYODKAFSA-N sulprostone Chemical compound O[C@@H]1CC(=O)[C@H](C\C=C/CCCC(=O)NS(=O)(=O)C)[C@H]1\C=C\[C@@H](O)COC1=CC=CC=C1 UQZVCDCIMBLVNR-TWYODKAFSA-N 0.000 description 5
- 229960003400 sulprostone Drugs 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 235000017803 cinnamon Nutrition 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 3
- 208000007416 Aberrant Crypt Foci Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 3
- 208000032177 Intestinal Polyps Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- XNCRUNXWPDJHGV-UHFFFAOYSA-N alpha-Methyl-cinnamic acid Chemical compound OC(=O)C(C)=CC1=CC=CC=C1 XNCRUNXWPDJHGV-UHFFFAOYSA-N 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 230000036724 intravesical pressure Effects 0.000 description 3
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000012160 loading buffer Substances 0.000 description 3
- GPSDUZXPYCFOSQ-UHFFFAOYSA-N m-toluic acid Chemical group CC1=CC=CC(C(O)=O)=C1 GPSDUZXPYCFOSQ-UHFFFAOYSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012457 nonaqueous media Substances 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 3
- 102000017953 prostanoid receptors Human genes 0.000 description 3
- 108050007059 prostanoid receptors Proteins 0.000 description 3
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 150000003852 triazoles Chemical class 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- PCSNYAOXMBRCLI-UHFFFAOYSA-N 3-[4-[[3-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]naphthalen-2-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC2=CC=CC=C2C=C1OCC1=CC=C(C=CC(O)=O)C=C1 PCSNYAOXMBRCLI-UHFFFAOYSA-N 0.000 description 2
- UNESDUKXRVPBMQ-UHFFFAOYSA-N 3-[4-[[6-[(2-hydroxy-2-methylpropyl)-(5-methylfuran-2-yl)sulfonylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound O1C(C)=CC=C1S(=O)(=O)N(CC(C)(C)O)C(C(=C1)OCC=2C=CC(C=CC(O)=O)=CC=2)=CC2=C1CCC2 UNESDUKXRVPBMQ-UHFFFAOYSA-N 0.000 description 2
- ALLLQQUASFFEKP-UHFFFAOYSA-N 3-methyl-4-[[6-[2-methylpropyl(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound N=1C=CSC=1S(=O)(=O)N(CC(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C(O)=O)C=C1C ALLLQQUASFFEKP-UHFFFAOYSA-N 0.000 description 2
- IQXOMZMFCPBOBN-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[(5-methylfuran-2-yl)sulfonyl-(2-methylpropyl)amino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1C IQXOMZMFCPBOBN-UHFFFAOYSA-N 0.000 description 2
- MXIGBNCPQASJEL-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenoxy]methyl]benzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1 MXIGBNCPQASJEL-UHFFFAOYSA-N 0.000 description 2
- QMHIMXFNBOYPND-UHFFFAOYSA-N 4-methylthiazole Chemical compound CC1=CSC=N1 QMHIMXFNBOYPND-UHFFFAOYSA-N 0.000 description 2
- 206010005052 Bladder irritation Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 2
- 206010029279 Neurogenic bladder Diseases 0.000 description 2
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010051482 Prostatomegaly Diseases 0.000 description 2
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 2
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- AYAOGOFNWOAMBJ-UHFFFAOYSA-N methyl 4-[(2-amino-4,5-dimethylphenoxy)methyl]-3-methylbenzoate Chemical compound CC1=CC(C(=O)OC)=CC=C1COC1=CC(C)=C(C)C=C1N AYAOGOFNWOAMBJ-UHFFFAOYSA-N 0.000 description 2
- AOKCRDODZVJVAF-UHFFFAOYSA-N methyl 4-[(4,5-dimethyl-2-nitrophenoxy)methyl]-3-methylbenzoate Chemical compound CC1=CC(C(=O)OC)=CC=C1COC1=CC(C)=C(C)C=C1[N+]([O-])=O AOKCRDODZVJVAF-UHFFFAOYSA-N 0.000 description 2
- UECBIIIPOXTTOK-UHFFFAOYSA-N methyl 4-[[4,5-dimethyl-2-[(5-methylfuran-2-yl)sulfonylamino]phenoxy]methyl]-3-methylbenzoate Chemical compound CC1=CC(C(=O)OC)=CC=C1COC1=CC(C)=C(C)C=C1NS(=O)(=O)C1=CC=C(C)O1 UECBIIIPOXTTOK-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- SFJGCXYXEFWEBK-UHFFFAOYSA-N oxazepine Chemical compound O1C=CC=CC=N1 SFJGCXYXEFWEBK-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- AEBWATHAIVJLTA-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropentalene Chemical compound C1CCC2CCCC21 AEBWATHAIVJLTA-UHFFFAOYSA-N 0.000 description 1
- PIHAUZGWAXLKCA-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydro-1,8-naphthyridine Chemical compound N1CCCC2CCCNC21 PIHAUZGWAXLKCA-UHFFFAOYSA-N 0.000 description 1
- NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical compound C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 description 1
- AEBKORRYDYKJLT-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydrophthalazine Chemical compound C1NNCC2CCCCC21 AEBKORRYDYKJLT-UHFFFAOYSA-N 0.000 description 1
- HZNXIPDYYIWDNM-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinazoline Chemical compound N1CNCC2CCCCC21 HZNXIPDYYIWDNM-UHFFFAOYSA-N 0.000 description 1
- POTIYWUALSJREP-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline Chemical compound N1CCCC2CCCCC21 POTIYWUALSJREP-UHFFFAOYSA-N 0.000 description 1
- MDEXMBGPIZUUBI-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoxaline Chemical compound N1CCNC2CCCCC21 MDEXMBGPIZUUBI-UHFFFAOYSA-N 0.000 description 1
- ZCZVGQCBSJLDDS-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridine Chemical compound C1=CC=C2CCCNC2=N1 ZCZVGQCBSJLDDS-UHFFFAOYSA-N 0.000 description 1
- WXRSSOIHEAVYLL-UHFFFAOYSA-N 1,2,3,4-tetrahydrocinnoline Chemical compound C1=CC=C2NNCCC2=C1 WXRSSOIHEAVYLL-UHFFFAOYSA-N 0.000 description 1
- STIWEDICJHIFJT-UHFFFAOYSA-N 1,2,3,4-tetrahydrophthalazine Chemical compound C1=CC=C2CNNCC2=C1 STIWEDICJHIFJT-UHFFFAOYSA-N 0.000 description 1
- JQIZHNLEFQMDCQ-UHFFFAOYSA-N 1,2,3,4-tetrahydropyridazine Chemical compound C1CC=CNN1 JQIZHNLEFQMDCQ-UHFFFAOYSA-N 0.000 description 1
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical compound C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 description 1
- PKORYTIUMAOPED-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinazoline Chemical compound C1=CC=C2NCNCC2=C1 PKORYTIUMAOPED-UHFFFAOYSA-N 0.000 description 1
- HORKYAIEVBUXGM-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoxaline Chemical compound C1=CC=C2NCCNC2=C1 HORKYAIEVBUXGM-UHFFFAOYSA-N 0.000 description 1
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 1
- UUZJJNBYJDFQHL-UHFFFAOYSA-N 1,2,3-triazolidine Chemical compound C1CNNN1 UUZJJNBYJDFQHL-UHFFFAOYSA-N 0.000 description 1
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- XEYKWYIXHMEQGM-UHFFFAOYSA-N 1,2-dihydro-1,8-naphthyridine Chemical compound C1=CC=C2C=CCNC2=N1 XEYKWYIXHMEQGM-UHFFFAOYSA-N 0.000 description 1
- QRDNXAYNXUKMOO-UHFFFAOYSA-N 1,2-dihydrocinnoline Chemical compound C1=CC=C2C=CNNC2=C1 QRDNXAYNXUKMOO-UHFFFAOYSA-N 0.000 description 1
- IOEPOEDBBPRAEI-UHFFFAOYSA-N 1,2-dihydroisoquinoline Chemical compound C1=CC=C2CNC=CC2=C1 IOEPOEDBBPRAEI-UHFFFAOYSA-N 0.000 description 1
- IRFSXVIRXMYULF-UHFFFAOYSA-N 1,2-dihydroquinoline Chemical compound C1=CC=C2C=CCNC2=C1 IRFSXVIRXMYULF-UHFFFAOYSA-N 0.000 description 1
- XXBQLHATYQHJQC-UHFFFAOYSA-N 1,2-dihydroquinoxaline Chemical compound C1=CC=C2N=CCNC2=C1 XXBQLHATYQHJQC-UHFFFAOYSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 1
- HGQBCKVFVUCIML-UHFFFAOYSA-N 1,3,3a,4,5,6,7,7a-octahydro-2-benzofuran Chemical compound C1CCCC2COCC21 HGQBCKVFVUCIML-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- BTUGGGLMQBJCBN-UHFFFAOYSA-N 1-iodo-2-methylpropane Chemical compound CC(C)CI BTUGGGLMQBJCBN-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 description 1
- OGHHATWOTABYKY-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1,3-benzothiazole Chemical compound C1CCCC2SCNC21 OGHHATWOTABYKY-UHFFFAOYSA-N 0.000 description 1
- DNZWAKVIOXCEHH-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1-benzofuran Chemical compound C1CCCC2OCCC21 DNZWAKVIOXCEHH-UHFFFAOYSA-N 0.000 description 1
- NZOBCFVNZQYCCZ-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1-benzothiophene Chemical compound C1CCCC2SCCC21 NZOBCFVNZQYCCZ-UHFFFAOYSA-N 0.000 description 1
- MDNGXAFGRWQHNZ-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-benzimidazole Chemical compound C1CCCC2NCNC21 MDNGXAFGRWQHNZ-UHFFFAOYSA-N 0.000 description 1
- LVJPACZOEKXFAY-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-indazole Chemical compound C1CCCC2CNNC21 LVJPACZOEKXFAY-UHFFFAOYSA-N 0.000 description 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical compound C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 description 1
- YTQQIHUQLOZOJI-UHFFFAOYSA-N 2,3-dihydro-1,2-thiazole Chemical compound C1NSC=C1 YTQQIHUQLOZOJI-UHFFFAOYSA-N 0.000 description 1
- RZQQXRVPPOOCQR-UHFFFAOYSA-N 2,3-dihydro-1,3,4-oxadiazole Chemical compound C1NN=CO1 RZQQXRVPPOOCQR-UHFFFAOYSA-N 0.000 description 1
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 description 1
- OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 description 1
- YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical compound C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 description 1
- QDKGOMZIPXGDDJ-UHFFFAOYSA-N 2,3-dihydro-1h-indazole Chemical compound C1=CC=C2CNNC2=C1 QDKGOMZIPXGDDJ-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- PZJFUNZDCRKXPZ-UHFFFAOYSA-N 2,5-dihydro-1h-tetrazole Chemical compound C1NNN=N1 PZJFUNZDCRKXPZ-UHFFFAOYSA-N 0.000 description 1
- CPEIKVFFPXMHQI-UHFFFAOYSA-N 2-(2,3-dihydro-1h-inden-5-yloxymethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1COC1=CC=C(CCC2)C2=C1 CPEIKVFFPXMHQI-UHFFFAOYSA-N 0.000 description 1
- YKNORODREYVARM-UHFFFAOYSA-N 2-(phenoxymethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1COC1=CC=CC=C1 YKNORODREYVARM-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- LYTMVABTDYMBQK-UHFFFAOYSA-N 2-benzothiophene Chemical compound C1=CC=CC2=CSC=C21 LYTMVABTDYMBQK-UHFFFAOYSA-N 0.000 description 1
- RTGLJCSUKOLTEM-UHFFFAOYSA-N 2-ethylhexyl carbonochloridate Chemical compound CCCCC(CC)COC(Cl)=O RTGLJCSUKOLTEM-UHFFFAOYSA-N 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- UMZCLZPXPCNKML-UHFFFAOYSA-N 2h-imidazo[4,5-d][1,3]thiazole Chemical compound C1=NC2=NCSC2=N1 UMZCLZPXPCNKML-UHFFFAOYSA-N 0.000 description 1
- QMEQBOSUJUOXMX-UHFFFAOYSA-N 2h-oxadiazine Chemical compound N1OC=CC=N1 QMEQBOSUJUOXMX-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 1
- ATVJJNGVPSKBGO-UHFFFAOYSA-N 3,4-dihydro-2h-thiopyran Chemical compound C1CSC=CC1 ATVJJNGVPSKBGO-UHFFFAOYSA-N 0.000 description 1
- UWMYBJNFGCWPEB-UHFFFAOYSA-N 3-[3-methyl-4-[[2-[2-methylpropyl(pyridin-2-ylsulfonyl)amino]-5-(trifluoromethyl)phenoxy]methyl]phenyl]prop-2-enoic acid Chemical compound C=1C=CC=NC=1S(=O)(=O)N(CC(C)C)C1=CC=C(C(F)(F)F)C=C1OCC1=CC=C(C=CC(O)=O)C=C1C UWMYBJNFGCWPEB-UHFFFAOYSA-N 0.000 description 1
- MHSMCCJZDRVYJK-UHFFFAOYSA-N 3-[4-[[2-[2-methylpropyl(1,3-thiazol-2-ylsulfonyl)amino]-5-(trifluoromethyl)phenoxy]methyl]phenyl]prop-2-enoic acid Chemical compound N=1C=CSC=1S(=O)(=O)N(CC(C)C)C1=CC=C(C(F)(F)F)C=C1OCC1=CC=C(C=CC(O)=O)C=C1 MHSMCCJZDRVYJK-UHFFFAOYSA-N 0.000 description 1
- VSUFEVORYFSLMG-UHFFFAOYSA-N 3-[4-[[4,5-dimethyl-2-[(5-methylfuran-2-yl)sulfonyl-propan-2-ylamino]phenoxy]methyl]phenyl]prop-2-enoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(C(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C=CC(O)=O)C=C1 VSUFEVORYFSLMG-UHFFFAOYSA-N 0.000 description 1
- STKIKAIFIBNEQG-UHFFFAOYSA-N 3-[4-[[4,5-dimethyl-2-[2-methylpropyl(1,3-thiazol-2-ylsulfonyl)amino]phenoxy]methyl]-3-methylphenyl]prop-2-enoic acid Chemical compound N=1C=CSC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C=CC(O)=O)C=C1C STKIKAIFIBNEQG-UHFFFAOYSA-N 0.000 description 1
- QEHNCKUAVGHHRV-UHFFFAOYSA-N 3-[4-[[4,5-dimethyl-2-[2-methylpropyl(1,3-thiazol-2-ylsulfonyl)amino]phenoxy]methyl]phenyl]prop-2-enoic acid Chemical compound N=1C=CSC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C=CC(O)=O)C=C1 QEHNCKUAVGHHRV-UHFFFAOYSA-N 0.000 description 1
- WEAQEKIPSVHJCL-UHFFFAOYSA-N 3-[4-[[5-chloro-4-methyl-2-[(5-methylfuran-2-yl)sulfonyl-propan-2-ylamino]phenoxy]methyl]phenyl]prop-2-enoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(C(C)C)C1=CC(C)=C(Cl)C=C1OCC1=CC=C(C=CC(O)=O)C=C1 WEAQEKIPSVHJCL-UHFFFAOYSA-N 0.000 description 1
- WXPCMBPGHJNNEX-UHFFFAOYSA-N 3-[4-[[5-chloro-4-methyl-2-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenoxy]methyl]-3-methylphenyl]prop-2-enoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(Cl)C=C1OCC1=CC=C(C=CC(O)=O)C=C1C WXPCMBPGHJNNEX-UHFFFAOYSA-N 0.000 description 1
- CIGNWBKXPVGMBM-UHFFFAOYSA-N 3-[4-[[6-[(2-hydroxy-2-methylpropyl)-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]-3-methylphenyl]prop-2-enoic acid Chemical compound CC1=CSC(S(=O)(=O)N(CC(C)(C)O)C=2C(=CC=3CCCC=3C=2)OCC=2C(=CC(C=CC(O)=O)=CC=2)C)=N1 CIGNWBKXPVGMBM-UHFFFAOYSA-N 0.000 description 1
- PMSJJQQHDLYFCS-UHFFFAOYSA-N 3-[4-[[6-[(5-methylfuran-2-yl)sulfonyl-(2-methylpropyl)amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CC(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C=CC(O)=O)C=C1 PMSJJQQHDLYFCS-UHFFFAOYSA-N 0.000 description 1
- RLZVGBQZOQJOJO-UHFFFAOYSA-N 3-[4-[[6-[(5-methylfuran-2-yl)sulfonyl-prop-2-enylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound O1C(C)=CC=C1S(=O)(=O)N(CC=C)C(C(=C1)OCC=2C=CC(C=CC(O)=O)=CC=2)=CC2=C1CCC2 RLZVGBQZOQJOJO-UHFFFAOYSA-N 0.000 description 1
- SLXDFDMNIPOHEH-UHFFFAOYSA-N 3-[4-[[6-[(5-methylfuran-2-yl)sulfonyl-propylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CCC)C1=CC=2CCCC=2C=C1OCC1=CC=C(C=CC(O)=O)C=C1 SLXDFDMNIPOHEH-UHFFFAOYSA-N 0.000 description 1
- GWTLKFFSJHPTPV-UHFFFAOYSA-N 3-[4-[[6-[2-methylpropyl(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoic acid Chemical compound N=1C=CSC=1S(=O)(=O)N(CC(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C=CC(O)=O)C=C1 GWTLKFFSJHPTPV-UHFFFAOYSA-N 0.000 description 1
- OWVGAPHELZCHQD-UHFFFAOYSA-N 3-chloro-4-[[4,5-dimethyl-2-[(4-methyl-1,3-thiazol-2-yl)sulfonyl-propan-2-ylamino]phenoxy]methyl]benzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(C(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1Cl OWVGAPHELZCHQD-UHFFFAOYSA-N 0.000 description 1
- ABDUMZDIPGTENO-UHFFFAOYSA-N 3-chloro-4-[[4,5-dimethyl-2-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenoxy]methyl]benzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1Cl ABDUMZDIPGTENO-UHFFFAOYSA-N 0.000 description 1
- BJSOJFPJSSHZQY-UHFFFAOYSA-N 3-chloro-4-[[5-chloro-4-methyl-2-[(5-methylfuran-2-yl)sulfonyl-(2-methylpropyl)amino]phenoxy]methyl]benzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(Cl)C=C1OCC1=CC=C(C(O)=O)C=C1Cl BJSOJFPJSSHZQY-UHFFFAOYSA-N 0.000 description 1
- GPYVZIKPXQBVAP-UHFFFAOYSA-N 3-methoxy-4-[[2-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]benzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1COC1=CC(C(F)(F)F)=CC=C1N(CC(C)C)S(=O)(=O)C1=NC(C)=CS1 GPYVZIKPXQBVAP-UHFFFAOYSA-N 0.000 description 1
- FEIOOBKESWXQMF-UHFFFAOYSA-N 3-methyl-4-[[3-[(4-methyl-1,3-thiazol-2-yl)sulfonyl-propan-2-ylamino]naphthalen-2-yl]oxymethyl]benzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(C(C)C)C1=CC2=CC=CC=C2C=C1OCC1=CC=C(C(O)=O)C=C1C FEIOOBKESWXQMF-UHFFFAOYSA-N 0.000 description 1
- ZUZMDJJNXMFVNU-UHFFFAOYSA-N 3-methyl-4-[[3-[(5-methylfuran-2-yl)sulfonyl-propan-2-ylamino]naphthalen-2-yl]oxymethyl]benzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(C(C)C)C1=CC2=CC=CC=C2C=C1OCC1=CC=C(C(O)=O)C=C1C ZUZMDJJNXMFVNU-UHFFFAOYSA-N 0.000 description 1
- SFKDOLFWLKZNGS-UHFFFAOYSA-N 3-methyl-4-[[6-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C(O)=O)C=C1C SFKDOLFWLKZNGS-UHFFFAOYSA-N 0.000 description 1
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 1
- KGDIYDUZVHFMHQ-UHFFFAOYSA-N 4,5-dimethyl-2-nitrophenol Chemical compound CC1=CC(O)=C([N+]([O-])=O)C=C1C KGDIYDUZVHFMHQ-UHFFFAOYSA-N 0.000 description 1
- GXLPOJIULXFCOP-UHFFFAOYSA-N 4-[[2-[(2-hydroxy-2-methylpropyl)-(5-methylfuran-2-yl)sulfonylamino]-4,5-dimethylphenoxy]methyl]benzoic acid Chemical compound O1C(C)=CC=C1S(=O)(=O)N(CC(C)(C)O)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1 GXLPOJIULXFCOP-UHFFFAOYSA-N 0.000 description 1
- LKVLUKLKSMVALG-UHFFFAOYSA-N 4-[[2-[cyclopropylmethyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-4,5-dimethylphenoxy]methyl]-3-methylbenzoic acid Chemical compound CC1=CSC(S(=O)(=O)N(CC2CC2)C=2C(=CC(C)=C(C)C=2)OCC=2C(=CC(=CC=2)C(O)=O)C)=N1 LKVLUKLKSMVALG-UHFFFAOYSA-N 0.000 description 1
- JXJGFXTVCBNZBV-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[(5-methylfuran-2-yl)sulfonyl-propan-2-ylamino]phenoxy]methyl]benzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(C(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1 JXJGFXTVCBNZBV-UHFFFAOYSA-N 0.000 description 1
- UGHUWTGFOHOVBR-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[(5-methylfuran-2-yl)sulfonyl-propylamino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(CCC)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1C UGHUWTGFOHOVBR-UHFFFAOYSA-N 0.000 description 1
- ABMIFRCKSUXDRL-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[2-methylpropyl(1,3-thiazol-2-ylsulfonyl)amino]phenoxy]methyl]-3-methylbenzoic acid Chemical compound N=1C=CSC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1C ABMIFRCKSUXDRL-UHFFFAOYSA-N 0.000 description 1
- DFIXLAXWAIPXQY-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[2-methylpropyl(1,3-thiazol-2-ylsulfonyl)amino]phenoxy]methyl]benzoic acid Chemical compound N=1C=CSC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1 DFIXLAXWAIPXQY-UHFFFAOYSA-N 0.000 description 1
- DGANNYNYWRMUGD-UHFFFAOYSA-N 4-[[4,5-dimethyl-2-[methyl-(5-methylfuran-2-yl)sulfonylamino]phenoxy]methyl]benzoic acid Chemical compound C=1C=C(C)OC=1S(=O)(=O)N(C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C(O)=O)C=C1 DGANNYNYWRMUGD-UHFFFAOYSA-N 0.000 description 1
- ZXNAMCPUBJESFS-UHFFFAOYSA-N 4-[[6-[2-methylprop-2-enyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoic acid Chemical compound N=1C(C)=CSC=1S(=O)(=O)N(CC(=C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C(O)=O)C=C1 ZXNAMCPUBJESFS-UHFFFAOYSA-N 0.000 description 1
- YNNRJWKCQVUBDZ-UHFFFAOYSA-N 5-methylfuran-2-sulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)O1 YNNRJWKCQVUBDZ-UHFFFAOYSA-N 0.000 description 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 239000005964 Acibenzolar-S-methyl Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- NTURVSFTOYPGON-UHFFFAOYSA-N Dihydroquinazoline Chemical compound C1=CC=C2C=NCNC2=C1 NTURVSFTOYPGON-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- IKYCZSUNGFRBJS-UHFFFAOYSA-N Euphorbia factor RL9 = U(1) = Resiniferatoxin Natural products COC1=CC(O)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 IKYCZSUNGFRBJS-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101000929796 Mus musculus Acyl-CoA-binding protein Proteins 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 102000004129 N-Type Calcium Channels Human genes 0.000 description 1
- 108090000699 N-Type Calcium Channels Proteins 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 102000048266 Nociceptin Human genes 0.000 description 1
- 108090000622 Nociceptin Proteins 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229940127315 Potassium Channel Openers Drugs 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- JZFICWYCTCCINF-UHFFFAOYSA-N Thiadiazin Chemical compound S=C1SC(C)NC(C)N1CCN1C(=S)SC(C)NC1C JZFICWYCTCCINF-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- PSPAOLHIZTZESO-UHFFFAOYSA-N [Na]C(=O)C1=CC=CC=C1 Chemical class [Na]C(=O)C1=CC=CC=C1 PSPAOLHIZTZESO-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940124538 antidiuretic agent Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 229940114078 arachidonate Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- MXMZCLLIUQEKSN-UHFFFAOYSA-N benzimidazoline Chemical compound C1=CC=C2NCNC2=C1 MXMZCLLIUQEKSN-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- KMDBQYUGIRWELS-UHFFFAOYSA-N benzotriazol-1-yl 4-methyl-1,3-thiazole-2-sulfonate Chemical compound CC1=CSC(S(=O)(=O)ON2C3=CC=CC=C3N=N2)=N1 KMDBQYUGIRWELS-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Substances OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- CHRHZFQUDFAQEQ-UHFFFAOYSA-L calcium;2-hydroxyacetate Chemical compound [Ca+2].OCC([O-])=O.OCC([O-])=O CHRHZFQUDFAQEQ-UHFFFAOYSA-L 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000037020 contractile activity Effects 0.000 description 1
- 239000000431 corpus luteum hormone Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical group C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- OAMZXMDZZWGPMH-UHFFFAOYSA-N ethyl acetate;toluene Chemical compound CCOC(C)=O.CC1=CC=CC=C1 OAMZXMDZZWGPMH-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- BNRNAKTVFSZAFA-UHFFFAOYSA-N hydrindane Chemical compound C1CCCC2CCCC21 BNRNAKTVFSZAFA-UHFFFAOYSA-N 0.000 description 1
- ARRNBPCNZJXHRJ-UHFFFAOYSA-M hydron;tetrabutylazanium;phosphate Chemical compound OP(O)([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC ARRNBPCNZJXHRJ-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- PMGPSOBNHFIPAR-UHFFFAOYSA-N methyl 3-methyl-4-(methylsulfonyloxymethyl)benzoate Chemical compound COC(=O)C1=CC=C(COS(C)(=O)=O)C(C)=C1 PMGPSOBNHFIPAR-UHFFFAOYSA-N 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000036453 micturition reflex Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- MDNASDRVZCHFNG-UHFFFAOYSA-N n-(2-methylpropyl)-n-[2-[[4-(2h-tetrazol-5-yl)phenyl]methoxy]-4-(trifluoromethyl)phenyl]pyridine-2-sulfonamide Chemical compound C=1C=CC=NC=1S(=O)(=O)N(CC(C)C)C1=CC=C(C(F)(F)F)C=C1OCC(C=C1)=CC=C1C=1N=NNN=1 MDNASDRVZCHFNG-UHFFFAOYSA-N 0.000 description 1
- FZYUIJASXBXSOZ-UHFFFAOYSA-N n-(2-methylpropyl)pyridine-2-sulfonamide Chemical compound CC(C)CNS(=O)(=O)C1=CC=CC=N1 FZYUIJASXBXSOZ-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- PULGYDLMFSFVBL-SMFNREODSA-N nociceptin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- RYDICHIKLKVOEJ-UHFFFAOYSA-N oxadiazepine Chemical compound O1C=CC=CN=N1 RYDICHIKLKVOEJ-UHFFFAOYSA-N 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- JXIFWVSAFQDTKN-UHFFFAOYSA-N oxadiazolidine Chemical compound C1CONN1.C1CONN1 JXIFWVSAFQDTKN-UHFFFAOYSA-N 0.000 description 1
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 1
- GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- SFLGSKRGOWRGBR-UHFFFAOYSA-N phthalane Chemical compound C1=CC=C2COCC2=C1 SFLGSKRGOWRGBR-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- ZAKWLULNQIXBNT-UHFFFAOYSA-M potassium;3-[4-[[6-[(4-methyl-1,3-thiazol-2-yl)sulfonyl-propan-2-ylamino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]phenyl]prop-2-enoate Chemical compound [K+].N=1C(C)=CSC=1S(=O)(=O)N(C(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C=CC([O-])=O)C=C1 ZAKWLULNQIXBNT-UHFFFAOYSA-M 0.000 description 1
- LDFSIKKPLWOEMQ-UHFFFAOYSA-M potassium;4-[[4,5-dimethyl-2-[2-methylpropyl(1,3-thiazol-2-ylsulfonyl)amino]phenoxy]methyl]benzoate Chemical compound [K+].N=1C=CSC=1S(=O)(=O)N(CC(C)C)C1=CC(C)=C(C)C=C1OCC1=CC=C(C([O-])=O)C=C1 LDFSIKKPLWOEMQ-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- DSDNAKHZNJAGHN-UHFFFAOYSA-N resinferatoxin Natural products C1=C(O)C(OC)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-UHFFFAOYSA-N 0.000 description 1
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 description 1
- 229940073454 resiniferatoxin Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- DXIHILNWDOYYCH-UHDJGPCESA-M sodium;(e)-3-phenylprop-2-enoate Chemical compound [Na+].[O-]C(=O)\C=C\C1=CC=CC=C1 DXIHILNWDOYYCH-UHDJGPCESA-M 0.000 description 1
- ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 1
- HIHFEVWQBIGCIR-UHFFFAOYSA-M sodium;2-methylbenzoate Chemical compound [Na+].CC1=CC=CC=C1C([O-])=O HIHFEVWQBIGCIR-UHFFFAOYSA-M 0.000 description 1
- HKWRZSXEWPTLQS-UHFFFAOYSA-M sodium;4-[[6-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-2,3-dihydro-1h-inden-5-yl]oxymethyl]benzoate Chemical compound [Na+].N=1C(C)=CSC=1S(=O)(=O)N(CC(C)C)C1=CC=2CCCC=2C=C1OCC1=CC=C(C([O-])=O)C=C1 HKWRZSXEWPTLQS-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- BXVYJQULAWJPSR-UHFFFAOYSA-N thiadiazepine Chemical compound S1C=CC=CN=N1 BXVYJQULAWJPSR-UHFFFAOYSA-N 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
- BISQTCXKVNCDDA-UHFFFAOYSA-N thiepine Chemical compound S1C=CC=CC=C1 BISQTCXKVNCDDA-UHFFFAOYSA-N 0.000 description 1
- 125000000034 thioazolyl group Chemical group 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Furan Compounds (AREA)
Description
BESKRIVELSE
TEKNISK OMRÅDE
Den foreliggende oppfinnelse vedrører en N-fenylarylsulfonylamidforbindelse.
Mer detaljert vedrører den foreliggende oppfinnelse
(1) en N-fenylarylsulfonylamidforbindelse med formel (I)
hvori alle symboler har de samme betydninger som definert i det etterfølgende,
(2) en prostaglandin E2 reseptor (EPi) antagonist som omfatter forbindelsen som en
aktiv bestanddel, og
(3) et farmasøytisk preparat som omfatter forbindelsen som en aktiv bestanddel.
BAKGRUNNSTEKNIKK
Prostaglandin E2 (forkortet som PGE2) har vært kjent som en metabolitt i arakidonat-kaskaden. Det har også vært kjent at PGE2 besitter en cyto-beskyttende aktivitet, en uterin-kontraktiv aktivitet, en smerte-induserende effekt, en effekt som fremmer digestiv peristaltikk, en oppvåkningseffekt, en under-trykkende effekt på magesyre-sekresjon, en hypotensiv effekt, en diuretisk aktivitet osv.
I en nylig undersøkelse ble det funnet at en PGE2 reseptor er inndelt i noen subtyper som besitter forskjellige fysiske roller i forhold til hverandre. For tiden er det kjent fire reseptor-substyper og de betegnes henholdsvis EP], EP2, EP3 og EP4 (Negishi M. et al., J. Lipid Mediators Cell Signaling, 12, 379-391 (1995)).
PGE2 besitter en rekke forskjellige fysiologiske aktiviteter, slik at den uønskede virkningen annet enn den som er tilsiktet er vist som bivirkning. Forskning med hensyn på rollen til hver reseptor-subtype og undersøkelse av forbindelsen som kun utviser en effekt på den spesifikke subtype er blitt utført for å overvinne et slikt problem.
Blanl disse subtypene har det vært kjent at EPi subtype vedrører induksjon av smerte, pyreksi (induksjonsfeber) og diurese (ref. Br. J. Pharmacol., 112, 735-740 (1994); European J. Pharmacol., 152 273-279 (1988); Gen Pharmacol., Sep 1992, 23(5) 805-809). Forbindelser som antagoniserer denne reseptoren er derfor ansett for å være anvendbare for analgetika, som antipyretiske midler og som midler for behandling av pollakisuri (hyppig urinering).
Det har også vært kjent at EPi antagonister besitter en undertrykkende effekt på aberrante kryptfoci og dannelse av intestinale polypper, og at de indikerer en effektiv anti-tumoraktivitet (ref. WO00/69465).
Etter at legemidler er absorbert i kroppen, vandrer de hovedsakelig inn i blod-strømmen. Deretter transporteres de i blodet og avleveres til målorganer. Til sist utøver de sin potens. Noen legemidler utøver imidlertid ikke sin potens fordi de forener seg med noen proteiner, som er inneholdt i blod som næringssubstanser. Mens noen forbindelser er effektive i in vitro forsøk, kan det ofte vise seg at de ikke er effektive i in vivo forsøk. Det har også vært velkjent at der ikke er et spesifikt struktur-aktivitet-forhold for binding mellom legemidler og proteiner, og at det er svært vanskelig å finne ut ordinaliteten.
De foreliggende oppfinnere fant en anvendbar forbindelse som er en EP] antagonist, og innleverte en patentsøknad. I beskrivelsen til WO98/27053 (EP947500), er det angitt at en sulfonamidforbindelse med formel (A)
hvori gruppen
er hver uavhengig C5.15 karbocyklisk ring etc; Z<1A> er -COR<1> etc,; Z<2A> er hydrogen etc; R1A erhydroksy etc; Z<3A> er en enkeltbinding etc; Z<4A> er S02 etc; Z<5A> er 5-til 7- leddet heterocyklisk ring inneholdende ett eller to oksygen-, svovel- eller nitrogenatomer, som kan være substituert med 1 til 5 R<5A> etc; R<5A> er (hvis to eller flere R<3Å>, hver uavhengig) hydrogen, Ci_6 alkyl, etc; R<2A> er Z<7A->Ci_4 alkylen etc;
Z7<A> er oksygen etc; R<3A> er trifluormetyl etc; R<4A> er Ci.g alkyl etc; n<A>ogt<A>erhver uavhengig 1 til 4 (som utdrag),
binder til en PGE2 reseptor, spesielt EPj reseptoren, til å utvise en agonistisk eller en antagonistisk aktivitet. Beskrivelsen angir at forbindelsen som har den antagonistiske aktiviteten er anvendbar for forebygging av abort, som et analgetikum, som et anti-diaremiddel, som et hypnagogisk middel og for behandling av pollakisuri (hyppig urinering), mens den som har en agonistisk aktivitet er anvendbar for abort, som en abstergent, som et anti-ulcusmiddel, som et anti-gastrittmiddel, som et anti-hyptensivt middel, som et diuretisk middel.
I denne patentsøknaden er for eksempel de følgende forbindelser spesifikt angitt.
(1) Eksempel 18(93)
(2) Eksempel 18(113) (3) Eksempel 18(125) (4) Eksempel 18(121) (5) Eksempel 18(126) (6) Eksempel 18(59) (7) Eksempel 18(124) (8) Eksempel 18(94) (9) Eksempel 21(13) (10) Eksempel 21(14)
I prosessen med forskning rundt disse forbindelsene, ble det vist at disse forbindelsene har noen problemer ved at de er ømfintlige overfor innvirkningen av proteinbindingen og de ikke har en tilfredsstillende in vivo aktivitet.
OMTALE AV OPPFINNELSEN
Som et resultat av inngående undersøkelser for å finne de forbindelser som selektivt binder til EP| subtype-reseptor og har en tilfredsstillende in vivo aktivitet på grunn av at de er mindre påvirket av proteinbinding, har de foreliggende oppfinnere funnet at bare N-fenylarylsulfonamidforbindelsen med formel (I) hai- en svært sterk in vivo aktivitet og fullførte den foreliggende oppfinnelse.
Et mellomprodukt med formel (II)
hvori alle symboler har de samme betydningene som definert i det etterfølgende, kan anvendes for fremstilling av forbindelsen med formel (I).
Forskjellige forbindelser er angitt i beskrivelsen til WO 98/27053, som det er vist til ovenfor, men ingen forbindelser i henhold til den foreliggende forbindelse er omhandlet og der er hverken noen beskrivelse eller forslag hva angår de oven-nevnte problemer eller løsningsmetoder.
Den foreliggende oppfinnelse vedrører en N-fenylarylsulfonylamidforbindelse, kjennetegnet ved at den har formel (I)
hvori R<1> er COOH, 5-tetrazolyl, 5-okso-l,2,4-oksadiazolyl, CH2OH eller 5-okso-1,2,4-tiadiazolyl,
R<2> er hydrogen, metyl, metoksy eller klor,
R og R er en kombinasjon av (1) metyl og metyl, (2) metyl og klor, (3) klor og metyl, eller (4) trifluormetyl og hydrogen; eller R3 og R<4> er tatt sammen med karbonet hvortil R<3> og R<4> er bundet til å danne (5) cyklopenten, (6) cykloheksen eller (7) benzenring,
R<5> er isopropyl, isobutyl, 2-metyl-2-propenyl, cyklopropylmetyl, metyl, etyl, propyl, 2-propenyl eller 2-hydroksy-2-metylpropyl,
Ar er tiazolyl eventuelt substituert med metyl, pyridyl eller 5-metyl-2-furyl; og n er null eller 1, og når R<1> er 5-tetrazolyl, 5-okso-l,2,4-oksadiazolyl eller 5-okso-1,2,4-tiadiazolyl, er n null,
en alkylester derav eller et ikke-toksisk salt derav.
Den foreliggende oppfinnelse vedrører også en antagonist av EPi reseptor, kjennetegnet ved at den er en prostaglandin E2 reseptor-subtype, omfattende N-fenylarylsulfonylamidforbindelsen med formel (I) i samsvar med oppfinnelsen, en ester derav eller et ikke-toksisk salt derav som en aktiv bestanddel.
Den foreliggende oppfinnelse vedrører videre et farmasøytisk preparat for forebygging og/eller behandling av algi, pyreksi (induksjonsfeber), pollakisuri (hyppig urinering), akraturese (urininkontinens), sykdomssyndrom i nedre urinveier og cancer, kjennetegnet ved at det omfatter forbindelsen med formel (I) i samsvar med oppfinnelsen som en aktiv bestanddel.
De foreliggende oppfinnere syntetiserte nesten alle kombinasjoner av forbindelsene med formel (I) i henhold til den foreliggende oppfinnelse, og bekreftet deres aktiviteter. Og alle forbindelsene derav er foretrukne.
Mer foretrukket forbindelse eller mer foretrukne forbindelser har Ar av 5-metyl-2-furyl, 2-tiazolyl, 5-metyl-2-tiazolyl, 2-pyridyl og 3-pyridyl.
Foretrukne forbindelser er spesifikt: 4-[2-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-5-trifluormetylfenoksy-metyljkanelsyre,
4-[2-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)amino]-5-trifluormetylfenoksymetyljbenzosyre,
4-[2-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-5-trifluormetylfenoksymetyljbenzosyre,
4- [2- [N-isobutyl-N-(5 -metyl-2-furylsulfony l)amino] -4-klor- 5 - metylfenoksymetyljbenzosyre,
4-[2-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)amino]-4,5-dimetylfenoksy-metyl]benzosyre,
4-[2-|^-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-4,5-dimetyl fen oksy metyl]-benzosyre,
3-metyl-4-[2-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-4-metyl-5-klorfenoksymetyljbenzosyre,
3-metyl-4-[2-P^-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-4-klor-5-metyl-fenoksy metyl] benzosyre,
3-klor-4-[2-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-4-metyl-5-klor-fenoksymetyl]benzosyre,
3-klor-4-[2-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)aiTiino]-4-me1yl-klorfenoksymetyl]benzosyre,
3-metoksy-4-[2-[N-isopropyl-N-(5-metyI-2-furyIsulfonyI)amino]-4-metyl-5-klorfenoksymetyljbenzosyre,
3-metyl-4-[2-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-4,5-dimetyl-fenoksymetyl]benzosyre,
3-metoksy-4-[2-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)amino]-4,5-dimetylfenoksymetyljbenzosyre,
3-metoksy-4-[2-|^-isobutyl-N-(5-metyl-2-mrylsulfonyl)amino]-4,5-dimetylfenoksymetyl]benzosyre,
3-metoksy-4-[2-|^-isopropyl-N-(5-me1yl-2-fLiry]sulfonyl)amino]-4-klor-5-metylfenoksymetyl]benzosyre,
3-klor-4-[2-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-4,5-dimetylfenoksymetyljbenzosyre,
3-klor-4-[2-[N-isopropyl-N-(5-metyl-2-furylsulfonyI)amino]-4,5-dimetyl-fenoksymetyl]benzosyre,
3- raetyI-4-[2-[N-isobutyl-N-(5-metyl-2-furylsuIfonyI)amino]-4-klor-5-metylfenoksymetyl]kanelsyre,
4- [2-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)amino]-4-metyl-5-klorfenoksymetyl]kanelsyre,
4-[2-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-4-metyl-5-klorfenoksy-metyl] kanelsyre,
4-[2-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)amino]-4,5-dimetylfenoksy-metyl]kanelsyre,
3-metyl-4-[2-|^-isopropyl-N-(5-metyl-2-furylsulfonyl)amino]-5-tri fluormety lfenoksym ety 1 ] kanelsyre,
3-raetyl-4-[2-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)-amino]-4,5-dimetyl-fenoksymety 1] benzosyre,
3-metyl-4-[2-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)amino]-4,5-dimetyl-fenoksy mety 1] kanelsyre,
3- metyl-4-[2-[N-isobu1yl-N-(5-melyl-2-furylsuIfonyl)amino]-4,5-dimetyl-fenoksymetyl]kanelsyre,
4- [2-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-4,5-dimetylfenoksymetyl]-kanelsyre,
N-[4-klor-5-metyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid,
3- metoksy-4-[2-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-4-metyl-5-klorfenoksymetyljkanelsyre,
N-[4,5-dimetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmelyloksy]-fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid,
N-[4,5-dimetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]-fenyl]-N-isopropyl-(5-metyl-2-furyl)sulfonylamid,
N-[4-klor-5-metyl-2-[4-(5-tetrazolyl)fenylmetyloksy]-fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid,
N-[4-klor-5-metyl-2-[4-(5-okso-l,2,4-oksadiazol-3-yl)-fenylmetyloksy]fenyl]-N-isopropyl-(5-metyl-2-furyl)sulfonylamid,
N-[4-klor-5-metyl-2-[4-(5-okso-1,2,4-oksadiazol-3-yl)-fenylmetyloksy]fenyl]-N-isobutyl-(5-metyl-2-furyl)-sulfonylamid,
4- [6- [N-isobuty l-N-(5 -mety 1-2-fury lsulfony l)amino] indan- 5 -y loksymety 1] - benzosyre,
4-[6-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)amino]indan-5-yloksymetyl]-benzosyre,
4-[7-rN-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-1,2,3,4-tetrahydronaftalen-6-yloksymetyl]benzosyre,
4-[7-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)amino]-1,2,3,4-tetrahydronaftalen-6-yloksymetyl]benzosyre,
N-[4,5-dimetyl-2-[2-metyl-4-(5-okso-l,2,4-oksadiazol-3-yl)-fenylmetyloksy]-fenyl]-N-isopropyl-(5-metyl-2-furyl)-sulfonylamid,
N-[4,5-dimetyl-2-[2-metyl-4-(5-okso-l,2,4-oksadiazol-3-yl)-fenylmetyloksy]-fenyl]-N-isobutyl-(5-metyl-2-furyl)-sulfonylamid,
N-[4,5-dimetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-(5-metyl-2-furyl)sulfonylamid,
N-[4,5-dimetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid,
N-[4,5-dimetyl-2-[4-(5-okso-l,2,4-oksadiazol-3-yl)-fenylmetyloksy]fenyl]-N-isobutyl-(5-metyl-2-furyl)-sulfonylamid,
3-metyl-4-[2-[N-isobu1yl-N-(5-metyl-2-furylsulfonyl)amino]-4-metyl-5-klorfenoksymetyl]kanelsyre,
N-[4,5-dimetyl-2-[2-metoksy-4-(5-okso-l,2,4-oksadiazol-3-yl)fenylmetyloksy]-fenyl]-N-isobutyl-(5-metyl-2-furyl)-sulfonylamid,
N-[4,5-diraetyl-2-[2-metoksy-4-(5-okso-1.2,4-oksadiazol-3-yl)fenylmetyloksy]-fenyl]-N-isopropyl-(5-metyl-2-furyl)-sulfonylamid,
4-[6-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]indan-5-yloksymetyl]-kanelsyre,
3-metyl-4-[6-[N-isobutyl-N-(5-metyl-2-fAirylsulfonyl)-amino]-indan-5-yloksymelyl]benzosyre,
3- metyl-4-[6-|^-isobutyl-N-(5-metyl-2-fuiylsulfonyl)-amino]indan-5-yloksymetyl]kanelsyre,
4- [2-|>f-(2-metyl-2-propenyl)-N-(5-metyl-2-furylsulfonyl)-amino]-4,5-dimetylfenoksymetyl]benzosyre,
3MTietyl-4-[6-|l^-isopropyl-N-(5-metyl-2-furylsulfonyl)-amino]indan-5-yloksymetyljbenzosyre,
3- metyl-4-[6-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)-amino]indan-5-y 1 oksy mety ljkanelsyre,
4- [6-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)amino]indan-5-yloksymetyljkanelsyre,
4-[3-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-2-naftyloksymetyl]-benzosyre,
3,5-dimetyl-4-[2-|^-isobutyl-N-(5-metyl-2-furylsulfonyl)-amino]-5-trifluormety 1 fenoksymety ljbenzosyre,
3- metyl-4-[6-[N-(2-metyl-2-propenyl)-N-(5-metyl-2-furyl-sulfonyl)amino]indan-5-yloksymetyl]benzosyre,
4- [6-|^-cyklopropylraetyl-N-(5-metyl-2-furyJsulfonyl)-amino]indan-5-yloksymetyl]-3-metylbenzosyre,
4-[6-|^-isobutyl-N-(5-metyl-2-mrylsulfonyl)amino]indan-5-yloksymetyl]-3-metylbenzylalkohol,
3- metyl-4-[6-[N-metyl-N-(5-metyl-2-fui7lsulfonyl)-amino]-indan-5-yloksymetyl] benzosyre,
4- [6-[N-etyl-N-(5-metyl-2-furylsulfonyl)amino]indan-5-yloksymetyl]-3-metylbenzosyre,
4-[6-[N-metyl-N-(5-metyl-2-furylsulfonyl)amino]indan-5-yloksymety ljkanelsyre,
4-[6-P^-etyl-N-(5-metyl-2-furylsulfonyl)amino]indan-5-yloksymetyljkanelsyre,
4-[6-[N-propyl-N-(5-metyl-2-furylsulfonyl)amino]indan-5-yloksymetyl]-kanelsyre,
4-[4,5-dimetyl-2-[N-(2-melyl-2-propenyl)-N-(5-metyl-2-furylsulfonyl)amino]-fenoksymetyl]-3-metylbenzosyre,
4-[6-[N[-(2-metyl-2-propenyl)-N-(5-metyl-2-furylsulfonyl)-amino]indan-
yl-oksymetyl]kanelsyre,
4-[6-|^-cyldopropylmetyl-N-(5-metyl-2-furylsulfonyl)-amino]indan-5-yloksymetyljkanelsyre,
4-[6-[N-(2-propenyl)-N-(5-metyl-2-furylsulfonyl)amino]-indan-5-yloksymetyl]-kanelsyre,
3-metyl-4-[6-[N-propyl-N-(5-metyl-2-åirylsulfonyl)amino]-indan-5-yloksy-metyljbenzosyre,
3- metyl-4-[6-[N-(2-propenyl)-N-(5-melyl-2-furylsulfonyl)-ai'nino]indan-5-yloksymetyljbenzosyre,
4- [4,5-dimetyl-2-[N-metyl-N-(5-metyl-2-furylsulfonyl)-amino] fenoksymety l]-benzosyre,
4-[4,5-dimetyl-2-P^-etyl-N-(5-metyl-2-fiirylsulfonyl)-amino]fenoksymetyl]-benzosyre,
4-[4,5-dimetyl-2-[N-(5-metyl-2-furylsulfonyl)-N-propylamino]fenoksy-metyl]-benzosyre,
4-[3-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)amino]naftalen-2-yloksymetyl]-3-metylbenzosyre,
4-[3-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]naftalen-2-y loksy metyl] -3 -mety lbenzosyre,
4-[3-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)-amino]naftalen-2-y loksy metyl]-kanelsyre,
4-[3-|^-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]naftalen-2-yloksymetyl]-kanelsyre,
3-metyl-4-[3-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)-amino]natfalen-2-yloksymetyl]kanelsyre,
3- metyl-4-[3-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)-amino]naftalen-2-yloksymetyl]kanelsyre,
4- [4,5-dimetyl-2-[N-[(5-metyl-2-furyl)sulfonyl]-N-2-propenylamino]fenoksymetyl]benzosyre,
4-[4,5-dimetyl-2-[N-metyI-N-(5-metyl-2-furylsulfonyl)-amino]fenoksymetyl]-3-metylbenzosyre,
4-[4,5-dimetyl-2-[N-etyl-N-(5-metyl-2-furylsulfonyl)-amino]fenoksymetyl]-3-metylbenzosyre,
4-[4,5-dimetyl-2-[N-(5-metyl-2-furylsulfonyl)-N-propyl-amino] fenoksymety 1] -3 -mety lbenzosyre,
4-[4,5-dimetyl-2-[N-(5-metyl-2-furylsulfonyl)-N-(2-propenyl)amino]fenoksymetyl]-3-metylbenzosyre,
4-[4,5-dimetyl-2-[N-(2-hydroksy-2-metylpropyl)-N-(5-metyl-2-rurylsulfonyl)-amino]fenoksymetyl]-3-metylbenzosyre,
4-[6-[N-(2-hydroksy-2-metylpropyl)-N-(5-metyl-2-fuiyIsulfonyl)amino]indan-5-yloksymetyl]-3-metylbenzosyre,
4-[4,5-dime1yl-2-[N-cyklopropylmetyl-N-(5-me1yl-2-furylsulfonyl)amino]-fenoksymetyl]benzosyre,
4-[4,5-dimetyl-2-[N-(2-hydroksy-2-metylpropyl)-N-(5-metyl-2-furylsulfonyl)-arnino]fenoksymetyl]benzosyre,
4-[6-[N-(2-hydroksy-2-metylpropyl)-N-(5-metyl-2-furylsulfonyl)amino]indan-5-yloksymetyl]kanelsyre,
4-[4,5-dimetyl-2-[N-cyklopropylmetyI-N-(5-metyl-2-mrylsulfonyl)amino]-fenoksymetyl]-3-metylbenzosyre,
4-[2-[N-isopropyl-N-(2-tiazolylsulfonyl)amino]-5-trifluormetylfenoksymetyl]-benzosyre,
4- [2- [N-isobuty l-N-(2-tiazoly lsulfony l)amino] - 5-trifluormetylfenoksymetyl]-benzosyre,
4- [2- [N-isopropy l-N-(2-tiazoly lsulfony l)amino]- 5 -
trifluonnetylfenoksymetylj-kanelsyre,
4-[2-[N-isobu1yl-N-(2-tiazolylsulfonyl)aiTiino]-5-trifluormetylfenoksymetyl]-kanelsyre,
4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-5-trifluormetylfenoksymetyl]benzosyre,
4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]-5-trifluormetylfenoksymetyl]kanelsyre,
4-[2-[N-isopropyl-N-(2-tiazolylsulfonyl)amino]-4-klor-5-metylfenoksymetyljbenzosyre,
N-[4-trifluormetyl-2-[4-(5-tetrazolyl)-fenylmetyloksy]-fenyl]-N-isobutyl-2-tia-zolylsulfonylamid,
N-[4-trifluormetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]-fenyl]-N-isopropyl-2-tia-zolylsulfonylamid,
N-[4-trifluormetyl-2-[4-(5-okso-1,2,4-oksadiazol-3-yl)-fenylmetyloksy]-fenyl]-N-isopropyl-2-tiazolylsulfonylamid}
N-[4-trifluormetyl-2-[4-(5-okso-l32,4-tiadiazol-3-yl)-fenylmetyloksy]fenyl]-N-isopropy 1-2-tiazoly lsulfony lamid,
4-[2-[N-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4-klor-5-metylfenoksymetyljbenzosyre,
4-[2-psf-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4-klor-5-melylfenoksymetyl]benzosyre,
3-kIor-4-[2-[N-isopropyI-N-(4-metyl-2-tiazolyIsuIfonyl)-amino]-4-kIor-5-metylfenoksymetyl]benzosyre,
3-metyl-442-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-aiTiino]-5-trifluormetylfenoksymetyljbenzosyre,
3-metyl-4-[2-|^-isobutyl-N-(4-metyI-2-tiazolylsulfonyl)-arnino]-4-klor-5-metylfenoksymetyl]benzosyre,
3-metoksy-4-[2-P<f-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]-4-klor-5-metylfenoksymetyl]benzosyre,
3- metoksy-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]-5-trifluormetylfenoksymetyl]benzosyre,
N44-trifluormetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid,
N-[4-trilfuormetyl-2-[4-(5-okso-l,2,4-oksadiazol-3-yl)-fenylmetyloksy]fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)-sulfonylamid,
N-[4-trifluormetyl-2-[4-(5-okso-l,2,4-oksadiazol-3-yl)-fenylmetyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)-sulfonylamid,
4- [2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4-metyl-5-klorfenoksym etyl] benzosyre,
3-klor-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]-4-metyl-5-klorfenoksymetyl]benzosyre,
3-metoksy-4-[2-,[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]-4-metyl-5-klorfenoksymetyl]benzosyre,
N-[4-trifluormetyl-2-[4-(5-tetrazolyl)-fenylmetyloksy]-fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid,
3-metyl-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]-4,5-dimetylfenoksymetyl]benzosyre,
3-metyl-4-[2-[N-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]-4,5-dimetylfenoksymetyl]benzosyre,
3-metoksy-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]-4,5-dimetylfenoksymetyl]benzosyre,
3-klor-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]-4,5-dimetyl-fenoksymetyl]benzosyre,
3-klor-4-[2-[N-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]-4,5-dimetylfenoksymetyl]benzosyre,
4-[2-[N-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksymetyljbenzosyre,
4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksy-metyl]benzosyre,
4-[2-[lvf-isobu1yl-N-(4-me1yl-2-tiazolylsulfonyl)amino]-4-klor-5-metylfenoksymetyl]kanelsyre,
3-metyl-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]-5-trifluormetylfenoksymetyl]kanelsyre, 3 -klor-4- [2- [N-i sobuty l-N-(4-metyl-2-tiazo ly 1 sulfony l)-amino] -5 - trifluormetylfenoksymetyl]kanelsyre,
3-metyl-4-[2-[N-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]-4,5-dimetylfenoksymetyljkanelsyre,
3- metyl-4-[2-|TSJ-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]-4,5-dimetylfenoksymetyl]kanelsyre,
4- [2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4-metyl-5-klorfenoksymety ljkanelsyre,
3-metyl-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]-4-metyl-5-klorfenoksymetyl] kanelsyre,
3- metyl-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]-4-klor-5-metylfenoksymetyljkanelsyre,
N-[4-klor-5-metyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid,
N-[4-klor-5-metyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid,
4- [2-[N-isobulyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksymetyl]kanelsyre,
N-[4-trifluormetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid,
N-[4-trifluormetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid,
3-klor-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]-4,5-dimetylfenoksymetyljkanelsyre,
N-[4,5-dimetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid,
N-[4,5-dimetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]-fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid,
N-[4,5-dimetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid,
N-[4,5-dimetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid,
N-[4-klor-5-metyI-2-[4-(5-tetrazolyl)fenylmetyIoksy]fenyI]-N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid,
N-[4-klor-5-metyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid,
N-[4-klor-5-metyl-2-[4-(5-okso-l,2,4-oksadiazol-3-yl)fenylmetyloksy]fenyl]-N-isobulyl-(4-metyl-2-tiazolyl)sulfonylamid,
N-[4-klor-5-metyl-2-[2-metyl-4-(5-okso-1,2,4-oksadiazol-3-yl)fenylmetyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid,
3- metoksy-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]-4,5-dimetylfenoksymetyljkanelsyre,
N-[4,5-dimetyl-2-[2-metyl-4-(5-okso-l,2,4-oksadiazol-3-yl)-fenylmetyloksy]fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)-sulfonylamid,
N-[4,5-dimetyl-2-[2-metyl-4-(5-okso-l,2,4-oksadiazol-3-yl)-fenylmetyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid,
N-[4,5-dimetyl-2-[4-(5-okso-l,2,4-oksadiazoI-3-yl)fenylmetyloksy]fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)-sulfonylamid,
N-[4,5-dimetyl-2-[4-(5-okso-l,2,4-oksadiazol-3-yl)fenylmetyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid,
N-[4,5-dimetyl-2-[2-metoksy-4-(5-okso-l,2,4-oksadiazol-3-yl)fenylmetyloksy]fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)-suIfonylamid,
N-[4,5-dimetyl-2-[2-metoksy-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid,
4- [6-|^-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]indari-5-yloksymetyl]benzosyre,
4-[6-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymetyljkanelsyre,
3-metyl-4-[6-I^-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]indan-5-yloksymetyljbenzosyre,
3-me1yl-4-[6-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]indan-5-y loksymety 1] kanelsyre,
3- metyl-4-[2-[N-(2-metyl-2-propenyl)-N-(4-metyl-2-tiazolyl-sulfonyl)amino]-4-klor-5-metylfenoksymetyl]benzosyre,
4- [2-|^-(2-metyl-2-propenyl)-N-(4-metyl-2-tiazolylsulfonyl)amino]-5-trifluor-metylfenoksymetyljkanelsyre,
3-metyl-4-[2-[N-(2-metyl-2-propenyl)-N-(4-metyl-2-tiazolyl-sulfonyl)amino]-4,5-dimetylfenoksymetyl]benzosyre, 3 -mety 1-4- [6- [N-isopropy l-N-(2-tiazoly lsul fony l)-amino] -1 ndan-5 - yloksymetyljbenzosyre,
3-metyl-4-[6-[N-isobutyl-N-(2-tiazolylsulfonyI)amino]indan-5-yloksymetyl]benzosyre, 3- metyl-4-[6-[N-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]indan-5-yloksymetyljbenzosyre, 4- [6-[N-isopropyl-N-(2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]benzosyre,
4-[6-[N-isobutyl-N-(2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]benzosyre,
4-[6-[N-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]-indan-5-yloksymetyljbenzosyre,
4-[6-[N-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-indan-5-yloksymetyl]-kanelsyre, 3- metyl-4-[6-pSf-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]indan-5-yloksymetyljkanelsyre, 4- [2-[N-isopropyl-N-(2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksymetyljbenzosyre,
4-[2-[N-isobutyl-N-(2-tiazolylsulfonyI)amino]-4,5-dimetylfenoksymetyl]benzosyre,
4-[2-pM-isopropyl-N-(2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksymetyl]-kanelsyre, 4- [2- [N-isobuty l-N-(2-tiazoly lsulfony l)amino] -4,5 -dimetyl fenoksymety 1] - kanelsyre,
4-[6-[N-isopropyl-N-(2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]kanelsyre,
4-[6-[N-isobutyl-N-(2-tiazolylsulfonyl)amino]indan-5-yl-oksymetyljkanelsyre,
3-metyl-4-[2-[N-isopropyl-N-(2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksymetyljbenzosyre,
3-metyl-4-[2-pSl-isobutyl-N-(2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksy-metyl] benzosyre, 3 -mety 1-4- [2- [N-isopropy l-N-(2-tiazoly lsulfony l)amino] -4,5-dimetylfenoksymetyl]kanelsyre,
3-metyl-4-[2-[N-isobutyl-N-(2-tiazolylsuJfonyl)amino]-4,5-dimetylfenoksy-metyljkanelsyre,
3-metyl-4-[6-[N-isopropyl-N-(2-tiazolylsulfonyl)-amino]-indan-5-yloksymetyl]kanelsyre,
3- metyl-4-[6-[N-isobutyl-N-(2-tiazolylsulfonyl)amino]indari-5-yloksymetyl]kanelsyre,
4- [3-[N-isobu1yl-N-(4-metyl-2-tiazolylsulfonyl)amino]naftalen-2-yloksymetyljbenzosyre,
4-[3-[N-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)amino]naftalen-2-yloksymetyljbenzosyre,
4-[3-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]naftalen-2-yloksymetyl]-3-mety lbenzosyre,
4-[3-[N-isopropyl-N-[2-(4-metyltiazolyl)sulfonyl]amino]-naftalen-2-yloksymetyl]-3-metylbenzosyre,
4-[3-[N-isobutyl-N-(4-metyl-2-tiazoIylsulfonyl)amino]naftalen-2-yloksy metyl]-kanelsyre,
4-[3-[N-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)amino]naftalen-2-yloksymetyljkanelsyre,
4-[4,5-dimetyl-2-[N-metyl-N-(4-metyl-2-tiazolylsulfonyl)amino]fenoksymetyl]-3-metylbenzosyre,
4-[4,5-dimetyl-2-pSf-etyl-N-(4-metyl-2-tiazolylsulfonyl)amino]fenoksymetyl]-3-metylbenzosyre,
4-[4,5-dimetyl-2-[N-propyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]fenoksymetyl]-3-metylbenzosyre,
4-[4,5-dimetyl-2-[N-(2-propenyl)-N-(4-metyl-2-tiazolylsulfonyl)-amino]fenoksy-metyl]-3-metylbenzosyre,
4-[4,5-dimetyl-2-[N-cyklopropylmetyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-fenoksymetyl]-3-mety lbenzosyre,
4-[4,5-dimetyl-2-[N-(2-hydroksy-2-metylpropyl)-N-(4-metyl-2-tiazolylsulfonyl)amino]fenoksymetyl]-3-metylbenzosyre,
4-[6-[N-(2-metyl-2-propenyl)-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yl-oksymetyljbenzosyre,
4-[6-[N-(4-metyl-2-tiazolylsulfonyl)-N-(2-propenyl)amino]-indan-5-yloksymetyl]benzosyre,
4-[6-[N-cyklopropylmetyl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]benzosyre,
4-[3-[N-isobutyl-N-[2-(4-metyltiazolyl)-sulfonyl]amino]naftalen-2-yloksymetyl]benzosyre,
4-[3-[N-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)amino]naftalen-2-yloksymetyl]-3-metyIbenzosyre,
4-[6-[N-etyl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymetyljbenzosyre,
4-[6-[N-(4-metyl-2-tiazolylsulfonyl)-N-propylamino]indan-5-yloksymetyl]benzosyre3
4-[6-[N-metyl-N-(4-metyl-2-tiazolylsulfonyl)aiTiino]indan-5-yloksymetyl]-benzosyre,
3- metyl-4-[6-[N-metyl-N-(4-metyl-24iazolylsulfonyl)amino]indan-5-yloksymetyl]kanelsyre,
4- [6- [N-ety l-N-(4-mety 1-2-tiazoly lsulfony l)amino] -indan- 5 -y loksymety l]-3 - metyl kanel syre,
3- metyl-4-[6-[N-(2-metyl-2-propenyl)-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]kanelsyre,
4- [6-[N-cyklopropylmetyl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymety 1] -3 -mety lkanelsyre,
3- metyl-4-[6-|N-(4-metyl-2-tiazolylsulfonyl)-N-(2-propenyl)amino]indan-5-yl-oksy mety 1] kanelsyre,
4- [6-[N-(2-hydroksy-2-metylpropyl)-N-(4-metyl-2-tiazolylsulfonyl)amino]-indan-5-yloksymetyl]-3-mety lkanelsyre,
3- metyl-4-[6-[N-(4-metyl-2-tiazolylsulfonyl)-N-propylamino]indan-5-yloksymetyljkanelsyre,
4- [6-[N-(2-hydroksy-2-metylpropyl)-N-(4-metyl-2-tiazolylsulfonyl)amino]-indan-5-yloksymetyl]benzosyre,
4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-5-trifluormetylfenoksymetyl]-kanelsyre,
4-[2-pS[-isobutyl-N-(3-pyridylsulfonyl)amino]-5-trifluormetylfenoksymetylj-benzosyre,
3-klor-4-[2-[N-isopropyl-N-(2-pyridylsulfonyl)amino]-4-klor-5-metylfenoksymetyl]benzosyre,
3-metyl-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4-klor-5-metylfenoksymetyl]benzosyre,
3-metyl-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4-klor-5-metylfenoksymetyl]benzosyre,
3- metyl-4-[2-PsJ-isobutyl-N-(2-pyridylsulfonyl)amino]-4-metyl-5-klorfenoksymetyl]benzosyre,
N-[4-trifluormetyl-2-[4-(5-tetrazolyl)feny]metyloksy]-fenyl]-N-isopropyl-3-pyri-dylsulfonylamid,
N-[4-trifluormetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-3-pyri-dylsulfonylamid,
4- [2-[N-isobutyl-N-(3-pyridylsulfonyl)araino]-4-metyl-5-klorfenoksymetyl]-benzosyre,
3-ldor-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4-metyl-5-klorfenoksymetyljbenzosyre,
3-metyl-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-5-trifluormetylfenoksymetyl]kanelsyre,
3-metoksy-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4,5-dimetylfenoksymetyl]benzosyre,
3-metoksy-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4,5-dimetylfenoksymetyl]benzosyre,
3-metyl-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4,5-dimetylfenoksymetyljbenzosyre,
3-metyl-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4,5-dimetylfenoksymetyl]benzosyre,
N-[4-trifluormetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-2-pyridylsulfonylamid,
N-[4-trifIuormetyI-2-[4-(5-tetrazolyI)fenylmetyloksy]fenyI]-N-isobutyl-2-pyridylsulfonylamid,
3- metyl-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4-metyl-5-klorfenoksymetyljbenzosyre,
4- [2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4,5-dimetylfenoksymetyl]-benzosyre,
N-[4-trifluoraietyl-2-[4-(5-okso-l,2,4-oksadiazol-3-yl)-fenylraetyloksy]fenyl]-N-isobutyl-2-pyridylsuIfonylamid,
4-[2-[Nf-isopropyl-N-(2-pyridylsulfonyl)amino]-4-metyl-5-klorfenoksymetyl]kanelsyre.
3-metyl-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4-metyl-5-klorfenoksymetyljkanelsyre,
3-metyl-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4,5-dimetylfenoksymetyl]kanelsyre,
4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4,5-dimetylfenoksymetyl^ kanelsyre, 3 -metyl-4- [2-[N-isobutyl-N-(3 -pyridylsulfony l)amino]-4,5 - dimetylfenoksymetyl]kanelsyre,
N-[4-trifluormetyl-2-[2-melyl-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-2-pyridylsulfonylamid,
3-klor-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4,5-dimetylfenoksymety ljkanelsyre,
N-[4,5-dimetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-2-pyridylsulfonylamid,
N-[4,5-dimetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-3-pyridylsulfonylamid,
N-[4-klor-5-metyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-3-pyridylsulfonylamid,
N-[4,5-dimetyl-2-[2-klor-4-(5-tetrazolyl)fenylmetyloksy]-fenyl]-N-isobutyl-2-pyridylsulfonylamid,
N-[4,5-dimetyl-2-[2-klor-4-(5-tetrazoIyl)fenylmetyloksy]fenyl]-N-isopropyl-3-pyridylsulfonylamid,
N-[4,5-dimety 1-2-[2-klor-4-(5-tetrazoly l)feny lmety 1 oksy]-fenyl]-N-isobutyl-3 -pyridylsulfony lamid,
3-nietyl-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4-klor-5-metylfenoksymetyljkanelsyre,
N-[4,5-dimetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-2-pyridylsulfonylamid,
N-[4,5-dimetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-2-pyri-dylsulfonylamid,
N-[4,5-dimetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-3-pyri-dylsulfonylamid,
3-klor-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-5-trifluormetylfenoksymetyljkanelsyre,
N-[4-klor-5-metyl-2-[2-metyl-4-(5-tetrazolyI)fenylmetyloksy]fenyl]-N-isopropyl-2-pyridylsulfonylamid,
N-[4-klor-5-metyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-2-pyridylsulfonylaiTiid,
N-[4,5-dimetyl-2-[2-metyl-4-(5-okso-l,2,4-oksadiazol-3-yl)fenylmetyloksy]fenyl]-N-isopropyl-2-pyridylsulfonylamid,
N-[4,5-dimetyl-2-[2-metyl-4-(5-okso-l,2,4-oksadiazol-3-yl)fenylmetyloksy]fenyl]-N-isobutyl-3-pyridylsulfonylamid,
N-[4,5-dimetyl-2-[2-metoksy-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-2-pyridylsulfonylamid,
N44,5-dimetyl-2-[2-metoksy-4-(5-tetrazoIyI)fenylmetyIoksy]fenyl]-N-isopropyl-2-pyridylsulfonylamid,
N-[4,5-dimetyl-2-[2-meloksy-4-(5-okso-l,2,4-oksadiazol-3-yl)fenylmetyl-oksy]fenyl]-N-isobutyl-2-pyridylsulfonylamid og
N-[4,5-dimetyl-2-[2-metoksy-4-(5-okso-1,2,4-oksadiazol-3-yl)fenylmetyloksy]fenyl]-N-isopropyl-2-pyridylsulfonylamid.
Estere:
Blant forbindelsene med formel (I) i henhold til den foreliggende oppfinnelse, kan forbindelsen med formel (I-B) omdannes til den korresponderende ester ved hjelp av i og for seg kjente metoder. Omdanningen til ester er nyttig, på grunn av økning av stabilitet og absorberbarhet til forbindelsen. En alkylester er foretrukket. CM alkylester er mer foretrukket. Esteren med formel (I-B) kan fremstilles ved hjelp av i og for seg kjente metoder. Den kan også oppnås som forbindelsen med formel (I-A) i fremgangsmåten for fremstilling av forbindelsen i den foreliggende oppfinnelse.
Salter'
Forbindelsen med formel (I) i henhold til den foreliggende oppfinnelse kan omdannes til det korresponderende salt ved hjelp av i og for seg kjente metoder. Et ikke-toksisk og vannoppløselig salt er foretrukket. Et passende salt inkluderer for eksempel et salt av alkalimetaller (kalium, natrium, etc.), et salt av jordalkalimetaller (kalsium, magnesium, etc), et ammoniumsalt, et salt av farmasøytisk akseptable organiske aminer (tetrametylammonium, trietylamim, metylamin, dimetylamin, cyklopentylamin, benzylamin, fenetylamin, pipendin, monoetanolamin, dietanolamin, tris(hydroksymetyl)metylamin, lysin, arginin, N-metyl-D-glukamin, etc).
Metode for fremstilling av forbindelsen i den foreliggende oppfinnelse: Forbindelsen med formel (I) i henhold til den foreliggende oppfinnelse kan fremstilles ved hjelp av metoder beskrevet i WO98/27053, eller i overensstemmelse med reaksjonsskjemaene skissert nedenfor. Detaljer ved prosessen er beskrevet i det etterfølgende.
I skjemaene er R Ci.4 alkyl, Tf er trifluormetansulfonyl og de andre symbolene har de samme betydningene som definert i det foregående.
R: C,.4 alkyl,
Ms : mesyl,
Tf20 : trifluormetansulfonsyreanhydrid,
Et: etyl,
TCDI : l,l'-tiokarbonyldiimidazol.
Blant forbindelsene med formel (I), når Ar er en heterocyklisk ring som har en basisk del, er dens korresponderende sylfonylhalogenid (forbindelsen med formel (VIII)) beskrevet i reaksjonsskjemaet (A) ømfintlig overfor varme, og det ble funnet at den lett spaltes når den etterlates som den er (se sammenligningseksempel 1).
Særlig forventes det lett at et sulfonylhalogenid som har en basisk del slik som en heterocyklisk ring inneholdende et nitrogenatom lett spaltes, siden sulfonylhalo-genidforbindelser generelt er ustabile overfor baser.
Fra dette, ved fremstilling av et sulfonylhalogenid som har en basisk del, var man opptatt av at (1) det er vanskelig å isolere et sulfonylhalogenid fordi det konsentrerte sulfonylhalogenidet er ustabilt etter avdampning av løsningsmidlet etter at reaksjonen var terminert, og at (2) det var sannsynlig at sulfonylhalogenidet kunne spaltes i prosessen med fremstilling av et sulfonamid fra dette, når underkastet en høyere temperatur enn omgivelsestemperaturen i lang tid.
Som beskrevet ovenfor, når sulfonylhalogenidet lett spaltes, er det vanskelig å bestemme den faktiske mengden av sulfonylhalogenidet, og det er tungvint å behandle det. Når sulfonamidforbindelsen fremstilles ved å underkastes kondensasjonsreaksjon med en aminforbindelse, er det fare for lavt utbytte på grunn av spaltingen av sulfonylhalogenidet i industriell masseproduksjon.
Hva angår metoden for fremstillingen av et sulfonamid, er kondensasjonsreaksjon med et sulfonylhalogenid og et amin generelt kjent.
De omhandler en metode for omdanning av et fenylsulfonylklorid til et sulfonamid eller en sulfonsyreester via en addisjon av et imidazol til et fenylsulfonylklorid etterfulgt av N-metylering
(J. Org. Chem., 57, 4775-4777 (1992)), og det er beskrevet at metoden er anvendbar i tilfellet med reaksjon med en nukleofil som har lav nukleofilisitet eller en som er sterisk hindret. Det er imidlertid hverken beskrevet eller foreslått at metodene forbedrer stabiliteten til sulfonylhalogenidet.
De foreliggende oppfinnere har undersøkt omdanning av et sulfonylhalogenid som har en heterocyklisk ring med formel (III) til en mer stabil forbindelse og fant at formålet ble oppnådd ved å omdanne det til forbindelsene med formler (II-A) og (II-B) i samsvar med fremstillingsmetoden som vist i det etterfølgende reaksjonsskjema
(C).
I reaksjons skjemaet (C) er trinn (a) en metode for omdanning til en stabil
sulfonylforbindelse med 1-hydroksybenzotriazol. Den utføres for eksempel med 1-hydroksybenzotriazol, i et organisk løsningsmiddel (en eter (t-butylmetyleter, dietyleter, tetrahydrofuran, etc.), et halogenløsningsmiddel (metylenklorid, kloroform, etc), etc.) i nærvær av en base (trietylamin, diisopropyletylamin, dimetylaminopyridin, pyridin, etc.), ved en temperatur på -20 til 30 °C.
Trinn (b) er også en metode for fremstilling av en stabil sulfonylforbindelse. Den utføres for eksempel i et organisk løsningsmiddel (en eter (t-butylmetyleter, dietyleter, tetrahydrofuran, etc), et halogenløsningsmiddel (metylenklorid, kloroform, etc), etc med N-metylimidazol ved en temperatur på -20 til 30 °C.
Trinnene (a) og (b) utføres foretrukket under vannfrie betingelser og i en atmosfære med inert gass.
Når forbindelsen med formel (III) er ustabil overfor varme, kan hvert trinn (a) og (b) særlig utføres uten konsentrering av den fremstilte sulfonylhalogenidoppløsningen.
Sulfonylhalogenid med formel (III) oppnås som en oppløsning etter fremstilling, og det kan generelt isoleres ved konsentrering av oppløsningen. Hvis materialene eksponeres for høy temperatur under konsentrering, er der en mulighet for at et sulfonylhalogenid kan spaltes ved oppvarming i en stor målestokk, mens der ikke er noe problem særlig i liten målestokk (se sammenligningseksempel). Omdanningen til forbindelsen med formler (II-A) eller (II-B) uten konsentrering av oppløsningen sikrer derfor en lav nedbrytbarhet av et sulfonylklorid med dets høye reaktivitet (se eksempel 7 og 8).
I reaksjonsskjemaet er sulfonylhalogenidet med formel (III) anvendt som et ut-gangs-material i og for seg kjent eller kan enkelt fremstilles ved hjelp av en konvensjonell metode fra en kjent forbindelse. De andre utgangsmaterialene og reagensene i den foreliggende oppfinnelse er i og for seg kjente eller kan fremstilles i overensstemmelse med konvensjonelle metoder.
Reaksjonsskjemaet (C) kan tilveiebringe en metode for fremstillingen av forbindelsen med formel (VIII), hvori Ar er en basisk heterocyklisk ring. Metoden i forbindelse med den foreliggende oppfinnelse er anvendbar for stabilisering av ikke bare et ustabilt mellomprodukt av forbindelsen med formel (I) men også et ustabilt sulfonylklorid med en basisk heterocyklisk ring.
I den foreliggende oppfinnelse er 5- til 10-leddet heterocyklisk ring representert ved Ar' 5- til 10-leddet heterocyklisk ring omfattende 1 til 4 nitrogenatomer, 1 til 2 oksygenatomer og/eller 1 svovelatom. Spesifikt representerer den en basisk heterocyklisk ring slik som tiazol, isotiazol, isoksazol, pyrazin, pyrimidin, pyradizin, pyridin, pyrrol, imidazol, pyrazol, triazol, indol, indolin, purin, kinolin, isokinolin, ftalazin, naftyridin, kinoksalin, cinnolin, pyrrolidin, pyrrolin, imidazolidin, imidazolin, pyrazolin, etc.
I den foreliggende oppfinnelse kan Ar' være substituert med 1 til 4 av Ci_8 alkyl, Ci.g alkoksy, halogenatom, cyano, nitro, C2.8 acyl, dialkylamino, monoalkylamino, mono-alkylaminokarbonyl, dialkylaminokarbonyl, C5_i0 karbocyklisk ring eller 5 - til 10-leddet heterocyklisk ring.
I den foreliggende oppfinnelse er Ci_g alkyl som en substituent for Ar' metyl, etyl, propyl, butyl, pentyl, heksyl, heptyl, oktyl eller isomerer derav.
I den foreliggende oppfinnelse er C]_8 alkoksy metoksy, etoksy, propoksy, butoksy, pentyloksy, heksyloksy, heptyloksy, oktyloksy eller isomerer derav.
I den foreliggende oppfinnelse er halogenatom som en substituent for Ar' fluor-, klor-, brom- eller jodatom.
I den foreliggende oppfinnelse er C3.i0 karbocyklisk ring som en substituent for Ar' cyklopropan, cyklobutan, cyklopentan, cykloheksan, cykloheptan, cyklopenten, cykloheksen, cyklopentadien, cykloheksadien, benzen, pentalen, inden, naftalen, bifenylen, perhydropentalen, perhydroinden, perhydronatfalenring, etc.
I den foreliggende oppfinnelse er 5- til 10-leddet heterocyklisk ring som en substituent for Ar' 5- til 10-leddet mono- eller bi-heterocyklisk ring inneholdende 1 til 4 nitrogenatomer, 1 til 2 oksygenatomer og/eller 1 svovelatom, inkluderende 5- til 10-leddet mono- eller bi-heterocyklisk aryl, eller delvis eller fullstendig mettet ring derav.
I den foreliggende oppfinnelse er 5- til 10-leddet mono- eller bi-heterocyklisk aryl inneholdende 1 til 4 nitrogenatomer, 1 til 2 oksygenatomer og/eller 1 svovelatom som en substituent for Ar' pyrrol, imidazol, triazol, tetrazol, pyrazol, pyridin, pyrazin, pyrimidin, pyridazin, azepin, diazepin, furan, pyran, oksepin, oksazepin, tiofen, tiain (tiopyran), tiepin, oksazol, isoksazol, tiazol, isotiazol, oksadiazol, oksazin, oksa-diazin, oksazepin, oksadiazepin, tiadiazol, tiazin, tiadiazin, tiazepin, tiadia-zepin, indol, isoindol, benzofuran, isobenzofuran, benzotiofen, isobenzotiofen, indazol, kinolin, isokinolin, ftalazin, naftyridin, kinoksalin, kinazolin, cinnolin, benzoksazol, benzotiazol, benzimidazolring, etc.
I den foreliggende oppfinnelse er 5- til 10-leddet mono- eller bi-heterocyklisk ring delvis eller fullstendig mettet en derav pyrrolin, pyrrolidin, imidazolin, imidazolidin, triazolin, triazolidin, tetrazolin, tetrazolidin, pyrazolin pyrazolidin, piperidin, piperazin, tetrahydropyridin, tetrahydropyrimidin, tetrahydropyridazin, dihydrofuran, tetrahydrofuran, dihydropyran, tetrahydropyran, dihydrotiofen, tetrahydrotiofen, dihydrotiain (dihydrotiopyran), tetrahydrotiain (tetrahydrotiopyran), oksazolin (dihydrooksazol), oksazolidin (tetrahydrooksazol), dihydroisoksazol, tetrahydro-isoksazol, oksadiazolin (dihydrooksadiazol), oksadiazolidin (tetrahydrooksadiazol), tiazolin (dihydrotiazol), tiazolidin (tetrahydrotiazol), dihydroisotiazol, tetrahydro-isotiazol, morfolin, tiomorfolin, indolin, isoindolin, dihydrobenzofuran, perhydro-benzofuran, dihydroisobenzofuran, perhydroisobenzofuran, dihydrobenzotiofen, perhydrobenzotiofen, dihydroisobenzotiofen, perhydroisoberizotiofen, dihydro-indazol, perhydroindazol, dihydrokinolin, tetrahydrokinolin, perhydrokinolin, dihydroisokinolin, tetrahydroisokinolin, perhydroisokinolin, dihydroftalazin, tetrahydroftalazin, perhydrotfalazin, dihydronaftyridin, tetrahydronaftyridin, perhydronaftyridin, dihydrokinoksalin, tetrahydrokinoksalin, perhydrokinoksalin, dihydrokinazolin, tetrahydrokinazolin, perhydrokinazolin, dihydrocinnolin, tetra-hydrocinnolin, perhydrocinnolin, dihydrobenzoksazol, perhydrobenzoksazol, dihydrobenzotiazol, perhydrobenzotiazol, dihydrobenzimidazol, perhydro-benzimidazol, benzofurazan, benzotiadiazol, benzotriazole, imidazotiazol, dioksolan, dioksan, dioksadinring, etc.
I den foreliggende oppfinnelse er Ar' foretrukket 5- til 10-leddet basisk heterocyklisk ring inneholdende 1 til 4 nitrogenatomer, og tiazol, isotiazol, isoksazol, pyrazin, pyrimidin, pyridazin, pyridin, pyrrol, imidazol, pyrazol, triazol, indol, indolin, purin, kinolin, isokinolin, ftalazin, naftyridin, kinoksalin, cinnolin, pyrrolidin, pyrrolin, imidazolidin, imidazolin og pyrazolinring er mer foretrukne. Mest foretrukket er pyridin- eller tioazolring.
Utgangsmaterialene og reagensene i den foreliggende oppfinnelse er i og for seg kjente eller kan fremstilles ved hjelp av kjente metoder. Forbindelse med formler (III), (IV), (V), (VIII) og (X) er i og for seg kjente eller kan fremstille ved hjelp av kjente metoder.
I hver reaksjon i den foreliggende beskrivelse kan oppnådde produkter renses ved hjelp av kjente teknikker. Rensing kan for eksempel utføres ved destillering ved atmosfærisk eller redusert trykk, ved høyytelses-væske-kromatografi, ved tynnsjikts-kromatografi eller ved kolonnekromatografi under anvendelse av silikagel eller magnesiumsilikat, ved vasking eller ved rekrystallisering. Rensing kan utføres etter hver reaksjon, eller etter en serie reaksjoner.
Farmakologisk aktivitet av forbindelsene i henhold til den foreliggende oppfinnelse: Forbindelsen med formel (I) i henhold til den foreliggende oppfinnelse kan binde sterkt til EP| reseptoren som er en subtype av prostaglandin E2 reseptor og utviser en antagonistisk aktivitet. Som nevnt i det foregående, er det kjent at EPi reseptoren står i forbindelse med induksjon av smerte, pyreksi (induksjon av feber), diurese eller blære-kontraktiv aktivitet. Forbindelsen med formel (I), en ester derav og et ikke-toksisk salt derav som kan antagonisere denne reseptoren er derfor anvendbar som analgetika, som anti-pyretiske midler eller som midler for forebygging og/eller behandling av pollakisuri (nevrogen blære, nervøs blære, stimulert blære (irritabel blære), detrusor-ustabilitet, dysuri som ledsager prostatomegali), acraturese (urininkontinens), sykdomssyndrom i nedre urinveier. I tillegg binder forbindelsen i henhold til den foreliggende oppfinnelse knapt til de andre subtypene av PGE2 og forventes å gi et middel uten noen bivirkning.
Det har også vært kjent at en EP! antagonist besitter en undertrykkende effekt på aberrante kryptfoci og dannelse av intestinale polypper, og følgelig indikerer den en effektiv anti-tumoraktivitet.
Forsøket beskrevet nedenfor viser åpenbart at forbindelsen i henhold til den foreliggende oppfinnelse påvirkes mindre av proteinbinding, slik at den har en tilfredsstillende in vivo aktivitet.
Farmakologisk eksperimentelt forsøk
(i) Bindingsanalyse ved anvendelse av ekspresjonscelle av prostanoid reseptor-subtype.
Fremstillingen av membranfraksjon ble utført i overensstemmelse med metoden til Sugimoto et al. (J. Biol. Chem., 267, 6463-6466 (1992)), ved anvendelse av CHO ekspresjonscelle av prostanoid receptor-subtype (mus EP|, EP2, EP3a eller EP4).
Standard analyseblandingen inneholdende membranfraksjon (0.5 mg/ml) og H-PGE2 i et sluttvolum på 200 ul ble inkubert i 1 time ved romtemperatur. Reaksjonen ble terminert ved tilsetning av iskald buffer (3 ml). Blandingen ble hurtig filtrert gjennom et glassfilter (GF/B). Radioaktiviteten assosiert med filteret ble målt ved hjelp av væskescintillasjonstelling.
Kd og Bmax verdier ble bestemt fra Scatchard-plottinger (Ann. N.Y. Acad. Sei., 5_1, 660 (1949)). Ikke-spesifikk binding ble beregnet som bindingen i nærvær av et overskudd (2,5 uM) av umerket PGE2. I eksperimentet for konkurranse av spesifikt H-PGE2 binding ved forbindelsen i henhold til den foreliggende oppfinnelse, ble H-PGE2 (2,5 iiM) og forbindelsen i henhold til den foreliggende oppfinnelse tilsatt. Den følgende buffer ble anvendt i hele reaksjonen.
Buffer : kaliumfosfat (pH 6,0, 10 mM), EDTA (1 mM), MgCl2 (10 mM) og NaCl (0,1 M).
Dissosiasjonskonstanten K, (uM) for hver forbindelse ble beregnet ved hjelp av den følgende ligning.
Ki = IC50/(l + ([C]/Kd))
hvori [C] er konsentrasjonen av of 3H-PGE2 anvendt i reaksjonen.
Resultatene er vist i tabell 1.
Kommentarer:
Det er bekreftet at bindingsaffiniteten til forbindelsen med formel (I) i henhold til den foreliggende oppfinnelse overfor en EPi subtype -reseptor er ekvivalent med den til forbindelsen spesifikt beskrevet i ovennevnte WO98/27053.
(ii) Eksperimentell måling av aktiviteten av reseptorantagonisme ved anvendelse av celler som uttrykker prostanoid reseptor-subtype EP) i nærvær av BSA (bovint serumalbumin)
Cellene som uttrykker mus EPi reseptor ble sådd med 1 x IO<4> celler/brønn i 96-brønns plater og dyrket i 2 døgn med 10% FBS (føtalt bovint serum)/mmimum essensielt medium Eagel alfa modifisert (aMEM) i en inkubator (37°C, 5% CO2). Cellene i hver brønn ble renset med fosfatbuffer (PBS(-)), og lastingsbuffer ble tilsatt. Etter inkubering i 1 time ble lastingsbufferen fjernet. Etter tilsetning av analysebufferen til hver brønn ble cellene inkubert på et mørkt sted ved romtemperatur i 1 time. Etter tilsetning av en forbindelse i henhold til den forelliggende oppfinnelse (10 u.1) og PGE2 (10 ul) som var tilberedt med analysebuffer, ble intracellulær kalsiumkonsentrasjon målt med Fluorescence legemiddel-screeningsystem (Fluorescence Drug Screening System) FDSS-4000, Hamamatsu Photonics). Et par av fluorescenceintensiteter emittert 500 nm ved en eksitasjonsbølgelengde på hver 340 nm og 380 nm ble målt.
EPi antagonistaktiviteten ble estimert som prosent inhibering av økningen av intracellulær kalsiumkonsentrasjon indusert ved PGE2 (100 nM).
Lastingsbuffer : 10% FBS/ctMEM inneholdende 5 uM Fura 2/AM, 20 uM indometacin, 2,5 mM probenecid
Analysebuffer: Hank's balanserte saltoppløsning (HBSS , Hank' balanced salt solution) inneholdende 1% (vekt/volum) BSA, 2 uM indometacin, 2,5 mM probenecid og 10 mM HEPES-NaOH
Resultatene er vist i tabell 2 .
Kommentarer:
I eksperimentet sameksisterende med proteiner (måling av aktivitet av signalering i celler), indikerte forbindelsen med formel (I) i henhold til den foreliggende oppfinnelse ti ganger så høy aktivitet av inhibering av signalering som forbindelsen spesifikt beskrevet i WO98/27053, eller mer.
Det viser at forbindelsen spesifikt beskrevet i WO98/27053 påvirkes av proteinbinding til å senke sin aktivitet i sameksistens med serumprotein. På den annen side, viser det også at alle forbindelsene med formel (I) i henhold til den foreliggende oppfinnelse påvirkes mindre av sameksisterende protein, og dets aktivitet senkes mindre. (iii) Eksperiment for å vurdere inhiberingen av sulproston-indusert økning av intravesicalt trykk i blære hos rotte.
Hunnrotter (Wistar) ble bedøvet med uretan og begge deres urinledere ble ligert og skåret av ved nyresiden. Det ble gjort innsnitt i toppen av urinblæren og et kateter ble innført. Den andre enden av kateteret ble forbundet med en trykkgiver og en infusjonspumpe . Gjentatt miksjonsrefleks, som ble indusert ved den kontinuerlige infusjon av citratbuffer (pH 3,5) inn i blæren ble registrert. Økningen av miksjonstrykk ble utløst ved subkutan injeksjon av diclofenac (5 mg/kg) og sulproston (300 u,g/kg). Siden en slik økende effekt ikke ble observert ved behandlingen EP3 agonist, ble det vurdert at denne økningen var forårsaket av aktiveringen av EP] reseptor. De inhiberende effektene av forbindelsen i henhold til den foreliggende oppfinnelse på denne økningen av intravesikaltrykk ble målt i 60 minutter etter den intraduedenale administrering (2 ml/kg).
Tabell 3 viser prosent inhibering av økning av intravesikaltrykk ved 40 minutter etter administreringen (1 mg/kg).
Kommentarer:
Det er bekreftet at forbindelsen med formel (I) i henhold til den foreliggende oppfinnelse indikerte en sterkere undertrykkende effekt enn den til forbindelsen spesifikt beskrevet i WO98/27053 i in vivo eksperiment, og at den utviste effektiv aktivitet.
(iY) Eksperiment for å vurdere den antagonistiske aktiviteten på økningen i urineringsvolum og antall indusert ved sulproston til rotter.
Hannrotter (CD (SD) IGS) ble anvendt, og miksjonsantall og urineringsvolum ble målt ved hjelp av et Micturition volum-målesystem (Neuroscience).
En forbindelse i henhold til den foreliggende oppfinnelse ble administrert oralt (4 ml/kg), og 30 minutter senere ble sulproston (200 u,g/4ml/kg) administrert subkutant. Antall og volum av urinering ble kontinuerlig overvåket i 3 timer fra administreringen av sulproston.
Prosent inhibering for hver forbindelse ble beregnet ved den følgende ligning.
Kommentarer:
Det er bekreftet at forbindelsen med formel (I) i henhold til den foreliggende oppfinnelse indikerte en sterkere undertrykkende effekt enn den til forbindelsen spesifikt beskrevet i WO98/27053 i in vivo eksperiment.
Toksisitet:
Toksisiteten til forbindelsen i henhold til den foreliggende oppfinnelse er svært lav og det er derfor bekreftet at forbindelsen er sikker for medisinsk anvendelse.
INDUSTRIELL ANVENDBARHET
Anvendelse med hensyn til farmasøytiske midler:
Forbindelsen med formel (I) i henhold til den foreliggende oppfinnelse, en ester derav og et ikke-toksisk salt derav, som antagoniserer EP} reseptoren, anses derfor for å være anvendbare som analgetika, som anti-pyretiske midler eller som midler for behandling av pollakisuri (nevrogen blære, nervøs blære, stimulert blære (irritabel blære), detrusor-ustabilitet, dysuri som ledsager prostatomegali), acraturese (urininkontinens), sykdomssyndrom i nedre urinveier. I tillegg binder forbindelsen i henhold til den foreliggende oppfinnelse knapt til de andre subtypene av PGE2 og forventes å gi et middel med svært liten bivirkning.
Det har også vært kjent at en EP] antagonist besitter en undertrykkende effekt på aberrante kryptfoci og dannelse av intestinale polypper, og følgelig indikerer den en effektiv anti-tumoraktivitet.
Forbindelsen med formel (I) i henhold til den foreliggende oppfinnelse og et ikke-toksisk salt derav kan administreres i kombinasjon med andre medikamenter for det formål å 1) komplettere og/eller øke forebyggings- og/eller behandlingseffekten av forbindelsen, 2) å forbedre farmakokinetikken og/eller absorpsjonen av forbindelsen, å senke dosen, og/eller
3) å lindre en bivirkning av forbindelsen.
Forbindelsen med formel (1) kan administreres i kombinasjon med andre medikamenter som et preparat i et legemiddelprodukt omfattende disse komponentene, eller kan administreres separat. I tilfellet med den separerte administreringen, kan de administreres samtidig eller med tidens løp. Ved administrering med tidens løp, kan forbindelsen med formel (I) administreres først, etterfulgt av administrering av de andre medikamentene. Alternativt kan de andre medikamentene administreres først, etterfulgt av administrering av forbindelsen med formel (I). Administreringsruter kan være enten de samme eller forskjellige fra hverandre.
Det ovennevnte kombinasjonslegemiddel virker på en hvilken som helst sykdom og forebyggende og/eller behandlende effekt av forbindelsen med formel (I) kompletteres og/eller økes.
De andre medikamentene som kompletterer og/eller øker effekten til forbindelsen med fonnel (I) for forebyggingen og/eller behandlingen av pollakisuri (hyppig urinering) er antikolinerge legemidler, tricykliske antidepressive midler, a agonister, ai antagonister, GABA agonister, antidiuretiske midler, anti-androgene hormoner, corpus luteum-hormoner, NKj antagonister, (33 agonister, P2X antagonister, kaliumkanal-åpnere, LP A, EP3 antagonister, capsaicin, resiniferatoksin, 5a-reduktase inhibitorer, etc.
Andre medikamenter som er anvendbare for komplementeringen og/eller økningen av effekten til forbindelsen med formel (I) for forebygging og/eller behandling av algi er opioider, gabapentin, pregabalin, a2 antagonister, NMDA antagonister, TTX-resistente natriumkanal-blokkere, VRI antagonister, nociceptin antagonister, P2X antagonister, IP antagonister, EP3 antagonister, N-type kalsiumkanal-blokkere, iNOS inhibitorer, etc.
Et vektforhold mellom forbindelsen med formel (I) og andre medikamenter er ikke spesielt begrenset.
De andre medikamentene kan administreres i kombinasjon av to eller flere vilkårlige.
Basert på mekanismen, inkluderer de andre medikamentene som kompletterer og/eller øker effekten til forbindelsen med formel (I) for forebygging og/eller behandling av sykdommer ikke bare medikamenter som allerede er funnet så langt men også slike som vil finnes i fremtiden.
For det ovenfor beskrevede formål, kan forbindelsen med formel (I) i henhold til den foreliggende oppfinnelse, en ester derav, et ikke-toksisk salt derav eller kombinasjon av deres og andre medikamenter normalt administreres systemisk eller partielt, vanligvis ved oral eller parenteral administrering.
Doseringene bestemmes avhengig av pasientens alder, kroppsvekt, symtom, en ønsket terapeutisk effekt, administreringsrute og varighet av behandlingen, etc. Generelt er dosene per person per administrering til et voksent menneske fra 1 til 100 mg opp til flere ganger per døgn ved oral administrering. Alternativt er de fra 1 til 100 mg opp til flere ganger per døgn ved parenteral administrering (foretrukket inn i vene). Eller de administreres i vene kontinuerlig i fra 1 til 24 timer per døgn.
Som nevnt ovenfor, avhenger dosene som skal anvendes av forskjellige betingelser. Dosene som skal administreres kan således være lavere enn dosen spesifisert ovenfor i noen tilfeller og enkelte ganger kan de være noe over.
Forbindelsen med formel (I) i henhold til den foreliggende oppfinnelse og et ikke-toksisk salt derav eller en kombinasjon av forbindelsen med formel (I) og andre medikamenter kan administreres i form av for eksempel faste preparater, flytende preparater eller andre preparater for oral administrering, eller som injeksjoner, utvortes medisiner eller stikkpiller, etc. for parenteral administrering.
Faste preparter for oral administrering inkluderer tabletter, piller, kapsler, dispergerbare pulvere og granuler, etc.
Kapsler inkluderer harde kapsler og myke kapsler.
I slike faste preparter er en eller flere av de aktive forbindelser blandet med minst ett inert fortynningsmiddel, for eksempel laktose, mannitol, glykose, hydroksy-propylcellulose, mikrokrystallinsk cellulose, stivelse, polyvinylpyrrolidon, magnesiummetasilikataluminat, etc. Slike preparater kan inneholde ytterligere substanser annet enn inert fortynningsmiddel, for eksempel smøremidler, for eksempel magnesiumstearat, desintegrasjonsmidler, for eksempel cellulosekalsium-glykolat, midler for stabilisering, for eksempel laktose, hjelpemidler for oppløsning, for eksempel glutaminsyre, asparaginsyre. Tabletter eller piller kan om ønsket være belagt med gastriske eller enteriske filmer slik som sukker, gelatin, hydroksy-propylcellulose eller hydroksypropylmetylcelluloseftalat, etc, eller være belagt med to eller flere filmer. Videre inkluderer preparatene også kapsler av absorber-bare materialer slik som gelatin.
Flytende preparater for oral administrering inkluderer farmasøytisk akseptable emulsjoner, oppløsninger, siruper og eliksirer etc. I slike flytende preparater er en eller flere av de aktive forbindelser inneholdt i ett eller flere inerte fortynningsmidler alminnelig anvendt i teknikken (for eksempel renset vann, etanol). Foruten inerte fortynningsmidler, kan slike preparater også omfatte adjuvanser slik som fuktemidler, suspensjonsmidler, søtningsmidler, smaksstoffer, velluktende midler, konserveringsmidler.
Andre preparater for oral administrering inkluderer spraypreparater som kan være fremstilt ved hjelp av i og for seg kjente metoder og som omfatter en eller flere av de aktive forbindelser. Spraypreparater kan omfatte ytterligere substanser annet enn inerte fortynningsmidler: for eksempel stabiliseringsmidler slik som natrium-hydrogensulfat, stabiliseringsmidler for å gi tittelforbindelsen isotonisitet, isotonisk buffer, slik som natriumklorid, natriumcitrat og sitronsyre. For fremstilling av slike spraypreparater kan det benyttes for eksempel metoden beskrevet i US patenter nr. 2868691 eller 3095355.
Injeksjoner for parenteral administrering inkluderer sterile vandige eller ikke-vandige oppløsninger, suspensjoner og emulsjoner. Vandige oppløsninger eller suspensjoner inkluderer for eksempel destillert vann for injeksjon og fysiologisk saltoppløsning. Ikke-vandige oppløsninger eller suspensjoner inkluderer for eksempel propylenglykol, polyetylenglykol, planteoljer slik som olivenolje, alko-holer slik som etanol, POLYSORBATE80 (registrert varemerke), etc. Det kan anvendes ved blanding av sterile vandige eller ikke-vandige oppløsninger, suspensjoner og emulsjoner. Slike preparater kan omfatte ytterligere fortynningsmidler: for eksempel konserveringsmidler, fuktemidler, emulgeringsmidler, dispergerings-midler, stabiliseringsmidler (for eksempel laktose), hjelpemidler slik som hjelpemidler for oppløsning (for eksempel glutaminsyre, asparaginsyre). De kan være sterilisert for eksempel ved filtrering gjennom et bakterie-tilbakeholdende filter, ved innlemmelse av steriliseringsmidler i preparatene eller ved bestråling. De kan også være fremstilt i fonn av sterile faste preparater (for eksempel frysetørkede preparater) og som kan være oppløst i sterilt vann eller andre sterile fortynningsmidler for injeksjon umiddelbart før bruk.
Andre preparater for parenteral administrering inkluderer væsker for utvortes bruk, og endemiske linimenter, salver, stikkpiller og pessarer som omfatter en eller flere av de aktive forbindelser og kan være fremstilt ved hjelp av kjente metoder.
BESTE MÅTE FOR UTFØRELSE AV OPPFINNELSEN
De etterfølgende referanseeksempler og eksempler er ment å illustrere den foreliggende oppfinnelse.
Løsningsmidlene i parenteser i delen med kromatografiske separasjoner viser ut-viklende eller eluerende løsningsmidler og forholdene av de anvendte løsnings-midler er angitt på volumbasis. Uten spesiell forklaring ble NMR-data bestemt i CDCl3-oppløsning. Videre viser løsningsmidlene i parenteser i delen med NMR-data løsningsmidler anvendt i bestemmelsen.
Referanseeksempel 1
4-(2-nitro-4,5-dimetylfenoksymetyl)-3-metylbenzosyre- metylester
Under argonatmosfære ble en blanding av 2-nitro-4,5-dimetylfenol (4 g), DMF (100 ml), kaliumkarbonat (6,6 g) og 4-mesyloksymetyl-3-metylbenzosyremetyl-ester (6,8 g) omrørt i 15 minutter ved 60 °C. Etter terminering av reaksjonen ble blandingen avkjølt og helt i isvann. Blandingen ble ekstrahert med etylacetat-heksan. Det organiske laget ble vasket, tørket og konsentrert under redusert trykk til å gi tittelforbindelsen (7,22 g) som har de følgende fysiske data.
TLC : Rf 0,24 (n-heksan : etylacetat = 4:1).
Referanseeksempel 2
4-(2-amino-4,5-dimetylfenoksymetyl)-3-metylbenzosyre-metylester
En blanding av 4-(2-nitro-4,5-dimetylfenoksymetyl)-3-metylbenzosyremetylester
fremstilt i referanseeksempel 1 (7,21 g), eddiksyre (88 ml) og vann (8,8 ml) ble om-rørt ved 50°C. Til reaksjonsoppløsningen ble jernpulver (6,11 g) gradvis tilsatt, og blandingen ble omrørt i 1 time ved 50°C. Etter avkjøling ble blandingen filtrert og filtratet ble konsentrert og azeotropbehandlet med toluen. Til resten ble det tilsatt etylacetat - vann (100 ml - 100 ml) og blandingen ble filtrert over Celite (registrert varemerke). Det organiske laget ble vasket, tørket og konsentrert under redusert trykk til å gi tittelforbindelsen (4,66 g) som har de følgende fysiske data.
TLC : Rf 0,51 (n-heksan : etylacetat = 2 : 1).
Referanseeksempel 3
3-metyl-4-[2-[N-(5-metyl-2-furylsulfonyl)amino]-4,5-dimetylfenoksymetyl]-benzosyremetylester
En oppløsning av 4-(2-amino-4,5-dimetylfenoksymetyl)-3-metylbenzosyremetyl-ester fremstilt i referanseeksempel 2 (632 mg) i pyridin (4 ml) ble avkjølt til 0°C, og deretter ble 5-metylfuran-2-sulfonylklorid (490 mg) dråpevis tilsatt dertil. Etter at oppløsningen var omrørt i 1 time ved romtemperatur, ble reaksjonsblandingen fortynnet med etylacetat og helt i vann. Det organiske laget ble vasket, tørket og konsentrert under redusert trykk. Resten ble vasket med blandet løsningsmiddel av diisopropyleter og heksan til å gi tittelforbindelsen (875 mg) som har de følgende fysiske data.
TLC : Rf 0,42 (n-heksan : etylacetat = 2:1).
Eksempel 1
3-metyl-4-[2-|^-isobutyl-N-(5-metyl-2-mi<y>lsulfon<y>l)aiTiino]-4,5-dimetylfenoksy-metyl]benzosyremetylester
Til en oppløsning av 3-metyl-4-[2-[N-(5-metyl-2-furylsulfonyl)amino]-4,5-dimetyl-fenoksymetyl]benzosyremetylester fremstilt i referanseeksempel 3 (870 mg) i N,N-dimetylacetamid (2 ml), ble cesiumkarbonat (1,37 g) og isobutyljodid(0,36 ml) tilsatt og blandingen ble omrørt i 1 time ved 100°C. Reaksjonsblandingen fikk av-kjøles og ble helt i etylacetat - vann (40 ml - 40 ml). Det organiske laget ble vasket, tørket og konsentrert under redusert trykk. Resten ble renset ved kolonnekromatografi på silikagel (toluen - etylacetat) til å gi tittelforbindelsen (855 mg) som har de følgende fysiske data.
TLC : Rf 0,51 (n-heksan : etylacetat = 2:1);
NMR : 8 7.87 (d, J = 8.4 Hz, 1H), 7.86 (s, 1H), 7.38 (d, J = 8.4 Hz, 1H), 7.04 (s, 1H), 6.70 (m, 2H), 5.93 (m, 1H), 4.91 (brs, 2H), 3.92 (s, 3H), 3.48 (m, 2H), 2.34 (s, 3H), 2.23 (s, 3H), 2.18 (s, 3H), 2.09 (s, 3H), 0.90 (brs, 6H).
Eksempel 2
3-metyl-4-[2-pN-isobutyl-N-(5-metyl^ metyllbenzosyre
Til en oppløsning av 3-metyI-4-[2-[N-isobutyl-N-(5-melyl-2-furyIsulfonyl)amino]-4,5-dimetylfenoksymetyl]benzosyremetylester fremstilt i eksempel 1 (850 mg) i dioksan (10 ml), ble det tilsatt 2N vandig natriumhydroksyd (2,5 ml) og metanol (4 ml), og blandingen ble omrørt i 30 timer ved romtemperatur. Til blandingen ble 2N saltsyre tilsatt, og deretter ble etylacetat - vann (30 ml - 15 ml) også tilsatt. Det organiske laget ble vasket, tørket og konsentrert under redusert trykk. Resten ble oppløst i varm etanol (40 ml) og tilsatt varmt vann (40 ml), og fikk deretter av-kjøles. Presipiteringen ble filtrert, og tørket til å gi tittelforbindelsen (755 mg) som har de følgende fysiske data.
TLC : Rf 0,78 (kloroform : metanol: vann = 8:2: 0,2);
NMR : 5 7.94 (d, J = 7.8 Hz, 1H), 7.93 (s, 1H), 7.44 (d, J = 7.8 Hz, 1H), 7.04 (s, 1H), 6.74-6.70 (m, 2H), 5.94 (dd, J = 3.3, 0.9 Hz, 1H), 4.94 (br, 2H), 3.48 (d, J = 6.6 Hz, 2H), 2.37 (s, 3H), 2.24 (s, 3 H), 2.19 (s, 3H), 2.11 (s, 3H), 1.68 (sep, J = 6.6 Hz, 1H), 0.91 (d, J = 6.6 Hz, 6H).
Eksempel 2(1) til eksempel 2(124)
Ved hjelp av de samme prosedyrer som er beskrevet i referanseeksempel 1 til 3, eksempler 1 og 2 ved anvendelse av korresponderende forbindelser, ble tittelforbindelsene som har de følgende fysiske data oppnådd.
Eksempel 2(1)
4-[2-(>J-isobutyl-N-(5-metyl-2-furylsulfonyl)aiTiino]-5-trifluormety^ metyljkanelsyre
TLC : Rf 0,51 (n-heksan : etylacetat: eddiksyre =1:1: 0,02);
NMR : 8 7.80 (d, J = 16.2 Hz, 1H), 7.59 (d, J = 8.0 Hz, 2H), 7.45 - 7.36 (m, 3H), 7.26 (dd, J = 8.2, 1.8 Hz, 1H), 7.18 (d, J = 1.8 Hz, 1H), 7.00- 5.00 (br, 1H), 6.75 (d, J = 3.4 Hz, 1H), 6.49 (d, J = 16.2 Hz, 1H), 5.98 (dq, J = 3.4, 0.8 Hz, 1H), 5.05 (brs, 2H), 3.51 (d, J = 7.4 Hz, 2H), 2.16 (s, 3H), 1.75 - 1.50 (m, 1H), 0.88 (d, J = 6.8 Hz, 6H).
Eksempel 2(2)
4-[2-|^-isopropyl-N-(5-metyl-2-furylsulfonyl)aiTiino]-5-trifluormety benzosyre
TLC : Rf 0,44 (kloroform : metanol = 9:1);
NMR : 8 8.16 (d, J = 8.4 Hz, 2H), 7.60 (d, J = 8.4 Hz, 2H), 7.21-7.26 (m, 3H), 6.84 (d, J = 3.2 Hz, 1H), 6.05 (m, 1H), 5.21 (m, 2H), 4.49 (m, 1H), 2.33 (s, 3H), 1.10 (d, J = 6.6 Hz, 6H).
Eksempel 2(3)
4-[2-P<[-isobutyl-N-(5-metyl-2-benzosyre
TLC : Rf 0,46 (kloroform : metanol = 9:1);
NMR : 8 8.15 (d, J = 8.6 Hz, 2H), 7.46 (d, J = 8.6 Hz, 2H), 7.41 (m, 1H), 7.29 (m, 1H), 7.18 (m, 1H), 6.76 (d, J = 3.4 Hz, 1H), 5.98 (m, 1H), 5.10 (s, 2H), 3.51 (d, J = 6.2 Hz, 2H), 2.16 (s, 3H), 1.64 (m, 1H), 0.90 (d, J = 6.8 Hz, 6H).
Eksempel 2(4)
4-[2-P^-isobutyl-N-(5-metyl-2-miylsulfonyl)amino]-4-klor-5-metylfenoksymetyl]-benzosyre
TLC : Rf 0,30 (kloroform : metanol = 9:1);
NMR : 8 8.12 og 7.46 (hver d, J = 8.1 Hz, hver 2H), 7.20 (s, 1H), 6.81-6.75 (m, 2H), 6.01-5.98 (m, 1H), 5.12-4.98 (m, 2H), 3.45 (d, J = 7.5 Hz, 2H), 2.34 og 2.19 (hver s, hver 3H), 1.75-1.59 (m, 1H), 0.91 (d, J = 6.9 Hz, 6H).
Eksempel 2(5)
4-[2-[N-isopropy l-N-(5-metyl-2-ft^ benzosyre
TLC : Rf 0,38 (kloroform : metanol = 10 : 1);
NMR : 8 8.12-8.09 (m, 2H), 7.56 (d, J = 8.4 Hz, 2H), 6.81 (s, 1H), 6.79 (d, J = 3.3 Hz, 1H), 6.75 (s, 1H), 6.02 (dd, J = 3.3, 1.2 Hz, 1H), 5.10 (s, 2H), 4.48 (m, 1H), 2.30 (s, 3H), 2.23 (s, 3H), 2.17 (s, 3H), 1.11 (d, J = 6.6 Hz, 6H).
Eksempel 2(6)
4-[2-[N-isobutyl-N-(5-meytl-2-fu^ benzosyre
TLC : Rf 0,38 (kloroform : metanol = 10 : 1);
NMR : 8 8.12-8.08 (m, 2H), 7.42 (d, J = 8.4 Hz, 2H), 7.03 (s, 1H), 6.71 (d, J = 3.3 Hz, 1H), 6.68 (s, 1H), 5.92 (dd, J = 3.3, 0.9 Hz, 1H), 5.00 (brs, 2H), 3.52-3.46 (m, 2H), 2.22 (s, 3H), 2.18 (s, 3H), 2.13 (s, 3H), 1.68 (m, 1H), 0.91 (d, J = 6.6 Hz, 6H).
Eksempel 2(7)
3-metyl-4-[2-P^-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-4-metyl-5-ldorfenoks metyllbenzosyre
TLC : Rf 0,42 (kloroform : metanol = 9:1); NMR : 8 8.00-7.89 (m, 2H), 7.41 (d, J = 8.4 Hz, 1H), 7.16 (s, 1H), 6.95 (s, 1H), 6.74 (d, J = 3.3 Hz, 1H), 5.96 (m, 1H), 4.94 (s, 2H), 3.47 (d, J = 6.3 Hz, 2H), 2.37 (s, 3H), 2.30 (s, 3H), 2.11 (s, 3H), 1.64 (m, 1H), 0.90 (d, J = 6.6 Hz, 6H). Eksempel 2(8) 3-metyl-4-[2-[N-isobutyl-N-(5-metyl-2-mrylsulfonyl)airiino]-4-klor-5-metylfeno metvllbenzosYre
TLC : Rf 0,58 (kloroform : metanol = 9:1);
NMR : 8 7.96 (d, J = 7.5 Hz, 1H), 7.94 (s, 1H), 7.47 (d, J = 7.5 Hz, 1H), 7.20 (s, 1H), 6.81 (s, 1H), 6.77 (d, J = 3.3 Hz, 1H), 6.03-5.97 (m, 1H), 4.99 (brs, 2H), 3.44 (d, J = 7.5 Hz, 2H), 2.39 (s, 3H), 2.36 (s, 3H), 2.17 (s, 3H), 1.75-1.60 (m, 1H), 0.89 (d, J = 6.6 Hz, 6H).
Eksempel 2(9)
3-ldor-4-[2-|^-isobutyl-N-(5-metyl-2-furylsulfonyl)aiTiino] metyllbenzosyre
TLC : Rf 0,38 (kloroform : metanol = 9:1);
NMR : 8 8.13 (d, J = 1.5 Hz, 1H), 8.02 (dd, J = 8.4, 1.5 Hz, 1H), 7.58 (d, J = 8.4 Hz, 1H), 7.15 (s, 1H), 6.94 (s, 1H), 6.76 (d, J = 3.3 Hz, 1H), 5.98 (m, 1H), 5.25-4.90 (br, 2H), 3.48 (d, J = 6.6 Hz, 2H), 2.31 (s, 3H), 2.16 (s, 3H), 1.64 (m, 1H), 0.92 (d, J = 6.6 Hz, 6H).
Eksempel 2(10)
3-klor-4-[2-|TSf-isopropyl-N-(5-metyl-2-mrylsulfonyl)amino]-4-metyl-5-klorfe^ metyllbenzosyre
TLC : Rf 0,38 (kloroform : metanol = 9:1);
NMR : 8 8.12 (d, J = 1.5 Hz, 1H), 8.07 (dd, J = 8.4, 1.5 Hz, 1H), 7.88 (d, J = 8.4 Hz, 1H), 6.99 (s, 1H), 6.95 (s, 1H), 6.85 (d, J = 3.3 Hz, 1H), 6.06 (m, 1H), 5.20 (d, J = 14.4 Hz, 1H), 5.15 (d, J = 14.4 Hz, 1H), 4.48 (m, 1H), 2.33 (s, 3H), 2.30 (s, 3H), 1.11 (d, J = 6.3 Hz, 3H), 1.09 (d, J = 6.3 Hz, 3H).
Eksempel 2(11)
3-metoksy-4-[2-pS[-isopropyl-N-(5-metyl-2-furylsulfonyl)ainino]-4-metyl-5-klorfenoksymetyl]benzosyre
TLC : Rf 0,49 (kloroform : metanol = 9:1);
NMR : 8 7.78 (dd, J = 8.1, 1.5 Hz, 1H), 7.76 (d, J = 1.5 Hz, 1H), 7.59 (d, J = 1.5 Hz, 1H), 7.01 (s, 1H), 6.96 (s, 1H), 6.83 (d, J = 3.3 Hz, 1H), 6.05- 6.00 (m, 1H), 5.11 (d, J = 14.1 Hz, 1H), 5.07 (d, J = 14.1 Hz, 1H), 4.55-4.40(m, 1H), 3.94 (s, 3H), 2.30 (s, 3H), 2.29 (s, 3H), 1.12 (d, J = 6.9 Hz, 6H).
Eksempel 2(12)
3-metoksy-4-[2-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)amino]-4,5-dimetyl-fenoksymetyllbenzosyre
TLC : Rf 0,44 (kloroform : metanol = 9:1);
NMR : 8 7.77 (dd, J = 8.1, 1.2 Hz, 1H), 7.74 (d, J = 8.1 Hz, 1H), 7.58 (d, J = 1.2 Hz, 1H), 6.84 (s, 1H), 6.81 (d, J = 3.3 Hz, 1H), 6.78 (s, 1H), 6.05- 6.00 (m, 1H), 5.09 (s, 2H), 4.60-4.40 (m, 1H), 3.94 (s, 3H), 2.29 (s, 3H), 2.24 (s, 3H), 2.17 (s, 3H), 1.12 (d, J = 6.9Hz, 6H).
Eksempel 2(13)
3-metoksy-4-[2-|^-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-4,5-dimetylfenok^^ metyllbenzosyre
TLC : Rf 0,45 (kloroform : metanol = 9:1);
NMR : 8 7.73 (dd, J = 8.1, 1.2 Hz, 1H), 7.58 (d, J = 1.2 Hz, 1H), 7.40 (d, J = 8.1 Hz, 1H), 7.07 (s, 1H), 6.75-6.70 (m, 2H), 5.95-5.90 (m, 1H), 5.15-4.85 (m, 2H), 3.94 (s, 3H), 3.51 (br, 2H), 2.23 (s, 3H), 2.19 (s, 3H), 2.11 (s, 3H), 1.80-1.60 (m, 1H), 0.94 (br, 6H).
Eksempel 2(14) 3-metoksy-4-[2-[N-isopropyl-N-(5-fenoksymetyllbenzosyre
TLC : Rf 0,46 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 8 13.02 (s, 1H), 7.58-7.50 (m, 3H), 7.24 (s, 1H), 6.98 (s, 1H), 6.94 (d, J = 3.3 Hz, 1H), 6.25 (m, 1H), 5.10 (d, J = 13.5 Hz, 1H), 5.04 (d, J = 13.5 Hz, 1H), 4.24 (m, 1H), 3.87 (s, 3H), 2.34 (s, 3H), 2.27 (s, 3H), 0.99 (d, J = 6.6 Hz, 3H), 0.98 (d,J = 6.6 Hz, 3H).
Eksempel 2(15)
3-klor-4-[2-[N-isobuty l-N-(5-mety^^ metyllbenzosyre
TLC : Rf 0,40 (kloroform : metanol = 9:1);
NMR : 8 8.12 (d, J = 1.8 Hz, 1H), 8.02 (dd, J = 8.1, 1.8 Hz, 1H), 7.61 (d, J = 8.1 Hz, 1H), 7.03 (s, 1H), 6.75 (d, J = 3.3 Hz, 1H), 6.70 (s, 1H), 5.96 (m, 1H), 5.25-4.85 (br, 2H), 3.50 (d, J = 6.6 Hz, 2H), 2.24 (s, 3H), 2.19 (s, 3H), 2.16 (s, 3H), 1.79 (m, 1H), 0.93 (d, J = 6.6 Hz, 6H).
Eksempel 2(16)
3-klor-4-[2-|l^-isopropyl-N-(5-metyl-2-fr^ metyllbenzosyre
TLC : Rf 0,39 (kloroform : metanol = 9:1);
NMR: 8 8.11 (d,J=1.8Hz, 1H), 8.06 (dd, J = 8.1, 1.8 Hz, 1H), 7.90 (d,J=8.1 Hz, 1H), 6.86-6.80 (m, 2H), 6.75 (s, 1H), 6.05 (m, 1H), 5.17 (s, 2H), 4.51 (m, 1H), 2.32 (s, 3H), 2.25 (s, 3H), 2.18 (s, 3H), 1.12 (d, J = 6.6 Hz, 3H), 1.11 (d, J = 6.6 Hz, 3H).
Eksempel 2(17)
3-mety 1-4-[2-[N-isobutyl-^ metvllkanelsvre
TLC : Rf 0,37 (kloroform : metanol = 9 :1);
NMR(CD3OD): 5 7.63 (d, J = 16.2 Hz, 1H), 7.45 (s) og 7.44 (d, J = 8.1 Hz) total 2H,7.34 (d, J=8.1Hz, lH),7.17(s, 1H), 7.10 (s, 1H), 6.72 (d,J = 3.3Hz, 1H), 6.50 (d, J = 16.2 Hz, 1H), 6.08 (dd, J = 3.3, 1.2 Hz, 1H), 4.98 (brs, 2H), 3.44 (d, J = 6.9 Hz, 2H), 2.37 (s, 3H), 2.35 (s, 3H), 2.10 (s, 3H), 1.60 (m, 1H), 0.87 (d, J = 6.6 Hz, 6H).
Eksempel 2(18)
4-[2-|^-isopropyl-N-(5-metyl-2-mrylsutf kanels<y>re
TLC : Rf 0,31 (kloroform : metanol = 9:1);
NMR.: 5 7.73 (d, J = 15.9 Hz, 1H), 7.57 og 7.49 (hver d, J = 8.1 Hz, hver 2H), 6.98 og 6.92 (hver s, hver 1H), 6.81 (d, J = 3.3 Hz, 1H), 6.46 (d, J = 15.9 Hz, 1H), 6.03 (d, J = 3.3 Hz, 1H), 5.05 (s, 2H), 4.50-4.38 (m, 1H), 2.30 og 2.28 (hver s, hver 3H), 1.10 og 1.09 (hver d, J = 6.6 Hz, hver 3H).
Eksempel 2(19)
4-[2-[N-isobutyl-N-(5-metyl-2-mryte kanelsyre
TLC : Rf 0,31 (kloroform : metanol = 9:1);
NMR : 5 7.77 (d, J = 15.9 Hz, 1H), 7.56 og 7.35 (hver d, J = 7.8 Hz, hver 2H), 7.14 og 6.92 (hver s, hver 1H), 6.72 (d, J = 3.6 Hz, 1H), 6.47 (d, J = 15.9 Hz, 1H), 5.95 (d, J = 3.6 Hz, 1H), 5.00-4.88 (m, 2H), 3.52-3.42 (m, 2H), 2.29 og 2.13 (hver s, hver 3H), 1.72-1.60 (m, 1H),0.90 (d, J = 6.3 Hz, 6H).
Eksempel 2(20)
4-[2-[N-isopropyl-N-(5-metyl-2-faiylsulfo kanelsyre
TLC : Rf 0,39 (kloroform : metanol = 9:1);
NMR : 5 7.78 (d, J = 15.9 Hz, 1H), 7.57 (d, J = 8.4 Hz, 2H), 7.50 (d, J = 8.4 Hz, 2H), 6.80 (s, 1H), 6.79 (d, J = 3.3 Hz, 1H), 6.76 (s, 1H), 6.46 (d, J = 15.9 Hz, 1H), 6.01 (m, 1H), 5.06 (s, 2H), 4.47 (sept, J = 6.6 Hz, 1H), 2.30 (s, 3H), 2.23 (s, 3H), 2.16 (s, 3H), 1.11 og 1.10 (hver d, J = 6.6 Hz, hver 3H).
Eksempel 2(21)
3-metyl-4-[2-psT-isopropyl-N-(5-metyl-2-furylsulfonyl)amino]-5-M fenoksymetyllkanelsyre
TLC : Rf 0,42 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 8 12.36 (br s, 1H), 7.61-7.52 (m, 5H), 7.38 (d, J = 8.0 Hz, 1H), 7.24 (d, J = 8.0 Hz, 1H), 6.96 (d, J = 3.5 Hz, 1H), 6.54 (d, J = 16.0 Hz, 1H), 6.28 (d, J = 3.5 Hz, 1H), 5.24 (d, J = 13.0 Hz, 1H), 5.18 (d, J = 13.0 Hz, 1H), 4.26 (septett, J = 6.5 Hz, 1H), 2.35 (s, 3H), 2.30 (s, 3H), 0.97 (d, J = 6.5 Hz, 6H).
Eksempel 2(22)
3-metyl-4-[2-[N-isopropyl-N-(5-metyl-2-mrylsulfonyl)amino]-4,5-dimetylfenoksy-metvllbenzosvre ,
TLC : Rf 0,28 (n-heksan : etylacetat =1:1);
NMR : 8 7.97 (d, J = 7.8 Hz, 1H), 7.93 (s, 1H), 7.65 (d, J = 7.8 Hz, 1H), 6.82 (s, 1H), 6.79 (d, J = 3.3 Hz, 1H), 6.77 (s, 1H), 6.01 (dd, J = 3.3, 1.2 Hz, 1H), 5.08 (d, J = 13.2 Hz, 1H), 5.02 (d, J = 13.2 Hz, 1H), 4.47 (kvint, J = 6.6 Hz, 1H), 2.40 (s, 3H), 2.29 (s, 3H), 2.25 (s, 3H), 2.17 (s, 3H), 1.11 (d, J = 6.6 Hz, 6H).
Eksempel 2(23)
3-metyl-4-[2-P^-isopropyl-N-(5-metyl-2-fuiylsulfonyl)amino]-4,5-dimetylfenoksy metyllkanelsyre
TLC : Rf 0,30 (n-heksan : etylacetat =1:2);
MS (FAB, Pos.) : 498 (M + H)<+>.
Eksempel 2(24)
3 -mety 1-4- [2- [N-isobuty l-N-(5 -mety l-2-furylsulfonyl)amino] -4,5 -dimety lfenoksy-metyllkanelsyre
TLC : Rf 0,26 (n-heksan : etylacetat =1:2);
MS (FAB, Pos.): 512 (M + H)<+>.
Eksempel 2(25)
4-[2-psT-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-4,5-dimetylfenoksymetyl]-kanelsyre
TLC : Rf 0,47 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 8 7.69 (d, J = 8.1 Hz, 2H), 7.58 (d, J = 16.2 Hz, 1H), 7.34 (d, J = 8.1 Hz, 2H), 6.93 (s, 1H), 6.90 (s, 1H), 6.79 (d, J = 3.3 Hz, 1H), 6.54 (d, J = 16.2 Hz, 1H), 6.13 (m, 1H), 5.10-4.80 (m, 2H), 3.40- 3.20 (m, 2H, dekket med H20 i
fy
DMSO-d6), 2.18 (s, 3H), 2.11 (s, 3H), 2.10 (s, 3H), 1.58-1.42 (m, 1H), 0.82 (d, J = 6.6 Hz, 6H).
Eksempel 2(26)
3-metoksy-4-[2-[N-isobutyl-N-(5-metyl-2-ofiylsulfonyl)amino]-4-mety klorfenoksymetyllkanelsyre
TLC : Rf 0,30 (kloroform : metanol = 9:1);
NMR : 8 7.76 (d, J = 15.9 Hz, 1H), 7.30 (d, J = 8.1 Hz, 1H), 7.26 (s, 1H), 7.20 (d, J = 8.1 Hz, 1H), 7.04 (s, 1H), 6.96 (s, 1H), 6.72 (d, J = 3.3 Hz, 1H), 6.46 (d, J = 15.9 Hz, 1H), 6.00-5.90 (m, 1H), 4.95 (brs, 2H), 3.91 (s, 3H), 3.48 (brs, 2H), 2.29 (s, 3H), 2.13 (s, 3H), 1.75-1.60 (m, 1H), 0.91 (brd, J = 6.6 Hz, 6H).
Eksempel 2(27)
4-[6-p^-isobu1yl-N-(5-metyl-2-furylsulfonyl)amino]indan-5-yloksymetyl^ svre
TLC : Rf 0,45 (kloroform : metanol = 9:1);
NMR : 8 8.11 (d, J = 8.1 Hz, 2H), 7.43 (d, J = 8.1 Hz, 2H), 7.12 (s, 1H), 6.77 (s, 1H), 6.73 (d, J = 3.3 Hz, 1H), 5.94 (m, 1H), 5.15-4.85 (br, 2H), 3.60-3.40 (br, 2H), 2.86 (t, J = 7.2 Hz, 4H), 2.14 (s, 3H), 2.13-2.00 (m, 2H), 1.68 (m, 1H), 1.02-0.82 (br, 6H).
Eksempel 2(28)
4-[6-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)amino]indan-5-yloksymetyl]benzo-svre
TLC : Rf 0,45 (kloroform : metanol = 9:1);
NMR : 8 8.12 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.4 Hz, 2H), 6.90 (s, 1H), 6.83 (s, 1H), 6.81 (d, J = 3.3 Hz, 1H), 6.02 (m, 1H), 5.17-5.05 (m, 2H), 4.49 (m, 1H), 2.93-2.79 (m, 4H), 2.31 (s, 3H), 2.15-2.00 (m, 2H), 1.12 (d, J = 6.6 Hz, 3H), 1.11 (d, J = 6.6 Hz, 3H).
Eksempel 2(29)
4-[7-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)ainino]-l,2,3,4-tetrahydro yloksymetyl]benzosyre
TLC : Rf 0,45 (kloroform : metanol = 9:1);
NMR : 8 8.10 (d, J = 8.1 Hz, 2H), 7.42 (d, J = 8.1 Hz, 2H), 6.95 (s, 1H), 6.73 (d, J = 3.3 Hz, 1H), 6.57 (s, 1H), 5.93 (m, 1H), 5.15-4.82 (br, 2H), 3.48 (d, J = 7.2 Hz, 2H), 2.77-2.60 (m, 4H), 2.13 (s, 3H), 1.82-1.60 (m, 5H), 0.92 (d, J = 6.6 Hz, 6H).
Eksempel 2(30)
4-[7-[N-isopropyl-N-(5-metyl-2-mrylsulfonyl)ainino]-l,2,3,4-tetrahydronaftalen-6-yloksymetyl]benzosyre
TLC : Rf 0,45 (kloroform : metanol = 9-1);
NMR : 8 8.12 (d, J = 8.4 Hz, 2H), 7.56 (d, J = 8.4 Hz, 2H), 6.80 (d, J = 3.3 Hz, 1H), 6.74 (s, 1H), 6.64 (s, 1H), 6.02 (m, 1H), 5.16-5.04 (m, 2H), 4.48 (m, 1H), 2.77-2.58 (m, 4H),2.30(s, 3H), 1.82-1.69 (m, 4H), 1.12 (d, J = 6.6 Hz, 3H), 1.11 (d, J = 6.6 Hz, 3H).
Eksempel 2(31)
3-metyl-4-[2-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-4-metyl-5-klorfenoksy-metvll kanel svre
TLC : Rf 0,30 (kloroform : metanol = 9:1);
NMR(CD3OD) : 8 7.65 (d, J = 15.9 Hz, 1H), 7.46 (s) og 7.44 (d, J = 7.8 Hz) total 2H, 7.34 (d, J = 7.8 Hz, 1H), 7.18 (s, 1H), 7.14 (s, 1H), 6.71 (d, J = 3.3 Hz, 1H), 6.50 (d, J = 15.9 Hz, 1H), 6.07 (dd, J = 3.3, 0.9 Hz, 1H), 4.95 (m, 2H), 3.44 (d, J = 7.5 Hz, 2H), 2.35 (s, 3H), 2.28 (s, 3H), 2.09 (s, 3H), 1.61 (m, 1H), 0.87 (d, J = 6.6 Hz, 6IT).
Eksempel 2(32)
4-[6-pSf-isobutyl-N-(5-metyl-2-fuiylsulfonyl)amino]indan-5-yloksymetyl]kanelsy
TLC : Rf 0,42 (kloroform : metanol = 9:1);
NMR : 8 7.79 (d, J = 15.9 Hz, 1H), 7.55 (d, J = 8.1 Hz, 2H), 7.37 (d, J= 8.1 Hz, 2H), 7.11 (s, 1H), 6.78 (s, 1H), 6.71 (d, J = 3.3 Hz, 1H), 6.47 (d, J = 15.9 Hz, 1H), 5.93 (m, 1H), 5.10-4.80 (br, 2H), 3.60-3.40 (br, 2H), 2.86 (t, J = 7.5 Hz, 4H), 2.14 (s, 3H), 2.08 (m, 2H), 1.68 (m, 1H), 1.00-0.82 (br, 6H).
Eksempel 2(33)
3-metyl-4-[6-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)airiino]indan-5-yloksymetyl]-benzosyre
TLC : Rf 0,33 (kloroform : metanol = 10 : 1);
NMR(CDC13 + 1 dråpe CD3OD) : 8 7.89 (d, J = 8.4 Hz, 1H), 7.88 (s, 1H), 7.39 (d, J = 8.4 Hz, 1H), 7.12 (s, 1H), 6.79 (s, 1H), 6.71 (d, J = 3.3 Hz, 1H), 5.94 (m, 1H), 5.06-4.74 (m, 2H), 3.60-3.37 (m, 2H), 2.92-2.82 (m, 4H), 2.34 (s, 3H), 2.17-2.03 (m, 2H), 2.10 (s, 3H), 1.69 (m, 1H), 1.01-0.80 (m, 6H).
Eksempel 2(34)
3-metyl-4-[6-[N-isobu1yl-N-(5-me1yl-2-mrylsulfonyl)amino]indan-5-yloksymetyl]-kanelsyre
TLC : Rf 0,30 (kloroform : metanol =10:1);
NMR : 5 7.78 (d, J= 15.9 Hz, 1H), 7.42-7.36 (m, 3H), 7.10 (s, 1H), 6.80 (s, 1H), 6.72 (d, J = 3.3 Hz, 1H), 6.46 (d, J = 15.9 Hz, 1H), 5.94 (m, 1H), 5.04-4.77 (m, 2H), 3.59-3.37 (m, 2H), 2.91-2.82 (m, 4H), 2.34 (s, 3H), 2.14-2.05 (m, 2H), 2.12 (s, 3H), 1.68 (m, 1H), 1.00-0.82 (m, 6H).
Eksempel 2(35)
4-[2-[N-(2-metyl-2-propenyl)-N-(5-metyl-2-furylsulfonyl)amino]-4,5-dimety fenoksvmetvllbenzosvre
TLC : Rf 0,42 (kloroform : metanol = 10 : 1);
NMR : 5 8.11 (d, J = 8.1 Hz, 2H), 7.42 (d, J = 8.1 Hz, 2H), 7.02 (s, 1H), 6.74 (d, J = 3.3 Hz, 1H), 6.67 (s, 1H), 6.00-5.95 (m, 1H), 5.00 (brs, 2H), 4.77 (s, 2H), 4.26 (brs, 2H), 2.21 (s, 3H), 2.17 (s, 3H), 2.13 (s, 3H), 1.78 (s, 3H).
Eksempel 2(36)
4-[2-[N-isopropyl-N-(2-tiazolylsulfonyl)amino]-5-trifluormetylfenoksymetyl]-benzosyre
TLC : Rf 0,58 (etylacetat);
NMR(CD3OD): 5 8.03 (d, J = 8.7 Hz, 2H), 7.92 (d, J = 3.3 Hz, 1H), 7.82 (d, J = 3.3 Hz, 1H), 7.54 (d, J = 8.4 Hz, 2H), 7.43 (brs, 1H), 7.37 (d, J = 8.1 Hz, 1H), 7.30 (brd, J = 8.1 Hz, 1H), 5.23 (ABd, J = 12.6 Hz) og 5.14 (ABd, J = 12.6 Hz) total 2H, 4.64 (sept, J = 6.9 Hz, 1H), 1.15 (d, J = 6.9 Hz) og 1.14 (d, J = 6.9 Hz) total 6H.
Eksempel 2(37) 4-[2-[N-isobutyl-N-(2-tiazoly lsulfony l)amin^ benzosyre
TLC : Rf 0,60 (etylacetat);
NMR(CD3OD): 8 8.02 (d, J = 8.7 Hz, 2H), 7.74 (m, 2H), 7.52 (d, J = 7.2 Hz, 1H), 7.38 (d, J = 8.7 Hz) og 7.37 (s) total 3H, 7.32 (brd, J = 7.2 Hz, 1H), 5.02 (br, 2H), 3.60 (brd, J = 7.5 Hz, 2H), 1.70-1.58 (m, 1H), 0.92 (d, J = 6.9 Hz, 6H).
Eksempel 2(38)
4-[2-^-isopropyl-N-(2-tiazolylsulfonyl)amino]-5-trifluoniie1ylfenoksymetyl]-kanelsyre
TLC : Rf 0,42 (kloroform : metanol = 9:1);
NMR(CD3OD) : 8 7.91 (d, J = 3 Hz, 1H), 7.81 (d, J = 3 Hz, 1H), 7.69 (d, J = 15.9 Hz, 1H), 7.63 (d, J = 8.4 Hz, 2H), 7.48 (d, J = 8.4 Hz, 2H), 7.42 (s, 1H), 7.36 (d, J = 8.1 Hz, 1H), 7.29 (brd, J = 8.1 Hz, 1H), 6.52 (d, J = 15.9 Hz, 1H), 5.18 (ABd, J = 12.3 Hz) og 5.09 (ABd, J = 12.3 Hz) total 2H, 4.63 (sept, J = 6.6 Hz, 1H), 1.15 (d, J = 6.6 Hz) og 1.13 (d, J = 6.6 Hz) total 6H.
Eksempel 2(39)
4-[2-[N-isobutyl-N-(2-tiazolylsulfonyl)airiino]-5-trifluormetylfenoksymetyl]-kanelsyre
TLC : Rf 0,42 (kloroform : metanol = 9:1);
NMR(CD3OD): 8 7.76-7.70 (m, 2H), 7.64 (s) og 7.63 (d, J = 15.9 Hz) total 3H, 7.52 (d, J = 8.1 Hz, 1H), 7.38-7.28 (m, 4H), 6.53 (d, J = 15.9 Hz, 1H), 5.04-4.90 (rn, 2H), 3.60 (brd, J = 6.9 Hz, 2H), 1.72-1.56 (m, 1H), 0.92 (d, J = 6.6 Hz, 6H).
Eksempel 2(40)
4-[2-[N-isobutyl-N-(4-mety 1-2-tiaz benzosyre
TLC : Rf 0,42 (kloroform : metanol = 9:1);
NMR(CD3OD): 6 8.03 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 8.1 Hz, 1H), 7.42-7.30 (m) og 7.27 (s) total 5H, 5.18-4.90 (m, 2H), 3.63-3.58 (m, 2H), 2.23 (d, J = 0.9 Hz, 3H), 1.66 (m, 1H), 0.93 (d, J = 6.6 Hz, 6H).
Eksempel 2(41)
4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-5-trifluormetylfenoksymetyl]-kanelsyre
TLC : Rf 0,32 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 8 7.70 (d, J = 8.1 Hz, 2H), 7.60 (d, J = 15.9 Hz, 1H), 7.56-7.46 (m, 3H), 7.38 (d, J = 8.7 Hz, 1H), 7.29 (d, J = 8.1 Hz, 2H), 6.56 (d, J = 15.9 Hz, 1H), 5.20-4.85 (m, 2H), 3.49 (d, J = 6.9 Hz, 2H), 2.21 (s, 3H), 1.53 (m, 1H), 0.84 (d, J = 6.6 Hz, 6H).
Eksempel 2(42)
4-[2-[N-isopropyl-N-(2-tiazolylsulfonyl)amino]-4-klor-5-metylfenoksymetyl]-benzosyre
TLC : Rf 0,39 (kloroform : metanol = 9:1);
NMR : 8 8.13 (d, J = 8.1 Hz, 2H), 7.91 (d, J = 3.0 Hz, 1H), 7.52 (d, J = 8.1 Hz, 2H), 7.50 (d, J = 3.0 Hz, 1H), 7.10 (s, 1H), 6.85 (s, 1H), 5.09 (s, 2H), 4.67 (m, 1H), 2.36 (s, 3H), 1.16 (d, J = 6.6 Hz, 3H), 1.15 (d, J = 6.6 Hz, 3H).
Eksempel 2(43)
4-[2-[N-isopropyl-N-(4-metyl-2-ti^ metyllbenzosyre
TLC : Rf 0,39 (kloroform : metanol = 10 : 1);
NMR : 5 8.13 (d, J = 8.1 Hz, 2H), 7.52 (d, J = 8.1 Hz, 2H), 7.09 (s, 1H), 7.04 (m, 1H), 6.85 (s, 1H), 5.10 (s, 2H), 4.68 (m, 1H), 2.49 (d, J = 0.6 Hz, 3H), 2.36 (s, 3H), 1.15 (d, J = 6.6 Hz, 3H), 1.14 (d, J = 6.6 Hz, 3H).
Eksempel 2(44)
4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4-klor-5-metylfenoksymetyl]-benzosyre
TLC : Rf 0,40 (kloroform : metanol = 10 : 1);
NMR : 8 8.12 (d, J = 7.5 Hz, 2H), 7.37 (d, J = 7.5 Hz, 2H), 7.27 (d, J = 1.2 Hz, 1H), 6.96 (m, 1H), 6.78 (s, 1H), 5.10-4.78 (m, 2H), 3.57 (brs, 2H), 2.35 (s, 3H), 2.34 (s, 3H), 1.70 (m, 1H), 0.94 (d, J = 6.6 Hz, 6H).
Eksempel 2(45)
3-klor-4-[2-[N-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4-klor-5-metyl-fenoksymetyllbenzosyre
TLC : Rf 0,69 (kloroform : metanol: vann = 8:2: 0.2);
NMR : 8 8.12 (d, J = 1.5 Hz, 1H), 8.06 (dd, J = 8.1, 1.5 Hz, 1H), 7.83 (d, J = 8.1 Hz, 1H), 7.11-7.10 (m, 2H), 6.86 (s, 1H), 5.23 (d, J= 14.4 Hz, 1H), 5.15 (d, J = 14.4 Hz, 1H), 4.71 (kvint, J = 6.6 Hz, 1H), 2.52 (d, J = 1.2 Hz, 3H), 2.38 (s, 3H), 1.56 (d, J = 6.6 Hz, 3H), 1.34 (d, J = 6.6 Hz, 3H).
Eksempel 2(46)
3-metyl-4-[2-|^-isobutyl-N-(4-fenoksymetyllbenzosyre
TLC : Rf 0,44 (kloroform : metanol = 9:1);
NMR : 6 7.96 (d, J = 8.4 Hz, 1H), 7.95 (s, 1H), 7.48 (d, J = 8.1 Hz, 1H), 7.35 (d, J = 8.4 Hz, 1H), 7.32-7.24 (m, 1H), 7.20 (s, 1H), 6.98 (s, 1H), 5.06-4.85 (m, 2H), 3.70-3.50 (m, 2H), 2.39 (s, 3H), 2.34 (s, 3H), 1.75-1.59 (m, 1H), 0.91 (d, J = 6.6 Hz, 6H).
Eksempel 2(47)
3-metyl-4-[2-[Nf-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4-klor-5-metyl-fenoksymetyllbenzosyre
TLC : Rf 0,44 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 5 7.79 (s, 1H), 7.76 (d, J = 8.1 Hz, 1H), 7.56 (s, 1H), 7.29 (s, 1H), 7.27 (d, J = 8.1 Hz, 1H), 7.23 (s, 1H), 5.20-4.65 (m, 2H), 3.55-3.35 (m, 2H), 2.36 (s, 3H),2.31 (s, 3H), 2.21 (s, 3H), 1.65-1.47 (m, 1H), 0.84 (d, J = 6.6 Hz, 6H).
Eksempel 2(48)
3-metoksy-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4-klor-5-metylfenoksymetyl]benzosyre
TLC : Rf 0,48 (kloroform : metanol = 9:1);
NMR : 5 7.74 (dd, J = 7.8, 1.2 Hz, 1H), 7.59 (d, J = 1.2 Hz, 1H), 7.31 (d, J = 7.8 Hz, 1H), 7.30 (s, 1H), 6.94 (s, 1H), 6.81 (s, 1H), 5.10-4.70 (m, 2H), 3.94 (s, 3H), 3.59 (br, 2H), 2.35 (s, 3H), 2.34 (s, 3H), 1.80-1.60 (m, 1H), 1.12 (d, J = 6.9 Hz, 6H).
Eksempel 2(49)
3-metoksy-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-5-trifluom fenoksymetyllbenzosyre
TLC : Rf 0,40 (kloroform : metanol = 9:1);
NMR : 8 7.73 (dd, J = 8.1, 1.5 Hz, 1H), 7.60 (d, J = 1.5 Hz, 1H), 7.50 (d, J = 8.1
Hz, 1H), 7.34-7.19 (m, 3H), 6.95 (m, 1H), 5.12-4.80 (m, 2H), 3.95 (s, 3H), 3.77-3.48 (m, 2H), 2.34 (s, 3H), 1.77-1.60 (m, 1H), 0.94 (d, J = 6.6 Hz, 6H).
Eksempel 2(50)
4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4-metyl-5-klorfenoksymetyl]-benzosyre
TLC : Rf 0,38 (kloroform : metanol = 9:1);
NMR : 5 8.11 og 7.33 (hver d, J = 8.4 Hz, hver 2H), 7.22 (s, 1H), 6.92 og 6.91 (hver s, hver 1H), 5.10-4.70 (m, 2H), 3.74-3.42 (m, 2H), 2.31 og 2.30 (hver s, hver 3H), 1.78-1.62 (m, 1H), 1.05-0.83 (m, 6H).
Eksempel 2(51)
3-klor-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4-metyl-5-klor-fenoksvmetvllbenzosvre
TLC : Rf 0,28 (kloroform : metanol = 9:1);
NMR : 5 8.11 (s, 1H), 8.02 og 7.45 (hver d, J = 8.1 Hz, hver 1H), 7.21 (s, 1H), 6.97 \
(s, 1H), 6.94 (s, 1H), 5.12-4.74 (m, 2H), 3.75-3.45 (m, 2H), 2.32 og 2.31 (hver s,
hver 3H), 1.80-1.62 (m, 1H), 1.05-0.82 (m, 6H).
Eksempel 2(52)
3-metoksy-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)aiTiino]-4-metyl-5-klor-fenoksymetyllbenzosyre
TLC : Rf 0,35 (kloroform : metanol = 9:1);
NMR : 8 7.73 (d, J = 7.8 Hz, 1H), 7.59 (s, 1H), 7.30-7.20 (m, 2H), 6.95 (s, 1H), 6.91 (s, 1H), 5.09-4.62 (m, 2H), 3.94 (s, 3H), 3.78-3.45 (m, 2H), 2.31 (s, 6H), 1.79-1.63 (m, 1H), 1.08-0.85 (m, 6H).
Eksempel 2(53)
3-metyl-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksy-metyl] benzosyre
TLC : Rf 0,76 (kloroform : metanol: vann = 8:2: 0.2); NMR : 8 7.93 (d, J = 8.1 Hz, 1H), 7.92 (s, 1H), 7.30 (d, J = 8.1 Hz, 1H), 7.08 (s, 1H), 6.90 (d, J = 0.9 Hz, 1H), 6.71 (s, 1H), 4.91 (br, 1H), 4.79 (br, 1H), 3.65 (br, 1H), 3.56 (br, 1H), 2.35 (s, 3H), 2.30 (d, J = 0.9 Hz, 3H), 2.24 (s, 3H), 2.19 (s, 3H), 1.71 (sep, J = 6.9 Hz, 1H), 1.03-0.92 (br, 6H). Eksempel 2(54) 3-metyl-4-[2-[N-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksy-metyllbenzosyre
TLC : Rf 0,78 (kloroform : metanol: vann = 8:2: 0.2);
NMR : 5 7.95 (d, J = 8.1 Hz, 1H), 7.93 (s, 1H), 7.54 (d, J = 8.1 Hz, 1H), 6.98 (d, J = 0.9 Hz, 1H), 6.86 (s, 1H), 6.78 (s, 1H), 5.03 (d, J = 13.2 Hz, 1H), 4.98 (d, J = 13.2 Hz, 1H), 4.69 (kvint, J = 6.6 Hz, 1H), 2.46 (d, J = 0.9 Hz, 3H), 2.39 (s, 3H), 2.25 (s, 3H),2.16(s, 3H), 1.17 (d, J = 6.6Hz, 3H), 1.13 (d, J = 6.6 Hz, 3H).
Eksempel 2(55)
3-metoksy-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4,5-dimetyl-fenoksymety 1] benzosyre
TLC : Rf 0,39 (kloroform : metanol = 9:1);
NMR : 8 7.72 (dd, J = 8.1, 1.2 Hz, 1H), 7.57 (d, J = 1.2 Hz, 1H), 7.26 (d, J = 8.1 Hz, 1H), 7.11 (s, 1H), 6.87 (s, 1H), 6.71 (s, 1H), 4.95 (br, 1H), 4.75 (br, 1H), 3.93 (s, 3H), 3.69 (br, 1H), 3.56 (br, 1H), 2.29 (s, 3H), 2.23 (s, 3H), 2.19 (s, 3H), 1.80-1.65 (m, 1H), 0.97 (br, 6H).
Eksempel 2(56)
3-klor-4-[2-[>J-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksy-metyl] benzosyre
TLC : Rf 0,36 (kloroform : metanol = 9:1);
NMR : 8 8.11 (d, J = 1.8 Hz, 1H), 8.01 (dd, J = 8.1, 1.8 Hz, 1H), 7.49 (d, J = 8.1 Hz, 1H), 7.08 (s, 1H), 6.95 (d, J = 0.6 Hz, 1H), 6.69 (s, 1H), 5.20-4.70 (br, 2H), 3.80-3.45 (br, 2H), 2.32 (d, J = 0.6 Hz, 3H), 2.24 (s, 3H), 2.19 (s, 3H), 1.75 (m, 1H), 1.07-0.85 (br, 6H).
Eksempel 2(57)
3-ldor-4-[2-P^-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksy-metyljbenzosyre
TLC : Rf 0,36 (kloroform : metanol = 9:1);
NMR(CDC13 + CD3OD): 8 8.06 (d, J = 1.8 Hz, 1H), 7.98 (dd, J = 8.1, 1.8 Hz, 1H), 7.70 (d, J = 8.1 Hz, 1H), 7.05 (d, J = 0.6 Hz, 1H), 6.86 (s, 1H), 6.76 (s, 1H), 5.14 (d, J = 14.1 Hz, 1H), 5.08 (d, J= 14.1 Hz, 1H), 4.70 (m, 1H), 2.47 (d, J = 0.6 Hz, 3H), 2.25 (s, 3H), 2.17 (s, 3H), 1.17 (d, J = 6.6 Hz, 3H), 1.15 (d, J = 6.6 Hz, 3H).
Eksempel 2(58)
4-[2-[N-isopropyl-N-(4-metyl-24iazolylsulfonyl)amino]-4,5-dimetylfenoksymetyl]-benzosyre
TLC : Rf 0,45 (kloroform : metanol =10:1);
NMR : 8 8.11-8.08 (m, 2H), 7.49 (d, J = 8.4 Hz, 2H), 6.97 (d, J = 0.9 Hz, 1H), 6.86 (s, 1H), 6.75 (s, 1H), 5.06 (d, J = 12.9 Hz, 1H), 5.04 (d, J = 12.9 Hz, 1H), 4.71 (m, 1H), 2.46 (d, J = 0.9 Hz, 3H), 2.23 (s, 3H), 2.16 (s, 3H), 1.18 (d, J = 6.6 Hz, 3H), 1.15 (d, J = 6.6Hz, 3H).
Eksempel 2(59)
4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksymetyl]-benzosyre
TLC : Rf 0,43 (kloroform : metanol =10:1);
NMR : 8 8.09 (d, J = 8.1 Hz, 2H), 7.33 (d, J = 8.1 Hz, 2H), 7.08 (s, 1H), 6.89 (d, J = 0.9 Hz, 1H), 6.68 (s, 1H), 5.08-4.68 (m, 2H), 3.75-3.45 (m, 2H), 2.30 (s, 3H), 2.23 (s, 3H), 2.18 (s, 3H), 1.71 (m, 1H), 1.04-0.83 (m, 6H).
Eksempel 2(60) 4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4-klor-5-metylfen kanelsyre
TLC : Rf 0,22 (kloroform : metanol = 9:1);
NMR(CD3OD): 8 7.69 (d, J = 16.2 Hz, 1H), 7.61 (d, J = 8.1 Hz, 2H), 7.32-7.24 (m) og 7.29 (d, J = 8.1 Hz) total 4H, 7.05 (s, 1H), 6.52 (d, J = 16.2 Hz, 1H), 5.05-4.70 (m, 2H, dekket med H20 in CD3OD), 3.63-3.50 (m, 2H), 2.37 (s, 3H), 2.22 (d, J = 0.9 Hz, 3H), 1.65 (m, 1H), 0.93 (d, J = 6.3 Hz, 6H).
Eksempel 2(61)
3-metyl-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-5-trifluormetyl-fenoksymety 1] kanelsyre
TLC : Rf 0,37 (kloroform : metanol = 9:1);
NMR : 8 7.76 (d, J = 16.2 Hz, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.45-7.35 (m, 2H), 7.32-7.23 (m, 2H), 7.20 (m, 1H), 6.98 (s, 1H), 6.48 (d, J = 16.2 Hz, 1H), 5.03-4.82 (m, 2H), 3.70-3.50 (m, 2H), 2.36 (s, 3H), 2.34 (s, 3H), 1.74-1.58 (m, 1H), 0.91 (d, J = 6.9 Hz, 6H).
Eksempel 2(62)
3-klor-4-[2-|^-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-5-trifluormetyl-fenoksymety 1] kanelsyre
TLC : Rf 0,28 (n-heksan : etylacetat =1:2);
NMR : 8 7.71 (d, J = 16.2 Hz, 1H), 7.58 (s, 1H), 7.52-7.44 (m, 3H), 7.29 (d, J = 8.1 Hz, 1H) 7.19 (s, 1H), 7.01 (d, J = 0.9 Hz, 1H), 6.50 (d, J = 16.2 Hz, 1H), 5.02 (br, 2H), 3.62 (d, J = 6.6 Hz, 2H), 2.35 (s, 3H), 1.68 (sep, J = 6.6 Hz, 1H), 0.93 (d, J = 6.6 Hz, 6H).
Eksempel 2(63)
3-metyl-4-[2-|^-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4,5-dimetylfen metyllkanelsyre
TLC : Rf 0,20 (n-heksan : etylacetat =1:2);
MS (FAB, Pos.): 515(M + H)<+>.
Eksempel 2(64)
3-metyl-4-[2-[>J-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksy-metyljkanelsyre
TLC : Rf 0,22 (n-heksan : etylacetat =1:2);
MS (FAB, Pos.): 529(M + H)<+>.
Eksempel 2(65)
4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4-metyl-5-klorfenoksymetyl]-kanelsyre
TLC : Rf 0,31 (kloroform : metanol = 9:1);
NMR : 8 7.79 (d, J = 15.9 Hz, 1H), 7.56 og 7.27 (hver d, J = 8.1 Hz, hver 2H), 7.21 (s, 1H), 6.95-6.88 (m, 2H), 6.48 (d, J = 15.9 Hz, 1H), 5.00-4.65 (m, 2H), 3.72-3.42 (m, 2H), 2.33-2.22 (m, 6H), 1.78-1.60 (m, 1H), 1.05-0.83 (m, 6H).
Eksempel 2(66)
3 -metyl-4- [2- [N-isobuty l-N-(4-mety l-2-tiazolylsulfonyl)amino] -4-metyl-5 -klor-fenoksymetyl]kanelsyre
TLC : Rf 0,30 (kloroform : metanol = 9:1);
NMR : 8 7.76 (d, J = 16.2 Hz, 1H), 7.42-7.37 (m, 2H), 7.30-7.15 (m, 2H), 6.98-6.89 (m, 2H), 6.47 (d, J = 16.2 Hz, 1H), 4.95-4.67 (m, 2H), 3.72-3.40 (m, 2H), 2.38-2.22 (m, 9H), 1.77-1.61 (m, 1H), 1.05-0.82 (m, 6H).
Eksempel 2(67)
3-metyl-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4-klor-5-metyl-fenoksymetyllkanelsyre
TLC : Rf 0,41 (kloroform : metanol = 9:1);
NMR : 8 7.76 (d, J = 16.2 Hz, 1H), 7.39 (d, J = 8.4 Hz, 1H), 7.38 (s, 1H), 7.27 (d, J = 8.4 Hz, 1H), 7.23 (s, 1H), 6.97 (s, 1H), 6.81 (s, 1H), 6.47 (d, J = 16.2 Hz, 1H), 5.04-4.66 (m, 2H), 3.65-3.39 (m, 2H), 2.36 (s, 3H), 2.35 (s, 3H), 2.33 (s, 3H), 1.75-1.61 (m, 1H), 0.92 (d, J = 6.6 Hz, 6H).
Eksempel 2(68)
4-[2-pSI-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksymetyl]-kanelsyre
TLC : Rf 0,33 (kloroform : metanol = 10 : 1);
MS (APCI, Neg. 20V): 513 (M - H)\
Eksempel 2(69) 3-klor-4-[2-[N-isobutyl-N-(4-m metyl] kanelsyre
TLC : Rf 0,17 (kloroform : metanol = 9:1);
NMR(CD3OD): 5 7.69 (d, J = 1.8 Hz, 1H), 7.65 (d, J = 15.9 Hz, 1H), 7.59 (dd, J = 8.1, 1.5 Hz, 1H), 7.35 (d, J - 8.1 Hz, 1H), 7.29 (d, J = 1.2 Hz, 1H), 7.04 (s, 1H), 6.88 (s, 1H), 6.57 (d, J = 15.9 Hz, 1H), 5.10-4.60 (m, 2H), 3.63-3.50 (m, 2H), 2.28 (s, 3H), 2.21 (d, J = 1.2 Hz) og 2.20 (s) total 6H, 1.66 (m, 1H), 1.03-0.85 (m, 6H).
Eksempel 2(70)
3-metoksy-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4,5-dimetyl-fenoksymetyl]kanelsyre
TLC : Rf 0,40 (diklormetan : metanol = 10 : 1);
MS (FAB, Pos.) : 545 (M + H)<+>.
Eksempel 2(71)
4-[6-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]benzosyre
TLC : Rf 0,43 (kloroform : metanol = 9:1);
NMR : 5 8.10 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), 7.16 (s, 1H), 6.89 (d, J = 0.9 Hz, 1H), 6.76 (s, 1H), 5.06-4.70 (br, 2H), 3.78-3.45 (br, 2H), 2.87 (t, J = 7.5 Hz, 4H), 2.31 (d, J = 0.9 Hz, 3H), 2.09 (m, 2H), 1.74 (m, 1H), 1.04-0.86 (br, 6H).
Eksempel 2(72) 4-[6-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksym svre
TLC : Rf 0,42 (kloroform : metanol = 9:1); NMR : 8 7.79 (d, J = 15.9 Hz, 1H), 7.55 (d, J = 8.1 Hz, 2H), 7.28 (d, J = 8.1 Hz, 2H), 7.15 (s, 1H), 6.89 (d, J = 0.9 Hz, 1H), 6.77 (s, 1H), 6.47 (d, J = 15.9 Hz, 1H), 5.05-4.60 (br, 2H), 3.78-3.45 (br, 2H), 2.86 (t, J = 7.8 Hz, 4H), 2.30 (d, J = 0.9 Hz, 3H), 2.08 (m, 2H), 1.73 (m, 1H), 1.06-0.83 (br, 6H). Eksempel 2(73) 3-metyl-4-[6-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]-benzosyre
TLC : Rf 0,34 (diklormetan : metanol = 19 : 1);
NMR : 8 7.95-7.92 (m, 2H), 7.31 (d, J = 7.8 Hz, 1H), 7.16 (s, 1H), 6.91 (brs, 1H), 6.79 (s, 1H), 4.93 (brs, 1H), 4.73 (brs, 1H), 3.75-3.45 (m, 2H), 2.92-2.84 (m, 4H), 2.34 (s, 3H), 2.31 (d, J = 0.6 Hz, 3H), 2.10 (m, 2H), 1.74 (m, 1H), 1.08-0.80 (brs, 6H).
Eksempel 2(74)
3 -metyl-4- [6- [N-isobuty l-N-(4-mety 1-2-tiazolylsulfony l)amino] indan-5 -y loksymety 1] - kanels<y>re
TLC : Rf 0,32 (diklormetan : metanol = 19 : 1);
NMR : 8 7.76 (d, J = 15.9 Hz, 1H), 7.40-7.36 (m, 2H), 7.25 (m, 1H), 7.14 (s, 1H), 6.91 (brs, 1H), 6.80 (s, 1H), 6.46 (d, J = 15.9 Hz, 1H), 4.90 (brs, 1H), 4.69 (brs, 1H), 3.75-3.43 (m, 2H), 2.95-2.80 (m, 4H), 2.31 (s, 6H), 2.09 (m, 2H), 1.72 (m, 1H), 1.05-0.85 (brs, 6H).
Eksempel 2(75)
4-[2-[N-isobutyl-N-(2-pyridy lsulfony l)amm^ svre
TLC : Rf 0,37 (kloroform : metanol = 9:1);
NMR(CD3OD): 8 8.39 (ddd, J = 4.5, 1.5, 0.9 Hz, 1H), 7.82 (dt, J = 7.5, 1.5 Hz, 1H), 7.72-7.64 (m, 2H), 7.60 (d, J = 8.1 Hz, 2H), 7.53 (d, J = 7.5 Hz, 1H), 7.38 (ddd, J = 7.5, 4.5, 0.9 Hz, 1H), 7.34-7.22 (m, 4H), 6.54 (d, J = 15.9 Hz, 1H), 4.95-4.78 (m, 2H), 3.61 (d, J = 6.6 Hz, 2H), 1.60 (m, 1H), 0.91 (d, J = 6.9 Hz, 6H).
Eksempel 2(76)
4-[2-pvf-isobutyl-N-(3-pyridylsulfony syre
TLC : Rf 0,27 (kloroform : metanol = 9:1);
NMR(CD3OD): 8 8.63 (m, 1H), 8.53 (dd, J = 5.1, 1.8 Hz, 1H), 7.99 (d, J = 8.4 Hz) og 7.94 (m) total 3H, 7.56 (d, J = 7.5 Hz, 1H), 7.40-7.29 (m, 3H), 7.23 (d, J = 8.4 Hz, 2H), 5.10-4.80 (m, 2H), 3.58-3.40 (m, 2H), 1.61 (m, 1H), 0.92 (brd, J = 6 Hz, 6H).
Eksempel 2(77)
3-klor-4-[2-[N-isopropyl-N-(2-pyridylsulfonyl)amino]-4-klor-5-metylfenoksymetyl]-benzosyre
TLC : Rf 0,43 (kloroform : metanol = 9:1);
NMR(CD3OD): 8 8.63 (m, 1H), 8.02 (d, J = 1.8 Hz, 1H), 7.98-7.84 (m, 3H), 7.70 (d, J = 8.1 Hz, 1H), 7.50 (m, 1H), 7.11 (s, 1H), 7.09 (s, 1H), 5.16 (ABd, J= 13.5 Hz) og 5.08 (ABd, J = 13.5 Hz) total 2H, 4.61 (sept, J = 6.6 Hz, 1H), 2.39 (3, 3H), 1.12 (d, J = 6.6 Hz) og 1.10 (d, J = 6.6 Hz) total 6H.
Eksempel 2(78)
3-metyl-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4-klor-5-metylfen^ benzosyre
TLC : Rf 0,37 (kloroform : metanol = 10 : 1);
NMR : 8 8.52 (m, 1H), 7.94-7.92 (m, 2H), 7.77-7.68 (m, 2H), 7.31-7.24 (m, 3H), 6.76 (s, 1H), 4.83 (brs, 2H), 3.65-3.50 (m, 2H), 2.34 (s, 6H), 1.66 (m, 1H), 0.91 (d, J = 6.6 Hz, 6H).
Eksempel 2(79)
3-metyl-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4-klor-5-metylfenoksy-metyllbenzosyre
TLC : Rf 0,16 (diklormetan : metanol = 20 : 1);
NMR : 8 12.90 (s, 1H), 8.67 (d, J = 1.8 Hz, 1H), 8.62 (dd, J = 4.8, 1.8 Hz, 1H), 7.94 (dt, J = 8.1, 1.8 Hz, 1H),7.74 (s, 1H), 7.68 (d, J = 8.1 Hz, 1H), 7.37 (dd, J= 8.1, 4.8 Hz, 1H), 7.27 (s, 1H), 7.24 (s, 1H), 7.01 (d, J = 8.1 Hz, 1H), 4.95 (br, 1H), 4.76 (br, 1H), 3.45-3.30 (m, 2H), 2.34 (s, 3H), 2.24 (s, 3H), 1.49 (sept, J = 6.6 Hz, 1H), 0.90-0.70 (br, 6H).
Eksempel 2(80)
3-metyl-4-[2-|>I-isobu1yl-N-(2-pyridylsulfonyl)amino]-4-metyl-5-klorfenoksymetyl]-benzosyre
TLC : Rf 0,40 (kloroform : metanol = 9:1);
NMR : 8 8.50-8.40 (m, 1H), 7.95-7.85 (m, 2H), 7.75-7.60 (m, 2H), 7.30-7.20 (ra, 3H), 6.89 (s, 1H), 4.76 (br, 2H), 3.61 (br, 2H), 2.31 (s, 3H), 2.29 (s, 3H), 1.75-1.55 (m, 1H), 1.00-0.80 (m, 6H).
Eksempel 2(81)
4-[2-P^-isobutyl-N-(3-pyridylsulfonyl)amino]-4-metyl-5-klorfenoksymetyl]benzosyre
TLC : Rf 0,31 (kloroform : metanol = 9:1);
NMR: 5 8.83 (d,J = 2.4, 0.6 Hz, 1H), 8.61 (dd,J = 5.1, 1.8 Hz, 1H), 8.10 (d,J = 8.4 Hz, 2H), 7.78-7.71 (m, 1H), 7.36 (s, 1H), 7.29-7.22 (m, 1H), 7.08 (d, J = 8.4 Hz, 2H), 6.90 (s, 1H), 4.94-4.72 og 4.50-4.25 (hver m, hver 1H), 3.75-3.56 og 3.45-3.24 (hver m, hver 1H), 2.36 (s, 3H), 1.79-1.63 (m, 1H), 1.16-0.80 (m, 6H).
Eksempel 2(82)
3 -klor-4- [2- [N-isobutyl-N-(3 -pyridylsulfony l)amino]-4-metyl-5 -kl orfenoksym etyl] - benzosyre
TLC : Rf 0,29 (kloroform : metanol = 9:1);
NMR : 8 8.87 (d, J = 1.8 Hz, 1H), 8.63 (dd, J = 5.1, 1.8 Hz, 1H), 8.13 (d, J = 1.8 Hz, 1H), 8.03 (dd, J = 8.1, 1.8 Hz, 1H), 7.73-7.66 (m, 1H), 7.40 (s, 1H), 7.36 (dd, J = 8.1, 5.1 Hz, 1H), 7.05 (d, J = 8.1 Hz, 1H), 6.96 (s, 1H), 4.92-4.74 og 4.54-4.34 (hver m, hver 1H), 3.72-3.63 og 3.50-3.33 (hver m, hver 1H), 2.39 (s, 3H), 1.84-1.68 (m, 1H), 1.20-0.92 (m, 6H).
TLC : Rf 0,32 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 8 12.39 (br s, 1H), 8.51 (d, J = 4.5 Hz, 1H), 7.90 (dd, J = 7.5,
7.5 Hz, 1H), 7.70 (d, J = 7.5 Hz, 1H), 7.55 (d, J = 16.0 Hz, 1H), 7.53-7.46 (m, 5H), 7.35 (d, J = 8.0 Hz, 1H), 7.14 (d, J = 8.0 Hz, 1H), 6.55 (d, J = 16.0 Hz, 1H), 5.00
(br s, 2H), 3.49 (d, J = 7.0 Hz, 2H), 2.25 (s, 3H), 1.45 (trippel septett, J = 7.0, 7.0 Hz, 1H), 0.78 (d, J = 7.0 Hz, 6H).
Eksempel 2(84)
3 -metoksy-4- [2- [N-isobuty l-N-(2-pyridylsulfony l)amino]-4,5 -dimety Ifenoksymety 1] - benzosyre
TLC : Rf 0,38 (kloroform : metanol = 9:1);
NMR : 8 8.47 (d, J = 4.8 Hz, 1H), 7.75-7.60 (m, 3H), 7.56 (d, J = 1.5 Hz, 1H), 7.20-7.15 (m, 2H), 7.12 (s, 1H), 6.65 (s, 1H), 4.84 (br, 1H), 4.66 (br, 1H), 3.92 (s, 3H), 3.61 (br, 2H), 2.22 (s, 3H), 2.18 (s, 3H), 1.80-1.60 (m, 1H), 0.96 (br, 6H).
Eksempel 2(85)
3-metoksy-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4,5-dimetylfenoksymetyl]-benzosyre
TLC : Rf 0,35 (kloroform : metanol = 9:1);
NMR : 8 8.86 (dd, J = 2.1, 0.9 Hz, 1H), 8.57 (dd, J = 5.1, 1.5 Hz, 1H), 7.75-7.65 (m, 2H), 7.61 (d, J = 1.5 Hz, 1H), 7.30-7.20 (m, 2H), 6.92 (d, J = 7.8 Hz, 1H), 6.72
(s, 1H), 4.75 (d, J = 12.3 Hz, 1H), 4.43 (d, J = 12.3 Hz, 1H), 3.93 (s, 3H), 3.75-3.60 (m, 1H), 3.45-3.35 (m, 1H), 2.29 (s, 3H), 2.25 (s, 3H), 1.85-1.65 (m, 1H), 1.09 (d, J = 6.3 Hz, 3H), 0.92 (d, J = 6.3 Hz, 3H).
Eksempel 2(86)
3-metyl-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4,5-dimetylfenoksymetyl]^ benzosyre
TLC : Rf 0,61 (kloroform : metanol: vann = 8:2: 0,2);
NMR(DMSO-d6): 5 12.87 (brs, 1H), 8.64 (d, J = 1.8 Hz, 1H), 8.59 (dd, J = 4.8, 1.8 Hz, 1H), 7.91 (dt, J = 8.1, 1.8 Hz, 1H), 7.73 (s, 1H), 7.67 (d, J = 8.1 Hz, 1H), 7.35 (dd, J = 8.1,4.8 Hz, 1H), 7.04-6.96 (m, 3H), 4.92 (br, 1H), 4.66 (br, 1H), 3.48-3.22 (br, 2H), 2.23 (s, 3H), 2.22 (s, 3H), 2.15 (s, 3H), 1.49 (sep, J = 6.9 Hz, 1H), 0.98-0.75 (m, 6H).
Eksempel 2(87)
3-me1yl-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4,5-dimetylfenoksymetyl]-benzosvre
TLC : Rf 0,66 (kloroform : metanol: vann = 8:2: 0,2);
NMR(DMSO-d6): 8 12.88 (s, 1H), 8.47 (d, J = 4.5 Hz, 1H), 7.87 (dt, J = 1.5, 7.8 Hz, 1H), 7.75 (s, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.63 (d, J = 7.8 Hz, 1H), 7.42 (ddd,
J = 7.8, 4.5, 1.5 Hz, 1H), 7.16 (d, J = 7.8 Hz, 1H), 6.93 (s, 1H), 6.91 (s, 1H), 4.80 (br, 2H), 3.57 (d, J = 6.6 Hz, 2H), 2.25 (s, 3H), 2.18 (s, 3H), 2.09 (s, 3H), 1.49
(sept, J = 6.6 Hz, 1H), 0.81 (d, J = 6.6 Hz, 6H).
Eksempel 2(88)
3-metyl-4-[2-P^-isobutyl-N-(3-pyridylsulfonyl)amino]-4-metyl-5-klorfenoksymetyl]-benzosyre
TLC : Rf 0,31 (kloroform : metanol = 9:1);
NMR : 5 8.83 (d, J = 1.8 Hz, 1H), 8.61 (dd, J = 5.4, 1.8 Hz, 1H), 7.93 (d, J = 8.1 Hz, 1H), 7.92 (s, 1H), 7.78 (dt, J = 8.1, 1.8 Hz 1H), 7.34 (s, 1H), 7.23 (dd, J = 8.1, 5.4 Hz, 1H), 6.95 (d, J = 8.1 Hz, 1H), 6.94 (s, 1H), 4.88-4.65 og 4.54-4.34 (hver m, hver 1H), 3.71-3.53 og 3.43-3.24 (hver m, hver 1H), 2.36 (s, 3H), 2.27 (s, 3H), 1.78-1.63 (m, 1H), 1.08-0.79 (m, 6H).
Eksempel 2(89)
4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4,5-dimetylfenoksymetyllb
TLC : Rf 0,33 (kloroform : metanol =10:1);
NMR : 8 8.46 (m, 1H), 8.09-8.05 (m, 2H), 7.71-7.60 (m, 2H), 7.28-7.25 (m, 2H), 7.20 (m, 1H), 7.09 (s, 1H), 6.62 (s, 1H), 5.02-4.50 (m, 2H), 3.83-3.43 (m, 2H), 2.21 (s, 3H), 2.17 (s, 3H), 1.67 (m, 1H), 1.04-0.82 (m, 6H).
Eksempel 2(90)
4-[2-[N-isopropyl-N-(2-pyridylsulfonyl)amino]-4-metyl-5-klorfenoksymetyl]kanelsyre
TLC : Rf 0,44 (kloroform : metanol = 9:1);
NMR : 8 8.70-8.60 (m, 1H), 7.84 (d, J = 7.5 Hz, 1H), 7.79 (d, J = 15.9 Hz, 1H), 7.71 (dt, J = 1.8, 7.5 Hz, 1H), 7.55 (d, J = 8.4 Hz, 2H), 7.39 (d, J = 8.4 Hz, 2H), 7.35-7.25 (m, 1H), 6.99 (s, 1H), 6.96 (s, 1H), 6.48 (d, J = 15.9 Hz, 1H), 4.96 (d, J = 12.3 Hz, 1H), 4.92 (d, J = 12.3 Hz, 1H), 4.75-4.60(m, 1H), 2.26 (s, 3H), 1.14 (d, J = 6.9 Hz, 3H), 1.11 (d, J = 6.9 Hz, 3H).
Eksempel 2(91) 3-metyl-4-[2-[N-isobutyl-N-(2-pyridylsulfonyty kanelsyre
TLC : Rf 0,37 (kloroform : metanol = 9:1);
NMR : 8 8.50-8.40 (m, 1H), 7.77 (d, J= 15.9 Hz, 1H), 7.75-7.60 (m, 2H), 7.40-7.35 (m, 2H), 7.25-7.20 (m, 2H), 7.15 (d, J= 8.4 Hz, 1H), 6.90 (s, 1H), 6.49 (d, J = 15.9 Hz, 1H), 4.73 (br, 2H), 3.60 (br, 2H), 2.29 (s, 3H), 2.28 (s, 3H), 1.70-1.55 (m, 1H), 0.91 (d, J = 6.6 Hz, 6H).
Eksempel 2(92)
3-metyl-4-[2-|>J-isobutyl-N-(2-pyridylsulfonyl)amino]-4,5-dimetylfenoksymetyl]-kanelsyre
TLC : Rf 0,36 (diklormetan : metanol = 20 : 1);
MS (FAB, Pos.): 509 (M + H)<+>.
Eksempel 2(93)
4-[2-P^-isobutyl-N-(3-pyridylsulfonyl)amino]-4,5-dime1ylfenoksymetyl]kanel^
TLC : Rf 0,27 (kloroform : metanol =10:1);
MS (APCI, Neg. 20V) : 493 (M - H)-.
Eksempel 2(94)
3 -mety 1-4- [2- [N-isobutyl-N-(3 -pyridy lsulfonyl)amino] -4,5-dimetylfenoksymety lj-kanelsyre
TLC : Rf 0,33 (diklormetan : metanol = 20 : 1);
MS (FAB, Pos.): 509 (M + H)<+>.
Eksempel 2(95)
3-ldor-4-[2-[N-isobu1yl-N-(3-pyridylsulfonyl)aiTiino]-4,5-dimetylfenoksymetyl]-kanelsyre
TLC : Rf 0,43 (kloroform : metanol = 3:1);
NMR : 8 8.88-8.82 (m, 1H), 8.61-8.52 (m, 1H), 7.75-7.68 (m, 1H), 7.61 (d, J = 15.9 Hz, 1H), 7.52 (d, J = 1.5 Hz, 1H), 7.47 (d, J = 8.1 Hz, 1H), 7.32-7.20 (m, 2H), 6.97 (d, J = 8.1 Hz, 1H), 6.70 (s, 1H), 6.50 (d, J = 15.9 Hz, 1H), 4.88-4.75 og 4.53-4.41(hver m, hver 1H), 3.74-3.58 og 3.48-3.32 (hver m, hver 1H), 2.29 og 2.25 (hver s, hver 3H), 1.82-1.63 (m, 1H), 1.15-0.82 (m, 6H).
Eksempel 2(96)
3-metyl-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4-klor-5-metylfenoksymetyl]-kanelsyre
TLC : Rf 0,36 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 8 8.65 (m, 2H), 7.94 (m, 1H), 7.54 (d, J = 16.2 Hz) og 7.51 (s) total 2H, 7.43 (d, J = 8.1 Hz, 1H), 7.38 (dd, J = 8.1,4.8 Hz, 1H), 7.26 (s, 1H), 7.22 (s, 1H), 6.98 (d, J = 8.1 Hz, 1H), 6.53 (d, J = 16.2 Hz, 1H), 5.00-4.85 (m, 2H), 3.48-3.10 (m, 2H, dekket med H20 i DMSO-d6), 2.34 (s, 3H), 2.21 (s, 3H), 1.48 (m, 1H), 0.93 (m, 6H).
Eksempel 2(97)
3-klor-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)a^ kanelsyre
TLC : Rf 0,25 (kloroform : metanol = 10 : 1);
MS (APCI, Neg. 20V): 567 (M - H)_.
Eksempel 2(98)
3-metyl-4-[6-fN-isopropyl-N-(5-metyl-2-furylsulfonyl)amino]indan-5-yloksymetyr benzosyre
TLC : Rf 0,45 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 8 7.79 (s, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.11 (s, 1H), 6.90 (d, J = 3.3 Hz, 1H), 6.82 (s, 1H), 6.30-6.20 (m, 1H), 5.08 (s, 2H), 4.30-4.20 (m, 1H), 2.87 (t, J = 7.5 Hz, 2H), 2.79 (t, J = 7.5 Hz, 2H), 2.35 (s, 3H), 2.28 (s, 3H), 2.10-1.95 (m, 2H), 0.97 (d, J = 6.6 Hz, 6H).
Eksempel 2(99)
3 -mety 1-4- [6- [N-isopropy l-N-(5 -mety l-2-furylsulfonyl)amino] indan-5 -yloksymety 1] - kanelsyre
TLC : Rf 0,50 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 8 7.60-7.50 (m, 4H), 7.11 (s, 1H), 6.89 (d, J = 3.3 Hz, 1H), 6.80 (s, 1H), 6.52 (d, J = 16.2 Hz, 1H), 6.30-6.20 (m, 1H), 5.04 (d, J = 13.5 Hz, 1H), 5.01 (d, J = 13.5 Hz, 1H), 4.30-4.20 (m, 1H), 2.87 (t, J = 7.2 Hz, 2H), 2.78 (t, J = 7.2 Hz, 2H), 2.32 (s, 3H), 2.28 (s, 3H), 2.10-1.95 (m, 2H), 0.97 (d, J = 6.6 Hz, 6H).
Eksempel 2(100)
4-[6-|^-isopropyl-N-(5-mety^ syre
TLC : Rf 0,42 (kloroform : metanol = 9:1);
NMR : 5 7.79 (d, J = 16.2 Hz, 1H), 7.57 (d, J = 8.4 Hz, 2H), 7.51 (d, J = 8.4 Hz, 2H), 6.89 (s, 1H), 6.84 (s, 1H), 6.80 (d, J = 3.3 Hz, 1H), 6.46 (d, J = 16.2 Hz, 1H), 6.02 (m, 1H), 5.14-5.00 (m, 2H), 4.46 (m, 1H), 2.91-2.80 (m, 4H), 2.31 (s, 3H), 2.14-2.02 (m, 2H), 1.11 (d, J = 6.6 Hz, 3H), 1.10 (d, J = 6.6 Hz, 3H).
Eksempel 2(101)
3-metyl-4-[2-[N-(2-metyl-2-propenyl)-N-(4-metyl-2-tiazolylsulfonyl)amino]-4-klor-5-metylfenoksymetyl]benzosyre
TLC : Rf 0,44 (kloroform : metanol = 9 : 1);
NMR(DMSO-d6): 5 7.79 (s, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.57 (s, 1H), 7.28 (d, J = 8.4 Hz, 1H), 7.27 (s, 1H), 7.23 (s, 1H), 4.97 (m, 2H), 4.77 (m, 1H), 4.72 (m, 1H), 4.21 (m, 2H), 2.34 (s, 3H), 2.32 (s, 3H), 2.22 (s, 3H), 1.68 (s, 3H).
Eksempel 2(102)
4-[2-[N-(2-metyl-2-propenyl)-N-(4-metyl-2-tiazolylsulfonyl)amino]-5-trifluormetyl-fenoksymetyllkanelsyre
TLC : Rf 0,43 (kloroform : metanol = 9:1);
NMR : 5 7.80 (d, J = 15.9 Hz, 1H), 7.58 (d, J = 8.4 Hz, 2H), 7.45 (d, J= 8.1 Hz, 1H), 7.33 (d, J = 8.4 Hz, 2H), 7.30-7.20 (m, 1H), 7.15 (s, 1H), 6.99 (s, 1H), 6.50 (d, J = 15.9 Hz, 1H), 4.97 (s, 2H), 4.77 (s, 1H), 4.72 (s, 1H), 4.37 (s, 2H), 2.35 (s, 3H), 1.77 (s, 3H).
Eksempel 2(103)
3 -mety 1-4-[2-[N-(2-metyl-2-propenyl)-N-(4-metyl-2-tiazoly lsulfony l)amino]-4,5-dimetylfenoksymetyllbenzosyre
TLC : Rf 0,24 (diklormetan : metanol = 19 : 1);
NMR(DMSO-d6): 8 7.77-7.73 (m, 2H), 7.50 (brs, 1H), 7.23 (d, J = 6.9 Hz, 1H), 6.99 (s, 1H), 6.96 (s, 1H), 4.87 (brs, 2H), 4.74 (brs, 1H), 4.71 (brs, 1H), 4.20 (brs, 2H), 2.28 (s, 3H), 2.19 (s, 3H), 2.16 (d, J = 0.6 Hz, 3H), 2.11 (s, 3H), 1.68 (s, 3H).
Eksempel 2(104)
3 -mety 1-4- [6- [N-isopropy l-N-(2-tiazoly lsulfony l)amino] indan-5-yloksymety 1] - benzosyre
TLC : Rf 0,43 (kloroform : metanol = 9:1);
NMR : 5 7.96 (d, J = 8.1 Hz, 1H), 7.93 (s, 1H), 7.89 (d, J = 3.0 Hz, 1H), 7.58 (d, J = 8.1 Hz, 1H), 7.46 (d, J = 3.0 Hz, 1H), 6.95 (s, 1H), 6.86 (s, 1H), 5.05 og 4.99 (hver d, J = 13.5 Hz, hver 1H), 4.69 (sept, J = 6.6 Hz, 1H), 2.94-2.79 (m, 4H), 2.39 (s, 3H), 2.16-2.02 (m, 2H), 1.18 og 1.15 (hver d, J = 6.6 Hz, hver 3H).
Eksempel 2(105)
3-metyl-4-[6-[N-isobutyl-N-(2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]benzosyre
TLC : Rf 0,41 (kloroform : metanol = 9:1);
NMR : 5 7.93 (d, J = 8.4 Hz, 1H), 7.92 (s, 1H), 7.71 (d, J = 3.0 Hz, 1H), 7.35 (d, J = 3.0 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 7.15 (s, 1H), 6.77 (s, 1H), 5.02-4.64 (m, 2H), 3.81-3.43 (m, 2H), 2.95-2.76 (m, 4H), 2.34 (s, 3H), 2.17-2.01 (m, 2H), 1.82-1.64 (m, 1H), 1.08-0.83 (m, 6H).
Eksempel 2(106)
3-metyl-4-[6-|^-isopropyl-N-(4-met^ metyl]benzosyre
TLC : Rf 0,34 (diklormetan : metanol = 19 : 1);
NMR : 5 7.97 (d, J = 8.1 Hz, 1H), 7.94 (s, 1H), 7.57 (d, J = 8.1 Hz, 1H), 7.00 (brs, 1H), 6.94 (s, 1H), 6.86 (s, 1H), 5.05 (d, J = 13.5 Hz, 1H), 4.99 (d, J = 13.5 Hz, 1H), 4.70 (m, 1H), 2.92-2.81 (m, 4H), 2.47 (s, 3H), 2.39 (s, 3H), 2.09 (m, 2H), 1.18 (d, J = 6.6 Hz, 3H), 1.15 (d, J = 6.6 Hz, 3H).
Eksempel 2(107)
4-[6-[N-isopropyl-N-(2-tiazolylsulfonyl)aininolindan-5-yloksymetyllbenzosyre
TLC : Rf 0,37 (kloroform : metanol =10:1);
NMR : 5 8.13 (d, J = 8.1 Hz, 2H), 7.88 (d, J = 3.3 Hz, 1H), 7.51 (d, J = 8.1 Hz, 2H), 7.44 (d, J = 3.3 Hz, 1H), 6.95 (s, 1H), 6.84 (s, 1H), 5.06 (d, J = 13.5 Hz, 1H), 5.05 (d, J = 13.5 Hz, 1H), 4.71 (m, 1H), 2.92-2.78 (m, 4H), 2.14-2.02 (m, 2H), 1.18 (d, J = 6.6 Hz, 3H), 1.16 (d, J = 6.6 Hz, 3H).
Eksempel 2(108)
4-[6-W-isobutyl-N-(2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]benzosyre
TLC : Rf 0,35 (kloroform : metanol =10:1);
NMR : 5 8.11 (d, J = 8.1 Hz, 2H), 7.71 (d, J = 3.3 Hz, 1H), 7.35 (d, J = 3.3 Hz, 1H), 7.34 (d, J = 8.1 Hz, 2H), 7.15 (s, 1H), 6.75 (s, 1H), 4.97 (m, 1H), 4.77 (m, 1H), 3.80-3.47 (m, 2H), 2.89-2.82 (m, 4H), 2.15-2.01 (m, 2H), 1.73 (m, 1H), 1.05-0.85 (m, 6H).
Eksempel 2(109)
4-[6-[N-isopropyl-N-(4-metyl-2-tiaz^ benzosyre
TLC : Rf 0,41 (kloroform : metanol = 9:1);
NMR : 8 8.11 (d, J = 8.4 Hz, 2H), 7.50 (d, J = 8.4 Hz, 2H), 6.98 (d, J = 0.9 Hz, 1H), 6.94 (s, 1H), 6.84 (s, 1H), 5.11-5.00 (m, 2H), 4.71 (m, 1H), 2.91-2.79 (m, 4H), 2.47 (d, J = 0.9 Hz, 3H), 2.15-2.03 (m, 2H), 1.18 (d, J = 6.6 Hz, 3H), 1.15 (d, J = 6.6 Hz, 3H).
Eksempel 2(110)
4-[6-[N-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]-kanelsyre
TLC : Rf 0,40 (kloroform : metanol = 9:1);
NMR : 8 7.79 (d, J = 15.9 Hz, 1H), 7.56 (d, J = 8.4 Hz, 2H), 7.45 (d, J = 8.4 Hz, 2H), 6.98 (d, J = 0.6 Hz, 1H), 6.92 (s, 1H), 6.85 (s, 1H), 6.47 (d, J = 15.9 Hz, 1H), 5.06-4.95 (m, 2H), 4.70 (m, 1H), 2.92-2.78 (m, 4H), 2.46 (d, J = 0.6 Hz, 3H), 2.16-2.01 (m, 2H), 1.17 (d, J = 6.6 Hz, 3H), 1.14 (d, J = 6.6 Hz, 3H).
Eksempel 2(111)
3-metyl-4-[6-rN-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]kanelsyre
TLC : Rf 0,30 (diklormetan : metanol = 19 : 1);
NMR(DMSO-d6): 8 12.38 (brs, 1H), 7.57 (brs, 1H), 7.56 (d, J = 15.9 Hz, 1H), 7.53 (s, 1H), 7.49 (brd, J= 8.1 Hz, 1H), 7.39 (d,"J = 8.1 Hz, 1H), 7.13 (s, 1H), 6.83 (s, 1H), 6.53 (d, J = 15.9 Hz, 1H), 4.99 (brs, 2H), 4.47 (m, 1H), 2.87 (m, 2H), 2.77 (m, 2H), 2.37 (d, J = 0.9 Hz, 3H), 2.30 (s, 3H), 2.02 (m, 2H), 1.04 (d, J = 6.6 Hz, 3H), 1.00 (d, J = 6.6Hz, 3H).
Eksempel 2(112)
4-[2-[N-isopropy l-N-(24iazolylsulfo syre
TLC : Rf 0,57 (kloroform : metanol = 9:1);
NMR : 8 8.10 (d, J = 8.1 Hz, 2H), 7.86 (d, J = 3.0 Hz, 1H), 7.49 (d, J = 8.1 Hz, 2H), 7.43 (d, J = 3.0 Hz, 1H), 6.85 (s, 1H), 6.75 (s, 1H), 5.04 (s, 2H), 4.72 (sept, J = 6.9 Hz, 1H), 2.23 (s, 3H), 2.15 (s, 3H), 1.19 (d, J = 6.9 Hz, 3H), 1.15 (d, J = 6.9 Hz, 3H).
Eksempel 2(113)
4- [2- [N-isobutyl-N-(2-tiazolylsulfonyl)amino] -4,5 -dimetylfenoksymetyl]benzosyre
TLC : Rf 0,56 (kloroform : metanol = 9:1);
NMR : 8 8.11 (d, J = 8.4 Hz, 2H), 7.70 (d, J = 3.0 Hz, 1H), 7.36-7.32 (m, 3H), 7.07 (s, 1H), 6.66 (s, 1H), 5.10-4.65 (m, 2H), 3.80-3.45 (m, 2H), 2.22 (s, 3H), 2.18 (s, 3H), 1.71 (sept, J = 6.9 Hz, 1H), 1.15-0.95 (m, 6H).
Eksempel 2(114)
4-[2-[N-isopropyl-N-(2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksymetyl]kanelsyre
TLC : Rf 0,56 (kloroform : metanol = 9:1);
NMR : 5 7.86 (d, J = 3.0 Hz, 1H), 7.79 (d, J = 15.9 Hz, 1H), 7.56 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 3.0 Hz, 1H), 6.84 (s, 1H), 6.76 (s, 1H), 6.46 (d, J = 15.9 Hz, 1H), 5.04 (d, J = 11.7 Hz, 1H), 4.98 (d, J = 11.7 Hz, 1H), 4.71 (sept, J = 6.6 Hz, 1H), 2.23 (s, 3H), 2.13 (s, 3H), 1.18 (d, J = 6.6 Hz, 3H), 1.15 (d, J = 6.6 Hz, 3H).
Eksempel 2(115)
4- [2- [N-isobutyl-N-(2-tiazolylsulfony l)amino] -4,5-dimety lfenoksymety 1] kanelsyre
TLC : Rf 0,58 (kloroform : metanol = 9:1);
NMR : 5 7.79 (d, J = 15.9 Hz, 1H), 7.67 (d, J = 3.0 Hz, 1H), 7.55 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 3.0 Hz, 1H), 7.27 (d, J = 8.4 Hz, 2H), 7.05 (s, 1H), 6.67 (s, 1H), 6.47 (d, J = 15.9 Hz, 1H), 5.00-4.62 (m, 2H), 3.80-3.45 (m, 2H), 2.22 (s, 3H), 2.17 (s, 3H), 1.70 (sept, J = 6.6 Hz, 1H), 1.10-0.96 (m, 6H).
Eksempel 2(116)
4-[6-W-isopropyl-N-(2-tiazolylsulfonyl)amino]indan-5-yloksymetyllkanelsyre
TLC : Rf 0,39 (kloroform : metanol = 10 : 1);
NMR : 6 7.87 (d, J = 3.3 Hz, 1H), 7.80 (d, J = 15.9 Hz, 1H), 7.56 (d, J = 7.8 Hz, 2H), 7.45 (d, J = 7.8 Hz, 2H), 7.44 (d, J = 3.3 Hz, 1H), 6.94 (s, 1H), 6.85 (s, 1H), 6.48 (d, J = 15.9 Hz, 1H), 5.01 (d, J = 13.2 Hz, 1H), 5.00 (d, J = 13.2 Hz, 1H), 4.70 (m, 1H), 2.91-2.79 (m, 4H), 2.14-2.01 (m, 2H), 1.17 (d, J = 6.6 Hz, 3H), 1.15 (d, J = 6.6 Hz, 3H).
Eksempel 2(117)
4-[6-[N-isobutyl-N-(2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]kanelsyre
TLC : Rf 0,40 (kloroform : metanol = 10 : 1);
NMR : 5 7.80 (d, J = 15.9 Hz, 1H), 7.69 (d, J = 3.3 Hz, 1H), 7.55 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 3.3 Hz, 1H), 7.27 (d, J = 8.4 Hz, 2H), 7.14 (s, 1H), 6.75 (s, 1H), 6.48 (d, J = 15.9 Hz, 1H), 4.92 (m, 1H), 4.70 (m, 1H), 3.78-3.46 (m, 2H), 2.90-2.80 (m, 4H), 2.14-2.01 (m, 2H), 1.72 (m, 1H), 1.02-0.83 (m, 6H).
Eksempel 2(118)
3-metyl-4-[2-pST-isopropyl-N-(2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksymetyl]-benzosyre
TLC : Rf 0,27 (kloroform : metanol = 9:1);
NMR : 5 8.00-7.90 (m, 2H), 7.87 (d, J = 3.0 Hz, 1H), 7.55 (d, J = 7.8 Hz, 1H), 7.44 (d, J = 3.0 Hz, 1H), 6.85 og 6.77 (hver s, hver 1H), 5.09-4.92 (m, 2H), 4.78-4.62 (m, 1H), 2.39 (s, 3H), 2.25 (s, 3H), 2.16 (s, 3H), 1.19 og 1.15 (hver d, J = 6.6 Hz, hver 3H).
Eksempel 2(119)
3-metyl-4-[2-[N-isobutyl-N-(2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksymetyl]-benzosyre
TLC : Rf 0,27 (kloroform : metanol = 9:1);
NMR : 8 7.95-7.89 (m, 2H), 7.70 og 7.34 (hver d, J = 3.3 Hz, hver 1H), 7.32-7.29 (m, 1H), 7.06 og 6.69 (hver s, hver 1H), 5.00-4.68 (m, 2H), 3.78-3.48 (m, 2H), 2.34 (s, 3H), 2.23 (s, 3H), 2.18 (s, 3H), 1.80-1.65 (m, 1H), 1.08-0.82 (m, 6H).
Eksempel 2(120)
3-metyl-4-[2-|^-isopropyl-N-(2-tiazolylsulfonyl)am kanelsyre
TLC : Rf 0,25 (kloroform : metanol = 9:1);
NMR : 5 7.87 (d, J = 3.0 Hz, 1H), 7.77 (d, J = 16.2 Hz, 1H), 7.52-7.32 (m, 4H), 6.83 og 6.79 (hver s, hver 1H), 6.46 (d, J = 16.2 Hz, 1H), 5.05-4.87 (m, 2H), 4.75-4.62 (m, 1H), 2.36 (s, 3H), 2.25 (s, 3H), 2.15 (s, 3H), 1.17 og 1.13 (hver d, J = 6.6 Hz, hver 3H).
Eksempel 2(121)
3-metyl-4-[2-[N-isobutyl-N-(2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksymetyl]-kanelsyre
TLC : Rf 0,25 (kloroform : metanol = 9:1);
NMR : 5 7.76 (d, J = 16.2 Hz, 1H), 7.69 (d, J = 3.0 Hz, 1H), 7.42-7.35 (m, 2H), 7.34 (d, J = 3.0 Hz, 1H), 7.25-7.19 (m, 1H), 7.05 og 6.70 (hver s, hver 1H), 6.47 (d, J = 16.2 Hz, 1H), 4.95-4.62 (m, 2H), 3.75-3.48 (m, 2H), 2.31 (s, 3H), 2.24 (s, 3H), 2.18 (s, 3H), 1.78-1.62 (m, 1H), 1.78-1.62 (m, 6H).
Eksempel 2(122)
3-metyl-4-[6-[N-isopropyl-N-(2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]-kanelsvre
TLC : Rf 0,44 (kloroform : metanol = 9:1);
NMR : 5 7.88 (d, J = 3.0 Hz, 1H), 7.77 (d, J = 16.2 Hz, 1H), 7.51 (d, J = 8.1 Hz, 1H), 7.45 (d, J = 3.0 Hz, 1H), 7.42 (d, J = 8.1 Hz, 1H), 7.38 (s, 1H), 6.93 (s, 1H), 6.87 (s, 1H), 6.46 (d, J = 16.2 Hz, 1H), 5.02 og 4.95 (hver d, J = 12.9 Hz, hver 1H), 4.68 (sept, J = 6.6 Hz, 1H), 2.94-2.78 (m, 4H), 2.36 (s, 3H), 2.16-2.02 (m, 2H), 1.17 og 1.14 (hver d, J = 6.6 Hz, hver 3H).
Eksempel 2(123)
3-metyl-4-[6-P^-isobutyl-N-(2-tiazolylsulfonyl)amino]indan-5-yloksym kanelsyre
TLC : Rf 0,39 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 5 7.98 (d, J = 3.0 Hz, 1H), 7.87 (d, J = 3.0 Hz, 1H), 7.56 (d, J = 16.2 Hz, 1H), 7.52 (s, 1H), 7.50 (d, J = 8.1 Hz, 1H), 7.18 (d, J = 8.1 Hz, 1H), 7.06 (s, 1H), 7.00 (s, 1H), 6.54 (d, J = 16.2 Hz, 1H), 5.04-4.66 (m, 2H), 3.57-3.37 (m, 2H), 2.93-2.68 (m, 4H), 2.27 (s, 3H), 2.11-1.93 (m, 2H), 1.64-1.46 (m, 1H), 0.94-0.74 (m, 6H).
Eksempel 2(124)
4-[3-rN-isobutyl-N-(5-me1yl-2-mrylsulfonyl)aminol-2-naftyloksymetyllb
TLC : Rf 0,33 (kloroform : metanol = 9:1);
NMR(CD3OD) : 5 8.05 (d, J = 8.4 Hz, 2H), 7.82-7.75 (m, 3H), 7.53 (d, J = 8.4 Hz, 2H), 7.51-7.35 (m, 3H), 6.71 (d, J = 3.3 Hz, 1H), 6.05 (m, 1H), 5.42-4.95 (br, 2H), 3.62 (d, J = 7.5 Hz, 2H), 2.13 (s, 3H), 1.79-1.61 (m, 1H), 0.94 (d, J = 6.3 Hz, 6H).
Referanseeksempel 4
N-[4,5-dimetyl-2-(2-metyl-4-cyanofenylmetyloksy)fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid
Under argonatmosfære ble en oppløsning av 3-metyl-4-[2-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-4,5-dimetylfenoksymetyl]benzosyre fremstilt i eksempel 2 (178 mg) i diklormetan (1,5 ml) avkjølt til 0°C, og deretter ble oksalylklorid (48 ul) og en katalytisk mengde av N,N-dimetylformamid tilsatt dertil. Etter at oppløs-ningen var omrørt i 1 time ved romtemperatur, ble reaksjonsblandingen konsentrert under redusert trykk og azeotropbehandlet med toluen. Under argonatmosfære ble resten oppløst i diklormetan (1,5 ml), og blandingen ble avkjølt til 0°C. Oppløs-ningen ble tilsatt 28% vandig ammoniakk (1 ml) og omrørt i 5 minutter. Oppløs-ningen ble tilsatt vann og etylacetat. Det organiske laget ble vasket, tørket og konsentrert under redusert trykk. Under argonatmosfære ble resten oppløst i diklormetan (1,5 ml), og blandingen ble avkjølt til 0°C. Oppløsningen ble tilsatt pyridin (0,18 ml) og trifluormetansulfonsyreanhydride (0,12 ml) og omrørt i 50 minutter. Reaksjonsblandingen ble helt i vann, og deretter ble den tilsatt etylacetat. Det organiske laget ble vasket, tørket og konsentrert under redusert trykk. Resten ble renset ved kolonnekromatografi på silikagel (heksan - etylacetat) til å gi tittelforbindelsen (149 mg) som har de følgende fysiske data.
TLC : Rf 0,74 (n-heksan : etylacetat =1:1).
Eksempel 3
N-[4,5-dimetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid
Til N-[4,5-dimetyl-2-(2-metyl-4-cyanofenylmetyloksy)fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid fremstilt i referanseeksempel 4 (79 mg), ble trimetyltinnazid (43 mg) tilsatt, og blandingen ble kokt under tilbakeløp i 7 timer og deretter omrørt i 1 døgn ved romtemperatur. Reaksjonsblandingen ble tilsatt metanol (3 ml) og 2N saltsyre (2 ml), og deretter omrørt i 2 timer. Oppløsningen ble tilsatt vann og etylacetat. Det organiske laget ble vasket, tørket og konsentrert under redusert trykk. Resten ble vasket med heksan - etylacetat til å gi tittelforbindelsen (81 mg) som har de følgende fysiske data.
TLC : Rf 0,52 (kloroform : metanol: vann = 8:2: 0,2);
MS (FAB, Pos.) : 510 (M + H)<+.>
Eksempel 3(1) til eksempel 3(38)
Ved hjelp av de samme prosedyrene som er beskrevet i referanseeksempler 1 til 3 og eksempel 3, ble tittelforbindelsene som har de følgende fysiske data oppnådd.
Eksempel 3(1)
N-[4-klor-5-metyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid
TLC : Rf 0,40 (diklormetan : metanol = 10 : 1);
MS (FAB, Pos.): 530 (M)<+.>
Eksempel 3(2)
N-[4,5-dimetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-(5-metyl-2-furyl)sulfonylamid
TLC : Rf 0,52 (kloroform : metanol: vann = 8:2: 0,2);
MS (FAB, Pos.): 496 (M + H)<+>.
Eksempel 3(3) N-[4-klor-5-metyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid
TLC : Rf 0,39 (kloroform : metanol: vann =8:2: 0,2);
NMR : 5 8.05 (d, J = 8.1 Hz, 2H), 7.47 (d, J = 8.1 Hz, 2H), 7.08 (s, 1H), 6.93 (s, 1H), 6.80 (d, J = 3.3 Hz, 1H), 6.01 (m, 1H), 5.15-4.80 (br, 2H), 3.46 (d, J = 7.2 Hz, 2H), 2.27 (s, 3H), 2.19 (s, 3H), 1.64 (m, 1H), 0.88 (d, J = 6.9 Hz, 6H).
Eksempel 3(4)
N-[4,5-dimety 1-2-[4-(5-tetrazo furyl)sulfonylamid
TLC : Rf 0,41 (kloroform : metanol: vann = 8:2: 0,2);
NMR(DMSO-d6): 8 8.04 (d, J = 8.1 Hz, 2H), 7.66 (d, J = 8.1 Hz, 2H), 7.01 (s, 1H), 6.91 (d, J = 3.3 Hz, 1H), 6.76 (s, 1H), 6.29-6.23 (m, 1H), 5.18 og 5.12 (hver d, J = 13.5 Hz, hver 1H), 4.30 (sept, J = 6.6 Hz, 1H), 2.30 (s, 3H), 2.23 (s, 3H), 2.14 (s, 3H), 1.02 og 1.00 (hver d, J = 6.6 Hz, hver 3H).
Eksempel 3(5)
N-[4,5-dimetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid
TLC : Rf 0,37 (kloroform : metanol: vann = 8:2: 0,2);
NMR(DMSO-d6) : 8 8.04 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 8.4 Hz, 2H), 6.96 (s, 1H), 6.92 (s, 1H), 6.82 (d, J = 3.3 Hz, 1H), 6.19-6.13 (m, 1H), 5.28-4.82 (m, 2H), 3.38 (d, J = 6.9 Hz, 2H), 2.21 (s, 3H), 2.14 (s, 6H), 1.64-1.44 (m, 1H), 0.85 (d, J = 6.6 Hz, 6H).
Eksempel 3(6)
N-[4-trifluormetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-2-tiazolylsulfonylamid
TLC : Rf 0,46 (kloroform : metanol: vann = 8:2: 0,2);
NMR : 5 8.09 (d, J = 8.4 Hz, 2H), 7.76 (d, J = 2.7 Hz, 1H), 7.49-7.44 (m, 4H), 7.27 (m, 1H), 7.19 (s, 1H), 5.01 (br, 2H), 3.63 (d, J = 7.2 Hz, 2H), 1.67 (m, 1H), 0.97 (d, J = 7.2 Hz, 6H).
Eksempel 3(7)
N- [4-trifluonnety 1-2- [4-(5 -tetrazoly l)feny lmetyloksy] feny 1] -N-isopropy 1-2-tiazolylsulfonylamid
TLC : Rf 0,31 (kloroform : metanol: vann = 8:2: 0,2);
NMR : 5 8.07 (d, J = 8.1 Hz, 2H), 7.94 (d, J = 3.3 Hz, 1H), 7.60 (d, J = 8.1 Hz, 2H), 7.56 (d, J = 3.3 Hz, 1H), 7.36-7.20 (m, 3H), 5.17 og 5.13 (hver d, J = 12.0 Hz, hver 1H), 4.68 (sept, J = 6.6 Hz, 1H), 1.15 og 1.14 (hver d, J = 6.6 Hz, hver 3H).
Eksempel 3(8)
N-[4-trifluormetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid
TLC : Rf 0,31 (kloroform : metanol: vann = 8:2: 0,2);
NMR : 8 8.04 (d, J = 8.1 Hz, 2H), 7.42 (d, J = 8.1 Hz, 1H), 7.37 (d, J = 8.1 Hz, 2H), 7.23 (m, 1H), 7.16 (s, 1H), 6.99 (s, 1H), 4.95 (br, 2H), 3.56 (d, J = 6.6 Hz, 2H), 2.26 (s, 3H), 1.59 (sept, J = 6.6 Hz, 1H), 0.84 (d, J = 6.6 Hz, 6H).
Eksempel 3(9)
N-[4-trifluormetyl-2-[4-(5-tetrazolyl)fe^ tiazolyl)sulfonylamid
TLC : Rf 0,42 (kloroform : metanol: vann = 8:2: 0,2);
NMR : 8 7.93 (d, J = 8.1 Hz, 2H), 7.41 (d, J = 8.1 Hz, 2H), 7.24-7.16 (m, 3H), 7.02 (s, 1H), 5.10-4.92 (m, 2H), 4.57 (kvint, J = 6.6 Hz, 1H), 2.39 (s, 3H), 1.04 (d, J = 6.6 Hz, 3H), 1.02 (d, J = 6.6 Hz, 3H).
Eksempel 3(10)
N-[4-klor-5-metyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid
TLC : Rf 0,24 (diklormetan : metanol = 10 : 1);
MS (FAB, Pos.) : 547 (M)<+>.
Eksempel 3(11)
N-[4-klor-5-metyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid
TLC : Rf 0,24 (diklormetan : metanol = 10 : 1);
MS (FAB, Pos.) : 533 (M)<+>.
Eksempel 3(12)
N-[4-trifluormetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid
TLC : Rf 0,38 (kloroform : metanol: vann = 8:2: 0,2);
NMR : 8 7.91 (s, 1H), 7.82 (d, J = 7.8 Hz, 1H), 7.64 (d, J = 7.8 Hz, 1H), 7.33-7.20 (m, 3H), 7.12 (s, 1H), 5.11 (s, 2H), 4.65 (sept, J = 6.6 Hz, 1H), 2.49 (s, 3H), 2.43 (s, 3H), 1.12 (d, J = 6.6Hz, 6H).
Eksempel 3(13)
N-[4-trifluormetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobu metyl-2-tiazolyl)sulfonylamid
TLC : Rf 0,34 (kloroform : metanol: vann = 8:2: 0,2);
NMR : 8 7.97 (s, 1H), 7.89 (d, J = 8.1 Hz, 1H), 7.48-7.38 (m, 2H), 7.34-7.18 (m, 2H), 7.05 (s, 1H), 5.12-4.84 (m, 2H), 3.59 (d, J = 7.2 Hz, 2H), 2.41 (s, 3H), 2.34 (s, 3H), 1.74-1.58 (m, 1H), 0.89 (d, J = 6.6 Hz, 6H).
Eksempel 3(14)
N- [4,5-dimety 1-2-[2-mety l-4-(5-tetrazolyl)feny lmety loksy] fenyl] -N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid
TLC : Rf 0,46 (kloroform : metanol: vann = 8:2: 0,2);
MS (FAB, Pos.) : 527 (M + H)<+>.
Eksempel 3(15)
N-[4,5-dimetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmety^ metyl-2-tiazolyl)sulfonylamid
TLC : Rf 0,52 (kloroform : metanol: vann = 8:2: 0,2);
MS (FAB, Pos.): 513 (M + H)<+>.
Eksempel 3(16)
N- [4,5 -dimety 1-2- [4-(5 -tetrazolyl)fenylmety loksy] fenyl] -N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid
TLC : Rf 0,29 (kloroform : metanol = 5:1);
MS (APCI, Neg. 20V) : 497 (M - H)\
Eksempel 3(17)
N- [4,5 -dimetyl-2- [4-(5-tetrazolyl)fenylmety loksy] fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid
TLC : Rf 0,26 (kloroform : metanol = 5:1);
MS (APCI, Neg. 20V): 511 (M - H)\
Eksempel 3(18)
N-[4-ldor-5-metyl-2-[4-(5-tetrazolyl)fenylm^ tiazolyl)sulfonylamid
TLC : Rf 0,31 (kloroform : metanol: vann = 8:2: 0,2);
NMR : 5 8.02 (d, J = 8.4 Hz, 2H), 7.51 (d, J = 8.4 Hz, 2H), 7.10 (s, 1H), 6.98 (s, 2H), 5.03 og 4.95 (hver d, J = 12.6 Hz, hver 1H), 4.65 (sept, J = 6.6 Hz, 1H), 2.46 (s, 3H), 2.26 (s, 3H), 1.13 og 1.12 (hver d, J = 6.6 Hz, hver 3H).
Eksempel 3(19)
N-[4-klor-5-metyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid
TLC : Rf 0,29 (kloroform : metanol: vann = 8:2: 0,2);
NMR(DMSO-d6) : 5 8.05 (d, J = 8.4 Hz, 2H), 7.52 (s, 1H), 7.45 (d, J = 8.4 Hz, 2H), 7.26 (s, 1H), 7.25 (s, 1H), 5.25-4.73 (m, 2H), 3.62-3.40 (m, 2H), 2.26 (s, 3H), 2.22 (s, 3H), 1.66-1.50 (m, 1H), 0.88 (d, J = 6.6 Hz, 6H).
Eksempel 3(20)
N-[4,5-dimetyl-2-[2-metoksy-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid
TLC : Rf 0,31 (kloroform : metanol = 5:1);
NMR(CDC13 + 1 dråpe CD3OD) : 8 7.71 (d, J = 7.5 Hz, 1H), 7.70 (d, J = 1.5 Hz, 1H), 7.51 (dd, J = 7.5, 1.5 Hz, 1H), 7.07 (d, J = 0.9 Hz, 1H), 6.83 (s, 1H), 6.82 (s, 1H), 5.09 (d, J = 13.8 Hz, 1H), 5.04 (d, J = 13.8 Hz, 1H), 4.68 (m, 1H), 3.97 (s, 3H), 2.46 (d, J = 0.9 Hz, 3H), 2.25 (s, 3H), 2.16 (s, 3H), 1.15 (d, J = 6.6 Hz, 3H), 1.14 (d, J = 6.6Hz, 3H).
Eksempel 3(21)
N-[4-1iifluormetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropy sulfonylamid
TLC : Rf 0,47 (kloroform : metanol = 3:1);
NMR(DMSO-d6) : 8 8.91 (dd, J = 2.4, 0.6 Hz, 1H), 8.73 (dd, J = 4.5, 1.8 Hz, 1H), 8.14 (ddd, J = 8.4, 2.4, 1.8 Hz, 1H), 8.04 (d, J = 8.4 Hz, 2H), 7.57 (s, 1H), 7.55 (d, J = 8.4 Hz, 2H), 7.47 (ddd, J = 8.4,4.5, 0.6 Hz, 1H), 7.43-7.38 (m, 2H), 5.28 (d, J = 12.3 Hz, 1H), 5.21 (d, J = 12.3 Hz, 1H), 4.45-4.25 (m, 1H), 1.04 (d, J = 6.6 Hz, 3H), 1.00 (d, J = 6.6 Hz, 3H).
Eksempel 3(22)
N-[4-trifluormetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-3-pyridyl-sulfonylamid
TLC : Rf 0,47 (kloroform : metanol = 3:1);
NMR : 8 8.89 (d, J = 1.5 Hz, 1H), 8.46 (dd, J = 4.8, 1.5 Hz, 1H), 8.00 (d, J = 8.4 Hz, 2H), 7.83 (dt, J = 8.1, 1.5 Hz, 1H), 7.59 (d, J = 8.4 Hz, 1H), 7.35 (dd, J = 8.4, 0.9 Hz, 1H), 7.26-7.20 (m, 1H), 7.19 (d, J = 0.9 Hz, 1H), 7.14 (d, J = 8.4 Hz, 2H), 4.95 (brs, 1H), 4.77 (brs, 1H), 3.56 (brs, 1H), 3.40 (brs, 1H), 1.70-1.60 (m, 1H), 0.94 (brs, 6H).
Eksempel 3(23)
N-[4-trifluormetyl-2-[4-(5-te1razolyl)fenylmetyloksy]fenyl]-N-isopropyl-2-pyridyl-sulfonylamid
TLC : Rf 0,47 (kloroform : metanol = 3:1);
NMR : 5 8.69 (d, J = 4.8 Hz, 1H), 8.02 (d, J = 8.4 Hz, 2H), 7.92-7.76 (m, 2H), 7.52 (d, J = 8.4 Hz, 2H), 7.46-7.38 (m, 1H), 7.30-7.26 (m, 3H), 5.08 (d, J = 12.0 Hz, 1H), 5.01 (d, J = 12.0 Hz, 1H), 4.75-4.55 (m, 1H), 1.11 (d, J = 7.5 Hz, 3H), 1.08 (d, J = 7.5 Hz, 3H).
Eksempel 3(24)
N-[4-trifluormetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-2-pyridyl-sulfonvlamid
TLC : Rf 0,38 (kloroform : metanol = 3:1);
NMR : 5 8.60-8.45 (m, 1H), 8.10 (d, J = 8.4 Hz, 2H), 7.80-7.70 (m, 2H), 7.49 (d, J = 8.1 Hz, 1H), 7.38 (d, J = 8.4 Hz, 2H), 7.38-7.31 (m, 1H), 7.30-7.20 (m, 1H), 7.14 (d, J = 1.8 Hz, 1H), 4.91 (brs, 2H), 3.63 (brd, J = 6.3 Hz, 2H), 1.70-1.55 (m, 1H), 0.89 (d, J = 6.6 Hz, 6H).
Eksempel 3(25)
N-[4-trifluormetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-2-pyridylsulfonylamid
TLC : Rf 0,24 (kloroform : metanol = 3:1);
NMR : 5 8.69 (d, J = 4.8 Hz, 1H), 7.92-7.75 (m, 4H), 7.58 (d, J = 7.8 Hz, 1H), 7.48-7.39 (m, 1H), 7.31-7.18 (m, 3H), 5.03 (s, 2H), 4.72-4.58 (m, 1H), 2.37 (s, 3H), 1.11 og 1.09 (hver d, J = 6.6 Hz, hver 3H).
Eksempel 3(26)
N- [4,5 -dimetyl-2- [2-mety l-4-(5 -tetrazolyl)feny lmetyloksy] feny l]-N-isobuty 1-2-pyridylsulfonylamid
TLC : Rf 0,40 (kloroform : metanol: vann = 8:2: 0,2);
MS (FAB, Pos.): 507 (M + H)<+>.
Eksempel 3(27)
N-[4,5-dimetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-3-pyridylsulfonylamid
TLC : Rf 0,44 (kloroform : metanol: vann = 8:2: 0,2);
MS (FAB, Pos.): 507 (M + H)<+>.
Eksempel 3(28)
N-[4-klor-5-metyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-3-pyridyl-sulfonylamid
TLC : Rf 0,28 (kloroform : metanol: vann = 8:2: 0,2);
NMR(DMSO-d6): 8 8.69 (d, J = 1.8 Hz, 1H), 8.64 (dd, J = 4.8,1.8 Hz, 1H), 8.00 (d, J = 8.1 Hz, 2H), 7.98-7.92 (m, 1H), 7.40 (dd, J = 8.1,4.8 Hz, 1H), 7.30 (d, J = 8.4 Hz, 2H), 7.27 (s, 1H), 7.24 (s, 1H), 5.17-4.68 (m, 2H), 3.46-3.16 (m, 2H), 2.28 (s, 3H), 1.60-1.42 (m, 1H), 1.00-0.73 (m, 6H).
Eksempel 3(29)
N-[4,5-dimetyl-2-[2-klor-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-2-pyridyl-sulfonylamid
TLC : Rf 0,22 (kloroform : metanol: vann = 40 : 10 : 1);
NMR : 8 8.52 (d, J = 4.5 Hz, 1H), 8.20 (d, J = 1.5 Hz, 1H), 7.98 (d, J = 7.8 Hz, 1H), 7.79 (dt, J = 1.5, 8.1 Hz, 1H), 7.71 (d, J = 8.1 Hz, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.35-7.30 (m, 1H), 7.04 (s, 1H), 6.63 (s, 1H), 4.90 (br, 1H), 4.64 (br, 1H), 3.67 (br, 1H), 3.57 (br, 1H), 2.21 (s, 3H), 2.15 (s, 3H), 1.80-1.60 (m, 1H), 0.91 (br, 6H).
Eksempel 3(30)
N-[4,5-dimetyl-2-[2-klor-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-3-pyridylsulfonylamid
TLC : Rf 0,22 (kloroform : metanol: vann = 40 : 10 : 1);
NMR : 8 9.11 (d, J = 1.8 Hz, 1H), 8.61 (dd, J = 4.8, 1.5 Hz, 1H), 8.20-8.10 (m, 2H), 7.88 (dd, J = 7.8, 1.5 Hz, 1H), 7.42 (dd, J = 8.1,4.8 Hz, 1H), 7.33 (d, J = 7.8 Hz, 1H), 7.01 (s, 1H), 6.79 (s, 1H), 4.96 (d, J = 13.5 Hz, 1H), 4.93 (d, J = 13.5 Hz, 1H), 4.60-4.45 (m, 1H), 2.29 (s, 3H), 2.23 (s, 3H), 1.25 (d, J = 6.6 Hz, 3H), 1.11 (d, J = 6.6 Hz, 3H).
Eksempel 3(31)
N-[4,5-dimetyl-2-[2-klor-4-(5-tetrazolyl)fenyl^^ sulfonylamid
TLC : Rf 0,22 (kloroform : metanol: vann = 40 : 10 : 1);
NMR : 5 8.97 (d, J = 1.8 Hz, 1H), 8.55-8.45 (m, 1H), 8.15 (d, J = 1.5 Hz, 1H), 7.89 (d, J = 7.8 Hz, 1H), 7.83 (dt, J = 8.1, 1.8 Hz, 1H), 7.31 (dd, J = 8.1,4.8 Hz, 1H), 7.24 (s, 1H), 7.07 (d, J = 7.8 Hz, 1H), 6.75 (s, 1H), 4.89 (d, J = 12.5 Hz, 1H), 4.63 (d, J = 12.5 Hz, 1H), 3.70-3.60 (m, 1H), 3.45-3.30 (m, 1H), 2.30 (s, 3H), 2.26 (s, 3H), 1.80-1.60 (m, 1H), J = 6.6 Hz, 3H), 0.93 (d, J = 6.6 Hz, 3H).
Eksempel 3(32)
N-[4,5-dimetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-2-pyridyl-sulfonylamid
TLC : Rf 0,23 (kloroform : metanol = 5:1);
MS (APCI, Neg. 20V) : 477 (M - H)_.
Eksempel 3(33)
N-[4,5-dimetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-2-pyridyl-sulfonylamid
TLC : Rf 0,23 (kloroform : metanol = 5:1);
MS (APCI, Neg. 20V): 491 (M - H)\
Eksempel 3(34)
N-[4,5-dimetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-3-pyridylsulfo-nylamid
TLC : Rf 0,23 (kloroform : metanol = 5:1);
MS (APCI, Neg. 20V): 491 (M - H)-.
Eksempel 3(35)
N-[4-klor-5-metyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-2-pyridylsulfonylamid
TLC : Rf 0,30 (kloroform : metanol: vann = 8:2: 0,2);
NMR(DMSO-d6): 8 8.67 (d, J = 3.6 Hz, 1H), 7.98-7.88 (m, 2H), 7.85-7.78 (m, 2H), 7.55-7.48 (m, 2H), 7.37 (s, 1H), 7.04 (s, 1H), 5.10 (ABd, J = 13.2 Hz) og 5.04 (ABd, J = 13.2 Hz) total 2H, 4.49 (sept, J = 6.9 Hz, 1H), 2.36 (s, 3H), 2.23 (s, 3H), 1.02 (d, J = 6.9 Hz) og 0.99 (d, J = 6.9 Hz) total 6H.
Eksempel 3(36)
N-[4-klor-5-metyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-2-pyridylsulfonylamid
TLC : Rf 0,26 (kloroform : metanol: vann = 8:2: 0,2);
NMR(DMSO-d6): 8 8.48 (m, 1H), 7.93-7.85 (m) og 7.90 (dd, J = 7.8, 1.8 Hz) total 2H, 7.81 (d, J = 8.1 Hz, 1H), 7.68 (d, J=8.1 Hz, 1H), 7.44 (ddd, J = 7.8, 4.8, 1.2
Hz, 1H), 7.29 (s) og 7.27 (d, J = 7.8 Hz) total 2H, 7.20 (s, 1H), 4.92 (m, 2H), 3.47 (m, 2H), 2.31 (s, 3H), 2.23 (s, 3H), 1.50 (m, 1H), 0.81 (d, J = 6.6 Hz, 6H).
Eksempel 3(37)
N-[4,5-dimetyl-2-[2-metoksy-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-2-pyridylsulfonylamid
TLC : Rf 0,23 (diklormetan : metanol =10:1);
MS (FAB, Pos.) : 523 (M + H)<+>.
Eksempel 3(38)
N-[4,5-dimetyl-2-[2-metoksy-4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-2-pyridylsulfonylamid
TLC : Rf 0,23 (kloroform : metanol =10:1); Referanseeksempel 5 N- [4,5 -dimetyl-2- [2-mety l-4-(N-hy droksyamidino)feny lmety loksy] feny 1] -N-isobuty 1-(5-metyl-2-furyl)sulfonylamid
Til en oppløsning av N-[4,5-dimetyl-2-(2-metyl-4-cyanofenylmetyloksy)fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid fremstilt i referanseeksempel 4 (70 mg) i etanol (2 ml) ble trietylamin (42 ul) og hydroksylaminhydrogenkloridsalt (21 mg) tilsatt ved romtemperatur, og deretter ble blandingen kokt under tilbakeløp i 5 timer. Etter terminering av reaksjonen ble reaksjonsblandingen helt i etylacetat-vann. Det organiske laget ble vasket, tørket og konsentrert under redusert trykk til å gi tittelforbindelsen (80 mg) som har de følgende fysiske data.
TLC : Rf 0,38 (n-heksan : etylacetat = 2:3).
Eksempel 4
N-[4,5-dimetyl-2-[2-metyl-4-(5-okso-l,2,4-oksadiazol-3-yl)fenylmetyloksy]fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid
Til en oppløsning avN-[4,5-dimetyl-2-[2-metyl-4-(N-hydroksyamidino)fenyl-metyloksy]fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid fremstilt i referanseeksempel 5 (78 mg) i N,N-dimetylformamid (1 ml), ble pyridin (16 (il) og klor-maursyre-2-etylheksylester (30 ul) tilsatt, og blandingen ble omrørt i 1 time ved 0°C. Etter terminering av reaksjonen ble reaksjonsblandingen helt i etylacetat-vann. Det organiske laget ble vasket, tørket og konsentrert under redusert trykk. Til resten ble xylener (2 ml) tilsatt, og blandingen ble kokt under tilbakeløp i 6 timer ved 140°C. Etter terminering av reaksjonen ble reaksjonsblandingen konsentrert under redusert trykk. Resten ble renset ved kolonnekromatografi på silikagel (heksan - etylacetat) til å gi tittelforbindelsen (42 mg) som har de følgende fysiske data.
TLC : Rf 0,43 (kloroform : metanol =19:1);
NMR : 8 10.69 (br, 1H), 7.62 (s, 1H), 7.59 (d, J = 8.1 Hz, 1H), 7.54 (d, J = 8.1 Hz, 1H), 6.97 (s, 1H), 6.78 (d, J = 3.3 Hz, 1H), 6.71 (s, 1H), 6.00 (d, J = 3.3 Hz, 1H), 4.94 (br, 2H), 3.46 (d, J = 7.5 Hz, 2H), 2.39 (s, 3H), 2.24 (s, 3H), 2.19 (s, 3H), 2.18 (s, 3H), 1.70-1.55 (m, 1H), 0.89 (d, J = 6.6 Hz, 6H).
Eksempel 4(1) til eksempel 4(22)
Ved hjelp av de samme prosedyrene som er beskrevet i referanseeksempler 1 til 5 og eksempel 4, ble forbindelsene som har de følgende fysiske data oppnådd.
Eksempel 4(1)
N-[4-klor-5-metyl-2-[4-(5-okso-l,2,4-oksadiazol-3-yl)fenylmetyloksy]fenyl]-N-isopropyl-(5-metyl-2-furyl)sulfonylamid
TLC : Rf 0,40 (kloroform : metanol = 19:1);
NMR : 8 10.81 (br, 1H), 7.79 (d, J = 8.3 Hz, 2H), 7.63 (d, J = 8.3 Hz, 2H), 6.97 (s, 1H), 6.92 (s, 1H), 6.84 (d, J = 3.3 Hz, 1H), 6.10-6.00 (m, 1H), 5.07 (s, 2H), 4.55-4.35 (m, 1H), 2.34 (s, 3H), 2.28 (s, 3H), 1.10 (d, J = 6.6 Hz, 3H), 1.07 (d, J = 6.6 Hz, 3H).
Eksempel 4(2)
N- [4-klor-5 -mety 1-2- [4-(5-okso-1,2,4-oksadiazol-3 -y l)feny lmetyloksy] feny 1] -N-isobutyl-(5-metyl-2-furyl)sulfonylamid
TLC : Rf 0,38 (kloroform : metanol = 19 : 1); NMR : 8 11.01 (br, 1H), 7.80 (d, J = 8.3 Hz, 2H), 7.52 (d, J = 8.3 Hz, 2H), 7.10 (s, 1H), 6.92 (s, 1H), 6.78 (d, J = 3.3 Hz, 1H), 6.05-5.95 (m, 1H), 5.02 (br, 2H), 3.45 (d, J = 7.2 Hz, 2H), 2.29 (s, 3H), 2.20 (s, 3H), 1.70-1.55 (m, 1H), 0.90 (d, J = 6.9 Hz, 6H). Eksempel 4(3) N- [4,5 -dimetyl-2- [2-metyl-4-(5-okso-1,2,4-oksadiazol-3 -yl)feny lmetyloksy ] fenyl] -N-isopropyl-(5-metyl-2-furyl)sulfonylamid
TLC : Rf 0,43 (kloroform : metanol =19:1);
NMR : 5 10.34 (br, 1H), 7.71 (d, J = 8.1 Hz, 1H), 7.65-7.55 (m, 2H), 6.86 (d, J = 3.3 Hz, 1H), 6.79 (s, 1H), 6.74 (s, 1H), 6.10-6.05 (m, 1H), 4.93 (s, 2H), 4.50-4.40 (m, 1H), 2.37 (s, 3H), 2.34 (s, 3H), 2.26 (s, 3H), 2.17 (s, 3H), 1.09 (d, J = 6.6 Hz, 3H), 1.07 (d,J = 6.6 Hz, 3H).
Eksempel 4(4)
N-[4,5-dimetyl-2-[4-(5-okso-l,2,4-oksadiazol-3-yl)fenylmetyloksy]fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid
TLC : Rf 0,53 (kloroform : metanol = 9:1);
NMR : 5 11.10-10.50 (br, 1H, NH), 7.78 (d, J = 8.7 Hz, 2H), 7.52 (d, J = 8.7 Hz, 2H), 6.97 (s, 1H), 6.78 (d, J = 3.3 Hz, 1H), 6.69 (s, 1H), 6.01-5.98 (m, 1H), 5.15-4.85 (m, 2H), 3.46 (d, J = 7.2 Hz, 2H), 2.22 (s, 3H), 2.20 (s, 3H), 2.17 (s, 3H), 1.73-1.60 (m, 1H), 0.90 (d, J = 6.9 Hz, 6H).
Eksempel 4(5)
N-[4,5-dimetyl-2-[2-metoksy-4-(5-okso-l,2,4-oksadiazol-3-yl)fenylmetyloksy]fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid
TLC : Rf 0,46 (diklormetan : metanol =10:1);
MS (FAB, Pos.): 542 (M + H)<+>.
Eksempel 4(6)
N- [4,5 -dimetyl-2- [2-metoksy-4-(5 -okso-1,2,4-oksadiazol-3 -y l)feny lmetyloksyJfenylJ-N-isopropyKS-metyl^-fary^sulfonylamid
TLC : Rf 0,44 (diklormetan : metanol =19:1);
NMR : 5 7.68 (d, J = 8.1 Hz, 1H), 7.35 (dd, J = 8.1, 1.5 Hz, 1H), 7.24 (d, J = 1.5 Hz, 1H), 6.91 (d, J = 3.3 Hz, 1H), 6.77 (s, 1H), 6.72 (s, 1H), 6.11 (dd, J = 3.3, 0.6
Hz, 1H), 4.92 (d, J = 14.7 Hz, 1H), 4.83 (d, J = 14.7 Hz, 1H), 4.49 (m, 1H), 3.93 (s, 3H), 2.37 (s, 3H), 2.25 (s, 3H), 2.17 (s, 3H), 1.09 (d, J = 6.9 Hz, 3H), 1.07 (d, J = 6.9 Hz, 3H).
Eksempel 4(7)
N-[4-trifluormetyl-2-[4-(5-okso isopropyl-2-tiazolylsulfonylamid
TLC : Rf 0,23 (n-heksan : etylacetat =1:1);
NMR : 8 7.96 (d, J = 3.3 Hz, 1H), 7.82 (d, J = 8.4 Hz, 2H), 7.65 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 3.3 Hz, 1H), 7.34-7.22 (m, 3H), 5.19 (s, 2H), 4.68 (sept, J = 6.6 Hz, 1H), 1.15 og 1.14 (hver d, J = 6.6 Hz, hver 3H).
Eksempel 4(8)
N- [4-trifluormety 1-2- [4-(5 -okso-1,2,4-oksadiazol-3 -yl)feny lmetyloksy] fenyl] -N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid
TLC : Rf 0,60 (kloroform : metanol: vann = 8:2: 0,2);
NMR : 8 7.82 (d, J = 8.4 Hz, 2H), 7.64 (d, J = 8.4 Hz, 2H), 7.32-7.24 (m, 3H), 7.11 (d, J = 0.9 Hz, 1H), 5.19 (s, 2H), 4.68 (kvint, J = 6.6 Hz, 1H), 2.51 (d, J = 0.9 Hz, 3H), 1.14 (d, J = 6.6Hz, 6H).
Eksempel 4(9)
N-[4-trifluormetyl-2-[4-(5-okso-l,2,4-oksadiazol-3-yl)fenylmetyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid
TLC : Rf 0,60 (kloroform : metanol: vann = 8:2: 0,2);
NMR : 8 7.83 (d, J = 8.4 Hz, 2H), 7.48 (d, J = 8.4 Hz, 2H), 7.45 (d, J = 7.8 Hz, 1H), 7.27 (m, 1H), 7.18 (d, J = 1.5 Hz, 1H), 7.04 (d, J = 0.6 Hz, 1H), 5.05 (br, 2H), 3.60 (d, J = 6.9 Hz, 2H), 2.38 (d, J = 0.6 Hz, 3H), 1.66 (sep, J = 6.9 Hz, 1H), 0.92 (d, J = 6.9 Hz, 6H).
Eksempel 4(10)
N-[4-klor-5-metyl-2-[4-(5-okso-l,2,4-oksadiazol-3-yl)fenylmetyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid
TLC : Rf 0,37 (kloroform : metanol =19:1);
NMR : 8 10.89 (br, 1H), 7.79 (d, J = 8.4 Hz, 2H), 7.44 (d, J = 8.4 Hz, 2H), 7.17 (s, 1H), 7.01 (s, 1H), 6.92 (s, 1H), 4.99 (br, 1H), 4.87 (br, 1H), 3.57 (br, 2H), 2.36 (s, 3H), 2.27 (s, 3H), 1.80-1.60 (m, 1H), 0.93 (d, J = 6.6 Hz, 6H).
Eksempel 4(11)
N-[4-klor-5-metyl-2-[2-metyl-4-(5-okso-l,2,4-oksadiazol-3-yl)fenylmetyloksy]-fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid
TLC : Rf 0,43 (etylacetat);
NMR(DMSO-d6): 8 7.67 (s, 1H), 7.64 (d, J = 8.1 Hz, 1H), 7.50 (s, 1H), 7.34 (s,
1H), 7.32 (d, J = 8.1 Hz, 1H), 7.21 (s, 1H), 5.06 (brs, 1H), 4.87 (brs, 1H), 3.45 (brs, 2H), 2.33 (s, 3H), 2.27 (s, 3H), 2.22 (s, 3H), 1.70-1.50 (m, 1H), 0.86 (brd, J = 6.3 Hz, 6H).
Eksempel 4(12)
N-[4,5-dimetyl-2-[2-metyl-4-(5-okso-l,2,4-oksadiazol-3-yl)fenylmetyloksy]fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid
TLC : Rf 0,45 (kloroform : metanol = 19 : 1);
NMR : 8 10.56 (br, 1H), 7.64 (d, J = 8.1 Hz, 1H), 7.62 (s, 1H), 7.57 (dd, J = 8.1, 1.8 Hz, 1H), 7.07 (s, 1H), 6.83 (s, 1H), 6.77 (s, 1H), 4.98 (s, 2H), 4.75-4.60 (m, 1H), 2.49 (s, 3H), 2.39 (s, 3H), 2.25 (s, 3H), 2.16 (s, 3H), 1.14 (d, J = 6.6 Hz, 3H), 1.13
(d, J = 6.6 Hz, 3H).
Eksempel 4(13)
N-[4,5-dimetyl-2-[2-metyl-4-(5-okso-l,2,4-oksadiazol-3-yl)fenylmetyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid
TLC : Rf 0,45 (kloroform : metanol =19:1);
NMR : 8 10.95 (br, 1H), 7.62 (s, 1H), 7.59 (d, J = 8.1 Hz, 1H), 7.40 (d, J = 8.1 Hz, 1H), 7.03 (s, 1H), 6.99 (s, 1H), 6.71 (s, 1H), 4.91 (br, 1H), 4,82 (br, 1H), 3.57 (br, 2H), 2.37 (s, 3H), 2.34 (s, 3H), 2.24 (s, 3H), 2.17 (s, 3H), 1.80-1.60 (m, 1H), 0.93 (br, 6H).
Eksempel 4(14)
N- [4,5 -dimety 1-2- [4-(5 -okso-1,2,4-oksadiazol-3 -yl)fenylmetyloksy]feny l]-N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid
TLC : Rf 0,42 (kloroform : metanol =10:1);
NMR : 8 7.77 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.4 Hz, 2H), 7.06 (d, J = 0.9 Hz, 1H), 6.83 (s, 1H), 6.74 (s, 1H), 5.05 (d, J = 12.9 Hz, 1H), 5.00 (d, J = 12.9 Hz, 1H), 4.68 (m, 1H), 2.49 (d, J = 0.9 Hz, 3H), 2.24 (s, 3H), 2.15 (s, 3H), 1.15 (d, J = 6.6 Hz, 3H), 1.13 (d, J = 6.6Hz, 3H).
Eksempel 4(15)
N- [4,5-dimety 1-2-[4-(5 -okso-1,2,4-oksadiazol-3 -yl)fenylmetyloksy] feny l]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid
TLC : Rf 0,39 (kloroform : metanol = 10 : 1);
NMR : 5 7.78 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.4 Hz, 2H), 7.03 (s, 1H), 6.97 (d, J = 0.9 Hz, 1H), 6.68 (s, 1H), 5.12-4.68 (m, 2H), 3.73-3.42 (m, 2H), 2.35 (d, J = 0.9
Hz, 3H), 2.23 (s, 3H), 2.17 (s, 3H), 1.69 (m, 1H), 1.03-0.86 (m, 6H).
Eksempel 4(16)
N- [4,5 -dimety 1-2- [2-metoksy-4-(5 -okso-1,2,4-oksadiazol-3 -y l)fenylmetyloksy] feny 1] - N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid
TLC : Rf 0,37 (diklormetan : metanol = 19 : 1);
NMR : 5 7.63 (d, J = 7.8 Hz, 1H), 7.33 (dd, J = 7.8, 1.5 Hz, 1H), 7.30 (d, J = 1.5 Hz, 1H), 7.08 (brs, 1H), 6.83 (s, 1H), 6.76 (s, 1H), 5.02 (d, J = 14.4 Hz, 1H), 4.93 (d, J = 14.4 Hz, 1H), 4.69 (m, 1H), 3.93 (s, 3H), 2.49 (d, J = 1.2 Hz, 3H), 2.25 (s, 3H), 2.16 (s, 3H), 1.14 (d, J = 6.9 Hz, 3H), 1.13 (d, J = 6.9 Hz, 3H).
Eksempel 4(17)
N-[4-trifluormetyl-2-[4-(5-okso-l,2,4-tiadiazol-3-yl)fenylmetyloksy]fenyl]-N-isopropyl-2-tiazolylsulfonylamid
TLC : Rf 0,44 (n-heksan : etylacetat =1:1);
NMR : 5 11.41 (brs, 1H), 7.94 (d, J = 8.4 Hz, 2H), 7.94 (d, J = 3.0 Hz, 1H), 7.60 (d, J = 8.4 Hz, 2H), 7.54 (d, J = 3.0 Hz, 1H), 7.34-7.20 (m, 3H), 5.16 (s, 2H), 4.69 (sept, J = 6.6 Hz, 1H), 1.15 (d, J = 6.6 Hz, 6H).
Eksempel 4(18)
N-[4-trifluoiTnetyl-2-[4-(5-okso-l,2,4-oksadiaz isobutyl-2-pyridylsulfonylamid
TLC : Rf 0,46 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 5 8.60-8.50 (m, 1H), 7.90 (dt, J = 1.8, 7.8 Hz, 1H), 7.81 (d, J = 8.4 Hz, 2H), 7.72 (d, J = 7.5 Hz, 1H), 7.55-7.35 (m, 6H), 5.08 (brs, 2H), 3.52 (brd, J = 7.5 Hz, 2H), 1.60-1.40 (m, 1H), 0.83 (d, J = 6.6 Hz, 6H).
Eksempel 4(19)
N-[4,5-dimetyl-2-[2-metyl-4-(5-okso-l,2,4-oksadiazol-3-yl)fenylmetyloksy]fenyl]-N-isopropyl-2-pyridylsulfonylamid
TLC : Rf 0,33 (kloroform : metanol = 19 : 1);
NMR : 5 10.41 (br, 1H), 8.75-8.70 (m, 1H), 7.90 (dd, J = 7.8, 0.9 Hz, 1H), 7.80 (dt, J = 0.9, 7.8 Hz, 1H), 7.65-7.50 (m, 3H), 7.41 (ddd, J = 7.8, 4.8, 0.9 Hz, 1H), 6.78 (s, 1H), 6.72 (s, 1H), 4.87 (d, J = 13.4 Hz, 1H), 4.83 (d, J = 13.4 Hz, 1H), 4.75-4.60 (m, 1H), 2.34 (s, 3H), 2.25 (s, 3H), 2.13 (s, 3H), 1.10 (d, J = 6.6 Hz, 6H).
Eksempel 4(20)
N- [4,5 -dimety 1-2- [2-mety l-4-(5-okso-1,2,4-oksadiazol-3 -yl)fenylmetyloksy] fenyl] -N-isobuty 1-3 -pyridylsulfony lamid
TLC : Rf 0,30 (kloroform : metanol = 19:1); NMR : 8 11.28 (br, 1H), 8.84 (d, J = 1.8 Hz, 1H), 8.49 (dd, J = 4.8, 1.8 Hz, 1H), 7.87 (dt, J = 8.1, 1.8 Hz, 1H), 7.62 (s, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.19 (dd, J = 8.1,4.8 Hz, 1H), 7.15 (s, 1H), 6.97 (d, J = 7.8 Hz, 1H), 6.69 (s, 1H), 4.82 (br, 1H), 4.62 (br, 1H), 3.53 (br, 1H), 3.34 (br, 1H), 2.30 (s, 3H), 2.27 (s, 3H), 2.22 (s, 3H), 1.80-1.60 (m, 1H), 1.00 (br, 3H), 0.87 (br, 3H). Eksempel 4(21) N- [4,5 -dimety 1-2- [2-metoksy-4-(5 -okso-1,2,4-oksadiazol-3 -yl)fenylmety loksy] fenyl] - N-isobutyl-2-pyridylsulfonylamid
TLC : Rf 0,36 (diklormetan : metanol = 10 : 1);
MS (FAB, Pos.) : 539 (M + H)<+>.
Eksempel 4(22)
N-[4,5-dimety 1-2-[2-metoksy-4-(5-okso-1,2,4-oksadiazol-3-yl)fenylmety loksy] feny 1]-N-isopropyl-2-pyridylsulfonylamid
TLC : Rf 0,37 (diklormetan : metanol = 19 : 1);
NMR : 8 8.73 (ddd, J = 4.8, 1.5, 0.9 Hz, 1H), 7.91 (ddd, J = 7.8, 1.2, 0.9 Hz, 1H), 7.82 (ddd, J = 7.8, 7.8, 1.5 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H), 7.43 (ddd, J = 7.8, 4.8, 1.2 Hz, 1H), 7.32 (dd, J = 7.8, 1.5 Hz, 1H), 7.26 (m, 1H), 6.76 (s, 1H), 6.72 (s, 1H), 4.88 (d, J = 14.1 Hz, 1H), 4.78 (d, J = 14.1 Hz, 1H), 4.71 (m, 1H), 3.91 (s, 3H), 2.24 (s, 3H), 2.13 (s, 3H), 1.10 (d, J = 6.6 Hz, 3H), 1.09 (d, J = 6.6 Hz, 3H).
Eksempel 5(1) til eksempel 5(63)
Ved hjelp av den samme prosedyren som beskrevet i referanseeksempler 1 til 3 og eksempel 2, ble forbindelsene i henhold til den foreliggene oppfinnelse som har de følgende fysiske data oppnådd.
Eksempel 5(1)
3,5-dimetyl-4-[2-|l^-isobutyl-N-(5-m fenoksymetyljbenzosyre
TLC : Rf 0,49 (kloroform : metanol = 10 : 1);
NMR : 8 7.82 (s, 2H), 7.40-7.20 (m, 3H), 6.70 (d, J = 3.3 Hz, 1H), 6.00-5.95 (m, 1H), 5.07 (s, 2H), 3.35 (d, J = 7.5 Hz, 2H), 2.43 (s, 6H), 2.19 (s, 3H), 1.60-1.45 (m, 1H), 0.79 (d, J = 6.6 Hz, 6H).
Eksempel 5(2)
3 -mety 1-4- [6- [N-(5 -mety 1-2-fury lsulfony l)-N-(2-metyl-2-propenyl)amino] indan-5 - yloksymetyljbenzosyre
TLC : Rf 0,54 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 8 7.80-7.70 (m, 2H), 7.37 (d, J = 7.8 Hz, 1H), 7.05 (s, 1H), 6.99 (s, 1H), 6.87 (d, J = 3.3 Hz, 1H), 6.17 (d, J = 3.3 Hz, 1H), 4.99 (br, 2H), 4.72 (s, 2H), 4.13 (br, 2H), 2.83 (t, J = 7.4 Hz, 2H), 2.77 (t, J = 7.4 Hz, 2H), 2.32 (s, 3H), 2.08 (s, 3H), 2.05-1.90 (m, 2H), 1.65 (s, 3H).
Eksempel 5(3)
4-[6-[N-cyklopropylmetyl-N-(5-metyl-2-f\^ 3-mety lbenzosyre
TLC : Rf 0,54 (kloroform : metanol = 9:1);
NMR(DMSO-d6) : 5 7.77 (s, 1H), 7.74 (d, J = 8.1 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.09 (s, 1H), 7.02 (s, 1H), 6.85 (d, J = 3.3 Hz, 1H), 6.20-6.15 (m, 1H), 5.01 (br, 2H), 3.41 (br, 2H), 2.86 (t, J = 7.4 Hz, 2H), 2.79 (t, J = 7.4 Hz, 2H), 2.32 (s, 3H), 2.10 (s, 3H), 2.10-1.95 (m, 2H), 0.90-0.70 (m, 1H), 0.35-0.25 (m, 2H), O.05-(-O.O5)
(m, 2H).
Eksempel 5(4)
4-[3-|]N'-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]naftalen-2-yloksymetyl^ benzosyre
TLC : Rf 0,55 (etylacetat: metanol = 9:1);
NMR : 5 8.14 (d, J = 8.4 Hz, 2H), 7.85 (s, 1H), 7.78 (d, J = 8.1 Hz, 1H), 7.70 (d, J = 8.1 Hz, 1H), 7.51-7.37 (m, 4H), 7.18 (s, 1H), 6.93 (s, 1H), 5.17 og 4.96 (hver br-m, total 2H), 3.85-3.62 (br-m, 2H), 2.34 (s, 3H), 1.82-1.69 (m, 1H), 0.97 (br-s, 6H).
Eksempel 5(5)
4-[3-|Tvl-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)amino]naftalen-2-yloksymetyl]-benzosyre
TLC : Rf 0,55 (etylacetat: metanol = 9:1);
NMR : 5 8.15 (d, J = 8.4 Hz, 2H), 7.72 (d, J = 9.0 Hz, 2H), 7.61 (s, 1H), 7.60 (d, J = 9.0 Hz, 2H), 7.51-7.46 (m, 1H), 7.44-7.35 (m, 1H), 7.24 (s, 1H), 7.03 (s, 1H), 5.24 (s, 2H), 4.84-4.75 (m, 1H), 2.52 (s, 3H), 1.26 (d, J = 6.6 Hz, 3H), 1.17 (d, J = 6.6 Hz, 3H).
Eksempel 5(6) 4-[3-|TN-isobutyl-N-(4-metyl-2-tiazolylsulf^^ metylbenzosyre
TLC : Rf 0,63 (etylacetat: metanol = 9:1);
NMR : 8 7.98-7.96 (m, 2H), 7.84 (s, 1H), 7.78 (d, J = 8.1 Hz, 1H), 7.72 (d, J = 8.1 Hz, 1H), 7.52-7.47 (m, 1H), 7.42-7.37 (m, 2H), 7.21 (s, 1H), 6.95 (s, 1H), 5.10 og 4.96 (hver br-m, total 2H), 3.84-3.60 (br-m, 2H), 2.41 (s, 3H), 2.34 (s, 3H), 1.82-1.68 (m, 1H), 0.96 (br-s, 6H).
Eksempel 5(7)
4-[3-[N-isopropy l-N-[2-(4-metyltiazolyl)sulfonyl]amino]naftalen-2-yloksymetyl]-3-metylbenzosyre
TLC : Rf 0,56 (etylacetat: metanol = 9:1); NMR : 5 8.00-7.97 (m, 2H), 7.76-7.65 (m, 3H), 7.61 (s, 1H), 7.52-7.47 (m, 1H), 7.40-7.35 (m, 1H), 7.26 (s, 1H), 7.04 (s, 1H), 5.22 (d, J = 15.0 Hz, 1H), 5.17 (d, J = 15.0 Hz, 1H), 4.83-4.73 (m, 1H), 2.53 (s, 3H), 2.46 (s, 3H), 1.25 (d, J = 6.6 Hz, 3H), 1.16 (d, J = 6.6Hz, 3H). Eksempel 5(8) 4-[3-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)ammo]naftalen-2-yloksymetyl]kanelsyre
TLC : Rf 0,67 (etylacetat: metanol = 9:1);
NMR : 8 7.84-7.69 (m, 4H), 7.58 (d, J = 8.1 Hz, 2H), 7.51-7.45 (m, 1H), 7.41-7.35 (m, 3H), 7.18 (s, 1H), 6.93 (s, 1H), 6.49 (d, J = 16.2 Hz, 1H), 5.02 og 4.91 (hver br-m, total 2H), 3.84-3.62 (br-m, 2H), 2.33 (s, 3H), 1.82-1.68 (m, 1H), 0.91 (br-s, 6H).
Eksempel 5(9)
4-[3-[N-isopropy l-N-(4-metyl-2-tiazoly lsulfony l)amino]naftalen-2-yloksymetyl]-kanelsyre
TLC : Rf 0,61 (etylacetat: metanol = 9:1);
NMR : 5 7.80 (d, J = 16.9 Hz, 1H), 7.71 (d, J = 8.7 Hz, 2H), 7.61-7.46 (m, 6H), 7.39-7.34 (m, 1H), 7.24 (s, 1H), 7.03 (s, 1H), 6.48 (d, J = 16.9 Hz, 1H), 5.19 (s, 2H), 4.85-4.72 (m, 1H), 2.51 (s, 3H), 1.25 (d, J = 6.6 Hz, 3H), 1.16 (d, J = 6.6 Hz, 3H).
Eksempel 5(10)
3-metyl-4-[6-[N-metyl-N-(5-metyl-2-furylsulfonyl)amino]indan-5-yloksymetyl]-hpri7r>cvrp
TLC : Rf 0,58 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 8 7.77 (s, 1H), 7.74 (d, J = 7.8 Hz, 1H), 7.36 (d, J = 7.8 Hz, 1H), 7.09 (s, 1H), 6.99 (s, 1H), 6.90 (d, J = 3.3 Hz, 1H), 6.25-6.15 (m, 1H), 5.02 (s, 2H), 3.15 (s, 3H), 2.84 (t, J = 7.4 Hz, 2H), 2.78 (t, J = 7.4 Hz, 2H), 2.32 (s, 3H), 2.12 (s, 3H), 2.10-1.95 (m, 2H).
Eksempel 5(11)
4-[6-[N-eytl-N-(5-metyl-2-mrylsulfonyl)amino]indan-5-yloksymetyl]-3-metyl-hpn7r>«!vrp
TLC : Rf 0,59 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 8 7.77 (s, 1H), 7.74 (d, J = 7.8 Hz, 1H),7.38 (d, J = 7.8 Hz, 1H), 7.10 (s, 1H), 6.95 (s, 1H), 6.86 (d, J = 3.3 Hz, 1H), 6.16 (d, J = 3.3 Hz, 1H), 5.01
(br, 2H), 3.58 (br, 2H), 2.86 (t, J = 7.4 Hz, 2H), 2.79 (t, J = 7.4 Hz, 2H), 2.32 (s, 3H), 2.10 (s, 3H), 2.10-1.95 (m, 2H), 0.99 (t, J = 7.2 Hz, 3H).
Eksempel 5(12)
4-r6-n>I-metyl-N-(5-metyl-2-mrylsulfo
TLC : Rf 0,53 (kloroform : metanol = 9:1);
NMR : 8 7.77 (d, J = 15.9 Hz, 1H), 7.55 (d, J = 8.4 Hz, 2H), 7.37 (d, J = 8.4 Hz, 2H), 7.14 (s, 1H), 6.80 (s, 1H), 6.79 (d, J = 3.6 Hz, 1H), 6.47 (d, J = 15.9 Hz, 1H), 5.97 (d, J = 3.6 Hz, 1H), 4.98 (s, 2 H), 3.31 (s, 3H), 2.90-2.80 (m, 4H), 2.17 (s, 3H), 2.08 (kvint, J = 7.5 Hz, 2H).
Eksempel 5(13)
4-[6-[N-eytl-N-(5-metyl-2-mrylsulfonyl)am
TLC : Rf.0.53 (kloroform : metanol = 9:1);
NMR: 8 7.77 (d, J = 16.2 Hz, 1H), 7.55 (d, J = 8.4 Hz, 2H), 7.37 (d, J = 8.4 Hz, 2H), 7.08 (s, 1H), 6.80 (s, 1H), 6.75 (d, J = 3.3 Hz, 1H), 6.47 (d, J = 16.2 Hz, 1H), 5.94 (d, J = 3.3 Hz, 1H), 4.97 (s, 2 H), 3.82-3.65 (m, 2H), 2.90-2.80 (m, 4H), 2.15 (s, 3H), 2.08 (kvint, J = 7.2 Hz, 2H), 1.14 (t, J = 7.2 Hz, 3H).
Eksempel 5(14)
4-r6-[>J-(5-metyl-2-furylsulfonyl)-N-propylaminolindan-5-yloksymetyllkanelsyre
TLC : Rf 0,54 (kloroform : metanol = 9:1);
NMR : 8 7.78 (d, J = 15.9 Hz, 1H), 7.55 (d, J = 8.1 Hz, 2H), 7.37 (d, J= 8.1 Hz, 2H), 7.08 (s, 1H), 6.79 (s, 1H), 6.74 (d, J = 3.3 Hz, 1H), 6.46 (d, J = 15.9 Hz, 1H), 5.94 (brd, J = 3.3 Hz, 1H), 4.97 (br s, 2H), 3.65-3 .61 (m, 2H), 2.90-2.80 (m, 4H), 2.15 (s, 3H), 2.08 (kvint, J = 7.5 Hz, 2H), 1.53 (sekst, J = 7.2 Hz, 2H), 0.89 (t, J = 7.2 Hz, 3H).
Eksempel 5(15)
4-[4,5-dimetyl-2-[N-(5-metyl-2-mrylsulfonyl)-N-(2-metyl-2-propenyl)amino]-fenoksYmetvll-3-metvlbenzosvre
TLC : Rf 0,45 (kloroform : metanol = 9:1);
NMR : 8 8.00-7.93 (m, 2H), 7.44 (d, J = 8.1 Hz, 1H), 7.02 (s, 1H), 6.75 (d, J = 3.3 Hz, 1H), 6.69 (s, 1H), 5.96 (m, 1H), 4.94 (s, 2H), 4.77 (s, 2H), 4.27 (s, 2H), 2.38 (s, 3H), 2.22 (s, 3H), 2.18 (s, 3H), 2.12 (s, 3H), 1.78 (s, 3H).
Eksempel 5(16)
4-[6-|^-(5-metyl-2-furylsulfonyl)-N-(2-metyl-2-propenyl)amino]indan-5-yloksy-metyllkanelsyre
TLC : Rf 0,61 (kloroform : metanol = 9:1);
NMR : 8 7.78 (d, J = 15.9 Hz, 1H), 7.56 (d, J = 8.4 Hz, 2H), '7.36 (d, J = 8.4 Hz, 2H), 7.09 (s, 1H), 6.76 (s, 1H), 6.74 (d, J = 3.0 Hz, 1H), 6.47 (d, J = 15.9 Hz, 1H), 5.94 (d, J = 3.0 Hz, 1H), 4.95 (brs, 2H), 4.77 (s, 2H), 4.38-4.18 (m, 2H), 2.90-2.75 (m, 4H), 2.14 (s, 3H), 2.07 (kvint, J = 7.5 Hz, 2H), 1.78 (s, 3H).
Eksempel 5(17)
4-[6-P^-cyklopropylmetyl-N-(5-metyl-2-mrylsulfonyl)amino]indan-5-yloksymetyl]-kanelsyre
TLC : Rf 0,51 (kloroform : metanol = 9:1);
NMR : 8 7.79 (d, J = 15.9 Hz, 1H), 7.55 (d, J = 8.4 Hz, 2H), 7.38 (d, J = 8.4 Hz, 2H), 7.15 (s, 1H), 6.79 (s, 1H), 6.74 (d, J = 3.3 Hz, 1H), 6.47 (d, J = 15.9 Hz, 1H), 5.94 (d, J = 3.3 Hz, 1H), 4.97 (brs, 2H), 3.65-3.50 (m, 2H), 2.92-2.70 (m, 4H), 2.15 (s, 3H), 2.08 (kvint, J = 7.5 Hz, 2H), 1.00-0.85 (m, 1H), 0.45-0.36 (m, 2H), 0.20-0.05 (m, 2H).
Eksempel 5(18)
4-[6-[N-(5-metyl-2-miylsulfonyl)-N-(2-propenyl)amino]indan-5-yloksymetyl]-kanelsyre
TLC : Rf 0,57 (kloroform : metanol = 9:1);
NMR : 8 7.79 (d, J = 15.9 Hz, 1H), 7.56 (d, J = 8.4 Hz, 2H), 7.38 (d, J = 8.4 Hz, 2H), 7.07 (s, 1H), 6.78 (s, 1H), 6.76 (d, J = 3.3 Hz, 1H), 6.47 (d, J = 15.9 Hz, 1H), 5.96 (d, J = 3.3 Hz, 1H), 5.96-5.77 (m, 1H), 5.13-5.03 (m, 2H), 4.97 (s, 2H), 4.42-4.20 (m, 2H), 2.90-2.80 (m, 4H), 2.16 (s, 3H), 2.07 (kvint, J = 7.5 Hz, 2H).
Eksempel 5(19)
3-metyl-4-[6-[N-(5-metyl-2-furylsulfonyl)-N-propylamino]indan-5-yloksymetyl]-benzosyre
TLC : Rf 0,40 (kloroform : metanol =10:1);
NMR : 8 7.95 (d, J = 7.8 Hz, 1H), 7.93 (s, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.10 (s, 1H), 6.81 (s, 1H), 6.75 (d, J = 3.3 Hz, 1H), 5.95 (dd, J = 3.3, 0.9 Hz, 1H), 4.96 (s, 2H), 3.76-3.47 (m, 2H), 2.92-2.82 (m, 4H), 2.37 (s, 3H), 2.13 (s, 3H), 2.15-2.03 (m, 2H), 1.60-1.47 (m, 2H), 0.89 (t, J = 7.5 Hz, 3H).
Eksempel 5(20)
3-metyl-4-[6-[N-(5-metyl-2-furylsulfonyl)-N-(2-propenyl)amino]indan-5-yloksymetyl] benzosyre
TLC : Rf 0,41 (kloroform : metanol =10:1);
NMR : 5 7.95 (d, J = 7.8 Hz, 1H), 7.94 (s, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.08 (s, 1H), 6.80 (s, 1H), 6.78 (d, J = 3.3 Hz, 1H), 5.97 (d, J = 3.3 Hz, 1H), 5.85 (m, 1H), 5.10 (dd, J = 16.8, 1.2 Hz, 1H), 5.05 (dd, J = 9.9, 1.2 Hz, 1H), 4.97 (s, 2H), 4.43-4.18 (m, 2H), 2.91-2.81 (m, 4H), 2.37 (s, 3H), 2.15 (s, 3H), 2.13-2.03 (m, 2H).
Eksempel 5(21)
4-[4,5-dimetyl-2-|^-metyl-N-(4-metyl-2-tiazolylsulfonyl)amino]fenoksymetyl]-3-metylbenzosyre
TLC : Rf 0,49 (diklormetan : metanol = 10 : 1);
NMR : 5 7.94-7.90 (m, 2H), 7.31 (d, J = 9.0 Hz, 1H), 7.13 (s, 1H), 6.94 (m, 1H), 6.73 (s, 1H), 4.88 (s, 2H), 3.42 (s, 3H), 2.35 (s, 3H), 2.34 (d, J = 0.9 Hz, 3H), 2.24 (s, 3H),2.19(s, 3H).
Eksempel 5(22)
4-[4,5-dimetyl-2-fN-etyl-N-(4-metyl-2-tiazolylsulfonyl)amino]fenoksymetyl]-3-metylbenzosyre
TLC : Rf 0,49 (diklormetan : metanol = 10 : 1);
NMR : 5 7.96-7.90 (m, 2H), 7.32 (d, J = 8.1 Hz, 1H), 7.06 (s, 1H), 6.90 (m, 1H), 6.74 (s, 1H), 4.87 (brs, 2H), 3.85 (br, 2H), 2.34 (s, 3H), 2.32 ,(d, J = 0.9 Hz, 3H), 2.25 (s, 3H), 2.19 (s, 3H), 1.18 (t, J = 7.2 Hz, 3H).
Eksempel 5(23)
4-[4,5-dimetyl-2-[N-(4-metyl-2-tiazolylsulfonyl)-N-propylamino]fenoksymetyl]-3-metylbenzosyre
TLC : Rf 0,49(diklormetan : metanol =10:1);
NMR(DMSO-d6): 5 12.88 (s, 1H), 7.78-7.72 (m, 2H), 7.49 (m, 1H), 7.25 (d, J = 7.8 Hz, 1H), 7.03 (s, 1H), 6.95 (s, 1H), 4.88 (br, 2H), 3.59 (br, 2H), 2.28 (s, 3H), 2.22 (s, 3H), 2.18 (s, 3H), 2.13 (s, 3H), 1.44-1.35 (m, 2H), 0.81 (t, J = 7.2 Hz, 3H).
Eksempel 5(24)
4-[4,5-dimetyl-2-|^-(4-metyl-2-tiazolylsulfonyl)-N-(2-propenyl)amino]fenoksy-metyll -3 -mety lbenzosyre
TLC : Rf 0,49 (diklormetan : metanol =10:1);
NMR(DMSO-d6): 5 12.88 (s, 1H), 7.78-7.72 (m, 2H), 7.50 (s, 1H), 7.26 (d, J = 7.5 Hz, 1H), 7.01 (s, 1H), 6.95 (s, 1H), 5.74 (m, 1H), 5.09 (d, J= 17.1 Hz, 1H), 5.04 (d, J = 9.9 Hz, 1H), 4.89 (br, 2H), 4.27 (br, 2H), 2.29 (s, 3H), 2.21 (s, 3H), 2.18 (s, 3H),2.12(s, 3H).
Eksempel 5(25)
4-[2-[N-cyklopropylmetyl-N-(4-metyl-2-tiazolylsulfonyl)amino-4,5-dimetyl]-fenoksymetyll-3-metylbenzosyre
TLC : Rf 0,49 (diklormetan : metanol = 10 : 1);
NMR(DMSO-d6): 8 12.87 (br, 1H), 7.78-7.72 (m, 2H), 7.48 (s, 1H), 7.25 (d, J = 7.5 Hz, 1H), 7.03 (s, 1H), 7.00 (s, 1H), 4.90 (br, 2H), 3.45 (br, 2H), 2.27 (s, 3H), 2.23 (s, 3H), 2.17 (s, 3H), 2.14 (s, 3H), 0.82 (m, 1H), 0.38-0.30 (m, 2H), 0.10-0.02 (m, 2H).
Eksempel 5(26)
4-[4,5-dimetyl-2-psT-(2-hy aminol fenoksymety 11 -3 -metylbenzosvre
TLC : Pvf 0,49 (diklormetan : metanol =10:1);
NMR : 5 7.99-7.94 (m, 2H), 7.47 (d, J = 8.1 Hz, 1H), 7.04 (m, 1H), 6.79 (s, 1H), 6.77 (s, 1H), 5.06 (d, J = 12.3 Hz, 1H), 4.95 (d, J = 12.3 Hz, 1H), 3.95 (d, J = 15.3 Hz, 1H), 3.73 (d, J = 15.3 Hz, 1H), 2.420 (s, 3H), 2.417 (s, 3H), 2.23 (s, 3H), 2.11 (s, 3H), 1.25 (s,3H), 1.21 (s, 3H).
Eksempel 5(27)
4-[4,5-dimetyl-2-|>f-me1yl-N-(5-metyl-2-furylsulfonyl)amino]fenoksymetyl]benzo-svre
TLC : Rf 0,46 (kloroform : metanol = 9:1);
NMR : 5 8.11 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 8.4 Hz, 2H), 7.08 (s, 1H), 6.79 (d, J = 3.3 Hz, 1H), 6.71 (s, 1H), 5.99-5.95 (m, 1H), 5.03 (s, 2H), 3.31 (s, 3H), 2.22 (s, 3H), 2.18 (s, 3H), 2.16 (s, 3H).
Eksempel 5(28)
4-[4,5-dimetyl-2-[N-etyl-N-(5-metyl-2-m^ svre
TLC : Rf 0,41 (kloroform : metanol = 9:1);
NMR: 8 8.10 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.4 Hz, 2H), 7.01 (s, 1H), 6.76 (d, J = 3.3 Hz, 1H), 6.71 (s, 1H), 5.96-5.93 (m, 1H), 5.02 (s, 2H), 3.83-3.65 (m, 2H), 2.23 (s, 3H), 2.18 (s, 3H), 2.14 (s, 3H), 1.14 (t, J = 7.2 Hz, 3H).
Eksempel 5(29)
4-[4,5-dimetyl-2-[N-(5-metyl-2-miylsulfonyl)-N-propylamino]fen benzosyre
TLC : Rf 0,43 (kloroform : metanol = 9:1);
NMR : 8 8.11 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.4 Hz, 2H), 7.02 (s, 1H), 6.74 (d, J = 3.0 Hz, 1H), 6.70 (s, 1H), 5.96-5.93 (m, 1H), 5.01 (s, 2H), 3.75-3.53 (m, 2H), 2.22 (s, 3H), 2.18 (s, 3H), 2.14 (s, 3H), 1.60-1.46 (m, 2H), 0.90 (t, J = 7.2 Hz, 3H).
Eksempel 5(30)
4-[6-[N-(2-metyl-2-propenyl)-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]benzosyre
TLC : Rf 0,36 (diklormetan : metanol = 19 : 1);
NMR : 8 8.11 (d, J = 8.7 Hz, 2H), 7.35 (d, J = 8.7 Hz, 2H), 7.14 (s, 1H), 6.92 (brs, 1H), 6.74 (s, 1H), 5.10-4.70 (brs, 2H), 4.80 (brs, 2H), 4.60-4.20 (brs, 2H), 2.88-2.82 (m, 4H), 2.32 (d, J = 0.9 Hz, 3H), 2.07 (m, 2H), 1.83 (s, 3H).
Eksempel 5(31)
4-[6-P^-(4-metyl-2-tiazolylsulfonyl)-N-(2-propenyl)amino]indan-5-yloksymetyl]-benzosyre
TLC : Rf 0,34 (diklormetan : metanol = 19 : 1);
NMR : 8 8.11 (d, J = 8.7 Hz, 2H), 7.35 (d, J = 8.7 Hz, 2H), 7.13 (s, 1H), 6.93 (brs, 1H), 6.76 (s, 1H), 5.89 (ddt, J = 17.1, 10.2, 6.3 Hz, 1H), 5.17-5.06 (m, 2H), 4.92 (brs, 2H), 4.70-4.10 (brs, 2H), 2.89-2.83 (m, 4H), 2.34 (d, J = 0.9 Hz, 3H), 2.08 (m, 2H).
Eksempel 5(32)
4-[6-[N-cyklopropylme1yl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksy-metyllbenzosyre
TLC : Rf 0,36 (diklormetan : metanol =19:1);
NMR : 5 8.10 (d, J = 8.7 Hz, 2H), 7.35 (d, J = 8.7 Hz, 2H), 7.22 (s, 1H), 6.89 (brs, 1H), 6.78 (s, 1H), 5.10-4.70 (m, 2H), 3.90-3.50 (m, 2H), 2.90-2.85 (m, 4H), 2.32 (d, J = 0.9 Hz, 3H), 2.09 (m, 2H), 1.00 (m, 1H), 0.43 (m, 2H), 0.20 (brs, 2H).
Eksempel 5(33)
4-[3-|lvl-isopropyl-N-(5-metyl-2-mrylsulfonyl)amino]naftalen-2-yloksyme1yl]-3^ metylbenzosyre
TLC : Rf 0,52 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 8 7.92-7.80 (m, 3H), 7.77 (d, J = 8.1 Hz, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.63 (s, 1H), 7.60 (s, 1H), 7.57-7.50 (m, 1H), 7.45-7.36 (m, 1H), 6.95 (d, J = 3.3 Hz, 1H), 6.29 (d, J = 3.3 Hz, 1H), 5.26 og 5.24 (hver d, J = 13.5 Hz, hver 1H), 4.34 (sept, J = 6.6 Hz, 1H), 2.42 (s, 3H), 2.34 (s, 3H), 1.06 og 1.00 (hver d, J = 6.6 Hz, hver 3H).
Eksempel 5(34)
4-[3-[N-isobutyl-N-(5-metyl-2-fiirylsulfonyl)amino]naftalen-2-yloks metylbenzosyre
TLC : Rf 0,50 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 8 7.88 (d, J = 7.8 Hz, 1H), 7.86-7.74 (m, 4H), 7.59 (s, 1H), 7.56-7.36 (m, 3H), 6.86 (d, J = 3.3 Hz, 1H), 6.19 (d, J = 3.3 Hz, 1H), 5.40-4.90 (br, 2H), 3.47 (brd, J = 6.9 Hz, 2H), 2.39 (s, 3H), 2.12 (s, 3H), 1.65-1.50 (m, 1H), 0.83 (brd, J = 6.3 Hz, 6H).
Eksempel 5(35)
4-[3-p<f-isopropyl-N-(5-melyl-2-furylsulfonyl)amino]naftalen^ kanels<y>re
TLC : Rf 0,45 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 8 7.87 (d, J = 7.8 Hz, 1H), 7.82 (d, J = 7.8 Hz, 1H), 7.73 (d, J = 8.4 Hz, 2H), 7.67-7.46 (m, 6H), 7.44-7.34 (m, 1H), 6.94 (d, J = 3.3 Hz, 1H), 6.56 (d, J = 15.9 Hz, 1H), 6.28 (d, J = 3.3 Hz, 1H), 5.27 og 5.21 (hver d, J = 13.2 Hz, hver 1H), 4.36 (sept, J = 6.6 Hz, 1H), 2.33 (s, 3H), 1.08 og 1.03 (hver d, J = 6.6 Hz, hver 3H).
Eksempel 5(36)
4-[3-[N-isobutyl-N-(5-metyl-2-mrylsulfo^ syre
TLC : Rf 0,45 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 8 7.88 (d, J = 8.4 Hz, 1H), 7.81 (s, 1H), 7.80 (d, J = 8.1 Hz, 1H), 7.72 (d, J = 7.8 Hz, 2H), 7.61 (d, J = 15.9 Hz, 1H), 7.55-7.34 (m, 2H), 7.50 (s, 1H), 7.44 (d, J = 7.8 Hz, 2H), 6.82 (d, J = 3.6 Hz, 1H), 6.56 (d, J = 15.9 Hz, 1H), 6.16 (d, J = 3.6 Hz, 1H), 5.40-4.90 (br, 2H), 3.49 (d, J = 6.6 Hz, 2H), 2.13 (s, 3H), 1.64-1.48 (m, 1H), 0.85 (d, J = 6.6Hz, 6H).
Eksempel 5(37) 4-[3-[N-isopropyl-N-(5-metyl-2-f^ mety lkanelsyre
TLC : Rf 0,46 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 5 7.87 (d, J = 8.1 Hz, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.64-7.48 (m, 7H), 7.44-7.36 (m, 1H), 6.93 (d, J = 3.6 Hz, 1H), 6.54 (d, J = 15.9 Hz, 1H), 6.29 (d, J = 3.6 Hz, 1H), 5.23 og 5.18 (hver d, J = 14.4 Hz, hver 1H), 4.33 (sept, J = 6.6 Hz, 1H), 2.39 (s, 3H), 2.34 (s, 3H), 1.06 og 1.00 (hver d, J = 6.6 Hz, hver 3H).
Eksempel 5(38)
4-[3-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]naftalen-2-yloksymetyl]-3-mety lkanelsyre
TLC : Rf 0,46 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 6 7.88 (d, J = 8.1 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.78 (s, 1H), 7.62-7.47 (m, 5H), 7.44-7.35 (m, 2H), 6.84 (d, J = 3.6 Hz, 1H), 6.54 (d, J = 16.2 Hz, 1H), 6.20 (d, J = 3.6 Hz, 1H), 5.35-4.90 (br, 2H), 3.47 (d, J = 7.2 Hz, 2H), 2.35 (s, 3H), 2.14 (s, 3H), 1.63-1.49 (m, 1H), 0.83 (d, J = 6.3 Hz, 6H).
Eksempel 5(39)
4-[3-[N-isobutyl-N-[2-(4-metyltiazolyl)sulfonyl]amino]naftalen-2-yloksymetyl]-3-mety lkanelsyre
TLC : Rf 0,71 (etylacetat: metanol = 9:1);
NMR : 5 7.82-7.71 (m, 4H), 7.51-7.46 (m, 1H), 7.43-7.32 (m, 4H), 7.21 (s, 1H), 6.95 (s, 1H), 6.48 (d, J = 16.2 Hz, 1H), 5.04 og 4.91 (hver br-m, total 2H), 3.83-3.60 (br-m, 2H), 2.38 (s, 3H), 2.34 (s, 3H), 1.81-1.67 (m, 1H), 0.95 (br-s, 6H).
Eksempel 5(40)
4-[3 - [N-isopropy l-N-(4-metyl-2-tiazo metylkanelsyre
TLC : Rf 0,71 (etylacetat: metanol = 9:1);
NMR(DMSO-d6): 8 7.88-7.83 (m, 2H), 7.65-7.47 (m, 8H), 7.42-7.37 (m, 1H), 6.55 (d, J = 15.9 Hz, 1H), 5.16 (s, 2H), 4.62-4.49 (m, 1H), 2.42 (s, 3H), 2.36 (s, 3H), 1.13 (d, J = 6.6 Hz, 3H), 1.03 (d, J = 6.6 Hz, 3H).
Eksempel 5(41)
4-\ 6-rN-etYl-N-(4-metYl-2-tiazolvlsulfonvl)aminol indan-5-yloksymetyllbenzosyre
TLC : Rf 0,34 (diklormetan : metanol = 19 : 1);
NMR : 5 8.10 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.4 Hz, 2H), 7.14 (s, 1H), 6.90 (brs, 1H), 6.79 (s, 1H), 4.92 (m, 2H), 4.20-3.60 (m, 2H), 2.90-2.83 (m, 4H), 2.33 (s, 3H), 2.09 (m, 2H), 1.20 (t, J = 7.2 Hz, 3H).
Eksempel 5(42)
4-[6-[N-(4-metyl-2-tiazolylsulfonyl)-N-propylamino]indan-5-yloksymetyl]benzosyre
TLC : Rf 0,34 (diklormetan : metanol = 19 : 1);
NMR : 6 8.11 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.4 Hz, 2H), 7.15 (s, 1H), 6.90 (brs, 1H), 6.78 (s, 1H), 5.10-4.70 (m, 2H), 4.00-3.50 (m, 2H), 2.90-2.84 (m, 4H), 2.32 (s, 3H), 2.09 (m, 2H), 1.58 (m, 2H), 0.93 (t, J = 7.5 Hz, 3H).
Eksempel 5(43)
4-[4,5-dimetyl-2-[N-(5-metyl-2-mrylsulfonyl)-N-(2-propenyl)amino]fen benzosyre
TLC : Rf 0,44 (kloroform : metanol = 9:1);
NMR : 8 8.12 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.4 Hz, 2H), 7.01 (s, 1H), 6.77 (d, J = 3.0 Hz, 1H), 6.68 (s, 1H), 5.99-5.94 (m, 1H), 5.92-5.75 (m, 1H), 5.16-5.03 (m, 2H), 5.02 (s, 2H), 4.42-4.20 (m, 2H), 2.21 (s, 3H), 2.17 (s, 3H), 2.15 (s, 3H).
Eksempel 5(44)
4-[4,5-dimetyl-2-[N-metyl-N-(5-metyl-2-furylsulfonyl)amino]fenoksymetyl]-3 metvlbenzosvre
TLC : Rf 0,42 (kloroform : metanol = 9:1);
NMR : 8 7.98-7.91 (m, 2H), 7.43 (d, J = 8.7 Hz, 1H), 7.08 (s, 1H), 6.79 (d, J = 3.3 Hz, 1H), 6.74 (s, 1H), 5.98 (m, 1H), 4.98 (s, 2H), 3.30 (s, 3H), 2.38 (s, 3H), 2.24 (s, 3H),2.19(s, 3H), 2.15 (s, 3H).
Eksempel 5(45)
4-[4,5-dimetyl-2-[>J-etyl-N-(5-metyl-2-furylsulfonyl)amino]fenoksymetyl]-3-metylbenzosyre
TLC : Rf 0,42 (kloroform : metanol = 9:1);
NMR : 8 7.97-7.90 (m, 2H), 7.45 (d, J = 8.1 Hz, 1H), 7.01 (s, 1H), 6.76 (s, 1H), 6.75 (d, J = 3.3 Hz, 1H), 5.95 (m, 1H), 4.96 (s, 2H), 3.82-3.66 (br, 2H), 2.37 (s, 3H), 2.25 (s, 3H), 2.19 (s, 3H), 2.13 (s, 3H), 1.14 (t, J = 7.2 Hz, 3H).
Eksempel 5(46) 4-[4,5-dimetyl-2-|^-(5-metyl-2-furylsulfonyl)-N-propylam metylbenzosyre
TLC : Rf 0,42 (kloroform : metanol = 9:1);
NMR : 5 7.98-7.90 (m, 2H), 7.45 (d, J = 8.1 Hz, 1H), 7.02 (s, 1H), 6.78-6.70 (m, 2H), 5.95 (m, 1H), 4.95 (s, 2H), 3.71-3.55 (br, 2H), 2.37 (s, 3H), 2.24 (s, 3H), 2.19 (s, 3H), 2.12 (s, 3H), 1.60-1.44 (m, 2H), 0.88 (t, J = 7.5 Hz, 3H).
Eksempel 5(47)
4-[4,5-dime1yl-2-[N-(5-metyl-2-furylsulfonyl)-N-(2-propenyl)amino]fenoksymetyl]-3 -metylbenzosyre
TLC : Rf 0,45 (kloroform : metanol = 9:1);
NMR : 5 7.98-7.90 (m, 2H), 7.45 (d, J = 8.1 Hz, 1H), 7.01 (s, 1H), 6.77 (d, J = 3.3 Hz, 1H), 6.71 (s, 1H), 5.96 (m, 1H), 5.83 (m, 1H), 5.15-5.00 (m, 2H), 4.96 (s, 2H), 4.40-4.20 (br, 2H), 2.38 (s, 3H), 2.23 (s, 3H), 2.18 (s, 3H), 2.14 (s, 3H).
Eksempel 5(48)
4-[4,5-dimetyl-2-[N-(2-hydroksy-2-metylpropyl)-N-(5-metyl-2-fiarylsulfonyl)amino]-fenoksy metyl]-3-metylbenzosyre
TLC : Rf 0,41 (kloroform : metanol = 9:1);
NMR : 5 8.00-7.94 (m, 2H), 7.53 (d, J = 7.8 Hz, 1H), 6.80 (s, 1H), 6.77 (s, 1H), 6.75 (d, J = 3.3 Hz, 1H), 6.01 (m, 1H), 5.08 (d, J = 12.3 Hz, 1H), 5.00 (d, J = 12.3 Hz, 1H), 3.84 (d, J = 14.4 Hz, 1H), 3.56 (d, J = 14.4 Hz, 1H), 2.42 (s, 3H), 2.23 (s, 3H), 2.21 (s, 3H), 2.14 (s, 3H), 1.25 (s, 3H), 1.18 (s, 3H).
Eksempel 5(49)
4- [6- [N-mety l-N-(4-metyl-2-tiazoly lsulfony l)amino] indan-5 -yloksymety l]benzosyre
TLC : Rf 0,34 (diklormetan : metanol = 19 : 1);
NMR : 5 8.11 (d, J = 8.7 Hz, 2H), 7.35 (d, J = 8.7 Hz, 2H), 7.20 (s, 1H), 6.94 (brs, 1H), 6.78 (s, 1H), 4.92 (brs, 2H), 3.44 (s, 3H), 2.89-2.83 (m, 4H), 2.35 (d, J = 0.9 Hz, 3H), 2.08 (m, 2H).
Eksempel 5(50)
4-[6-[N-(2-hydroksy-2-metylpropyl)-N-(5-metyl-2-fhrylsulfonyl)amino]indan-5-y loksymetyll -3 -metylbenzosyre
TLC : Rf 0,32 (kloroform : metanol =10:1);
NMR : 8 7.97 (d, J = 7.8 Hz, 1H), 7.95 (s, 1H), 7.53 (d, J = 7.8 Hz, 1H), 6.89 (s, 1H), 6.86 (s, 1H), 6.75 (d,J = 3.3Hz, 1H), 6.01 (dd, J = 3.3, 0.9 Hz, 1H), 5.08 (d, J = 12.9 Hz, 1H), 5.02 (d, J = 12.9 Hz, 1H), 3.85 (d, J = 14.7 Hz, 1H), 3.58 (d, J = 14.7 Hz, 1H), 2.90-2.78 (m, 4H), 2.42 (s, 3H), 2.21 (s, 3H), 2.13-2.01 (m, 2H), 1.25 (s, 3H), 1.18 (s, 3H).
Eksempel 5(51)
3-metyl-4-[6-[N-metyl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]-kanelsyre
TLC : Rf 0,45 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 8 7.60-7.50 (m, 3H), 7.49 (d, J = 8.1 Hz, 1H), 7.20 (d, J = 8.1 Hz, 1H), 7.09 (s, 1H), 7.04 (s, 1H), 6.53 (d, J = 15.9 Hz, 1H), 4.87 (br, 2H), 3.24 (s, 3H), 2.85 (t, J = 7.4 Hz, 2H), 2.77 (t, J = 7.4 Hz, 2H), 2.25 (s, 3H), 2.23 (s, 3H), 2.10-1.95 (m, 2H).
Eksempel 5(52)
4- [6- [N-etyl-N-(4-mety 1-2-tiazoly lsulfony l)amino] indan-5 -yloksymetyl] -3 -mety 1-kanelsyre
TLC : Rf 0,44 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 8 7.55 (d, J = 16.0 Hz, 1H), 7.50-7.40 (m, 3H), 7.19 (d, J = 8.1 Hz, 1H), 7.09 (s, 1H), 6.98 (s, 1H), 6.52 (d, J = 16.0 Hz, 1H), 4.84 (br, 2H), 3.66 (br, 2H), 2.85 (t, J = 7.4 Hz, 2H), 2.77 (t, J = 7.4 Hz, 2H), 2.23 (s, 3H), 2.19 (s, 3H), 2.10-1.90 (m, 2H), 1.01 (t, J = 7.0Hz, 3H).
Eksempel 5(53)
4- [2- [N-cyklopropy lmety l-N-(5 -mety 1-2-fury lsulfonyl)amino]-4,5 -dimety lfenoksy-metvll benzosyre
TLC : Rf 0,41 (kloroform : metanol = 9:1); NMR : 8 8.11 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.4 Hz, 2H), 7.09 (s, 1H), 6.74 (d, J = 3.0 Hz, 1H), 6.70 (s, 1H), 5.96-5.92 (m, 1H), 5.02 (brs, 2H), 3.68-3.40 (m, 2H), 2.23 (s, 3H), 2.19 (s, 3H), 2.14 (s, 3H), 1.03-0.86 (m, 1H), 0.46-0.35 (m, 2H), 0.21-0.06 (m, 2H). Eksempel 5(54) 4-[4,5-dimetyl-2-[N-(2-hydroksy-2-metylpropyl)-N-(5-me1yl-2-mrylsulfonyl)amino]-fenoksy mety 11 benzosyre
TLC : Rf 0,34 (kloroform : metanol = 9:1);
NMR : 5 8.13 (d, J = 8.4 Hz, 2H), 7.52 (d, J = 8.4 Hz, 2H), 6.81 (s, 1H), 6.75 (s, 1H), 6.74 (d, J = 3.0 Hz, 1H), 6.03-5.98 (m, 1H), 5.22-4.96 (m, 2H), 3.92-3.76 og 3.64-3.48 (hver m, total 2H), 2.21 (s, 6H), 2.13 (s, 3H), 1.28 og 1.19 (hver brs, hver 3H).
Eksempel 5(55)
3-mety 1-4-[6-[N-(2-metyl-2-propeny 0^ <y>loksvmet<y>llkanelsyre
TLC : Rf 0,60 (kloroform : metanol = 9:1);
NMR : 5 7.76 (d, J = 15.9 Hz, 1H), 7.42-7.34 (m, 2H), 7.27-7.22 (m, 1H), 7.12 (s, 1H), 6.92 (d, J = 0.9 Hz, 1H), 6.78 (s, 1H), 6.47 (d, J = 15.9 Hz, 1H), 4.90-4.72 (m, 4H), 4.50-4.14 (m, 2H), 2.92-2.80 (m , 4H), 2.31 (s, 6H), 2.18-2.00 (m, 2H), 1.81 (s, 3H).
Eksempel 5(56)
4-[6-[N-cyklopropylmetyl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksy-metvll-3-metvlkanelsvre
TLC : Rf 0,60 (kloroform : metanol = 9:1);
NMR : 8 7.77 (d, J = 15.9 Hz, 1H), 7.42-7.38 (m, 2H), 7.30-7.25 (m, 1H), 7.21 (s, 1H), 6.89 (d, J = 0.9 Hz, 1H), 6.82 (s, 1H), 6.46 (d, J = 15.9 Hz, 1H), 4.92-4.64 (m, 2H), 3.84-3.42 (m, 2H), 2.95-2.76 (m, 4H), 2.31 (s, 3H), 2.31 (s, 3H), 2.18-2.02 (m, 2H), 1.08-0.90 (m, 1H), 0.46-0.40 (m, 2H), 0.26-0.08 (m, 2H).
Eksempel 5(57)
4- [6- [N-(2-hy droksy-2-mety lpropyl)-N-(5 -metyl-2-fury lsulfonyl)amino] indan- 5 - yloksymetyl]kanelsyre
TLC : Rf 0,46 (kloroform : metanol = 9:1);
NMR : 8 7.78 (d, J = 15.9 Hz, 1H), 7.58 (d, J = 8.1 Hz, 2H), 7.47 (d, J = 8.1 Hz, 2H), 6.85 (d, J = 3.6 Hz, 2H), 6.74 (d, J = 3.6 Hz, 1H), 6.47 (d, J = 15.9 Hz, 1H), 6.01 (d, J = 2.1 Hz, 1H), 5.10 (d, J = 12.0 Hz, 1H), 4.99 (d, J = 12.0 Hz, 1H), 3.85 (d, J = 14.1 Hz, 1H), 3.53 (d, J = 14.1 Hz, 1H), 2.90-2.77 (m, 4H), 2.23 (s, 3H), 2.07 (m, 2H), 1.27 (s, 3H), 1.16 (s, 3H).
Eksempel 5(58)
3-metyl-4-[6-fN-(4-metyl-2-tiazolylsulfonyl)-N-(2-propenyl)amino]indan-5-yloksy-metvllkanelsvre
TLC : Rf 0,42 (diklormetan : metanol =10:1);
NMR : 8 7.76 (d, J = 15.9 Hz, 1H), 7.42-7.36 (m, 2H), 7.28 (m, 1H), 7.1 l(s, 1H), 6.92 (m, 1H), 6.80 (s, 1H), 6.47 (d, J = 15.9 Hz, 1H), 5.87 (m, 1H), 5.11 (dd, J = 17.1, 1.5 Hz, 1H), 5.07 (dd, J = 8.7, 1.5 Hz, 1H), 4.83 (br, 2H), 4.32 (br, 2H), 2.92-2.82 (m, 4H), 2.33 (d, J = 0.6 Hz, 3H), 2.32 (s, 3H), 2.16-2.04 (m, 2H).
Eksempel 5(59)
4-[6-[N-(2-hydroksy-2-metylpropyl)-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymety 1] -3 -mety lkanelsyre
TLC : Rf 0,42 (diklormetan : metanol =10:1);
NMR : 8 7.76 (d, J = 15.9 Hz, 1H), 7.44-7.38 (m, 3H), 7.05 (m, 1H), 6.88 (s, 1H), 6.82 (s, 1H), 6.46 (d, J = 15.9 Hz, 1H), 5.03 (d, J = 12.0 Hz, 1H), 4.93 (d, J = 12.0 Hz, 1H), 3.96 (d, J = 14.4 Hz, 1H), 3 .69 (d, J = 14.4 Hz, 1H), 2.87 (t, J = 7.5 Hz, 2H), 2.77 (t, J = 7.5 Hz, 2H), 2.43 (s, 3H), 2.40 (s, 3H), 2.13-2.00 (m, 2H), 1.23 (s, 3H), 1.18 (s, 3H).
Eksempel 5(60)
4-[4,5-dimetyl-2-[N-cyklopropylm metyl]-3-metylbenzosyre
TLC : Rf 0,45 (kloroform : metanol = 9:1);
NMR : 8 8.00-7.92 (m, 2H), 7.47 (d, J = 7.8 Hz, 1H), 7.09 (s, 1H), 6.78-6.71 (m, 2H), 5.94 (m, 1H), 4.96 (s, 2H), 3.63-3.45 (br, 2H), 2.37 (s, 3H), 2.25 (s, 3H), 2.19 (s, 3H), 2.13 (s, 3H), 0.95 (m, 1H), 0.44-0.35 (m, 2H), 0.15-0.22 (m, 2H).
Eksempel 5(61)
3-metyl-4-[6-[N-(4-me1yl-2-tiazolylsulfonyl)-N-propylamino]indan-5-yloksymetyl]-kanelsyre
TLC : Rf 0,41 (kloroform : metanol = 9:1);
NMR : 8 7.76 (d, J = 16.2 Hz, 1H), 7.44-7.34 (m, 2H), 7.32-7.20 (m, 1H), 7.13 (s, 1H), 6.90 (s, 1H), 6.82 (s, 1H), 6.46 (d, J = 16.2 Hz, 1H), 4.90- 4.70 (m, 2H), 3.90-3.50 (m, 2H), 2.89 (t, J = 7.5 Hz) og 2.86 (t, J = 7.5 Hz) total 4H, 2.31 (s) og 2.30 (s) total 6H, 2.09 (kvint, J = 7.5 Hz, 2H), 1.58 (m, 2H), 0.91 (t, J = 7.5 Hz, 3H).
Eksempel 5(62)
4-[6-[N-(2-hydroksy-2-metylpropyl)-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]benzosyre
TLC : Rf 0,29 (diklormetan : metanol =19:1);
NMR : 5 8.13 (d, J = 7.8 Hz, 2H), 7.48 (d, J = 7.8 Hz, 2H), 7.02 (brs, 1H), 6.90 (s, 1H), 6.83 (s, 1H), 5.12 (d, J = 12.6 Hz, 1H), 4.95 (d, J = 12.6 Hz, 1H), 3.96 (d, J = 15.0 Hz, 1H), 3.77 (d, J = 15.0 Hz, 1H), 2.88-2.75 (m, 4H), 2.42 (s, 3H), 2.06 (m, 2H), 1.29 (s, 3H), 1.22 (s, 3H).
Eksempel 6
3-metyl-4-[6-[N-isobu1yl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymety kanelsyrenatriumsalt
Til en suspensjon av forbindelsen fremstilt i eksempel 2(74) (213 g) i etanol (2 1) ble 5N vandig oppløsning av natriumhydroksyd (74,7 ml) tilsatt, og blandingen ble rørt i 0,5 time ved 80 °C. Reaksjonsoppløsningen ble filtrert under oppvarming for å fjerne de uoppløselige stoffer, blandingen ble deretter avkjølt og presipitatet ble samlet. Moderluten ble konsentrert og resten ble oppløst i etanol (500 ml) og vann (25 ml) under oppvarming. Blandingen ble filtrert under oppvarming for å fjerne de uoppløselige stoffer, blandingen ble deretter avkjølt og presipitatet ble samlet. Under oppvarming ble alle samlede faststoffer tørket under redusert trykk til å gi forbindelsen i henhold til den foreliggende oppfinnelse (165 g) som har de følgende fysiske data.
TLC : Rf 0,52 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 5 7.49 (s, 1H), 7.29 (s, 1H), 7.26 (d, J = 8.1 Hz, 1H), 7.10-7.00 (m, 4H), 6.38 (d, J = 15.9 Hz, 1H), 4.89 (br-d, J = 10.5 Hz, 1H), 4.63 (br-d, J = 10.5 Hz, 1H), 3.55-3.25 (m, 2H), 2.85 (t, J = 7.2 Hz, 2H), 2.78 (t, J = 7.2 Hz, 2H), 2.21 (s, 3H), 2.18 (s, 3H), 2.10-1.90 (m, 2H), 1.60-1.45 (m, 1H), 1.00-0.70 (m, 6H).
Eksempel 6(1)
4- [2- [N-isopropyl-N-(5 -mety 1-2-fury lsulfony l)amino] -5 -trifluonnety lfenoksymetyl] - benzosyrenatriumsalt
TLC : Rf 0,50 (kloroform : metanol = 9:1);
NMR : 5 7.84 (d, J = 8.1 Hz, 2H), 7.20-6.95 (m, 5H), 6.65 (d, J = 3.3 Hz, 1H), 5.84 (d, J = 3.3 Hz, 1H), 4.75 (brs, 2H), 4.30-4.10 (m, 1H), 2.12 (s, 3H), 0.86 (brd, J =
3.9 Hz, 6H).
Eksempel 6(2)
4-[2-[N-isobu1yl-N-(5-metyl-2-furylsulfonyl)amino]-4,5-dimetylfenoks^ syrenatriumsalt
TLC : Rf 0,40 (kloroform : metanol = 9:1);
NMR : 8 7.83 (d, J = 8.1 Hz, 2H), 7.00 (d, J = 8.1 Hz, 2H), 6.88 (s, 1H), 6.59 (s, 1H), 6.54 (d, J = 3.0 Hz, 1H), 5.74 (s, 1H), 4.90-4.50 (m, 2H), 3.33 (brd, J = 6.3 Hz, 2H), 2.09 (s, 3H), 2.05 (s, 3H), 1.93 (s, 3H), 1.60-1.40 (m, 1H), 0.73 (d, J = 6.3 Hz, 6H).
Eksempel 6(3)
3-metyl-4-[2-pSf-isobutyl-N-(5-me1yl-2-mrylsulfonyl)amino]-4,5-dimetylfenol« metyllbenzosyrenatriumsalt
TLC : Rf 0,41 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 8 7.70 (s, 1H), 7.66 (d, J = 7.8 Hz, 1H), 7.13 (d, J = 7.8 Hz, 1H), 6.99 (s, 1H), 6.91 (s, 1H), 6.76 (d, J = 3.3 Hz, 1H), 6.14 (d, J = 3.3 Hz, 1H), 4.88 (brs, 2H), 3.36 (d, J = 6.9 Hz, 2H), 2.26 (s, 3H), 2.22 (s, 3H), 2.14 (s, 3H), 2.10 (s, 3H), 1.60-1.45 (m, 1H), 0.81 (brd, J = 6.3 Hz, 6H).
Eksempel 6(4)
4-[6-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]benzosyrenatriumsalt
TLC : Rf 0,40 (kloroform : metanol = 9:1);
NMR(CD3OD): 8 7.91 (d, J = 8.1 Hz, 2H), 7.19 (s, 1H), 7.18 (d, J = 8.1 Hz, 2H), 7.13 (s, 1H), 6.93 (s, 1H), 5.00-4.80 (m, 1H), 4.65-4.58 (m, 1H), 3.65-3.48 (m, 2H), 2.95-2.80 (m, 4H), 2.21 (d, J = 0.9 Hz, 3H), 2.09 (kvint, J = 7.5 Hz, 2H), 1.66 (m, 1H), 1.03-0.85 (m, 6H).
Eksempel 6(5)
4-[6-|lNl-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]benzo-syrekaliumsalt
TLC : Rf 0,37 (kloroform : metanol = 9:1);
NMR(DMSO-d6): 8 7.81 (d, J = 8.0 Hz, 2H), 7.47 (q, J = 0.4 Hz, 1H), 7.06 (d, J = 8.0 Hz, 1H), 7.03 (s, 2H), 6.95 (s, 1H), 5.10-4.80 (m, 1H), 4.80-4.50 (m, 1H), 3.43 (brs, 2H), 2.80 (q, J = 7.0 Hz, 4H), 2.23 (d, J = 0.4 Hz, 3H), 2.01 (qn, J = 7.0 Hz, 2H), 1.53 (sept, J = 6.6 Hz, 1H), 0.85 (brs, 6H).
Eksempel 6(6)
4-[6-[N-isobutyl-N-(5-metyl-2-forylsulfonyl)amino]indan-5-yloksymetyl]kanelsyrenatriumsalt
TLC : Rf 0,51 (kloroform : metanol = 9:1);
NMR : 8 7.37 (d, J = 15.9 Hz, 1H), 7.17 (d, J = 7.5 Hz, 2H), 7.10-6.90 (m, 3H), 6.67 (s, 1H), 6.55 (s, 1H), 6.45 (d, J = 15.9 Hz, 1H), 5.74 (s, 1H), 4.80-4.45 (m, 2H), 3.35 (d, J = 6.3 Hz, 2H), 2.85-2.55 (m, 4H), 2.10-1.80 (m, 5H), 1.65-1.40 (m, 1H), 0.74 (brs, 6H).
Eksempel 6(7)
3-me1yl-4-[6-|l^-isobutyl-N-(5-metyl-2-mrylsulfonyl)amino]m^ benzosvrenatriumsalt
TLC : Rf 0,60 (kloroform : metanol = 9:1);
NMR(CD3OD) : 8 7.78 (s) og 7.75 (d, J = 8.1 Hz) total 2H, 7.24 (d, J = 8.1 Hz, 1H), 7.07 (s, 1H), 6.97 (s, 1H), 6.64 (d, J = 3.3 Hz, 1H), 6.03 (dd, J = 3.3, 0.9 Hz, 1H), 5.08-4.75 (m, 2H), 3.48 (d, J = 7.5 Hz, 2H), 2.94-2.80 (m, 4H), 2.32 (s, 3H), 2.15-2.00 (m) og 2.04 (s) total 5H, 1.87 (m, 1H), 0.98-0.80 (m, 6H).
Eksempel 6(8)
4-[6-[N-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]kanel-syrekaliumsalt
TLC : Rf 0,36 (kloroform : metanol = 9:1);
NMR : 8 7.27 (d, J = 15.9 Hz, 1H), 7.21 (d, J = 7.5 Hz, 2H), 6.98 (d, J = 7.5 Hz, 2H), 6.84 (s, 1H), 6.78 (s, 1H), 6.70 (s, 1H), 6.41 (d, J = 15.9 Hz, 1H), 4.70-4.40 (m, 3H), 2.85-2.60 (m, 4H), 2.24 (s, 3H), 2.05-1.90 (m, 2H), 1.01 (d, J = 6.6 Hz, 3H), 0.95 (d, J = 6.6 Hz, 3H).
Eksempel 6(9)
4-[2-[N-isobutyl-N-(2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksymetyl]benzo-syrekaliumsalt
TLC : Rf 0,32 (kloroform : metanol = 9:1);
NMR : 8 7.82 (d, J = 8.1 Hz, 2H), 7.33 (d, J = 3.0 Hz, 1H), 7.15 (d, J = 3.0 Hz, 1H), 6.94 (s, 1H), 6.89 (d, J = 8.1 Hz, 2H), 6.56 (s, 1H), 4.70-4.55 (m, 1H), 4.45-4.25
(m, 1H), 3.60-3.30 (m, 2H), 2.09 (s, 6H), 1.60-1.45 (m, 1H), 0.78 (brs, 3H), 0.72 (brs, 3H).
Eksempel 6(10)
3-metyl-4-[2-[TN-isobutyl-N-(2-tiazo^ benzosyrenatriumsalt
TLC : Rf 0,37 (kloroform : metanol =10:1);
NMR(DMSO-d6): 8 7.98 (d, J = 3.0 Hz, 1H), 7.82 (d, J = 3.0 Hz, 1H), 7.64 (s, 1H), 7.60 (d, J = 7.8 Hz, 1H), 6.99 (d, J = 7.8 Hz, 1H), 6.97 (s, 1H), 6.91 (s, 1H), 5.00-4.54 (m, 2H), 3.42 (d, J = 6.3 Hz, 2H), 2.20 (s, 3H), 2.20 (s, 3H), 2.11 (s, 3H), 1.50 (m, 1H), 0.90-0.73 (m, 6H).
Eksempel 7
4- [6- [N-isobuty l-N-(5 -metyl-2-furylsulfonyl)amino] indan-5 -y loksymety l]-3 -mety 1-benzylalkohol
Til en suspensjon av forbindelsen fremstilt i eksempel 2(33) (1,20 g) i tetrahydrofuran (10 ml) ble borhydrid-dimetyltiol-kompleks (2 M tetrahydrofuranoppløsning, 6,0 ml) tilsatt, og blandingen ble omrørt i 1 time. Til reaksjonsblandingen ble metanol, vann og IN saltsyre tilsatt, og blandingen ble ekstrahert med etylacetat to ganger. Det kombinerte organiske laget ble vasket med IN saltsyre, vann og en mettet vandig oppløsning av natriumklorid i rekkefølge, tørket over vannfritt natriumsulfat og ble renset ved kolonnekromatografi på silikagel (n-heksan : etylacetat = fra 8 :1 til 2 :1) til å gi forbindelsen i henhold til den foreliggende oppfinnelse (947 mg) som har de følgende fysiske data.
TLC : Rf 0,57 (n-heksan : etylacetat =1:1);
NMR : 8 7.20 (d, J = 7.8 Hz, 1H), 7.13 (s, 1H), 7.10 (d, J = 7.8 Hz, 1H), 7.07 (s, 1H), 6.95 (s, 1H), 6.79 (d, J = 3.3 Hz, 1H), 6.20-6.15 (m, 1H), 4.94 (br, 1H), 4.83 (br, 1H), 4.45 (s, 2H), 3.32 (d, J = 6.9 Hz, 2H), 2.84 (t, J = 7.4 Hz, 2H), 2.78 (t, J = 7.4 Hz, 2H), 2.25 (s, 3H), 2.13 (s, 3H), 2.10-1.90 (m, 2H), 1.55-1.40 (m, 1H), 0.90-0.70 (m, 6H).
Referanseeksempel 5
Metyl-t-butyleteroppløsning av 4-metyl-2-tiazolylsulfonylklorid
Under argonatmosfære ble det til en oppløsning av 4-metyltiazol (3,0 g) i metyl-t-butyleter (45 ml), tilsatt n-butyllitium (1,58 M heksanoppløsning, 19,1 ml) under omrøring ved -78°C, og blandingen ble omrørt i 1 time. 5,72 M oppløsning av svoveldioksyd i tetrahydrofuran (5,3 ml) ble tilsatt dråpevis til blandingen, og blandingen ble omrørt i 1 time. Til blandingen ble N-klorsuccinimid (4,44 g) tilsatt. Deretter ble blandingen oppvarmet til 0 °C og omrørt i ytterligere 1 time. Vann ble tilsatt til reaksjonsblandingen og det organiske laget ble vasket med vann to ganger, med en mettet vandig oppløsning av natriumklorid en gang, og ble tørket over et vannfritt magnesiumsulfat til å gi tittelforbindelsen, som metyl-t-butyleter-oppløsning (92 ml). Konsentrasjonen av denne oppløsningen var 0,20 M. Omdan-ningsutbyttet av tittelforbindelsen var 3,69 g.
Eksempel 8
1 -(4-mety ltiazol-2-y lsulfonyloksy)-1,2,3 -benzotriazol
Under argonatmosfære ble det til en oppløsning av 4-metyltiazol-2-sulfonylklorid i metyl-t-butyleter (0,20 M, 20 ml), tilsatt 1-hydroksybenzotriazol (549 mg) og trietylamin (0,57 ml) under omrøring med avkjøling på isbad, og blandingen ble omrørt i 1 time ved romtemperatur. Til reaksjonsblandingen ble etylacetat tilsatt. Det organiske laget ble vasket med vann tre ganger og med en mettet vandig opp-løsning av natriumklorid en gang i rekkefølge, tørket over et vannfritt magnesiumsulfat og konsentrert til å gi forbindelsen i henhold til den foreliggende oppfinnelse (1,1 g) som har de følgende fysiske data.
NMR: 8 8.03 (dt, J = 8.4, 1.0 Hz, 1H), 7.70-6.57 (m, 2H), 7.53 (d, J = 1.0 Hz, 1H), 7.46 (ddd, J= 8.4, 5.8, 2.0 Hz, 1H), 2.62 (d, J = 1.0 Hz, 3H).
Eksempel 9
1 -(4-metyltiazol-2-ylsulfonyl)-3-metylimidazol-1 -oniumhydrogenkloridsalt
Under argonatmosfære ble en oppløsning av 4-metyltiazol-2-sulfonylklorid i metyl-t-butyleter (0,14 M, 30 ml) avkjølt til 0°C, deretter ble 1-metylimidazol (0,68 ml) tilsatt og blandingen ble omrørt i 1 time. Det hvite presipitatet som kom til syne ble samlet og tørket til å gi forbindelsen i henhold til den foreliggende oppfinnelse (1,56 g) som har de følgende fysiske data.
NMR(DMSO-d6) : 6 9.08 (brs, 1H), 7.69 (t, J = 1.8 Hz, 1H), 7.63 (t, J = 1.8 Hz, 1H), 7.20-7.17 (m, 1H), 3.96 (s, 3H), 2.31 (d, J= 1.8 Hz, 3H).
Blant forbindelsene med formel (I) i henhold til den foreliggende oppfinnelse kan
forbindelsene hvori Ar er tiazol (fremstilt i eksempler 2(36) til (74), (101) til (123), eksempler 3(6) til (20), eksempler 4(7) til (17), eksempler 5(5) til (10), (22) til (27), (31) til (33), (40) til (43), (50), (52), (53), (56), (57), (59), (60), (62), (63), eksempel 6, eksempler 6(4), (5), (8) til (10)), forbindelsene hvori Ar er pyridin (fremstilt i eksempler 2(75) til (97), eksempler 3(21) til (38), eksempler 4(18) til (22)) fremstilles ved hjelp av de samme prosedyrene som referanseeksempel 3 ved anvendelse av forbindelsen fremstilt i eksempler 8 og 9 eller en tilsvarende forbindelse i stedet for et tilsvarende sulfonylklorid, etterfulgt av tilsvarende prosedyrer.
Sammenligningseksempel 1
En sammenligning av stabiliteten til 4-metyl-2-tiazolylsulfonylklorid med den til forbindelsen fremstilt i eksempler 8 og 9.
Oppløsningen fremstilt i referanseeksempel 1 ble konsentrert under redusert trykk til å gi 4-metyl-2-tiazolylsulfonylklorid. Stabiliteten til denne forbindelsen og forbindelsene fremstilt i eksempler 8 og 9 ble målt på HPLC: Betingelsene ved HPLC var som følger.
Kolonne: YMC-Pack ODS-AM-302(4,6 mm x 150 mm)
Eluerings-løsningsmiddel: MeCN/3 mM tetra-n-butylammoniumfosfat = 40/60 Strømningshastighet: 1 ml/min
Detektert ved UVabs 220 nm
Resultatene er vist i tabell 4.
Tabell 4 viser at 4-metyl-2-tiazolylsulfonylklorid er stabilt ved lav temperatur, men når underkastet romtemperatur eller høyre er det vanskelig å forsikre seg om stabiliteten.
På den annen side, er forbindelsene fremstilt i eksempler 8 og 9 stabile selv ved høy temperatur, siden restmengden derav knapt forandrer seg når de ble hensatt ved 40°C i ett døgn.
Forbindelsen med formel (II) er derfor anvendbar som et mellomprodukt for en sulfonylamidforbindelse, siden dens stabilitet er forbedret sammenlignet med den korresponderende sulfonylhalogenidforbindelsen.
Formuleringseksempel 1:
De følgende forbindelser ble blandet ved hjelp av en konvensjonell metode og stanset ut til å gi 100 tabletter som hver inneholder 5 mg aktiv bestanddel.
Formuleringseksempel 2:
De følgende forbindelser ble blandet ved hjelp av en konvensjonell metode og opp-løsningen steriliseres, fylles i ampuller som hver inneholder 1 ml og frysetørkes til å gi 100 ampuller som hver inneholder 5 mg aktiv bestanddel.
Claims (10)
1. N-fenylarylsulfonylamidforbindelse, karakterisert ved at den har formel (I)
hvori R<1> er COOH, 5-tetrazolyl, 5-okso-l,2,4-oksadiazolyl, CH2OH eller 5-okso-1,2,4-tiadiazolyl,
R er hydrogen, metyl, metoksy eller klor,
R<3> og R<4> er en kombinasjon av (1) metyl og metyl, (2) metyl og klor, (3) klor og metyl, eller (4) trifluormetyl og hydrogen; eller R<3> og R<4> er tatt sammen med karbonet hvortil R<3> og R<4> er bundet til å danne (5) cyklopenten, (6) cykloheksen eller (7) benzenring,
R<5> er isopropyl, isobutyl, 2-metyl-2-propenyl, cyklopropylmetyl, metyl, etyl, propyl, 2-propenyl eller 2-hydroksy-2-metylpropyl,
Ar er tiazolyl eventuelt substituert med metyl, pyridyl eller 5-metyl-2-furyl; og n er null eller 1, og når R<1> er 5-tetrazolyl, 5-okso-l,2,4-oksadiazolyl eller 5-okso-1,2,4-tiadiazolyl, er n null,
en alkylester derav eller et ikke-toksisk salt derav.
2. Forbindelse som angitt i krav 1, hvori Ar er 5-metyl-2-furyl, 2-tiazolyl, 5-metyl-2-tiazolyl, 2-pyridyl eller 3-pyridyl.
3. Forbindelse som angitt krav 1, hvori Ar er 5-metyl-2-furyl.
4. Forbindelse som angitt i krav 1 eller 3, som er valgt fra gruppen bestående av (1) 4-[2-[N-isoburyl-N-(5-metyl-2-furylsulfonyl)amino]-5-trifluormety lfenoksymety 1] kanelsyre,
(2) 4-[2-pSf-isopropyl-N-(5-metyl-2-furylsulfonyl)amino]-5-trifluormetylfenoksymetyl]benzosyre,
(3) 4-[2-[N-isobutyl-N-(5-metyl-2-mrylsulfonyl)amino]-5-trifluormetyl fenoksymetyl] benzosyre,
(4) 4-[2-|^-isobutyl-N-(5-metyL metylfenoksymetyl] benzosyre,
(5) 4-[2-P^-isopropyl-N-(5-metyl-2-furylsulfonyl)arnino]-4,5-dimetylfenoksymetyl]benzosyre,
(6) 4-[2-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)arnino]-4,5-dimetylfenoksymetyljbenzosyre,
(7) 3-metyl-4-[2-[N-isobu1yl-N-(5-metyl-2-furylsulfonyl)arnino]-4-metyl-5-klorfenoksymetyl]benzosyre,
(8) 3-metyl-4-[2-(T^-isobutyl-N-(5-metyl-2-furylsulfonyl)amino] - 4-klor-5-metylfenoksymetyl]benzosyre,
(9) 3-klor-4-[2-|^-isobutyl-N-(5-metyl-2-furylsulfonyl)arnino]-4-metyl-5-klorfenoksymetyl]benzosyre,
(10) 3-klor-4-[2-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)amino]-4-metyl-5-klorfenoksymetyl]benzosyre,
(11) 3-metoksy-4-[2-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)-amino]-4-metyl-5-klorfenoksymetyl]benzosyre,
(12) 3-metyl-4-[2-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-4,5 -dimety lfenoksy mety 1] benzosyre,
(13) 3-metoksy-4-[2-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)-amino] 4,5-dimetylfenoksymetyl]benzosyre,
(14) 3-metoksy-4-[2-[N-isobutyl-N-(5-metyl-2-furyl-sulfonyl)amino]-4,5-dimetylfenoksymetyl]benzosyre,
(15) 3-metoksy-4-[2-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)-amino]-4-klor-5-metylfenoksymetyl]benzosyre,
(16) 3-klor-4-[2-[N-isobutyl-N-(5-me1yl-2-furylsulfonyl)amino]-4,5-dimetylfenoksymetyl]benzosyre,
(17) 3 -klor-4- [2 - [N-isopropyl-N-(5 -mety 1-2-furylsulfonyl)amino] - 4,5 -dimety lfenoksymety 1] benzosyre,
(18) 3-metyl-4-[2-|>f-isobutyl-N-(5-me1yl-2-furylsulfonyl)amino]-4-klor-5-metylfenoksymetyl]kanelsyre,
(19) 4- [2- [N-isopropy l-N-(5 -mety 1-2 -fury lsulfony 1) amino] -4-mety 1-5 -klorfenoksymety 1] kanelsyre,
(20) 4-[2-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-4-metyl-5 -klorfenoksymety ljkanelsyre,
(21) 4-[2-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)amino]-4,5-dimetylfenoksymetyljkanelsyre,
(22) 3 -metyl-4-[2- [N-isopropy l-N-(5 -mety 1-2-furylsulfonyl)amino] - 5-trifluormetylfenoksymetyl]kanelsyre,
(23) 3 -metyl-4-[2- [N-isopropy l-N-(5 -metyl-2-furylsulfonyl)amino] - 4,5-dimetylfenoksymetyl]benzosyre,
(24) 3-metyl-4-[2-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)amino]-4,5 -dimety lfenoksymety 1] kanelsyre,
(25) 3-metyl-4-[2-[>l-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-4,5 -dimety lfenoksy mety 1] kanelsyre,
(26) 4-[2-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-4,5-dimetylfenoksymetyl]kanelsyre,
(27) N-[4-klor-5-metyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]-fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid,
(28) 3-metoksy-4-[2-[N-isobutyl-N-(5-metyl-2-furyl-sulfonyl)amino]-4-metyl-5-klorfenoksymetyl]kanelsyre,
(29) N-[4,5-dimetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]-fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid,
(30) N-[4,5-dimetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]-fenyl]-N-isopropyl-(5-metyl-2-furyl)sulfonylamid,
(31) N-[4-klor-5-metyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid,
(32) N-[4-klor-5-metyl-2-[4-(5-okso-l,2,4-oksadiazol-3-yl)fenyl-metyloksy] -fenyl] -N-isopropy l-(5 -metyl-2-furyl)sulfonylamid,
(33) N-[4-klor-5-metyl-2-[4-(5-okso-l,2,4-oksadiazol-3-yl)fenyl-metyloksy]fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid,
(34) 4-[6-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]indan-5-yloksymetyl]benzosyre,
(3 5) 4-[6-[N-isopropyl-N-(5-metyl-2-fury lsulfony l)amino]indan-5 - yloksymetyl]benzosyre,
(36) 4-[7-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-l ,2,3,4-tetrahydronaftalen-6-yloksymetyl]benzosyre,
(3 7) 4- [7- [N-isopropy l-N-(5 -mety l-2-furylsulfonyl)amino] -1,2,3,4-tetrahydronaftalen-6-yloksymetyl]benzosyre,
(38) N-[4,5-dimetyl-2-[2-metyl-4-(5-okso-l,2,4-oksadiazol-3-yl)-fénylmetyloksy]fenyl]-N-isopropyl-(5-metyl-2-furyl)sulfonylamid,
(39) N-[4,5-dimetyl-2-[2-metyl-4-(5-okso-l ,2,4-oksadiazol-3-yl)-fenylmetyloksy]fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid,
(40) N- [4,5 -dimetyl-2- [4-(5 -tetrazolyl)feny lmetyloksy] fenyl] -N-isopropyl-(5-metyl-2-furyl)sulfonylamid,
(41) N-[4,5-dimetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid,
(42) N-[4,5-dimetyl-2-[4-(5-okso-l,2,4-oksadiazol-3-yl)fenylmetyl-oksy]fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid,
(43) 3-metyl-4-[2-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-4-metyl-5-klorfenoksymetyl]kanelsyre,
(44) N-[4,5-dimeryl-2-[2-metoksy-4-(5-okso-l ,2,4-oksadiazol-3-yl)fenylmetyloksy]fenyl]-N-isobutyl-(5-metyl-2-furyl)sulfonylamid,
(45) N-[4,5-dimetyl-2-[2-metoksy-4-(5-okso-l ,2,4-oksadiazol-3-yl )fenylmetyloksy] feny 1] -N-isopropy l-(5 -metyl-2-furyl)sulfony lamid,
(46) 4-[6-pvf-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]indan-5-yloksymetyl]kanelsyre,
(47) 3-metyl-4-[6-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-indan-5-yloksymetyl]benzosyre,
(48) 3-metyl-4-[6-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-indan-5-yloksymetyl]kanelsyre,
(49) 4-[2-[N-(2-metyl-2-propenyl)-N-(5-metyl-2-furylsulfonyl)-amino]-4,5-dimetylfenoksymetyl]benzosyre,
(50) 3-metyl-4-[6-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)amino]-indan-5-yloksymetyl]benzosyre,
(51) 3-metyl-4-[6-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)amino]-indan-5-yloksymetyl]kanelsyre,
(52) 4- [6- [N-isopropyl-N-(5 -mety l-2-furylsulfonyl)amino] indan-5 - yloksymetyl]kanelsyre,
(53) 4-[3-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-2-naftyl-oksymetyl] benzosyre,
(54) 3,5-dimetyl-4-[2-|>r-isobutyl-N-(5-metyl-2-furylsulfonyl)-amino] -5 -trifluormety lfenoksymetyl] benzosyre,
(55) 3-metyl-4-[6-[N-(5-metyl-2-furylsulfonyl)-N-(2-metyl-2-propenyl)amino] indan-5 -yloksymetyl] benzosyre,
(56) 4-[6-[N-cyklopropylmetyl-N-(5-metyl-2-furylsulfonyl)amino]-indan-5-yloksymetyl]-3-metylbenzosyre,
(57) 4-[6-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]indan-5-y loksymety 1] -3-mety lbenzy lalkoho 1,
(58) 3-metyl-4-[6-[N-metyl-N-(5-metyl-2-furylsulfo-nyl)amino]indan-5-yloksymetyl]benzosyre,
(59) 4- [6- [N-etyl-N-(5-metyl-2-furylsulfonyl)amino] indan-5-y loksymetyl] -3 -metylbenzosyre,
(60) 4-[6-[N-me1yl-N-(5-me1yl-2-furylsulfonyl)amino]indan-5-yloksymetyl]kanelsyre,
(61) 4-[6-[N-etyl-N-(5-metyl-2-furylsulfonyl)amino]indan-5-yloksymetyljkanelsyre,
(62) 4-[6-[N-(5-metyl-2-furylsulfonyl)-N-propylamino]indan-5-yloksymetyljkanelsyre,
(63) 4-[4,5-dimetyl-2-[N-(2-metyl-2-propenyl)-N-(5-metyl-2-furyl-sulfonyl)amino]fenoksymetyl]-3-metylbenzosyre,
(64) 4-[6-[N-(5-metyl-2-furylsulfonyl)-N-(2-metyl-2-propenyl)amino]indan-5-yloksymetyl]kanelsyre,
(65) 4- [6- [N-cyklopropylmety l-N-(5 -metyl-2-furylsulfonyl)amino] - indan-5-yloksymetyl]kanelsyre,
(66) 4-[6-[N-(5-metyl-2-furylsulfonyl)-N-(2-propenyl)amino]indan-5 -y loksymety ljkanelsyre,
(67) 3-metyl-4-[6-[N-(5-metyl-2-furylsulfonyl)-N-propylamino]-indan- 5 -y loksymety 1] benzosyre,
(68) 3-metyl-4-[6-[N-(5-metyl-2-furylsulfonyl)-N-(2-propenyl)amino]indan-5-yloksymetyl]benzosyre,
(69) 4-[4,5-dimetyl-2-[N-metyl-N-(5-metyl-2-furylsulfonyl)amino]-fenoksymetyljbenzosyre,
(70) 4-[4,5-dimetyl-2-[N-etyl-N-(5-metyl-2-furylsulfonyl)amino]-fenoksymetyljbenzosyre,
(71) 4-[4,5-dimetyl-2-[N-(5-metyl-2-furylsulfonyl)-N-propylamino]fenoksymetyl]benzosyre,
(72) 4- [3 - [N-isopropyl-N-(5 -mety 1-2-furylsulfony l)amino]naftalen-2-yloksymetyl]-3-metylbenzosyre,
(73) 4-[3-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]naftalen-2-yloksymetyl]-3-metylbenzosyre,
(74) 4-[3-[N-isopropyl-N-(5-metyl-2-furylsulfonyl)amino]naftalen-2-yloksymetyl]kanelsyre,
(75) 4-[3-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]naftalen-2-yloksymetyl]kanelsyre,
(76) 3-metyl-4-[3 -[N-isopropy l-N-(5-mety l-2-furylsulfonyl)amino] - naftalen-2-yloksymetyl]kanelsyre,
(77) 3-metyl-4-[3-[N-isobutyl-N-(5-metyl-2-furylsulfonyl)amino]-naftalen-2-yloksymetyl]kanelsyre,
(78) 4-[4,5-dimetyI-2-[N-[(5-metyI-2-furyl)sulfonyl]-N-2-propenyl-amino]fenoksymetyl]benzosyre,
(79) 4-[4,5-dimetyl-2-[N-metyl-N-(5-metyl-2-furylsulfonyl)amino]-fenoksymetyl] -3-metylbenzosyre,
(80) 4-[4,5-dimetyl-2-[N-etyl-N-(5-metyl-2-furylsulfonyl)amino]-fenoksymetyl]-3-metylbenzosyre,
(81) 4-[4,5-dimetyl-2-[N-(5-metyl-2-furylsulfonyl)-N-propy lamino] fenoksym etyl] -3 -metylbenzosyre,
(82) 4-[4,5-dimetyl-2-[N-(5-metyl-2-furylsulfonyl)-N-(2-propenyl)-amino] fenoksymetyl] -3 -metylbenzosyre,
(83) 4-[4,5-dimetyl-2-[N-(2-hydroksy-2-metylpropyl)-N-(5-metyl-2-fui7lsulfonyl)amino]fenoksymetyl]-3-metylbenzosyre,
(84) 4-[6-|N-(2-hydroksy-2-metylpropyl)-N-(5-metyl-2-furylsulfo-nyl)amino]indan-5-yloksymetyl]-3-metylbenzosyre,
(85) 4-[4,5-dimetyl-2-[N-cyklopropylmetyl-N-(5-metyl-2-furylsulfonyl)amino]fenoksymetyl]benzosyre,
(86) 4-[4,5-dimety 1-2-[N-(2-hydroksy-2-metylpropyl)-N-(5-metyl-2-furylsulfonyl)amino]fenoksymetyl]benzosyre,
(87) 4-[6-[>r-(2-hydroksy-2-metylpropyl)-N-(5-metyl-2-furylsulfo-ny 1)amino] indan-5-yloksymety 1]kanelsyre, og
(88) 4-[4,5-dimetyl-2-[N-cyklopropylmetyl-N-(5-metyl-2-furylsulfonyl)amino]fenoksymetyl]-3-metylbenzosyre.
5. Forbindelse som angitt i krav 1, hvori Ar er 2-tiazolyl eller 5-metyl-2-tiazolyl.
6. Forbindelse som angitt i krav 1 eller 5, som er valgt fra gruppen bestående av (1) 4-[2-[N-isopropyl-N-(2-tiazoIylsulfonyl)amino]-5-trifluormetylfenoksymetyl]benzosyre,
(2) 4-[2-[N-isobutyl-N-(2-tiazolylsulfonyl)amino]-5-trifluormetyl-fenoksymetyl]benzosyre,
(3) 4-[2-[N-isopropyl-N-(2-tiazolylsulfonyl)amino]-5-trifluonnetylfenoksymetyl]kanelsyre,
(4) 4- [2- [N-isobutyl-N-(2-tiazoly lsulfony l)amino] -5 -trifluormety 1-fenoksy metyl] kanel syre,
(5) 4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-5-tri-fluormetylfenoksymetyl]benzosyre,
(6) 4- [2- [N-isobuty l-N-(4-metyl-2-tiazolylsulfony l)amino] -5 -tri-fluormetylfenoksymetyl]kanelsyre,
(7) 4- [2- [N-isopropyl-N-(2-tiazolylsulfony l)amino]-4-klor-5 - metylfenoksymetyl]benzosyre,
(8) N-[4-trifluormetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-2-tiazolylsulfonylamid,
(9) N-[4-nifluormetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-2-tiazolylsulfonylamid,
(10) N-[4-trifluormetyl-2-[4-(5-okso-l ,2,4-oksadiazol-3-yl)fenyl-metyloksy] fenyl] -N-isopropy 1-2-tiazolylsulfonylamid,
(11) N-[4-trifluormetyl-2-[4-(5-okso-l,2,4-tiadiazol-3-yl) fenyl-metyloksy]fenyl]-N-isopropyl-2-tiazolylsulfonylamid,
(12) 4-[2-[N-isopropyl-N-(4-metyl-2-tiazoly lsulfonyl)amino] -4-klor-5-metylfenoksymetyl]benzosyre,
(13) 4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4-klor-5-metylfenoksymetyl]benzosyre,
(14) 3-klor-4-[2-[N-isopropyl-N-(4-metyl-2-tiazolyl-sulfonyl)amino]-4-klor-5-metylfenoksymetyl]benzosyre,
(15) 3-metyl-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolyl-sulfonyl)amino]-5-trifluormetylfenoksymetyl]benzosyre,
(16) 3-metyl-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolyl-sulfonyl)amino]-4-klor-5-metylfenoksymetyl]benzosyre,
(17) 3-metoksy-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]-4-klor-5-metylfenoksymetyl]benzosyre,
(18) 3-metoksy-4-[2-[N-isobuty l-N-(4-metyl-2-tiazolylsulfonyl)-amino]-5-lrifluormetylfenoksymetyl]benzosyre,
(19) N-[4-trifluormetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid,
(20) N-[4-trifluormetyl-2-[4-(5-okso-l,2,4-oksadiazol-3-yl)fenyl-metyloksy]fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid,
(21) N-[4-trifluormetyl-2-[4-(5-okso-l,2,4-oksadiazol-3-yl)fenyl-metyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid,
(22) 4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4-metyl-5-klorfenoksymetyl]benzosyre,
(23) 3-klor-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4- metyl-5-klorfenoksymetyl]benzosyre,
(24) 3-metoksy-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]-4-metyl-5-klorfenoksymetyl]benzosyre,
(25) N-[4-trifluormetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid,
(26) 3-metyl-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolyl-sulfonyl)ammo]-4,5-dimetylfenoksymetyl]benzosyre,
(27) 3-metyl-4-[2-[N-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]-4,5-dimetylfenoksymetyl]benzosyre,
(28) 3-metoksy-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]-4,5-dimetylfenoksymetyl]benzosyre,
(29) 3-klor-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)aniino]-4,5 -dimetylfenoksymetyljbenzosyre,
(3 0) 3 -klor-4- [2-[N-isopropy l-N-(4-metyl-2-tiazolyl-sulfonyl)aniino]-4,5-dimetylfenoksymetyl]benzosyre,
(31) 4-[2-[N-isopropyl-N-(4-melyl-2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksym etyl] benzosyre,
(32) 4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksymetyljbenzosyre,
(33) 4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4-klor-5- metylfenoksymetyl]kanelsyre,
(34) 3-metyl-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsul-fony l)amino] -5 -trifluormety lfenoksymetyl] kanelsyre,
(35) 3 -klor-4- [2- [N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino] - 5-trifluormetylfenoksymetyl]kanelsyre,
(3 6) 3 -metyl-4- [2-[N-isopropyl-N-(4-metyl-2-tiazoly lsulfony 1)-amino]-4,5-dimetylfenoksymetyl]kanelsyre,
(37) 3-metyl-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolyl-sulfonyl)amino]-4,5-dimetylfenoksymetyl]kanelsyre,
(38) 4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4-metyl-5-klorfenoksymetyl]kanelsyre,
(39) 3-metyl-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolyl-sulfonyl)amino]-4-metyl-5-klorfenoksymeryl]kanelsyre,
(40) 3-metyl-4-[2-[N-isobuty]-N-(4-metyl-2-tiazolyl-sulfonyl)amino]-4-klor-5-metylfenoksymetyl]kanelsyre,
(41) N-[4-klor-5-metyl-2-[2-rnetyl-4-(5-tetrazolyl)fenylmetyloksy]-fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid,
(42) N-[4-klor-5-metyl-2-[2-metyl-4-(5-tetrazolyl)fenyl-metyloksy]fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid,
(43) 4-[2-[N-isobutyl-N-(4-mety]-2-tiazolylsulfonyl)amino]-4,5-dimety]fenoksymetyl]kanelsyre,
(44) N-[4-trifluormetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]-fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid,
(45) N-[4-trifluormetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]-fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylarnid,
(46) 3-klor-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksymetyl]kanelsyre,
(47) N-[4,5-dimetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]-fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid,
(48) N-[4,5-dimetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]-fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid,
(49) N-[4,5-dimetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid,
(50) N-[4,5-dimetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid,
(51) N-[4-klor-5-metyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid,
(52) N-[4-klor-5-metyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid,
(53) N-[4-klor-5-metyl-2-[4-(5-okso-l,2,4-oksadiazol-3-yl)fenyl-rnetyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylaniid,
(54) N-[4-klor-5-metyl-2-[2-metyl-4-(5-okso-l,2,4-oksadiazol-3-yl)fenylmetyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid,
(55) 3-metoksy-4-[2-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino] -4,5- dimety lfenoksymety 1] kanelsyre,
(56) N-[4,5-dimetyl-2-[2-metyl-4-(5-okso-l,2,4-oksadiazol-3-yl)-fenylmetyloksy]fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid,
(57) N-[4,5-dimetyl-2-[2-metyl-4-(5-okso-l,2,4-oksadiazol-3-yl)-fenylmetyloksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid,
(58) N-[4,5-dimetyl-2-[4-(5-okso-l,2,4-oksadiazoI-3-yl)fenylmetyl-oksy] fenyl] -N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid,
(59) N-[4,5-dimetyl-2-[4-(5-okso-l,2,4-oksadiazol-3-yl)fenylmetyl-oksy]fenyl]-N-isobutyl-(4-metyl-2-tiazolyl)sulfonylamid,
(60) N-[4,5-dimetyl-2-[2-metoksy-4-(5-okso-l ,2,4-oksadiazol-3-yl)fenylmetyloksy]fenyl]-N-isopropyl-(4-metyl-2-tiazolyl)sulfonylamid,
(61) N-[4,5-dimetyl-2-[2-metoksy-4-(5-tetrazolyl)fenylmetyloksy]-fenyl]-N'isopropyl-(4-metyl-2-tiazolyl)sulfonylamid,
(62) 4-[6-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]benzosyre,
(63) 4-[6-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]kanelsyre,
(64) 3-metyl-4-[6-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino] indan-5 -yl oksy mety 1] benzosyre,
(65) 3-metyl-4-[6-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]indan-5-yloksymetyl]kanelsyre,
(66) 3-metyl-4-[2-[N-(2-metyl-2-propenyl)-N-(4-metyl-2-tiazolyl-sulfonyl)amino]-4-klor-5-metylfenoksymetyl]benzosyre,
(67) 4-[2-[N-(2-metyl-2-propenyl)-N-(4-metyl-2-tiazolylsulfonyl)-amino]-5-tiifluormetylfenoksymetyl] kanelsyre,
(68) 3-metyl-4-[2-[N-(2-metyl-2-propenyl)-N-(4-metyl-2-tiazolyl-sulfonyl)amino]-4,5-dimetylfenoksymetyl]benzosyre,
(69) 3-metyl-4-[6-[N-isopropyl-N-(2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]benzosyre,
(70) 3 -mety 1-4- [6- [N-isobuty l-N-(2-tiazolylsulfonyl)amino] indan-5 - yloksymetyl]benzosyi-e,
(71) 3-metyl-4-[6-[N-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)-amino] indan-5 -y loksymety 1] benzo syre,
(72) 4-[6-[N-isopropyl-N-(2-tiazolylsulfonyl)amino]indan-5-yloksymetyl] benzosyre,
(73) 4-[6-[N-isobutyl-N-(2-tiazolylsulfonyl)amino]indan-5-yloksymetyl] benzosyre,
(74) 4-[6-[N-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]benzosyre,
(75) 4-[6-[N-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymetyl] kanelsyre,
(76) 3-metyl-4-[6-[N-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]indan-5-yloksymetyl]kanelsyre,
(77) 4- [2- [N-isopropy l-N-(2-tiazolylsulfony l)amino] -4,5 -dimety 1-fenoksymetyljbenzosyre,
(78) 4-[2-[N-isobutyl-N-(2-tiazolylsulfonyl)amino]-455-dimetyl-fenoksymetyl]benzosyre,
(79) 4-[2-[N-isopropyl-N-(2-tiazolylsulfonyl)amino]-4,5-dimetyl-fenoksymety 1] kanelsyre,
(80) 4-[2-[N-isobutyl-N-(2-tiazolylsulfonyl)amino]-4,5-dimetyl-fenoksy mety 1] kanelsyre,
(81) 4-[6-[N-isopropyl-N-(2-tiazolylsulfonyl)amino]indan-5-yloksymetyl] kanelsyre,
(82) 4-[6-[N-isobutyl-N-(2-tiazolylsulfonyl)amino]indan-5-yloksymety ljkanelsyre,
(83) 3-metyl-4-[2-[N-isopropyl-N-(2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksymetyl]benzosyre,
(84) 3-metyl-4-[2-[N-isobutyl-N-(2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksymetyljbenzosyre,
(85) 3-metyl-4-[2-[N-isopropyl-N-(2-tiazolylsulfonyl)amino]-4,5-dimetylfenoksymetyljkanelsyre,
(86) 3-metyl-4-[2-[N-isobutyl-N-(2-tiazolylsulfonyl)amino]-4,5-diinetylfenoksymetyljkanelsyre,
(87) 3-metyl-4-[6-[N-isopropyl-N-(2-tiazolylsulfonyl)amino]indan-5 -y loksymety 1] kanelsyre,
(88) 3-metyl-4-[6-[N-isobutyl-N-(2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]kanelsyre,
(89) 4-[3-[N-isobutyl-N-(4-metyl-2-tiazolylsulfo-nyl)amino]naftalen-2-yloksymetyl]benzosyre,
(90) 4-[3-[N-isopropyl-N-(4-metyl-2-tiazolylsulfo-nyl)amino]naftalen-2-yloksymetyl]benzosyre,
(91) 4- [3- [N-isobutyl-N-(4-metyl-2-tiazolylsulfo-nyl)amino]naftalen-2-yloksymetyl]-3-metylbenzosyre,
(92) 4- [3- [N-isopropy 1-N- [2-(4-metyltiazolyl)sulibny 1] amino] - naftalen-2-y loksymetyl] -3 -metylbenzosyre,
(93) 4-[3-[N-isobutyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]natfalen-2-yloksymetyl]kanelsyre,
(94) 4-[3-[N-isopropyl-N-(4-metyl-2-tiazolylsulfonyl)-amino]naftalen-2-yloksymetyl]kanelsyre,
(95) 4-[4,5-dimetyl-2-[N-metyl-N-(4-metyl-2-tiazolylsulfonyl)-amino] fenoksymetyl] -3 -metylbenzosyre,
(96) 4-[4,5-dimetyl-2-[N-etyl-N-(4-metyl-2-tiazolylsul-fonyl)amino]fenoksymetyl]-3-metylbenzosyre,
(97) 4-[4,5-dimetyl-2-[N-propyl-N-(4-metyl-2-tiazolylsulfonyl)-amino] fenoksymetyl] -3 -metylbenzosyre,
(98) 4-[4,5-dimetyl-2-[N-(2-propenyl)-N-(4-metyl-2-tiazolylsulfo-nyl)amino]fenoksymetyl]-3-metylbenzosyre,
(99) 4-[4,5-dimetyl-2-[N-cyklopropylmetyl-N-(4-metyl-2-tiazolyl-sulfony 1) amino] fenoksymetyl] -3-metylbenzosyre,
(100) 4-[4,5-dimetyl-2-[N-(2-hydroksy-2-metylpropyl)-N-(4-metyl-2-tiazolylsulfonyl)amino]fenoksymetyl]-3-metylbenzosyre,
(101) 4-[6-p^-(2-metyl-2-propenyl)-N-(4-metyl-2-tiazolylsulfonyl)-amino] indan-5-yloksymetyl]benzosyre,
(102) 4-[6-[N-(4-metyl-2-tiazolylsulfonyl)-N-(2-propenyl)amino]-indan-5-yloksymetyl]benzosyre,
(103) 4-[6-[N-cyklopropylmetyl-N-(4-metyl-2-tiazolyl-sulfonyl)amino]indan-5-yloksymetyl]benzosyre,
(104) 4-[3-[N-isobutyl-N-[2-(4-metyltiazolyl)sulfonyl]-amino]naftalen-2-yloksymetyl]-3-mety lkanelsyre,
(105) 4-[3-[N-isopropyl-N-(4-meryl-2-tiazolylsulfonyl)amino]-naftalen-2-yloksymetyl]-3-mety lkanelsyre,
(106) 4-[6-[N-etyl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-y loksymety 1] benzosyre,
(107) 4- [6- [N-(4-metyl-2-tiazolylsulfonyl)-N-propylamino] indan-5 - yloksymetyl] benzosyre,
(108) 4-[6-[N-metyl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymetyl] benzosyre,
(109) 3-metyl-4-[6-[N-metyl-N-(4-metyl-2-tiazolylsulfonyl)amino]-indan-5-yloksymetyl]kanelsyre,
(110) 4-[6-(TSf-etyl-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymetyl] -3-mety lkanelsyre,
(111) 3-metyl-4-[6-[N-(2-metyl-2-propenyl)-N-(4-metyl-2-tiazolyl-sulfonyl)amino]indan-5-yloksymetyl]kanelsyre,
(112) 4-[6-[N-cyklopropylmetyl-N-(4-metyl-2-tiazolyl-sulfonyl)arnino]indan-5-yloksymetyl]-3-mety lkanelsyre,
(113) 3-metyl-4-[6-[N-(4-metyl-2-tiazolylsulfonyl)-N-(2-propenyl)-amino]indan-5-yloksymetyl]kanelsyre,
(114) 4-[6-[N-(2-hydroksy-2-metylpropyl)-N-(4-metyl-2-tiazolyl-sulfonyl)amino]indan-5-yloksymetyl]-3-metylkanelsyi-e,
(115) 3-metyl-4-[6-[N-(4-metyl-2-tiazolylsulfonyl)-N-propylamino]-indan-5-yloksymetyl]kanelsyre, og
(116) 4-[6-[N-(2-hydroksy-2-metylpropyl)-N-(4-metyl-2-tiazolylsulfonyl)amino]indan-5-yloksymetyl]benzosyre.
7. Forbindelse som angitt i krav 1, hvori Ar er 2-pyridyl eller 3-pyridyl.
8. Forbindelse som angitt i krav 1 eller 7, som er valgt fra gruppen bestående av (1) 4-[2-[N-isobutyl-N-(2-pyridylsuIfonyl)amino]-5-trifluormetyl-fenoksymety 1] kanelsyre,
(2) 4-[2-[N-isobutyl-N-(3-pyi-idylsulfonyl)amino]-5-trifluormetyl-fenoksymety 1] benzosyre,
(3) 3 -klor-4-[2- [N-isopropyl-N-(2-pyridy lsulfony l)amino] -4-klor-5-metylfenoksymetyl]benzosyre,
(4) 3-metyl-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4-klor-5-metylfenoksymetyl]benzosyre,
(5) 3-metyl-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4-klor-5-metylfenoksymetyl]benzosyre,
(6) 3-metyl-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4-metyl-5-klorfenoksymetyl]benzosyre,
(7) N-[4-trifluormetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-3 -pyridylsulfony lamid,
(8) N-[4-trifluormetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-3-pyridylsulfonylamid,
(9) 4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4-metyl-5-klor-fenoksymetyl]benzosyre,
(10) 3-klor-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4-metyl-5-klorfenoksymetyl]benzosyre,
(11) 3-metyl-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-5-trifluormetylfenoksymetyljkanelsyre,
(12) 3-metoksy-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4,5-dimetylfenoksymetyl]benzosyre,
(13) 3 -metoksy-4- [2- [N-isobutyl-N-(3 -pyridy lsulfonyl)amino] -4,5-dimety lfenoksymetyl] benzosyre,
(14) 3-metyl-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4,5-dimety lfenoksymetyl] benzosyre,
(15) 3-metyl-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4,5-dimety lfenoksymetyl] b enzosyre,
(16) N-[4-trifluormetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isopropyl-2-pyridylsulfonylamid,
(17) N-[4-trifluormetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-2-pyridylsulfonylamid,
(18) 3-metyl-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4-metyl-5-klorfenoksymetyl]benzosyre,
(19) 4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4,5-dimetyl-fenoksymetyl]benzosyre,
(20) N-[4-trifluormetyl-2-[4-(5-okso-l ,2,4-oksadiazol-3-yl)fenyl-metylolcsy]fenyl]-N-isobutyl-2-pyridylsulfonylamid,
(21) 4-[2-[N-isopropyl-N-(2-pyridylsulfonyl)amino]-4-metyl-5-klorfenoksymetyl]kanelsyre,
(22) 3-metyl-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4-metyl-5-klorfenoksymetyl]kanelsyre,
(23) 3-metyl-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4,5-dimety lfenoksymetyl] kanelsyre,
(24) 4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)aminp]-4,5-dimetyl-fenoksymetyl]kanelsyre,
(25) 3-metyl-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4,5-dimetylfenoksymetyl]kanelsyre,
(26) N-[4-trifluormetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyl-oksy]fenyl]-N-isopropyl-2-pyridylsulfonylamid,
(27) 3-klor-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4,5-dimetylfenoksymetyl] kanelsyre,
(28) N-[4,5-dimetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]-fenyl]-N-isobutyl-2-pyridylsulfonylamid,
(29) N-[4,5-dimetyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]-fenyl]-N-isobutyl-3-pyridylsulfonylamid,
(30) N-[4-klor-5-meryl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-3-pyridylsulfonylamid,
(31) N-[4,5-dimetyl-2-[2-klor-4-(5-tetrazolyl)fenyl-metyloksy]fenyl]-N-isobutyl-2-pyridylsulfonylamid,
(32) N-[4,5-dimetyl-2-[2-klor-4-(5-telrazolyl)fenyl-metyloksy]fenyl]-N-isopropyl-3-pyridylsulfonylamid,
(33) N-[4,5-dimetyl-2-[2-klor-4-(5-tetrazolyl)fenyl-metyloksy]fenyl]-N-isobutyl-3-pyridylsulfonylamid,
(34) 3-metyl-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)arriino]-4-klor-5-mety lfenoksymetyl] kanelsyre,
(35) N-[4,5-dimetyl-2-[4-(5-tetrazolyl)fenylmetyIoksy]fenyl]-N-isopropyl-2-pyridylsulfonylamid,
(36) N-[4,5-dimetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-2-pyridylsulfonylamid,
(37) N-[4,5-dimetyl-2-[4-(5-tetrazolyl)fenylmetyloksy]fenyl]-N-isobutyl-3-pyridylsulfonylamid,
(38) 3-klor-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-5-trifluormetylfenoksymetyl]kanelsyre,
(39) N-[4-klor-5-metyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]-fenyl]-N-isopropyl-2-pyridylsulfonylamid,
(40) N-[4-klor-5-metyl-2-[2-metyl-4-(5-tetrazolyl)fenylmetyloksy]-fenyl]-N-isobutyl-2-pyridylsulfonylamid,
(41) N-[4,5-dimetyl-2-[2-metyl-4-(5-okso-1,2,4-oksadiazol-3-yl)-fenylmetyloksy]fenyl]-N-isopropyl-2-pyridylsulfonylamid,
(42) N-[4,5-dimetyl-2-[2-metyl-4-(5-okso-l,2,4-oksadiazol-3-yl)-fenylmetyloksy]fenyl]-N-isobutyl-3-pyridylsulfonylamid,
(43) N-[4,5-dimetyl-2-[2-metoksy-4-(5-tetrazolyl)fenylmetyloksy]-fenyl]-N-isobutyl-2-pyridylsulfonylamid,
(44) N-[4,5-dimetyl-2-[2-metoksy-4-(5-tetrazolyl)fenylinetyloksy]-fenyl]-N-isopropyl-2-pyridylsulfonylamid,
(45) N-[4,5-dimetyl-2-[2-metoksy-4-(5-okso-l ,2,4-oksadiazol-3-yl)fenylmetyloksy]fenyl]-N-isobutyl-2-pyridylsulfonylamid og
(46) N-[4,5-dimetyl-2-[2-metoksy-4-(5-okso-l ,2,4-oksadiazol-3-yl)fenylmetyloksy]fenyl]-N-isopropyl-2-pyridylsulfonylamid.
9. Antagonist av EP) reseptor,
karakterisert ved at den er en prostaglandin E2 reseptor-subtype, omfattende N-fenylaiylsulfonylamidforbindelsen med formel (I) i samsvar med krav 1, en ester derav eller et ikke-toksisk salt derav som en aktiv bestanddel.
10. Farmasøytisk preparat for forebygging og/eller behandling av algi, pyreksi (induksjonsfeber), pollakisuri (hyppig urinering), akraturese (urininkontinens), sykdomssyndrom i nedre urinveier og cancer,
karakterisert ved at det omfatter forbindelsen med formel (I) i samsvar • med krav 1 som en aktiv bestanddel.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001068498 | 2001-03-12 | ||
JP2001281569 | 2001-09-17 | ||
JP2002007760 | 2002-01-16 | ||
PCT/JP2002/002245 WO2002072564A1 (fr) | 2001-03-12 | 2002-03-11 | Compose de n-phenylarylsulfonamide, medicament contenant le compose en tant que principe actif, intermediaire pour le compose et ses procedes de production |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20034007D0 NO20034007D0 (no) | 2003-09-10 |
NO20034007L NO20034007L (no) | 2003-11-12 |
NO329682B1 true NO329682B1 (no) | 2010-11-29 |
Family
ID=27346214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20034007A NO329682B1 (no) | 2001-03-12 | 2003-09-10 | N-fenylarylsulfonamidforbindelse, og antagonist av EP1 reseptor og farmasoytisk preparat omfattende forbindelsen som aktiv bestanddel |
Country Status (24)
Country | Link |
---|---|
US (3) | US7235667B2 (no) |
EP (2) | EP1612208B1 (no) |
JP (3) | JP3555620B2 (no) |
KR (1) | KR100886854B1 (no) |
CN (1) | CN1294126C (no) |
AT (2) | ATE522513T1 (no) |
AU (1) | AU2002238855B2 (no) |
BR (1) | BR0208027A (no) |
CA (1) | CA2439604C (no) |
CZ (1) | CZ304035B6 (no) |
DE (1) | DE60220255T2 (no) |
DK (2) | DK1369419T3 (no) |
ES (1) | ES2286230T3 (no) |
HU (1) | HU230056B1 (no) |
IL (2) | IL157701A0 (no) |
MX (1) | MXPA03008134A (no) |
NO (1) | NO329682B1 (no) |
NZ (1) | NZ528120A (no) |
PL (1) | PL218750B1 (no) |
PT (2) | PT1612208E (no) |
RU (1) | RU2299202C2 (no) |
TW (1) | TWI317359B (no) |
WO (1) | WO2002072564A1 (no) |
ZA (1) | ZA200306884B (no) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003264388A1 (en) * | 2002-09-09 | 2004-03-29 | Ono Pharmaceutical Co., Ltd. | Process for producing 4-methyl-1,3-thiazol-2-ylsulfonyl halide |
DK1603893T3 (da) * | 2003-01-29 | 2008-09-08 | Asterand Uk Ltd | EP4 -Receptorantagonister |
GB0317500D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Treatment of bph |
WO2005000356A1 (ja) * | 2003-06-27 | 2005-01-06 | Ono Pharmaceutical Co., Ltd. | 尿路疾患治療剤 |
GB0401334D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
WO2006004115A1 (ja) * | 2004-07-05 | 2006-01-12 | Chugai Seiyaku Kabushiki Kaisha | 過活動膀胱治療剤 |
JP2008189549A (ja) * | 2005-05-12 | 2008-08-21 | Astellas Pharma Inc | カルボン酸誘導体またはその塩 |
JP2009057282A (ja) * | 2005-12-19 | 2009-03-19 | Astellas Pharma Inc | カルボン酸誘導体又はその塩 |
TW200817319A (en) * | 2006-08-10 | 2008-04-16 | Astellas Pharma Inc | Sulfonamide compound or salt thereof |
JP5439817B2 (ja) | 2007-02-16 | 2014-03-12 | 小野薬品工業株式会社 | 尿排出障害治療剤 |
PT2177512E (pt) * | 2007-08-01 | 2012-05-07 | Taisho Pharmaceutical Co Ltd | Inibidor da ligação de s1p1 |
SG157299A1 (en) * | 2008-05-09 | 2009-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
JP5304785B2 (ja) * | 2008-06-23 | 2013-10-02 | アステラス製薬株式会社 | スルホンアミド化合物又はその塩 |
TW201107309A (en) * | 2009-07-27 | 2011-03-01 | Kissei Pharmaceutical | Indole derivatives, or the pharmaceutically acceptable salts |
US8916553B2 (en) | 2010-07-26 | 2014-12-23 | Bristol-Myers Squibb Company | Sulfonamide compounds useful as CYP17 inhibitors |
JP5363636B2 (ja) * | 2011-10-21 | 2013-12-11 | ファイザー・リミテッド | 新規な塩および医学的使用 |
US20140039004A1 (en) * | 2012-07-31 | 2014-02-06 | Ono Pharmaceutical Co., Ltd. | Method of treating of gastroesophageal reflux disease |
JP6103893B2 (ja) * | 2012-11-15 | 2017-03-29 | サントリー食品インターナショナル株式会社 | コーヒーオイルの製造方法 |
PT3138633T (pt) * | 2014-04-30 | 2019-02-01 | Ind Penalver Sl | Cabeça concêntrica programável para aplicação de líquido em tampas de diferentes formatos |
ES2821962T3 (es) * | 2015-11-13 | 2021-04-28 | Dae Woong Pharma | Bloqueador de canales de sodio |
RU2659955C1 (ru) * | 2017-10-26 | 2018-07-04 | Галина Ильхамовна Лукина | Способ диагностики высоких гастроэзофагеальных рефлюксов |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5748534B2 (no) | 1974-03-04 | 1982-10-16 | ||
DE2419923A1 (de) * | 1973-04-28 | 1974-11-28 | Fujisawa Pharmaceutical Co | Sulfonsaeureester, verfahren zu deren herstellung und verwendung derselben als kondensationsmittel |
DE2555048A1 (de) * | 1975-12-06 | 1977-06-30 | Pfersee Chem Fab | Verfahren und vorrichtung zur herstellung bestaendiger, waessriger emulsionen wasserunloeslicher substanzen |
JPS5293469A (en) | 1976-02-02 | 1977-08-05 | Fuji Photo Film Co Ltd | Method of curing gelatin |
JPH05293469A (ja) | 1992-04-17 | 1993-11-09 | Toda Constr Co Ltd | 滅菌精製水の製造方法およびその装置 |
TW523506B (en) * | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
AU4431400A (en) * | 1999-05-12 | 2000-12-05 | Japan As Represented By President Of National Cancer Center | Anticancer agents containing ep1 antagonists as the active ingredient |
KR20020012639A (ko) | 1999-07-29 | 2002-02-19 | 우에노 도시오 | 술폰아미드 유도체 및 알로디니아 치료제 |
KR20030081520A (ko) * | 2001-03-14 | 2003-10-17 | 오노 야꾸힝 고교 가부시키가이샤 | Ep1 안타고니스트를 유효 성분으로서 함유하는 울병의치료제 |
-
2002
- 2002-03-11 CN CNB028097904A patent/CN1294126C/zh not_active Expired - Fee Related
- 2002-03-11 EP EP05109059A patent/EP1612208B1/en not_active Expired - Lifetime
- 2002-03-11 AT AT05109059T patent/ATE522513T1/de active
- 2002-03-11 PL PL365100A patent/PL218750B1/pl unknown
- 2002-03-11 NZ NZ528120A patent/NZ528120A/en not_active IP Right Cessation
- 2002-03-11 PT PT05109059T patent/PT1612208E/pt unknown
- 2002-03-11 AU AU2002238855A patent/AU2002238855B2/en not_active Ceased
- 2002-03-11 RU RU2003127677/04A patent/RU2299202C2/ru not_active IP Right Cessation
- 2002-03-11 CA CA2439604A patent/CA2439604C/en not_active Expired - Fee Related
- 2002-03-11 AT AT02705096T patent/ATE362924T1/de active
- 2002-03-11 US US10/471,673 patent/US7235667B2/en not_active Expired - Fee Related
- 2002-03-11 KR KR1020037011921A patent/KR100886854B1/ko not_active IP Right Cessation
- 2002-03-11 BR BR0208027-3A patent/BR0208027A/pt not_active IP Right Cessation
- 2002-03-11 DE DE60220255T patent/DE60220255T2/de not_active Expired - Lifetime
- 2002-03-11 JP JP2002571480A patent/JP3555620B2/ja not_active Expired - Fee Related
- 2002-03-11 MX MXPA03008134A patent/MXPA03008134A/es active IP Right Grant
- 2002-03-11 WO PCT/JP2002/002245 patent/WO2002072564A1/ja active IP Right Grant
- 2002-03-11 IL IL15770102A patent/IL157701A0/xx unknown
- 2002-03-11 TW TW091104451A patent/TWI317359B/zh not_active IP Right Cessation
- 2002-03-11 DK DK02705096T patent/DK1369419T3/da active
- 2002-03-11 CZ CZ20032452A patent/CZ304035B6/cs not_active IP Right Cessation
- 2002-03-11 ES ES02705096T patent/ES2286230T3/es not_active Expired - Lifetime
- 2002-03-11 EP EP02705096A patent/EP1369419B1/en not_active Expired - Lifetime
- 2002-03-11 HU HU0400155A patent/HU230056B1/hu not_active IP Right Cessation
- 2002-03-11 PT PT02705096T patent/PT1369419E/pt unknown
- 2002-03-11 DK DK05109059.5T patent/DK1612208T3/da active
-
2003
- 2003-09-02 IL IL157701A patent/IL157701A/en not_active IP Right Cessation
- 2003-09-03 ZA ZA2003/06884A patent/ZA200306884B/en unknown
- 2003-09-10 NO NO20034007A patent/NO329682B1/no not_active IP Right Cessation
- 2003-12-24 JP JP2003427226A patent/JP3741120B2/ja not_active Expired - Fee Related
-
2005
- 2005-08-26 JP JP2005245763A patent/JP4432051B2/ja not_active Expired - Fee Related
- 2005-09-30 US US11/239,406 patent/US7629369B2/en not_active Expired - Fee Related
-
2009
- 2009-10-21 US US12/603,194 patent/US8088802B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7629369B2 (en) | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | |
CA2898650C (en) | Quinoline and quinoxaline amides as modulators of sodium channels | |
KR20080040046A (ko) | 티아졸 유도체 | |
WO2006030807A1 (ja) | Hivインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体 | |
WO1992009279A1 (en) | 2-arylthiazole derivative and pharmaceutical composition containing the same | |
JPWO2002072145A1 (ja) | Ep1アンタゴニストを有効成分として含有するうつ病の治療剤 | |
EP2771332B1 (en) | Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS | |
KR20170042687A (ko) | 카르복실산 화합물, 이의 제조방법, 및 이의 용도 | |
KR20090121376A (ko) | 글루코키나아제 활성화 물질 | |
JP4542757B2 (ja) | 縮合複素環化合物 | |
WO2001055123A1 (fr) | Composes cycliques a 5 chainons, contenant de l'azote, et medicaments contenant ces composes comme ingredients actifs | |
WO2000012491A1 (fr) | Derives d'acide carboxylique et medicaments dont ils sont le principe actif | |
CN108699027B (zh) | 吲嗪类衍生物、组合物及使用方法 | |
CN110709393A (zh) | Ldha活性抑制剂 | |
ES2368334T3 (es) | Compuesto de n-fenilarilsulfonamida, composición farmacéutica que comprende el compuesto como principio activo, intermedio sintético para el compuesto y procedimientos para su preparación. | |
KR101691954B1 (ko) | 신규 n-아실유레아 유도체 및 이를 함유하는 심혈관질환의 예방 또는 치료용 조성물 | |
JP4624616B2 (ja) | ベンズイミダゾール化合物 | |
JPH0940669A (ja) | ベンズイミダゾール化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |